WO2019113375A2 - Dosing regimens for the mobilization of hematopoietic stem and progenitor cells - Google Patents

Dosing regimens for the mobilization of hematopoietic stem and progenitor cells Download PDF

Info

Publication number
WO2019113375A2
WO2019113375A2 PCT/US2018/064335 US2018064335W WO2019113375A2 WO 2019113375 A2 WO2019113375 A2 WO 2019113375A2 US 2018064335 W US2018064335 W US 2018064335W WO 2019113375 A2 WO2019113375 A2 WO 2019113375A2
Authority
WO
WIPO (PCT)
Prior art keywords
cells
donor
peripheral blood
population
cxcr2 agonist
Prior art date
Application number
PCT/US2018/064335
Other languages
French (fr)
Other versions
WO2019113375A3 (en
Inventor
Dwight Morrow
Patrick C. Falahee
Anthony Boitano
Michael P. Cooke
Kevin A. GONCALVES
Original Assignee
Magenta Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/834,017 external-priority patent/US10058573B1/en
Priority to CA3083783A priority Critical patent/CA3083783A1/en
Priority to AU2018378804A priority patent/AU2018378804A1/en
Priority to KR1020207019222A priority patent/KR20200096942A/en
Priority to MX2020005878A priority patent/MX2020005878A/en
Priority to EA202091092A priority patent/EA202091092A1/en
Priority to CN201880088815.6A priority patent/CN111712262A/en
Priority to BR112020011186-4A priority patent/BR112020011186A2/en
Priority to EP18829615.6A priority patent/EP3720494A2/en
Priority to JP2020531468A priority patent/JP2021505172A/en
Priority to SG11202004913TA priority patent/SG11202004913TA/en
Application filed by Magenta Therapeutics, Inc. filed Critical Magenta Therapeutics, Inc.
Priority to US16/352,578 priority patent/US11260079B2/en
Publication of WO2019113375A2 publication Critical patent/WO2019113375A2/en
Publication of WO2019113375A3 publication Critical patent/WO2019113375A3/en
Priority to IL275077A priority patent/IL275077A/en
Priority to CONC2020/0007275A priority patent/CO2020007275A2/en
Priority to JP2023188499A priority patent/JP2024023226A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to the mobilization of hematopoietic stem and progenitor cells from a donor, such as a human donor, and to the treatment of patients suffering from various pathologies, such as blood diseases, metabolic disorders, cancers, and autoimmune diseases, among others.
  • hematopoietic stem cells have significant therapeutic potential
  • a limitation that has hindered their use in the clinic has been the difficulty associated with releasing hematopoietic stem cells from the bone marrow into the peripheral blood of a donor, from which the hematopoietic stem cells may be isolated for infusion into a patient.
  • a further limitation is that up to 80% of mobilized peripheral blood (mPB) allogeneic recipients will experience graft-versus-host disease (GVHD).
  • GVHD graft-versus-host disease
  • G-CSF mobilized grafts contain myeloid-derived suppressor cells (MDSCs) possessing potent immunosuppressive properties capable of inhibiting T cell proliferation in vitro.
  • MDSCs myeloid-derived suppressor cells
  • the percentage of MDSCs is variable in grafts mobilized with G-CSF, and clinical data suggest that patients transplanted with mPB grafts that contain higher numbers of MDSCs may have better outcomes including lower rates of acute GVHD
  • compositions and methods for promoting the mobilization of hematopoietic stem and progenitor cells are currently a need for compositions and methods for promoting the mobilization of hematopoietic stem and progenitor cells, and particularly for methods of identifying populations of mobilized cells that are suitable for therapeutic use.
  • compositions and methods for promoting the mobilization of hematopoietic stem and progenitor cells that consistently produce higher numbers of MDSCs than do prior art methods.
  • the present invention provides compositions and methods for mobilizing
  • the subject may be a hematopoietic stem and progenitor cell donor (z.e., a donor), such as a mammalian donor, and particularly a human donor.
  • a donor hematopoietic stem and progenitor cell donor
  • the invention additionally provides compositions and methods for the treatment of disorders, such as stem cell disorders, in a patient, such as a human patient.
  • a C-X-C chemokine receptor type 2 (CXCR2) agonist such as Gro-b or a variant thereof, such as a truncated form of Gro- b (e.g, Gro-b T), as described herein, optionally in combination with a C-X-C chemokine receptor type 4 (CXCR4) antagonist, such as l,r-[l,4-phenylenebis(methylene)]-bis- 1,4,8, 1 l-tetra-azacyclotetradecane or a variant thereof, may be administered to a subject in amounts sufficient to mobilize hematopoietic stem and progenitor cells.
  • CXCR2 C-X-C chemokine receptor type 2
  • CXCR4 C-X-C chemokine receptor type 4
  • l,r-[l,4-phenylenebis(methylene)]-bis- 1,4,8, 1 l-tetra-azacyclotetradecane or a variant thereof may be administered to
  • compositions and methods described herein may be used to mobilize hematopoietic stem and progenitor cells from a stem cell niche within a donor, such as a human donor, into the circulating peripheral blood of the donor while reducing the mobilization of other cells of the hematopoietic lineage, such as white blood cells, neutrophils, lymphocytes, and monocytes.
  • a donor such as a human donor
  • the compositions and methods described herein thus enable the selective mobilization of hematopoietic stem and progenitor cells in a donor, which may then be isolated from a donor for therapeutic use.
  • the hematopoietic stem or progenitor cells may be mobilized from the bone marrow of the donor to the peripheral blood, from which the hematopoietic stem or progenitor cells may be collected and/or isolated. Upon collection of the mobilized cells, the withdrawn hematopoietic stem or progenitor cells may then be infused into a patient, which may be the donor or another subject, such as a subject that is HLA-matched to the donor, for the treatment of one or more pathologies of the hematopoietic system. In some embodiments, the withdrawn hematopoietic stem or progenitor cells are first expanded ex vivo prior to infusion of these cells, and/or progeny thereof, into the patient. The
  • compositions and methods described herein provide the important clinical benefit of enabling the production of populations of cells that are enriched in hematopoietic stem cells relative to other cell types, such as leukocytes, neutrophils, and monocytes.
  • the populations of mobilized hematopoietic stem and progenitor cells produced using the compositions and methods described herein are particularly suitable for hematopoietic stem cell transplantation therapy, optionally preceded by ex vivo expansion in order to increase the quantity of hematopoietic stem and progenitor cells available for infusion into a patient.
  • Leukocytosis in the donor. Leukocytosis may lead to adverse effects such as splenic rupture, renal dysfunction, acute febrile noninfectious pneumonitis (i.e., pulmonary toxicity), cardiovascular toxicity ( e.g ., hypercoagulation, heart attack, dyspnea, angina, arrhythmia, atherosclerotic plaque rupture due to proinflammatory actions related o high neutrophil counts), neurological disturbances (e.g., blurred vision, headache, and retinal hemorrhage), and sickle cell crisis. See, e.g, D’ Souza et al. (2008) Transfusion Medicine Reviews 22(4):280-290.
  • hematopoietic stem cells are capable of differentiating into a multitude of cell types in the hematopoietic lineage and can thus be administered to a patient in order to populate or repopulate a cell type that is defective or deficient in the patient.
  • the patient may be one, for example, that is suffering from one or more blood disorders, such as an autoimmune disease, cancer, hemoglobinopathy, or other hematopoietic pathology, and is therefore in need of hematopoietic stem cell transplantation.
  • the invention thus provides methods of treating a variety of hematopoietic conditions, such as sickle cell anemia, thalassemia, Fanconi anemia, Wiskott-Aldrich syndrome, adenosine deaminase deficiency- severe combined immunodeficiency, metachromatic leukodystrophy, Diamond-Blackfan anemia and Schwachman-Diamond syndrome, human immunodeficiency virus infection, and acquired immune deficiency syndrome, as well as cancers and autoimmune diseases, among others.
  • hematopoietic conditions such as sickle cell anemia, thalassemia, Fanconi anemia, Wiskott-Aldrich syndrome, adenosine deaminase deficiency- severe combined immunodeficiency, metachromatic leukodystrophy, Diamond-Blackfan anemia and Schwachman-Diamond syndrome, human immunodeficiency virus infection, and acquired immune deficiency syndrome, as well as cancers and autoimmune diseases, among others.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34 + cells to leukocytes of from about 0.0008 to about 0.0021 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist.
  • the ratio of CD34 + cells to leukocytes in the sample may be about
  • the ratio of CD34 + cells to leukocytes in the sample is from about 0.0010 to about 0.0018, such as a ratio of
  • hematopoietic stem cells to leukocytes in the sample of about 0.00100, 0.00101, 0.00102,
  • the ratio of CD34 + cells to leukocytes in the sample is about 0.0014.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34 + cells relative to leukocytes by a ratio of from about 3.40: 1 to about 6.90: 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
  • a mammalian donor e.g ., a human donor
  • the peripheral blood of the donor may be enriched with CD34 + cells relative to leukocytes by a ratio of about 3.40:1, 3.45:1, 3.50:1, 3.55:1, 3.60:1, 3.65:1, 3.70:1, 3.75:1, 3.80:1, 3.85:1, 3.90:1, 3.95:1, 4.00:1, 4.05:1, 4.10:1, 4.15:1, 4.20:1, 4.25:1, 4.30:1, 4.35:1, 4.40:1, 4.45:1,
  • the peripheral blood of the donor is enriched with CD34+ cells relative to leukocytes by a ratio of from about 3.5:1 to about 6.8:1, about 3.6:1 to about 6.7:1, about 3.8:1 to about 6.6:1, about 3.9:1 to about 6.5:1, about 4:1 to about 6.4:1, about 4.1:1 to about 6.3:1, about 4.2:1 to about 6.2:1, about 4.3:1 to about 6.1:1, about 4.4:1 to about 6:1, about 4.5:1 to about 6:1, about 4.6:1 to about 5.9:1, about 4.7:1 to about 5.8:1, or about 4.8:1 to about 5.7:1.
  • the peripheral blood of the donor is enriched with CD34 + cells relative to leukocytes by a ratio of about from about 4.0: 1 to about 6.0:1, such as a ratio of about 4.00:1, 4.05:1, 4.10:1, 4.15:1, 4.20:1, 4.25:1, 4.30:1, 4.35:1, 4.40:1, 4.45:1, 4.50:1, 4.55:1, 4.60:1, 4.65:1, 4.70:1, 4.75:1, 4.80:1, 4.85:1, 4.90:1, 4.95:1, 5.00: 1, 5.05: 1, 5.10: 1, 5.15: 1, 5.20: 1, 5.25: 1, 5.30: 1, 5.35: 1, 5.40: 1, 5.45: 1, 5.50: 1, 5.55: 1, 5.60: 1, 5.65: 1, 5.70: 1, 5.75: 1, 5.80: 1, 5.85: 1, 5.90: 1, 5.95: 1, or 6.00: 1.
  • the peripheral blood of the donor is enriched with CD34 + cells relative to leukocytes by a ratio of about from about 4.5: 1 to about 5.5: 1, such as a ratio of about 4.50: 1, 4.55: 1, 4.60: 1, 4.65: 1, 4.70: 1, 4.75: 1, 4.80: 1, 4.85: 1, 4.90: 1, 4.95: 1, 5.00: 1, 5.05: 1, 5.10: 1, 5.15: 1, 5.20: 1, 5.25: 1, 5.30: 1, 5.35: 1, 5.40: 1, 5.45: 1, or 5.50.
  • the peripheral blood of the donor is enriched with CD34 + cells relative to leukocytes by a ratio of about 5.1 : 1.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + cells of at least about 38,000 cells/ml, such as a density of CD34 + cells of from about 38,000 cells/ml to about 100,000 cells/ml, about 40,000 cells/ml to about 90,000 cells/ml, about 50,000 cells/ml to about 80,000 cells/ml, or about 60,000 cells/ml to about 70,000 cells/ml (e.g., about 38,00 cells/ml, 39,000 cells/ml, 40,000 cells/ml, 41,000 cells/ml, 42,000 cells/ml, 43,000 cells/ml, 44,000 cells/ml, 45,000 cells/ml,
  • the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + cells of from about 38,000 cells/ml to about 100,000 cells/ml, and having a density of leukocytes of from about 2.3 x 10 7 cells/ml to about 5.3 x 10 7 cells/ml.
  • the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + cells of from about 40,000 cells/ml to about 80,000 cells/ml, and having a density of leukocytes of from about 2.5 x 10 7 cells/ml to about 5 x 10 7 cells/ml.
  • the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + cells of from about 50,000 cells/ml to about 90,000 cells/ml, and having a density of leukocytes of from about 3 x 10 7 cells/ml to about 4 x 10 7 cells/ml.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34 + cells to neutrophils of from about 0.0018 to about 0.0058 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist.
  • the ratio of CD34 + cells to neutrophils in the sample may be about
  • the ratio of CD34 + cells to neutrophils in the sample is from about 0.002 to about 0.0056, about 0.0022 to about 0.0054, about 0.0024 to about 0.0052, about 0.0026 to about 0.005, about 0.0028 to about 0.0048, or about 0.003 to about 0.0046.
  • the ratio of CD34 + cells to neutrophils in the sample is from about 0.0026 to about 0.0046, such as a ratio of CD34 + cells to neutrophils in the sample of about 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266, 0.00267, 0.00268, 0.00269, 0.00270, 0.00271, 0.00272, 0.00273, 0.00274, 0.00275, 0.00276, 0.00277,
  • the ratio of CD34 + cells to neutrophils in the sample is about 0.0036.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34 + cells relative to neutrophils by a ratio of from about 2.1 : 1 to about 8.1 : 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
  • a mammalian donor e.g ., a human donor
  • the peripheral blood of the donor may be enriched with CD34 + cells relative to neutrophils by a ratio of about 2.10:1, 2.15:1, 2.20:1, 2.25:1, 2.30:1, 2.35:1, 2.40:1, 2.45:1, 2.50:1, 2.55:1, 2.60:1, 2.65:1, 2.70:1, 2.75:1, 2.80:1, 2.85:1, 2.90:1, 2.95:1, 3.00:1, 3.05:1, 3.10:1, 3.15:1,
  • the peripheral blood of the donor is enriched with CD34 + cells relative to neutrophils by a ratio of from about 2.5:1 to about 7:1, about 2.6: 1 to about 6.9:1, about 2.7:1 to about 6.8:1, about 2.8:1 to about 6.7:1, about 2.9:1 to about 6.6:1, about 3:1 to about 6.5:1, about 3.2:1 to about 6.4:1, about 3.3:1 to about 6.3:1, about 3.4:1 to about 6.2:1, or about 3.5 : 1 to about 6.1:1
  • the peripheral blood of the donor is enriched with CD34 + cells relative to neutrophils by a ratio of from about from about 5.4: 1 to about 7.4:1, such as a ratio of about 5.40:1, 5.45:1, 5.50:1, 5.55:1, 5.60:1, 5.65:1, 5.70:1, 5.75:1, 5.80:1, 5.85:1, 5.90:1, 5.95:1, 6.00:1, 6.05:1, 6.10:1, 6.15:1,
  • the peripheral blood of the donor is enriched with CD34 + cells relative to neutrophils by a ratio of about 6.4:1.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34 + cells to lymphocytes of from about 0.0021 to about 0.0094 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist.
  • a mammalian donor e.g ., a human donor
  • the ratio of CD34 + cells to lymphocytes in the sample may be about 0.00210, 0.00211, 0.00212, 0.00213, 0.00214, 0.00215, 0.00216, 0.00217, 0.00218, 0.00219,
  • the ratio of CD34 + cells to lymphocytes in the sample is from about 0.0022 to about 0.0093, about 0.0023 to about 0.0092, about 0.0024 to about 0.0091, about 0.003 to about 0.0085, about 0.0035 to about 0.0075, or about 0.0045 to about 0.0065.
  • the ratio of CD34 + cells to lymphocytes in the sample is from about 0.0025 to about 0.0035, such as a ratio of CD34 + cells to lymphocytes in the sample of about 0.00250, 0.00251, 0.00252, 0.00253, 0.00254, 0.00255, 0.00256, 0.00257, 0.00258, 0.00259, 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266, 0.00267,
  • the ratio of CD34 + cells to lymphocytes in the sample is about 0.0031.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34 + cells relative to lymphocytes by a ratio of from about 4.8: 1 to about 8.4: 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
  • a mammalian donor e.g ., a human donor
  • the peripheral blood of the donor may be enriched with CD34 + cells relative to lymphocytes by a ratio of about 4.80: 1, 4.85: 1, 4.90: 1, 4.95: 1, 5.00: 1, 5.05: 1, 5.10: 1, 5.15: 1, 5.20: 1, 5.25: 1, 5.30: 1, 5.35: 1, 5.40: 1, 5.45: 1, 5.50: 1, 5.55: 1, 5.60: 1, 5.65: 1, 5.70: 1, 5.75: 1, 5.80: 1, 5.85: 1,
  • the peripheral blood of the donor is enriched with CD34 + cells relative to lymphocytes by a ratio of from about 5: 1 to about 7:1, about 5.5:1 to about 6.5:1, or about 5.2:1 to about 5.7:1.
  • the peripheral blood of the donor is enriched with CD34 + cells relative to lymphocytes by a ratio of from about 5.0:1 to about 6.5:1, such as a ratio of about 5.00:1, 5.05:1, 5.10:1, 5.15:1, 5.20:1, 5.25:1, 5.30:1, 5.35:1, 5.40:1, 5.45:1, 5.50:1, 5.55:1, 5.60:1, 5.65:1, 5.70:1, 5.75:1, 5.80:1,
  • the peripheral blood of the donor is enriched with CD34 + cells relative to lymphocytes by a ratio of about 5.7:1.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + cells of at least about 38,000 cells/ml, such as a density of CD34 + cells of from about 38,000 cells/ml to about 100,000 cells/ml, about 40,000 cells/ml to about 90,000 cells/ml, about 50,000 cells/ml to about 80,000 cells/ml, or about 60,000 cells/ml to about 70,000 cells/ml (e.g., about 38,00 cells/ml, 39,000 cells/ml, 40,000 cells/ml, 41,000 cells/ml, 42,000 cells/ml, 43,000 cells/ml, 44,000 cells/ml, 45,000 cells/ml,
  • the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + cells of from about 38,000 cells/ml to about 100,000 cells/ml, and having a density of lymphocytes of from about 1 x 10 7 cells/ml to about 2.3 x 10 7 cells/ml.
  • the method includes
  • a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + cells of from about 40,000 cells/ml to about 80,000 cells/ml, and having a density of lymphocytes of from about 1.3 x 10 7 cells/ml to about 2.3 x 10 7 cells/ml.
  • the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + cells of from about 50,000 cells/ml to about 90,000 cells/ml, and having a density of lymphocytes of from about 1.5 x 10 7 cells/ml to about 2 x 10 7 cells/ml.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34 + cells to monocytes of from about 0.0071 to about 0.0174 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist.
  • the ratio of CD34 + cells to monocytes in the sample may be about 0.00710, 0.00711, 0.00712,
  • the ratio of CD34 + cells to monocytes in the sample is from 0.008 to about 0.016, about 0.009 to about 0.015, about 0.01 to about 0.014, or about 0.011 to about 0.013.
  • the ratio of CD34 + cells to monocytes in the sample is from about 0.0100 to about 0.0140, such as a ratio of CD34 + cells to monocytes in the sample of about 0.0100, 0.0101, 0.0103, 0.0104, 0.0105, 0.0106, 0.0107, 0.0108, 0.0109, 0.0110, 0.0111, 0.0112, 0.0113, 0.0114, 0.0115, 0.0116, 0.0117, 0.0118, 0.0119, 0.0120, 0.0121, 0.0122, 0.0123, 0.0124, 0.0125, 0.0126, 0.0127, 0.0128, 0.0129, 0.0130, 0.0131, 0.0132, 0.0133, 0.0134, 0.0135, 0.0136, 0.0137, 0.0138, 0.0139, or 0.0140.
  • the ratio of CD34 + cells to monocytes in the sample is about 0.0118.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + cells of at least about 38,000 cells/ml, such as a density of CD34 + cells of from about 38,000 cells/ml to about 100,000 cells/ml, about 40,000 cells/ml to about 90,000 cells/ml, about 50,000 cells/ml to about 80,000 cells/ml, or about 60,000 cells/ml to about 70,000 cells/ml (e.g., about 38,00 cells/ml, 39,000 cells/ml, 40,000 cells/ml, 41,000 cells/ml, 42,000 cells/ml, 43,000 cells/ml, 44,000 cells/ml, 45,000 cells/ml (e.g., about 38,
  • the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + cells of from about 38,000 cells/ml to about 100,000 cells/ml, and having a density of monocytes of from about 3.4 x 10 6 cells/ml to about 6 x 10 6 cells/ml.
  • the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + cells of from about 40,000 cells/ml to about 80,000 cells/ml, and having a density of monocytes of from about 4 x 10 6 cells/ml to about 5.5 x 10 6 cells/ml.
  • the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + cells of from about 50,000 cells/ml to about 90,000 cells/ml, and having a density of monocytes of from about 4 x 10 6 cells/ml to about 5 x 10 6 cells/ml.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34 + cells relative to monocytes by a ratio of from about 1.1 : 1 to about 2.3 : 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
  • a mammalian donor e.g ., a human donor
  • the peripheral blood of the donor may be enriched with CD34 + cells relative to monocytes by a ratio of about 1.10: 1, 1.15: 1, 1.20: 1, 1.25: 1, 1.30: 1, 1.35: 1, 1.40: 1, 1.45: 1, 1.50: 1, 1.55: 1, 1.60: 1, 1.65: 1, 1.70: 1, 1.75: 1, 1.80: 1, 1.85: 1, 1.90: 1, 1.95: 1, 2.00: 1, 2.05: 1, 2.10: 1, 2.15: 1, 2.20: 1, 2.25: 1, or 2.30: 1.
  • the peripheral blood of the donor is enriched with CD34 + cells relative to monocytes by a ratio of about from about 1.3 : 1 to about 1.9: 1, such as a ratio of about 1.30: 1, 1.35: 1, 1.40: 1, 1.45: 1, 1.50: 1, 1.55: 1, 1.60: 1, 1.65: 1, 1.70: 1, 1.75: 1, 1.80: 1, 1.85: 1, or 1.90: 1.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a frequency of CD34 + cells of from about 0.051% to about 0.140% in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist.
  • a mammalian donor e.g., a human donor
  • the population of cells may have a frequency of CD34 + cells of about
  • the population of cells has a frequency of CD34 + cells of from about 0.050% to about 0.120%, about 0.060% to about 0.110%, or about 0.080% to about 0.100%. In some embodiments, the population of cells has a frequency of CD34 + cells of from about 0.080% to about 0.120%, such as a frequency of hematopoietic stem cells of about 0.080%, 0.081%, 0.082%, 0.083%, 0.084%, 0.085%, 0.086%, 0.087%, 0.088%, 0.089%, 0.090%, 0.091%, 0.092%, 0.093%, 0.094%, 0.095%, 0.096%, 0.097%, 0.098%, 0.099%, 0.100%, 0.101%, 0.102%, 0.103%, 0.104%, 0.105%, 0.106%, 0.107%, 0.108%, 0.109%, 0.110%, 0.111%, 0.112%, 0.113%, 0.114%, 0.115%, 0.116%, 0.117%, 0.118%, 0.109%, 0.
  • the population of cells has a frequency of CD34 + cells of about 0.097%.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to induce an increase in the frequency of CD34 + cells in the peripheral blood of the donor by at least 3-fold as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist (e.g., by from about 3.4-fold to about 7.1 -fold, such as by about 3.4-fold, 3.5-fold, 3.6-fold, 3.7-fold, 3.8-fold, 3.9-fold, 4.0-fold, 4.
  • a mammalian donor e.g a human donor
  • the frequency of CD34 + cells in the peripheral blood of the donor is increased by from about 4-fold to about 7-fold, about 4.5-fold to about 6.5-fold, or about 5-fold to about 6-fold following administration of the CXCR2 agonist and CXCR4 antagonist.
  • the frequency of CD34 + cells in the peripheral blood of the donor is increased by from about 4.0-fold to about 6.0-fold following administration of the CXCR2 agonist and CXCR4 antagonist, such as by about 4.0-fold, 4.l-fold, 4.2-fold, 4.3-fold, 4.4- fold, 4.5-fold, 4.6-fold, 4.7-fold, 4.8-fold, 4.9-fold, 5.0-fold, 5.l-fold, 5.2-fold, 5.3-fold, 5.4- fold, 5.5-fold, 5.6-fold, 5.7-fold, 5.8-fold, 5.9-fold, or 6.0-fold.
  • the frequency of CD34 + cells in the peripheral blood of the donor is increased by about 4.8-fold.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34 + CD90 + CD45RA cells to leukocytes of from about 0.0003 to about 0.0016 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist.
  • the ratio of CD34 + CD90 + CD45RA cells to leukocytes in the sample may be about 0.00030, 0.00031, 0.00032, 0.00033, 0.00034,
  • the ratio of CD34 + CD90 + CD45RA cells to leukocytes in the sample is from about 0.0008 to about 0.0010. In some embodiments, the ratio of CD34 + CD90 + CD45RA cells to leukocytes in the sample is from about 0.0006 to about 0.0012, such as a ratio of hematopoietic stem cells to leukocytes in the sample of about 0.00060, 0.00061, 0.00062, 0.00063, 0.00064, 0.00065, 0.00066, 0.00067, 0.00068, 0.00069, 0.00070, 0.00071, 0.00072, 0.00073, 0.00074, 0.00075, 0.00076, 0.00077, 0.00078, 0.00079, 0.00080, 0.00081, 0.00082, 0.00083, 0.00084, 0.00085, 0.00086, 0.00087, 0.00088, 0.00089, 0.00090, 0.00091, 0.00092, 0.00093, 0.00094, 0.00095, 0.00096, 0.00097, 0.00098
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34 + CD90 + CD45RA cells relative to leukocytes by a ratio of from about 5.5:1 to about 26.9: 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
  • the peripheral blood of the donor may be enriched with CD34 + CD90 +
  • CD45RA cells relative to leukocytes by a ratio of about 5.50:1, 5.55:1, 5.60:1, 5.65:1, 5.70:1, 5.75:1, 5.80:1, 5.85:1, 5.90:1, 5.95:1, 6.00:1, 6.05:1, 6.10:1, 6.15:1, 6.20:1, 6.25:1, 6.30:1,
  • the peripheral blood of the donor is enriched with CD34 + CD90 + CD45RA cells relative to leukocytes by a ratio of about from about 5.5:1 to about 6.5:1, such asaratio of about 5.50:1, 5.55:1, 5.60:1, 5.65:1, 5.70:1, 5.75:1, 5.80:1, 5.85:1, 5.90:1, 5.95:1, 6.00:1, 6.05:1, 6.10:1, 6.15:1, 6.20:1, 6.25:1, 6.30:1, 6.35:1, 6.40:1, 6.45:1, or 6.50:1.
  • the peripheral blood of the donor is enriched with CD34 + CD90 + CD45RA cells relative to leukocytes by a ratio of about 6.0:1.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + CD90 + CD45RA cells of at least about 16,000 cells/ml, such as a density of from about 20,000 cells/ml to about 75,000 cells/ml, about 25,000 cells/ml to about 70,000 cells/ml, about 30,000 cells/ml to about 65,000 cells/ml, about 35,000 cells/ml to about 60,000 cells/ml, about 40,000 cells/ml to about 55,000 cells/ml, or about 45,000 cells/ml to about 50,000 cells/ml ( e.g ., about 16,000 cells/ml, 17,000 cells/ml, 18,000 cells/ml, 1
  • a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + CD90 + CD45RA cells of from about 20,000 cells/ml to about 75,000 cells/ml, and having a density of leukocytes of from about 2.3 x 10 7 cells/ml to about 5.3 x 10 7 cells/ml.
  • the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + CD90 + CD45RA cells of from about 30,000 cells/ml to about 60,000 cells/ml, and having a density of leukocytes of from about 2.5 x 10 7 cells/ml to about 5 x 10 7 cells/ml.
  • the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + CD90 + CD45RA cells of from about 40,000 cells/ml to about 50,000 cells/ml, and having a density of leukocytes of from about 3 x 10 7 cells/ml to about 4 x 10 7 cells/ml.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34 + CD90 + CD45RA cells to neutrophils of from about 0.0007 to about 0.0043 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist.
  • the ratio of CD34 + CD90 + CD45RA cells to neutrophils in the sample may be about 0.00070, 0.00071, 0.00072, 0.00073, 0.00074,
  • the ratio of CD34 + CD90 + CD45RA cells to neutrophils in the sample is from about 0.002 to about 0.003. In some embodiments, the ratio of CD34 + CD90 + CD45RA cells to neutrophils in the sample is from about 0.0014 to about 0.0034, such as a ratio of CD34 + CD90 +
  • CD45RA cells to neutrophils in the sample of about 0.00140, 0.00141, 0.00142, 0.00143,
  • the ratio of CD34 + CD90 + CD45RA cells to neutrophils in the sample is about 0.0024.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34 + CD90 + CD45RA cells relative to neutrophils by a ratio of from about 3.5:1 to about 22.0: 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
  • a mammalian donor e.g ., a human donor
  • the peripheral blood of the donor may be enriched with CD34 + CD90 + CD45RA cells relative to neutrophils by a ratio of about 3.50:1, 3.55:1, 3.60:1, 3.65:1, 3.70:1, 3.75:1, 3.80:1, 3.85:1, 3.90:1, 3.95:1, 4.00:1, 4.05:1, 4.10:1, 4.15:1, 4.20:1, 4.25:1,
  • the peripheral blood of the donor is enriched with CD34 + CD90 + CD45RA cells relative to neutrophils by a ratio of about from about 7.0:1 to about 10:1.
  • the peripheral blood of the donor is enriched with CD34 + CD90 + CD45RA cells relative to neutrophils by a ratio of from about 7.00:1 to about 9.00:1, such as a ratio of about 7.00:1, 7.05:1, 7.10:1, 7.15:1, 7.20:1, 7.25:1, 7.30:1, 7.35:1, 7.40:1, 7.45:1, 7.50:1, 7.55:1, 7.60:1, 7.65:1, 7.70:1, 7.75:1,
  • the peripheral blood of the donor is enriched with CD34 + CD90 + CD45RA cells relative to neutrophils by a ratio of about 8.2:1.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + CD90 + CD45RA cells of at least about 16,000 cells/ml, such as a density of from about 20,000 cells/ml to about 75,000 cells/ml, about 25,000 cells/ml to about 70,000 cells/ml, about 30,000 cells/ml to about 65,000 cells/ml, about 35,000 cells/ml to about 60,000 cells/ml, about 40,000 cells/ml to about 55,000 cells/ml, or about 45,000 cells/ml to about 50,000 cells/ml ( e.g ., about 16,000 cells/ml, 17,000 cells/ml, 18,000 cells/ml, 1
  • the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + CD90 + CD45RA cells of from about 20,000 cells/ml to about 75,000 cells/ml, and having a density of neutrophils of from about 1 x 10 7 cells/ml to about 2.5 x 10 7 cells/ml.
  • the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + CD90 + CD45RA cells of from about 30,000 cells/ml to about 60,000 cells/ml, and having a density of neutrophils of from about 1.3 x 10 7 cells/ml to about 2.3 x 10 7 cells/ml.
  • the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + CD90 + CD45RA cells of from about 40,000 cells/ml to about 50,000 cells/ml, and having a density of neutrophils of from about 1.5 x 10 7 cells/ml to about 2 x 10 7 cells/ml.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34 + CD90 + CD45RA cells to lymphocytes of from about 0.0008 to about 0.0069 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist.
  • the ratio of CD34 + CD90 + CD45RA cells to lymphocytes in the sample may be about 0.00080, 0.00081, 0.00082, 0.00083, 0.00084,
  • the ratio of CD34 + CD90 + CD45RA cells to lymphocytes in the sample is from about 0.0011 to about 0.0031, such as a ratio of CD34 + CD90 + CD45RA cells to lymphocytes in the sample of about 0.00110, 0.00111, 0.00112, 0.00113, 0.00114, 0.00115, 0.00116, 0.00117, 0.00118, 0.00119, 0.00120, 0.00121, 0.00122, 0.00123, 0.00124, 0.00125,
  • the ratio of CD34 + CD90 + CD45RA cells to lymphocytes in the sample is about 0.0021.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34 + CD90 + CD45RA cells relative to lymphocytes by a ratio of from about 5.6: 1 to about 37.0: 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
  • the peripheral blood of the donor may be enriched with CD34 + CD90 + CD45RA cells relative to lymphocytes by a ratio of about 5.60:1, 5.65:1, 5.70:1, 5.75:1,
  • CD45RA cells relative to lymphocytes by a ratio of about from about 8.0: 1 to about 10.0:1, such as a ratio of about 8.00: 1, 8.05: 1, 8.10: 1, 8.15: 1, 8.20: 1, 8.25: 1, 8.30: 1, 8.35: 1, 8.40: 1,
  • the peripheral blood of the donor is enriched with CD34 + CD90 + CD45RA cells relative to lymphocytes by a ratio of about 9.3 : 1.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + CD90 + CD45RA cells of at least about 16,000 cells/ml, such as a density of from about 20,000 cells/ml to about 75,000 cells/ml, about 25,000 cells/ml to about 70,000 cells/ml, about 30,000 cells/ml to about 65,000 cells/ml, about 35,000 cells/ml to about 60,000 cells/ml, about 40,000 cells/ml to about 55,000 cells/ml, or about 45,000 cells/ml to about 50,000 cells/ml (e.g., about 16,000 cells/ml, 17,000 cells/ml, 18,000 cells/ml, 19,000 cells
  • the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + CD90 + CD45RA cells of from about 20,000 cells/ml to about 75,000 cells/ml, and having a density of lymphocytes of from about 1 x 10 7 cells/ml to about 2.3 x 10 7 cells/ml.
  • the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + CD90 + CD45RA cells of from about 30,000 cells/ml to about 60,000 cells/ml, and having a density of lymphocytes of from about 1.3 x 10 7 cells/ml to about 2.3 x 10 7 cells/ml.
  • the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + CD90 + CD45RA cells of from about 40,000 cells/ml to about 50,000 cells/ml, and having a density of lymphocytes of from about 1.5 x 10 7 cells/ml to about 2 x 10 7 cells/ml.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34 + CD90 + CD45R a cells to monocytes of from about 0.0028 to about 0.0130 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist.
  • the ratio of CD34 + CD90 + CD45RA cells to monocytes in the sample may be about 0.00280. 0.00281. 0.00282. 0.00283. 0.00284. 0.00285. 0.00286. 0.00287. 0.00288
  • the ratio of CD34 + CD90 + CD45RA cells to monocytes in the sample is from about 0.0063 to about 0.0083, such as a ratio of CD34 + CD90 + CD45RA cells to monocytes in the sample of about 0.00630, 0.00631, 0.00632, 0.00633, 0.00634, 0.00635, 0.00636, 0.00637, 0.00638, 0.00639, 0.00640, 0.00641, 0.00642, 0.00643, 0.00644, 0.00645, 0.00646, 0.00647, 0.00648, 0.00649, 0.00650, 0.00651, 0.00652, 0.00653, 0.00654, 0.00655, 0.00656, 0.00657, 0.00658, 0.00659, 0.00660, 0.00661, 0.00662, 0.00663, 0.00664, 0.00665, 0.00666, 0.00667, 0.00668, 0.00669, 0.00670, 0.00671, 0.00672, 0.00673, 0.00674, 0.00675,
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34 + CD90 + CD45RA cells relative to monocytes by a ratio of from about 1.5: 1 to about 8.5: 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
  • the peripheral blood of the donor may be enriched with CD34 + CD90 + CD45RA cells relative to monocytes by a ratio of about 1.50: 1, 1.55: 1, 1.60: 1, 1.65: 1,
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + CD90 + CD45RA cells of at least about 16,000 cells/ml, such as a density of from about 20,000 cells/ml to about 75,000 cells/ml, about 25,000 cells/ml to about 70,000 cells/ml, about 30,000 cells/ml to about 65,000 cells/ml, about 35,000 cells/ml to about 60,000 cells/ml, about 40,000 cells/ml to about 55,000 cells/ml, or about 45,000 cells/ml to about 50,000 cells/ml (e.g., about 16,000 cells/ml, 17,000 cells/ml, 18,000 cells/ml, 19,000 cells
  • the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + CD90 + CD45RA cells of from about 20,000 cells/ml to about 75,000 cells/ml, and having a density of monocytes of from about 3.4 x 10 6 cells/ml to about 6 x 10 6 cells/ml.
  • the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + CD90 + CD45RA cells of from about 30,000 cells/ml to about 60,000 cells/ml, and having a density of monocytes of from about 4 x 10 6 cells/ml to about 5.5 x 10 6 cells/ml.
  • the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34 + CD90 + CD45RA cells of from about 40,000 cells/ml to about 50,000 cells/ml, and having a density of monocytes of from about 4 x 10 6 cells/ml to about 5 x 10 6 cells/ml.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34 + CD90 + CD45RA cells to CD34 + cells of from about 0.393 to about 0.745 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist.
  • a mammalian donor e.g ., a human donor
  • the ratio of CD34 + CD90 + CD45RA cells to CD34 + cells in the sample may be about 0.393, 0.394, 0.395, 0.396, 0.397, 0.398, 0.399, 0.401, 0.402, 0.403, 0.404, 0.405, 0.406, 0.407, 0.408, 0.409, 0.410, 0.411, 0.412, 0.413, 0.414, 0.415, 0.416, 0.417, 0.418,
  • the ratio of CD34 + CD90 + CD45RA cells to CD34 + cells in the sample is from about 0.625 to about 0.725, such as a ratio of CD34 + CD90 + CD45RA cells to CD34 + cells in the sample of about 0.625, 0.626, 0.627, 0.628, 0.629, 0.630, 0.631, 0.632, 0.633, 0.634, 0.635, 0.636, 0.637, 0.638, 0.639, 0.640, 0.641, 0.642, 0.643, 0.644, 0.645, 0.646, 0.647,
  • the ratio of CD34 + CD90 + CD45RA cells to CD34 + cells in the sample is about 0.676.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34 + CD90 + CD45RA cells relative to CD34 + cells by a ratio of from about 1.1 : 1 to about 4.8:1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
  • the peripheral blood of the donor may be enriched with CD34 + CD90 + CD45RA cells relative to monocytes by a ratio of about 1.10:1, 1.15:1, 1.20:1, 1.25:1,
  • the peripheral blood of the donor is enriched with CD34 + CD90 + CD45RA cells relative to CD34 + cells by a ratio of about 1.2:1.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a frequency of CD34 + CD90 + CD45RA cells of from about 0.020% to about 0.110% in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist.
  • a mammalian donor e.g ., a human donor
  • the population of cells may have a frequency of CD34 + CD90 + CD45RA cells of about 0.020%, 0.021%, 0.022%, 0.023%, 0.024%, 0.025%, 0.026%, 0.027%, 0.028%, 0.029%, 0.030%, 0.031%, 0.032%, 0.033%, 0.034%, 0.035%, 0.036%, 0.037%, 0.038%, 0.039%, 0.040%, 0.041%, 0.042%, 0.043%, 0.044%, 0.045%, 0.046%, 0.047%, 0.048%, 0.049%, 0.050%, 0.051%, 0.052%, 0.053%, 0.054%, 0.055%, 0.056%, 0.057%, 0.058%, 0.059%, 0.060%, 0.061%, 0.062%, 0.063%, 0.064%, 0.065%, 0.066%, 0.067%, 0.068%, 0.069%, 0.070%, 0.071%, 0.072%, 0.073%, 0.074%, 0.075%, 0.076%,
  • the population of cells has a frequency of CD34 + CD90 + CD45RA cells of from about 0.046% to about 0.086%, such as a frequency of hematopoietic stem cells of about 0.046%, 0.047%, 0.048%, 0.049%, 0.050%, 0.051%, 0.052%, 0.053%, 0.054%, 0.055%, 0.056%, 0.057%, 0.058%, 0.059%,
  • the population of cells has a frequency of CD34 + CD90 + CD45RA cells of about 0.066%.
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to induce an increase in the frequency of CD34 + CD90 + CD45RA cells in the peripheral blood of the donor by at least 3-fold as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist (e.g., by from about 5.1 -fold to about 25.7-fold, such as by about 5.
  • a mammalian donor e.g ., a human donor
  • the frequency of CD34 + CD90 + CD45RA cells in the peripheral blood of the donor is increased by from about 5.1 -fold to about 7.1 -fold following administration of the CXCR2 agonist and CXCR4 antagonist, such as by about 5. l-fold, 5.2-fold, 5.3-fold, 5.4- fold, 5.5-fold, 5.6-fold, 5.7-fold, 5.8-fold, 5.9-fold, 6.0-fold, 6. l-fold, 6.2-fold, 6.3-fold, 6.4- fold, 6.5-fold, 6.6-fold, 6.7-fold, 6.8-fold, 6.9-fold, 7.0-fold, or 7. l-fold.
  • the CXCR2 agonist and CXCR4 antagonist such as by about 5. l-fold, 5.2-fold, 5.3-fold, 5.4- fold, 5.5-fold, 5.6-fold, 5.7-fold, 5.8-fold, 5.9-fold, 6.0-fold, 6. l-fold, 6.2-fold, 6.3-fold,
  • the frequency of CD34 + CD90 + CD45RA cells in the peripheral blood of the donor is increased by about 5.8-fold.
  • the invention features a method of mobilizing a population of hematopoietic stem cells, from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor mobilizing amounts of a CXCR2 agonist and a CXCR4 antagonist; acquiring an input value for each of one or more parameters in TABLE 2 characterizing a sample of peripheral blood of the donor, and releasing the sample for ex vivo expansion of the hematopoietic stem cells or for use in the treatment of one or more stem cell disorders in a mammalian patient if the input value for each of the one or more parameters meets the corresponding reference criterion for each of the one or more parameters.
  • the one or more reference parameters are a set of parameters listed in any one of TABLES 3-6 herein.
  • the sample is isolated from the donor at from about 3 hours to about 5 hours following administration of the CXCR2 agonist and CXCR4 antagonist (e.g ., at about 3 hours, 3.1 hours, 3.2 hours, 3.3 hours, 3.4 hours, 3.5 hours, 3.6 hours, 3.7 hours, 3.8 hours, 3.9 hours, 4.0 hours, 4.1 hours,
  • the sample is isolated from the donor at about 4 hours following administration of the CXCR2 agonist and CXCR4 antagonist.
  • the CXCR2 agonist is Gro-b T or a variant thereof.
  • the CXCR2 agonist may be a peptide having at least about 85% (e.g., at least about 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity to the amino acid sequence of SEQ ID NO: 2.
  • the CXCR2 agonist is a peptide having from about 85% to 100% sequence identity to the amino acid sequence of SEQ ID NO: 2, such as a peptide having from about 86% to about 100%, from about 87% to about 99%, about 88% to about 98%, about 89%, to about 97%, about 90% to about 96%, or about 91% to about 95% sequence identity to the amino acid sequence of SEQ ID NO: 2.
  • the CXCR2 agonist is a peptide having an amino acid sequence that differs from that of SEQ ID NO: 2 only by way of one or more conservative amino acid substitutions (e.g ., only by way of from 1 to 10 conservative amino acid substitutions, from 1 to 5 conservative amino acid substitutions, or from 1 to 3 conservative amino acid substitutions, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative amino acid substitutions).
  • the CXCR2 agonist is Gro-b T.
  • the Gro-b T is not covalently modified.
  • the Gro-b T is not covalently modified with a polyalkylene glycol moiety, such as a polyethylene glycol moiety.
  • the CXCR2 agonist is Gro-b or a variant thereof.
  • the CXCR2 agonist may be a peptide having at least about 85% (e.g., about 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity to the amino acid sequence of SEQ ID NO: 1.
  • the CXCR2 agonist is a peptide having from about 85% to 100% sequence identity to the amino acid sequence of SEQ ID NO: 1, such as a peptide having from about 86% to about 100%, from about 87% to about 99%, about 88% to about 98%, about 89%, to about 97%, about 90% to about 96%, or about 91% to about 95% sequence identity to the amino acid sequence of SEQ ID NO: 1.
  • the CXCR2 agonist is a peptide having an amino acid sequence that differs from that of SEQ ID NO: 1 only by way of one or more conservative amino acid substitutions (e.g, only by way of from 1 to 10 conservative amino acid substitutions, from 1 to 5 conservative amino acid substitutions, or from 1 to 3 conservative amino acid substitutions, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative amino acid substitutions).
  • the CXCR2 agonist is Gro-b.
  • the Gro-b T is not covalently modified.
  • the Gro-b is not covalently modified with a polyalkylene glycol moiety, such as a polyethylene glycol moiety.
  • the CXCR2 agonist e.g, Gro-b or Gro-b T, such as unmodified Gro-b or Gro-b T
  • the CXCR2 agonist is administered to the donor at a dose of from about 50 pg/kg to about 1 mg/kg, such as a dose of about 50 pg/kg, 55 pg/kg, 60 pg/kg, 65 pg/kg, 70 pg/kg, 75 pg/kg, 80 pg/kg, 85 pg/kg, 90 pg/kg, 95 pg/kg, 100 pg/kg, 105 pg/kg, 1 10 pg/kg, 115 gg/kg, 120 pg/kg, 125 pg/kg, 130 pg/kg, 135 pg/kg, 140 pg/kg, 145 pg/kg, 150 pg/kg, 155 gg/kg, 160 pg/kg, 165 pg/kg, 170 pg
  • the CXCR2 agonist e.g, Gro-b or Gro-b T, such as unmodified Gro-b or Gro-b T
  • the CXCR2 agonist is administered to the donor at a dose of from about 50 gg/kg to about 300 gg/kg, such as a dose of from about 100 gg/kg to about 250 gg/kg, or from about 125 gg/kg to about 225 gg/kg.
  • the CXCR2 agonist e.g, Gro-b or Gro-b T, such as unmodified Gro-b or Gro-b T
  • the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g, a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof at a dose of from about 50 pg/kg to about 1 mg/kg (e.g., a dose of 50 pg/kg, 55 pg/kg, 60 pg/kg, 65 pg/kg, 70 pg/kg, 75 pg/kg, 80 pg/kg, 85 pg/kg, 90 pg/kg, 95 pg/kg, 100 pg/kg, 105 pg/kg, 110 pg/kg,
  • a mammalian donor e.g, a human donor
  • a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants
  • the CXCR2 agonist e.g ., Gro-b or Gro-b T, such as unmodified Gro-b or Gro-b T
  • the CXCR2 agonist is administered to the donor at a dose of from about 50 pg/kg to about 300 pg/kg, such as a dose of about 50 pg/kg, 55 pg/kg, 60 pg/kg, 65 pg/kg, 70 pg/kg, 75 pg/kg, 80 pg/kg, 85 pg/kg, 90 pg/kg, 95 pg/kg, 100 pg/kg, 105 pg/kg, 110 pg/kg, 115 pg/kg, 120 pg/kg, 125 pg/kg, 130 pg/kg, 135 pg/kg,
  • the CXCR2 agonist e.g ., Gro-b or Gro-b T, such as unmodified Gro-b or Gro-b T
  • the CXCR2 agonist is administered to the donor at a dose of from about 100 pg/kg to about 250 pg/kg, such as a dose of about 100 gg/kg, 105 pg/kg, 110 pg/kg, 115 pg/kg, 120 pg/kg, 125 pg/kg, 130 pg/kg, 135 pg/kg, 140 gg/kg, 145 pg/kg, 150 pg/kg, 155 pg/kg, 160 pg/kg, 165 pg/kg, 170 pg/kg, 175 pg/kg, 180 gg/kg, 185 pg/kg, 190 pg/kg, 195 gg/kg, 200 gg/kg, 205 gg/kg, 210 gg
  • the CXCR2 agonist e.g., Gro-b or Gro-b T, such as unmodified Gro-b or Gro-b T
  • the CXCR2 agonist is administered to the donor at a dose of about 150 pg/kg.
  • the CXCR2 agonist e.g, Gro-b or Gro-b T, such as unmodified Gro-b or Gro-b T
  • the CXCR2 agonist is administered to the donor at a dose of from about 50 pg/kg per day to about 1 mg/kg per day, such as a dose of about 50 pg/kg per day, 55 pg/kg per day, 60 pg/kg per day, 65 pg/kg per day, 70 pg/kg per day, 75 pg/kg per day, 80 pg/kg per day, 85 pg/kg per day, 90 pg/kg per day, 95 pg/kg per day, 100 pg/kg per day, 105 pg/kg per day, 110 pg/kg per day, 115 pg/kg per day, 120 pg/kg per day, 125 pg/kg per day, 130 pg/kg per day, 135 pg/kg per day, 140 pg/kg per day,
  • the CXCR2 agonist e.g ., Gro-b or Gro-b T, such as unmodified Gro-b or Gro- b T
  • the CXCR2 agonist is administered to the donor at a dose of from about 50 pg/kg per day to about 300 pg/kg per day, such as a dose of from about 100 pg/kg per day to about 250 pg/kg per day, or from about 125 pg/kg per day to about 225 pg/kg per day, or from about 125 pg/kg per day to about 175 pg/kg per day.
  • the CXCR2 agonist e.g., Gro-b or Gro-b T, such as unmodified Gro-b or Gro-b T
  • the CXCR2 agonist is administered to the donor at a dose of about 150 pg/kg per day.
  • the CXCR2 agonist may be administered as a single dose. In other embodiments, the CXCR2 agonist may be administered as two or more doses.
  • a human equivalent dose may be derived from animal dosage data using a conversion factor.
  • HED human equivalent dose
  • Nair and Jacob, ./. Basic Clin. Pharma. (2016) 7:27-31 disclose methods extrapolation of dose between species.
  • HED may be derived from rhesus monkey dose by multiplying the rhesus monkey dose by about 0.324.
  • the CXCR2 agonist e.g ., Gro-b or Gro-b T, such as unmodified Gro-b or Gro-b T
  • the CXCR2 agonist is administered intravenously to the donor.
  • the CXCR4 antagonist is a compound represented by formula (I)
  • A includes a monocyclic or bicyclic fused ring system including at least one nitrogen atom and B is H or a substituent of from 1 to 20 atoms;
  • A’ includes a monocyclic or bicyclic fused ring system including at least one nitrogen atom and B’ is H or a substituent of from 1 to 20 atoms; or
  • each R is independently H or Ci-C 6 alkyl, n is 1 or 2, and X is an aryl or heteroaryl group or a mercaptan;
  • linker is a bond, optionally substituted Ci-C 6 alkyl ene, optionally substituted Ci-C 6 heteroalkylene, optionally substituted C 2 -C 6 alkenylene, optionally substituted C 2 -C 6 heteroalkenylene, optionally substituted C 2 -C 6 alkynylene, optionally substituted C 2 -C 6 heteroalkynylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, or optionally substituted heteroaryl ene.
  • Z and Z’ are each independently a cyclic polyamine containing from 9 to 32 ring members, of which from 2 to 8 are nitrogen atoms separated from one another by 2 or more carbon atoms. Z and Z’ may be identical substituents. In some embodiments, Z and/or Z’ is a cyclic polyamine including from 10 to 24 ring members, such as a cyclic polyamine including 14 ring members. In some embodiments, Z includes 4 nitrogen atoms. Z and/or Z’ may be, for example, 1,4,8, 1 l-tetraazocy cl otetradecane.
  • the linker is represented by formula (ID)
  • ring D is an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted cycloalkyl group, or an optionally substituted heterocycloalkyl group;
  • X and Y are each independently optionally substituted Ci-C 6 alkylene, optionally substituted Ci-C 6 heteroalkylene, optionally substituted C 2 -C 6 alkenylene, optionally substituted C 2 -C 6 heteroalkenylene, optionally substituted C 2 -C 6 alkynylene, or optionally substituted C 2 -C 6 heteroalkynylene.
  • the linker is represented by formula (IE)
  • ring D is an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted cycloalkyl group, or an optionally substituted heterocycloalkyl group;
  • X and Y are each independently optionally substituted Ci-C 6 alkylene, optionally substituted Ci-C 6 heteroalkylene, optionally substituted C 2 -C 6 alkenylene, optionally substituted C 2 -C 6 heteroalkenylene, optionally substituted C 2 -C 6 alkynylene, or optionally substituted C 2 -C 6 heteroalkynylene.
  • X and Y are each independently optionally substituted Ci-C 6 alkylene.
  • X and Y are identical substituents, such as identical alkylene substituents (e.g ., methylene, ethylene, propylene, or butylene substituents).
  • the CXCR4 antagonist is plerixafor or a pharmaceutically acceptable salt thereof. In some embodiments, the CXCR4 antagonist (e.g., plerixafor or a pharmaceutically acceptable salt thereof) is administered subcutaneously to the donor.
  • the CXCR4 antagonist (e.g, plerixafor or a pharmaceutically acceptable salt thereof) is administered to the donor at a dose of from about 50 gg/kg to about 500 m /1 ⁇ , such as a dose of about 50 mm/1 ⁇ m, 55 mm/1 ⁇ m, 60 mm/1 ⁇ m, 65 mm/1 ⁇ m, 70 mm/1 ⁇ m, 75 mm/1 ⁇ m, 80 gg/kg, 85 mm/kg, 90 mm/kg, 95 gg/kg, 100 gg/kg, 105 gg/kg, 1 10 gg/kg, 1 15 gg/kg, 120 gg/kg, 125 gg/kg, 130 gg/kg, 135 gg/kg, 140 gg/kg, 145 gg/kg, 150 gg/kg, 155 gg/kg, 160 gg/kg, 165 gg/kg, 170 gg/kg, 175 gg/kg, 180 gg/kg, 185 gg/kg, 190 gg/kg, 100 gg
  • the CXCR4 antagonist e.g ., plerixafor or a pharmaceutically acceptable salt thereof
  • the CXCR4 antagonist is administered to the donor at a dose of from about 200 gg/kg to about 300 gg/kg, such as a dose of about 240 hg/kg.
  • the CXCR4 antagonist (e.g., plerixafor or a pharmaceutically acceptable salt thereof) is administered to the donor at a dose of from about 50 gg/kg per day to about 500 gg/kg per day, such as a dose of about 50 gg/kg per day, 55 gg/kg per day, 60 gg/kg per day, 65 gg/kg per day, 70 gg/kg per day, 75 gg/kg per day, 80 gg/kg per day, 85 gg/kg per day, 90 gg/kg per day, 95 gg/kg per day, 100 gg/kg per day, 105 gg/kg per day, 110 gg/kg per day, 115 gg/kg per day, 120 gg/kg per day, 125 gg/kg per day, 130 gg/kg per day, 135 gg/kg per day, 140 gg/kg per day, 145 gg/kg per day, 150 gg/kg per day, 155 gg/kg per day,
  • the CXCR4 antagonist (e.g, plerixafor or a pharmaceutically acceptable salt thereof) is administered to the donor at a dose of from about 200 gg/kg per day to about 300 gg/kg per day, such as a dose of about 240 gg/kg per day.
  • the CXCR4 antagonist may be administered as a single dose. In other embodiments, the CXCR4 antagonist may be administered as two or more doses.
  • the CXCR2 agonist and the CXCR4 antagonist are administered to the donor concurrently.
  • the CXCR4 antagonist is administered to the donor prior to administration of the CXCR2 agonist.
  • the CXCR4 antagonist may be administered to the donor from about 1 minute to about 180 minutes prior to administration of the CXCR2 agonist, such as from about 15 minutes to about 180 minutes, about 30 minutes to about 180 minutes, about 40 minutes to about 160 minutes, about 50 minutes to about 150 minutes, about 60 minutes to about 140 minutes, about 70 minutes to about 130 minutes, about 60 minutes to about 120 minutes, about 70 minutes to about 110 minutes, or about 80 minutes to about 100 minutes ( e.g ., about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 75 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 105 minutes, about 110 minutes, about 115 minutes, about 120 minutes, about 125 minutes, about 130 minutes, about 135 minutes, about 140 minutes, about 145 minutes, about 150 minutes, about 155 minutes, about 160 minutes, about 165 minutes, about 170 minutes, about 175 minutes, or about 180 minutes prior to
  • the CXCR4 antagonist is administered to the donor from about 30 minutes to about 60 minutes prior to administration of the CXCR2 agonist (e.g., about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, or about 60 minutes prior to administration of the CXCR2 agonist). In some embodiments, the CXCR4 antagonist may be administered to the donor about 45 minutes prior to administration of the CXCR2 agonist.
  • the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor (e.g, a human donor), wherein the ratio of CD34 + cells to leukocytes in the population is from about 0.0008 to about 0.0021.
  • the ratio of CD34 + cells to leukocytes may be about 0.00080, 0.00081, 0.00082, 0.00083, 0.00084, 0.00085, 0.00086, 0.00087, 0.00088, 0.00089, 0.00090, 0.00091, 0.00092, 0.00093, 0.00094, 0.00095, 0.00096,
  • the ratio of CD34 + cells to leukocytes is from about 0.0010 to about 0.0018, such as a ratio of CD34 + cells to leukocytes of about 0.00100, 0.00101, 0.00102, 0.00103, 0.00104, 0.00105, 0.00106, 0.00107, 0.00108, 0.00109, 0.00110, 0.00111, 0.00112, 0.00113,
  • the ratio of CD34 + cells to leukocytes is about 0.0014.
  • the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor (e.g ., a human donor), wherein the ratio of CD34 + cells to neutrophils in the population is from about 0.0018 to about 0.0058.
  • the ratio of CD34 + cells to neutrophils may be about 0.00180, 0.00181, 0.00182, 0.00183, 0.00184, 0.00185, 0.00186, 0.00187, 0.00188, 0.00189, 0.00190, 0.00191, 0.00192, 0.00193, 0.00194, 0.00195, 0.00196,
  • the ratio of CD34 cells to neutrophils is from about 0.0026 to about 0.0046, such as a ratio of CD34 + cells to neutrophils of about 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266, 0.00267, 0.00268, 0.00269, 0.00270, 0.00271, 0.00272, 0.00273, 0.00274, 0.00275, 0.00276, 0.00277, 0.00278, 0.00279, 0.00280, 0.00281, 0.00282, 0.00283, 0.00284, 0.00285, 0.00286, 0.00287, 0.00288, 0.00289, 0.00290, 0.00291, 0.00292 0.00293, 0.00294, 0.00295, 0.00296, 0.00297, 0.00298, 0.00299, 0.00300, 0.00300, 0.00301 0.00302, 0.00303, 0.00304, 0.00305, 0.00306, 0.00307, 0.00308, 0.00309
  • the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor (e.g, a human donor), wherein the ratio of CD34 + cells to lymphocytes in the population is from about 0.0021 to about 0.0094. In some embodiments, the ratio of CD34 + cells to lymphocytes may be about 0.00210, 0.00211, 0.00212, 0.00213, 0.00214, 0.00215, 0.00216,
  • the ratio of CD34 cells to lymphocytes is from about 0.0025 to about 0.0035, such as a ratio of CD34 + cells to lymphocytes of about 0.00250, 0.00251, 0.00252, 0.00253, 0.00254, 0.00255, 0.00256, 0.00257, 0.00258, 0.00259, 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266, 0.00267, 0.00268, 0.00269, 0.00270, 0.00271, 0.00272, 0.00273, 0.00274, 0.00275, 0.00276, 0.00277, 0.00278, 0.00279, 0.00280, 0.00281, 0.00282, 0.00283, 0.00284, 0.00285, 0.00286, 0.00287, 0.00288, 0.00289, 0.00290, 0.00291, 0.00292, 0.00293, 0.00294, 0.00295, 0.00296, 0.00297, 0.00298, 0.00299, 0.00290, 0.00
  • the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor e.g ., a human donor), wherein the ratio of CD34 + cells to monocytes in the population is from about 0.0071 to about 0.0174.
  • the ratio of CD34 + cells to monocytes may be about 0.00710, 0.00711, 0.00712, 0.00713, 0.00714, 0.00715, 0.00716,
  • the ratio of CD34 + cells to monocytes is from about 0.0100 to about 0.0140, such as a ratio of CD34 + cells to monocytes of about 0.0100, 0.0101, 0.0103, 0.0104, 0.0105, 0.0106, 0.0107, 0.0108, 0.0109, 0.0110, 0.0111, 0.0112, 0.0113, 0.0114, 0.0115,
  • the ratio of CD34 + cells to monocytes is about 0.0118.
  • the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor e.g ., a human donor), wherein the frequency of CD34 + cells in the population is from about 0.051% to about 0.140%.
  • the population of cells may have a frequency of CD34 + cells of about 0.051%, 0.052%, 0.053%, 0.054%, 0.055%, 0.056%, 0.057%, 0.058%, 0.059%, 0.060%, 0.061%, 0.062%, 0.063%, 0.064%, 0.065%, 0.066%,
  • the population of cells has a frequency of CD34 + cells of from about 0.080% to about 0.120%, such as a frequency of CD34 + cells of about 0.080%, 0.081%, 0.082%, 0.083%, 0.084%, 0.085%, 0.086%, 0.087%, 0.088%, 0.089%, 0.090%, 0.091%, 0.092%, 0.093%, 0.094%, 0.095%, 0.096%, 0.097%, 0.098%, 0.099%, 0.100%, 0.101%, 0.102%, 0.103%, 0.104%, 0.105%, 0.106%, 0.107%, 0.108%, 0.109%, 0.110%, 0.111%, 0.112%, 0.113%, 0.114%, 0.115%, 0.116%, 0.117%,
  • the population of cells has a frequency of CD34 + cells of about 0.097%.
  • the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor e.g ., a human donor), wherein the ratio of CD34 + CD90 + CD45RA cells to leukocytes in the population is from about 0.0003 to about 0.0016.
  • the ratio of CD34 + CD90 + CD45RA cells to leukocytes may be about 0.00030, 0.00031, 0.00032, 0.00033, 0.00034, 0.00035, 0.00036, 0.00037, 0.00038, 0.00039, 0.00040, 0.00041, 0.00042, 0.00043,
  • the ratio of CD34 + CD90 + CD45RA cells to leukocytes is from about 0.0006 to about 0.0012, such as a ratio of CD34 + CD90 + CD45RA cells to leukocytes of about 0.00060, 0.00061, 0.00062, 0.00063, 0.00064, 0.00065, 0.00066, 0.00067, 0.00068, 0.00069, 0.00070,
  • the ratio of CD34 + CD90 + CD45RA cells to leukocytes is about 0.0009.
  • the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor (e.g ., a human donor), wherein the ratio of CD34 + CD90 + CD45RA cells to neutrophils in the population is from about 0.0007 to about 0.0043. In some embodiments, the ratio of CD34 CD90 + CD45RA cells to neutrophils may be about 0.00070, 0.00071,
  • the ratio of CD34 + CD90 + CD45RA cells to neutrophils is from about 0.0014 to about 0.0034, such as a ratio of CD34 + CD90 + CD45RA cells to neutrophils of about 0.00140, 0.00141, 0.00142, 0.00143, 0.00144, 0.00145, 0.00146,
  • the ratio of CD34 + CD90 + CD45RA cells to neutrophils is about 0.0024.
  • the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor (e.g, a human donor), wherein the ratio of CD34 + CD90 + CD45RA cells to lymphocytes in the population is from about 0.0008 to about 0.0069. In some embodiments, the ratio of CD34 + CD90 + CD45RA cells to lymphocytes may be about 0.00080, 0.00081, 0.00082,
  • the ratio of CD34 + CD90 + CD45RA cells to lymphocytes is from about 0.0011 to about 0.0031, such as a ratio of CD34 + CD90 + CD45RA cells to lymphocytes of about 0.00110, 0.00111, 0.00112, 0.00113, 0.00114, 0.00115, 0.00116, 0.00117, 0.00118, 0.00119, 0.00120, 0.00121, 0.00122, 0.00123, 0.00124, 0.00125, 0.00126,
  • the ratio of CD34 + CD90 + CD45RA - cells to lymphocytes is about 0.0021.
  • the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor e.g ., a human donor), wherein the ratio of CD34 + CD90 + CD45RA cells to monocytes in the population is from about 0.0028 to about 0.0130. In some embodiments, the ratio of CD34 +
  • CD90 + CD45RA cells to monocytes may be about 0.00280, 0.00281, 0.00282, 0.00283,
  • the ratio of CD34 + CD90 + CD45RA cells to monocytes is from about 0.0063 to about 0.0083, such as a ratio of CD34 + CD90 + CD45RA cells to monocytes of about
  • the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor e.g ., a human donor), wherein the ratio of CD34 + CD90 + CD45RA cells to CD34 + cells in the population is from about 0.393 to about 0.745. In some embodiments, the ratio of CD34 +
  • CD90 + CD45RA cells to CD34 + cells may be about 0.393, 0.394, 0.395, 0.396, 0.397, 0.398,
  • the ratio of CD34 + CD90 + CD45RA cells to CD34 + cells is from about 0.625 to about 0.725, such as a ratio of CD34 + CD90 + CD45RA cells to CD34 + cells of about 0.625, 0.626, 0.627, 0.628, 0.629, 0.630, 0.631, 0.632, 0.633, 0.634, 0.635, 0.636, 0.637, 0.638, 0.639, 0.640, 0.641, 0.642, 0.643,
  • the ratio of CD34 + CD90 + CD45RA cells to CD34 + cells is about 0.676.
  • the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor e.g ., a human donor), wherein the frequency of CD34 + CD90 + CD45RA cells in the population is from about 0.020% to about 0.110%.
  • the population of cells may have a frequency of CD34 + CD90 + CD45RA cells of about 0.020%, 0.021%, 0.022%, 0.023%, 0.024%, 0.025%, 0.026%, 0.027%, 0.028%, 0.029%, 0.030%, 0.031%, 0.032%, 0.033%, 0.034%, 0.035%, 0.036%, 0.037%, 0.038%, 0.039%, 0.040%, 0.041%, 0.042%, 0.043%, 0.044%, 0.045%, 0.046%, 0.047%, 0.048%, 0.049%, 0.050%, 0.051%, 0.052%, 0.053%, 0.054%, 0.055%, 0.056%, 0.057%, 0.058%, 0.059%, 0.060%, 0.061%, 0.062%, 0.063%, 0.064%, 0.065%, 0.066%, 0.067%, 0.068%, 0.069%, 0.070%, 0.071%, 0.072%, 0.073%, 0.074%, 0.075%, 0.076%,
  • the population of cells has a frequency of CD34 + CD90 + CD45RA - cells of from about 0.046% to about 0.086%, such as a frequency of hematopoietic stem cells of about 0.046%, 0.047%, 0.048%, 0.049%, 0.050%, 0.051%, 0.052%, 0.053%, 0.054%, 0.055%, 0.056%, 0.057%, 0.058%, 0.059%, 0.060%, 0.061%, 0.062%, 0.063%, 0.064%, 0.065%, 0.066%, 0.067%, 0.068%, 0.069%, 0.070%, 0.071%, 0.072%, 0.073%, 0.074%, 0.075%, 0.076%, 0.077%, 0.078%, 0.079%, 0.080%, 0.081%, 0.082%, 0.083%, 0.084%, 0.085%, or 0.086%.
  • the population of cells has a frequency of CD34 + CD90 + CD45RA cells of about 0.066%.
  • the invention features a method of treating a stem cell disorder in a mammalian patient (e.g ., a human patient), the method including mobilizing a population of hematopoietic stem cells in a mammalian donor (e.g., a human donor) in accordance with any of the above-described methods, and infusing a therapeutically effective amount of the hematopoietic stem cells, or progeny thereof, into the patient.
  • a mammalian donor e.g., a human donor
  • the invention features a method of treating a stem cell disorder in a mammalian patient (e.g, a human patient), the method including infusing into the patient a therapeutically effective amount of the hematopoietic stem cells mobilized by any of the above-described methods, or progeny thereof.
  • the invention features a method of treating a stem cell disorder in a mammalian patient (e.g, a human patient), the method including administering to the patient any one or more of the above-described pharmaceutical compositions.
  • the stem cell disorder is a hemoglobinopathy disorder, such as sickle cell anemia, thalassemia, Fanconi anemia, aplastic anemia, and Wiskott-Aldrich syndrome.
  • the stem cell disorder is a myelodysplastic disorder.
  • the stem cell disorder may be an immunodeficiency disorder, such as a congenital immunodeficiency or an acquired immunodeficiency, for example, human immunodeficiency virus or acquired immune deficiency syndrome.
  • the stem cell disorder is a metabolic disorder, such as a metabolic disorder selected from glycogen storage diseases, mucopolysaccharidoses, Gaucher's Disease, Hurlers Disease, sphingolipidoses, and metachromatic leukodystrophy.
  • a metabolic disorder selected from glycogen storage diseases, mucopolysaccharidoses, Gaucher's Disease, Hurlers Disease, sphingolipidoses, and metachromatic leukodystrophy.
  • the stem cell disorder is cancer.
  • the cancer may be, for example, leukemia, lymphoma, multiple myeloma, and neuroblastoma. In some embodiments, tumor necrosis, tumor necrosis, tumor necrosis, tumor necrosis, tumor necrosis, and tumor necrosis.
  • the cancer is a hematological cancer.
  • the cancer is acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia, multiple myeloma, diffuse large B-cell lymphoma, or non-Hodgkin’s lymphoma.
  • the stem cell disorder is a disorder selected from the group consisting of adenosine deaminase deficiency and severe combined immunodeficiency, hyper immunoglobulin M syndrome, Chediak-Higashi disease, hereditary lymphohistiocytosis, osteopetrosis, osteogenesis imperfecta, storage diseases, thalassemia major, systemic sclerosis, systemic lupus erythematosus, multiple sclerosis, and juvenile rheumatoid arthritis.
  • the stem cell disorder is an autoimmune disorder, such as an autoimmune disorder selected from multiple sclerosis, human systemic lupus, rheumatoid arthritis, inflammatory bowel disease, treating psoriasis, Type 1 diabetes mellitus, acute disseminated encephalomyelitis, Addison's disease, alopecia universalis, ankylosing spondylitis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune
  • an autoimmune disorder selected from multiple sclerosis, human systemic lupus, rheumatoid arthritis, inflammatory bowel disease, treating psoriasis, Type 1 diabetes mellitus, acute disseminated encephalomyelitis, Addison's disease, alopecia universalis, ankylosing spondylitis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hemolytic anemia, autoimmune hepati
  • lymphoproliferative syndrome autoimmune oophoritis, Balo disease, Behcet's disease, bullous pemphigoid, cardiomyopathy, Chagas' disease, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Crohn's disease, cicatricial pemphigoid, coeliac sprue-dermatitis herpetiformis, cold agglutinin disease, CREST syndrome, Degos disease, discoid lupus, dysautonomia, endometriosis, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, Goodpasture' s syndrome, Grave's disease, Guillain-Barre syndrome, Hashimoto' s thyroiditis, Hidradenitis suppurativa, idiopathic and/or acute thrombocytopenic purpura, idiopathic pulmonary fibrosis, IgA neuropathy, interstitial cystitis, juvenile arthritis
  • the hematopoietic stem cells are autologous with respect to the patient. In some embodiments, the hematopoietic stem cells are allogeneic with respect to the patient, and may be, for example, HLA-matched with respect to the patient.
  • the hematopoietic stem cells have been genetically modified to disrupt an endogenous gene, such as a gene encoding a major histocompatibility complex protein.
  • the hematopoietic stem cells may be genetically modified to disrupt an endogenous by way of, for example, a CRISPR-associated protein, such as caspase 9, or another nuclease described herein, such as a transcription activator-like effector nuclease, a meganuclease, or a zinc finger nuclease.
  • the hematopoietic stem cells, or progeny thereof maintain hematopoietic stem cell functional potential after two or more days following infusion of the hematopoietic stem cells, or progeny thereof, into the patient.
  • the hematopoietic stem cells, or progeny thereof localize to hematopoietic tissue and/or reestablish hematopoiesis following infusion of the hematopoietic stem cells, or progeny thereof, into the patient.
  • the hematopoietic stem cells, or progeny thereof upon infusion into the patient, give rise to recovery of a population of cells selected from the group consisting of megakaryocytes, thrombocytes, platelets, erythrocytes, mast cells, myeoblasts, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, osteoclasts, antigen-presenting cells.
  • the disclosure relates to a method of mobilizing CD34 dim cells from the bone marrow of a human donor into peripheral blood, the method comprising
  • a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof at a dose of from about 50 pg/kg to about 1,000 pg/kg and (ii) a CXCR4 antagonist.
  • the disclosure relates to a method of performing an allogeneic hematopoietic stem cell transplant in a patient in need thereof, the method comprising infusing into the patient a therapeutically effective amount of allogeneic hematopoietic stem cells, wherein the hematopoietic stem cells were mobilized from bone marrow of a human donor into peripheral blood of the human donor by a method comprising administering to the donor (i) a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof at a dose of from about 50 pg/kg to about 1,000 pg/kg and (ii) a CXCR4 antagonist.
  • the disclosure relates to a method of preventing, reducing the risk of developing, or reducing the severity of a post-transplant infection in a patient in need thereof, the method comprising infusing into the patient a therapeutically effective amount of hematopoietic stem cells, wherein the hematopoietic stem cells were mobilized from bone marrow of a human donor into peripheral blood of the human donor by a method comprising administering to the human donor (i) a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof at a dose of from about 50 m /1 ⁇ to about 1,000 mm/1 ⁇ and (ii) a CXCR4 antagonist.
  • the disclosure relates to a method of preventing, reducing the risk of developing, or reducing the severity of graft versus host disease (GVHD) in a patient in need thereof, the method comprising infusing into the patient a therapeutically effective amount of hematopoietic stem cells, wherein the hematopoietic stem cells were mobilized from bone marrow of a human donor into peripheral blood of the human donor by a method comprising administering to the human donor (i) a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof at a dose of from about 50 pg/kg to about 1,000 pg/kg and (ii) a CXCR4 antagonist.
  • a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof
  • the CD34 dim cells are present in a higher amount in the peripheral blood than if the hematopoietic stem cells were mobilized using the CXCR4 antagonist alone. In certain embodiments, the CD34 dim cells are capable of suppressing alloreactive T lymphocyte proliferation when administered to a recipient.
  • the CXCR2 agonist is Gro-b T. In certain embodiments, the CXCR2 agonist is administered to the donor at a dose of from about 100 pg/kg to about 250 pg/kg. In certain embodiments, the CXCR2 agonist is administered to the donor at a dose of from about 125 pg/kg to about 225 pg/kg. In certain embodiments, the CXCR2 agonist is administered to the donor at a dose of about 150 pg/kg. In certain embodiments, the CXCR2 agonist is administered intravenously to the donor.
  • the CXCR4 antagonist is administered subcutaneously to the donor.
  • the CXCR4 antagonist is plerixafor or a pharmaceutically acceptable salt thereof.
  • the plerixafor or pharmaceutically acceptable salt thereof is administered to the donor at a dose of from about 50 pg/kg to about 500 pg/kg.
  • the plerixafor or pharmaceutically acceptable salt thereof is administered to the donor at a dose of from about 200 pg/kg to about 300 pg/kg.
  • the plerixafor or pharmaceutically acceptable salt thereof is
  • the method further includes testing a sample of peripheral blood for the presence of CD34 dim cells and releasing the sample for ex vivo expansion of the CD34 dim cells.
  • the disclosure relates to the population of CD34 dim cells derived from any of the above methods, or a composition comprising the same.
  • FIG. IB provides a graph showing that grafts containing cells mobilized by Gro-b T and plerixaflor led to higher relative numbers of competitive repopulating units (CRU) at week 16 than did grafts containing cells mobilized by G-CSF alone.
  • CRU competitive repopulating units
  • FIG. 2A is a graph demonstrating the pharmacokinetic profile of various dosages of Gro-b T when administered intravenously to Rhesus monkeys.
  • FIG. 2B is a graph demonstrating the pharmacokinetic profile of various dosages of Gro-b T when administered subcutaneously to Rhesus monkeys. In all experiments, Gro-b T was administered to subjects concurrently with plerixafor.
  • FIG. 3A shows a series of graphs demonstrating the mobilization response of leukocytes (white blood cells,“WBCs”) to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys.
  • Leukocyte response is shown both in terms of the quantity of cells mobilized (top) and the fold change in leukocyte density relative to baseline leukocyte density prior to administration (bottom).
  • FIG. 3B shows a series of graphs demonstrating the mobilization response of leukocytes (white blood cells,“WBCs”) to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys.
  • Leukocyte response is shown both in terms of the quantity of cells mobilized (top) and the fold change in leukocyte density relative to baseline leukocyte density prior to administration (bottom).
  • Gro-b T was administered to subjects concurrently with plerixafor.
  • FIG. 4A shows a series of graphs demonstrating the mobilization response of neutrophils to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys. Neutrophil response is shown both in terms of the quantity of cells mobilized (top) and the fold change in neutrophil density relative to baseline neutrophil density prior to administration (bottom).
  • FIG. 4B shows a series of graphs demonstrating the mobilization response of neutrophils to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys. Neutrophil response is shown both in terms of the quantity of cells mobilized (top) and the fold change in neutrophil density relative to baseline neutrophil density prior to administration (bottom). In all experiments, Gro-b T was administered to subjects concurrently with plerixafor.
  • FIG. 5A shows a series of graphs demonstrating the mobilization response of lymphocytes to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys. Lymphocyte response is shown both in terms of the quantity of cells mobilized (top) and the fold change in lymphocyte density relative to baseline lymphocyte density prior to administration (bottom).
  • FIG. 5B shows a series of graphs demonstrating the mobilization response of lymphocytes to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys. Lymphocyte response is shown both in terms of the quantity of cells mobilized (top) and the fold change in lymphocyte density relative to baseline lymphocyte density prior to administration (bottom). In all experiments, Gro-b T was administered to subjects concurrently with plerixafor.
  • FIG. 6A shows a series of graphs demonstrating the mobilization response of monocytes to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys. Monocyte response is shown both in terms of the quantity of cells mobilized (top) and the fold change in monocyte density relative to baseline monocyte density prior to administration (bottom).
  • FIG. 6B shows a series of graphs demonstrating the mobilization response of monocytes to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys. Monocyte response is shown both in terms of the quantity of cells mobilized (top) and the fold change in monocyte density relative to baseline monocyte density prior to administration (bottom). In all experiments, Gro-b T was administered to subjects concurrently with plerixafor.
  • FIG. 7A shows a series of graphs demonstrating the mobilization response of CD34 + cells to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys.
  • CD34 + cell response is shown both in terms of the frequency of CD34 + cells in the sample obtained from peripheral blood of the subjects (top) and the fold change in CD34 + cell frequency relative to baseline CD34 + cell frequency prior to administration (bottom).
  • FIG. 7B shows a series of graphs demonstrating the mobilization response of CD34 + cells to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys.
  • CD34 + cell response is shown both in terms of the frequency of CD34 + cells in the sample obtained from peripheral blood of the subjects (top) and the fold change in CD34 + cell frequency relative to baseline CD34 + cell frequency prior to administration (bottom).
  • FIG. 8A shows a series of graphs demonstrating the mobilization response of CD34 + cells to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys.
  • CD34 + cell response is shown both in terms of the quantity of cells mobilized (top) and the fold change in CD34 + cell density relative to baseline CD34 + cell density prior to
  • FIG. 8B shows a series of graphs demonstrating the mobilization response of CD34 + cells to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys.
  • CD34 + cell response is shown both in terms of the quantity of cells mobilized (top) and the fold change in CD34 + cell density relative to baseline CD34 + cell density prior to administration (bottom).
  • Gro-b T was administered to subjects concurrently with plerixafor.
  • FIG. 9A shows a series of graphs demonstrating the mobilization response of hematopoietic stem cells (CD34 + CD90 + CD45RA cells) to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys.
  • CD34 + CD90 + CD45RA cell response is shown both in terms of the frequency of CD34 + CD90 + CD45RA cells in the sample obtained from peripheral blood of the subjects (top) and the fold change in CD34 + CD90 + CD45RA cell frequency relative to baseline CD34 + CD90 + CD45RA cell frequency prior to administration (bottom).
  • FIG. 9A shows a series of graphs demonstrating the mobilization response of hematopoietic stem cells (CD34 + CD90 + CD45RA cells) to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys.
  • CD34 + CD90 + CD45RA cell response is shown both in terms of the frequency of CD34 + CD90 + CD45RA cells in the sample obtained from peripheral blood of the subjects (top) and the fold change
  • CD34 + CD90 + CD45RA cells hematopoietic stem cells
  • FIG. 9B shows a series of graphs demonstrating the mobilization response of hematopoietic stem cells (CD34 + CD90 + CD45RA cells) to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys.
  • CD34 + CD90 + CD45RA cell response is shown both in terms of the frequency of CD34 + CD90 + CD45RA cells in the sample obtained from peripheral blood of the subjects (top) and the fold change in CD34 + CD90 + CD45RA cell frequency relative to baseline CD34 + CD90 + CD45RA cell frequency prior to administration (bottom).
  • Gro-b T was administered to subjects concurrently with plerixafor.
  • FIG. 10A shows a series of graphs demonstrating the mobilization response of hematopoietic stem cells (CD34 + CD90 + CD45RA cells) to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys.
  • CD34 + CD90 + CD45RA cell response is shown both in terms of the quantity of cells mobilized (top) and the fold change in CD34 + CD90 + CD45RA cell density relative to baseline CD34 + CD90 + CD45RA cell density prior to administration (bottom).
  • FIG. 10B shows a series of graphs demonstrating the mobilization response of hematopoietic stem cells (CD34 + CD90 + CD45RA cells) to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys.
  • CD34 + cell response is shown both in terms of the quantity of cells mobilized (top) and the fold change in CD34 + CD90 + CD45RA cell density relative to baseline CD34 + CD90 + CD45RA cell density prior to administration (bottom).
  • Gro-b T was administered to subjects concurrently with plerixafor.
  • FIG. 11 shows a series of graphs demonstrating the increase in the quantity of colony-forming units (CFU) of hematopoietic stem cells achieved by the intravenous administration of various dosages of Gro-b T to Rhesus monkeys.
  • CFR response is shown both in terms of the concentration of CFUs (top) and the fold change in CFU concentration relative to baseline CFU concentration prior to administration (bottom).
  • Gro-b T was administered to subjects concurrently with plerixafor.
  • FIG. 12A shows a series of graphs demonstrating the response of plasma matrix metalloproteinase 9 (MMP9) to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys. Plasma MMP9 response is shown both in terms of absolute
  • FIG. 12B shows a series of graphs demonstrating the response of plasma MMP9 to various dosages of Gro-b T upon
  • Plasma MMP9 response is shown both in terms of absolute concentration (top) and the fold change in plasma MMP9 concentration relative to baseline MMP9 concentration prior to administration (bottom).
  • Gro-b T was administered to subjects concurrently with plerixafor.
  • FIG. 13A shows a series of graphs demonstrating the response of plasma tissue inhibitor of matrix metalloproteinase 1 (TIMP-l) to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys.
  • Plasma TIMP-l response is shown both in terms of absolute concentration (top) and the fold change in plasma TIMP-l concentration relative to baseline TIMP-l concentration prior to administration (bottom).
  • FIG. 13B shows a series of graphs demonstrating the response of plasma TIMP-l to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys.
  • Plasma TIMP-l response is shown both in terms of absolute concentration (top) and the fold change in plasma TIMP-l concentration relative to baseline TIMP-l concentration prior to administration (bottom).
  • Gro-b T was administered to subjects concurrently with plerixafor.
  • FIG. 14A is a graph showing the response of the molar ratio of plasma MMP9 to plasma TIMP-l to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys.
  • FIG. 14B is a graph showing the response of the molar ratio of plasma MMP9 to plasma TIMP-l to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys.
  • Gro-b T was administered to subjects concurrently with plerixafor.
  • FIG. 15 provides representative flow plots from blood samples taken four hours post mobilization from Rhesus monkeys. Intravenous administration of 450 pg/kg Gro-b T and subcutaneous administration of 1 mg/kg plerixafor (AMD3100) leads to the mobilization of a population of CD34 dim cells.
  • AMD3100 1 mg/kg plerixafor
  • FIG. 16 provides representative flow plots from blood samples taken at baseline versus four hours post-mobilization from Rhesus monkeys. Mobilization was induced by (1) intravenous administration of 450 pg/kg Gro-b T and subcutaneous administration of 1 mg/kg plerixafor (AMD3100) or (2) subcutaneous administration of 1 mg/kg plerixafor (AMD3100). The combination of Gro-b T and plerixafor (as compared to plerixafor alone) leads to enhanced mobilization of O ⁇ 34 ⁇ 111 cells.
  • FIG. 17 is a graph quantifying the concentration of CD34 dim cells in peripheral blood from untreated Rhesus monkeys (“Unmobilized”), Rhesus monkeys that have been treated with intravenous administration of 450 pg/kg Gro-b T and subcutaneous administration of 1 mg/kg plerixafor (“Gro-b T + plerixafor”), Rhesus monkeys that have been treated with subcutaneous administration of 1 mg/kg plerixafor (“plerixafor”) and Rhesus monkeys that have been treated with subcutaneous administration of 50 pg/kg (q.d. x 5) G-CSF (“G-CSF”).
  • CD34 dim cells were present at a significantly higher concentration in blood mobilized using Gro-b T plus plerixafor.
  • FIG. 18 is a graph depicting the composition of unmobilized cells and grafts mobilized by G-CSF, Gro-b T and AMD3100 and AMD3100 alone. As shown, grafts mobilized using Gro-b T and AMD3100 show a 3 fold increase in CD34 dim cells and a 3 fold increase in T-cells as compared to grafts mobilized using G-CSF.
  • FIG. 19 provides graphs showing that Gro-b T and AMD3100 mobilized CD34 dim cells suppressed T-cell proliferation as measured by carboxyfluorescein succinimidyl ester (CFSE) staining after four days in culture.“Beads” indicates stimulation of T-cells using anti-CD2/CD3/CD28 coated microbeads.
  • CFSE carboxyfluorescein succinimidyl ester
  • FIG. 20 provides a survival curve showing that by day 24, all mice (13/13) transplanted with unmobilized PBMCs had died of aGVHD compared to 5/16 mice transplanted with AMD3100 mobilized peripheral blood, 3/16 mice transplanted with G-CSF mobilized PBMCs and none of the mice transplanted with Gro-b T and AMD3100 mobilized PBMCs.
  • 15/16 mice transplanted with Gro-b T and AMD3100 remained alive, whereas only 10/16 mice transplanted with AMD3100 mobilized PBMCs and 11/16 mice transplanted with G-CSF mobilized PBMCs remained alive.
  • FIG. 21A shows rhesus CD45+CD3+ T-cell numbers in mice at day 14 post- transplant with unmobilized PBMCs, PBMCs mobilized with Gro-b T and plerixafor (i.e., AMD3100), PBMCs mobilized with plerixafor alone, and PBMCs mobilized with G-CSF alone.
  • FIG. 21B shows T-cell numbers in mice at day 14 post-transplant with unmobilized PBMCs, Gro-b T and plerixafor (i.e., AMD3100) mobilized PBMCs, and Gro-b T and plerixafor mobilized PBMCs that have been depleted of CD34dim cells.
  • FIG. 21A shows rhesus CD45+CD3+ T-cell numbers in mice at day 14 post- transplant with unmobilized PBMCs, PBMCs mobilized with Gro-b T and plerixafor (i.e., AMD3100), PBMCs mobilized with plerix
  • 21C provides a survival curve of mice transplanted with unmobilzied PBMCs, Gro-b T and AMD3100 mobilized PBMCs, and Gro-b T and AMD3100 mobilized PBMCs that have been depleted of CD34dim cells.
  • the present invention provides compositions and methods for mobilizing
  • the subject may be a hematopoietic stem and progenitor cell donor (i.e ., a donor), such as a mammalian donor ( e.g ., a human donor).
  • a hematopoietic stem and progenitor cell donor i.e ., a donor
  • a mammalian donor e.g ., a human donor
  • the compositions and methods described herein can additionally be used for the treatment of one or more stem cell disorders in a patient, such as a human patient.
  • a C-X-C chemokine receptor type 2 (CXCR2) agonist such as Gro-b or a variant thereof, such as a truncated form of Gro- b (e.g., Gro-b T), as described herein, optionally in combination with a C-X-C chemokine receptor type 4 (CXCR4) antagonist, such as l,r-[l,4-phenylenebis(methylene)]-bis- 1,4,8, 1 l-tetra-azacyclotetradecane or a variant thereof, may be administered to a donor, as described herein, in amounts sufficient to mobilize hematopoietic stem and progenitor cells.
  • CXCR2 C-X-C chemokine receptor type 2
  • CXCR4 C-X-C chemokine receptor type 4
  • compositions and methods described herein are capable of mobilizing hematopoietic stem and progenitor cells from a stem cell niche within a donor into circulating peripheral blood while reducing the mobilization of other cells of the hematopoietic lineage, such as leukocytes, neutrophils, lymphocytes, and monocytes.
  • the compositions and methods described herein thus enable the selective mobilization of hematopoietic stem and progenitor cells in a donor, which may then be isolated from a donor for therapeutic use.
  • the invention is based, in part, on the discovery that administration of a CXCR2 agonist, such as Gro-b, Gro-b T, or a variant thereof, optionally in combination with a CXCR4 antagonist, such as plerixafor or a pharmaceutically acceptable salt thereof, at particular doses can provide the important clinical benefit of mobilizing populations of cells that are enriched in hematopoietic stem cells relative to other cell types, such as leukocytes, neutrophils, and monocytes. This ability is advantageous, as these other cell types may be undesirable for administration to a human patient undergoing hematopoietic stem cell transplant therapy.
  • the populations of mobilized hematopoietic stem and progenitor cells produced using the compositions and methods described herein are particularly suitable for hematopoietic stem cell transplantation therapy.
  • the hematopoietic stem or progenitor cells may be isolated for ex vivo expansion and/or for therapeutic use.
  • the withdrawn cells may be infused into a patient, such as the donor or another subject (e.g ., a subject that is HLA-matched to the donor) for the treatment of one or more pathologies of the hematopoietic system.
  • the mobilized cells may be withdrawn and then expanded ex vivo , such as by contacting the cells with an aryl hydrocarbon receptor antagonist, so as to produce a population of hematopoietic stem cells having a sufficient quantity of cells for transplantation.
  • hematopoietic stem cells are capable of differentiating into a multitude of cell types in the hematopoietic lineage, and can thus be administered to a patient in order to populate or repopulate a cell type that is defective or deficient in the patient.
  • the patient may be one, for example, that is suffering from one or more blood disorders, such as an autoimmune disease, cancer, hemoglobinopathy, or other hematopoietic pathology, and is therefore in need of hematopoietic stem cell transplantation.
  • the invention thus provides methods of treating a variety of hematopoietic conditions, such as sickle cell anemia, thalassemia, Fanconi anemia, Wiskott-Aldrich syndrome, adenosine deaminase deficiency- severe combined immunodeficiency, metachromatic leukodystrophy, Diamond-Blackfan anemia and Schwachman-Diamond syndrome, human immunodeficiency virus infection, and acquired immune deficiency syndrome, as well as cancers and autoimmune diseases, among others.
  • hematopoietic conditions such as sickle cell anemia, thalassemia, Fanconi anemia, Wiskott-Aldrich syndrome, adenosine deaminase deficiency- severe combined immunodeficiency, metachromatic leukodystrophy, Diamond-Blackfan anemia and Schwachman-Diamond syndrome, human immunodeficiency virus infection, and acquired immune deficiency syndrome, as well as cancers and autoimmune diseases, among others.
  • the sections that follow provide a description of CXCR4 antagonists and CXCR2 agonists that can be administered to a donor so as to induce mobilization of a population of hematopoietic stem or progenitor cells from a stem cell niche into peripheral blood, from which the cells may subsequently be isolated and infused into a patient for the treatment, for example, of one or more stem cell disorders, such as a cancer, autoimmune disease, of metabolic disorder described herein.
  • the following sections additionally describe methods of determining whether populations of cells mobilized with a CXCR2 agonist and/or a CXCR antagonist are suitable for release for ex vivo expansion and/or for therapeutic applications.
  • the term“about” refers to a value that is within 10% above or below the value being described.
  • the term“about 5 nM” indicates a range of from 4.5 nM to 5.5 nM.
  • the terms "acquire” and “acquiring” means obtaining possession of a physical entity, or a value, such as a numerical value, directly acquiring or indirectly acquiring the physical entity or value.
  • Directly acquiring means performing a process (e.g ., performing an assay or test on a sample or analyzing a sample) to obtain the physical entity or value.
  • Indirectly acquiring refers to receiving the physical entity or value from another party or source (e.g., a third party laboratory that directly acquired the physical entity or value).
  • Directly acquiring a physical entity includes performing a process, e.g, analyzing a sample, such as a sample of hematopoietic cells isolated from a donor that has undergone or is undergoing a hematopoietic stem cell mobilization regimen described herein.
  • Directly acquiring a value includes performing a process, such as an assay, on a sample or another substance, e.g, performing an analytical process which includes determining the quantity of hematopoietic stem cells in a sample, the ratio of hematopoietic stem cells to cells of another type within the hematopoietic lineage, or the frequency of hematopoietic stem cells among the total quantity of cells in a sample.
  • affinity refers to the strength of the non-covalent interaction between two or more molecules, such as two or more proteins (e.g ., a
  • Affinity can be expressed quantitatively, for example, as an equilibrium dissociation constant (K d ) or, in cases in which one of the binding partners is an enzyme, as an inhibition constant (3 ⁇ 4).
  • Binding affinity can be determined using standard techniques, such as enzyme-linked immunosorbent assays (ELISA), surface plasmon resonance assays, and isothermal titration calorimetry assays, among others.
  • ELISA enzyme-linked immunosorbent assays
  • surface plasmon resonance assays surface plasmon resonance assays
  • isothermal titration calorimetry assays among others.
  • antibody refers to an immunoglobulin molecule that specifically binds to, or is immunologically reactive with, a particular antigen, and includes polyclonal, monoclonal, genetically engineered, and otherwise modified forms of antibodies, including but not limited to chimeric antibodies, humanized antibodies, heteroconjugate antibodies (e.g., bi- tri- and quad-specific antibodies, diabodies, triabodies, and tetrabodies), and antigen binding fragments of antibodies, including, for example, Fab', F(ab') 2 , Fab, Fv, rlgG, and scFv fragments.
  • the term“monoclonal antibody” is meant to include both intact molecules, as well as antibody fragments (including, for example, Fab and F(ab') 2 fragments) that are capable of specifically binding to a target protein.
  • the Fab and F(ab') 2 fragments refer to antibody fragments that lack the Fc fragment of an intact antibody. Examples of these antibody fragments are described herein.
  • antigen-binding fragment refers to one or more fragments of an antibody that retain the ability to specifically bind to a target antigen.
  • the antigen binding function of an antibody can be performed by fragments of a full-length antibody.
  • the antibody fragments can be, for example, a Fab, F(ab’) 2 , scFv, diabody, a triabody, an affibody, a nanobody, an aptamer, or a domain antibody.
  • binding fragments encompassed of the term“antigen-binding fragment” of an antibody include, but are not limited to: (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL, and CH!
  • a dAb which consists of a V H or a V L domain
  • CDR complementarity determining region
  • the two domains of the Fv fragment, V L and V H are coded for by separate genes, they can be joined, using recombinant methods, by a linker that enables them to be made as a single protein chain in which the V L and V H regions pair to form monovalent molecules (known as single chain Fv (scFv); see, for example, Bird et al. (1988) Science 242:423-426 and Huston el al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883).
  • scFv single chain Fv
  • These antibody fragments can be obtained using conventional techniques known to those of skill in the art, and the fragments can be screened for utility in the same manner as intact antibodies.
  • Antigen-binding fragments can be produced by recombinant DNA techniques, enzymatic or chemical cleavage of intact immunoglobulins, or, in certain cases, by chemical peptide synthesis procedures known in the art.
  • bispecific antibody refers to, for example, a monoclonal, often a human or humanized antibody that is capable of binding at least two different antigens.
  • CD34 dim cells refers to a population of cells, of which at least a portion of the population expresses the markers CD34, CD1 lb, and CD45 and does not substantially express the markers CD3, CD8, or CD20, wherein CD34 and CD45 are expressed at a relatively low level.
  • This cell population exhibits characteristics of monocytes, for example, the ability to suppress alloreactive T lymphocyte proliferation. (D’Aveni et al. (2015) Science Translational Medicine 7(281): 1-12.
  • a population of CD34 dim cells may be CD14+.
  • CD34 dim cell population when viewing a flow cytometry plot as a population of cells that is CD34 + but has a brightness between the base level of fluorescence (e.g, autofluorescence) in the cell population being examined and the brightness of a CD34 + bright cell (e.g., a hematopoietic stem cell and/or a CD34 + CD90 + cell) population.
  • a CD34 dim cell population exhibits between 5% and 95% of the brightness of a CD34 + bright cell (e.g., a hematopoietic stem cell) population, but is brighter than a CD34 cell population.
  • CD34 dim cells exhibit between 10% and 90%, 10% and 80%, 10% and 70%, 10% and 60%, 10% and 50%, 10% and 40%, 10% and 30%, 10% and 20%,
  • 20% and 90% 20% and 80%, 20% and 70%, 20% and 60%, 20% and 50%, 20% and 40%
  • the CD34 dim cells are at least 5% brighter, at least 10% brighter, at least 20% brighter or at least 30% brighter than CD34 cells, but is less bright than CD34 + bright cells (e.g., a hematopoietic stem cells).
  • CD34 dim cells are identified in a cell sample by using flow cytometry with magnetic beads instead of fluorescence.
  • the magnetic beads will selectively pull down CD34 + bright cells, leaving CD34 dim cells in the cell sample.
  • CD34 dim cells are identified by measuring the number of copies of CD34 expressed by the cells.
  • CD34 dim cells can exhibit between 5% and 95% of the number of copies of CD34 as compared to CD34 + bright cells (e.g., hematopoietic stem cells), or between 10% and 90%, 10% and 80%, 10% and 70%, 10% and 60%, 10% and 50%, 10% and 40%, 10% and 30%, 10% and 20%, 20% and 90%, 20% and
  • CD34 + bright cells e.g., hematopoietic stem cells
  • CDR complementarity determining region
  • FRs framework regions
  • the amino acid positions that delineate a hypervariable region of an antibody can vary, depending on the context and the various definitions known in the art. Some positions within a variable domain may be viewed as hybrid hypervariable positions in that these positions can be deemed to be within a hypervariable region under one set of criteria while being deemed to be outside a hypervariable region under a different set of criteria. One or more of these positions can also be found in extended hypervariable regions.
  • variable domains of native heavy and light chains each contain four framework regions that primarily adopt a b-sheet configuration, connected by three CDRs, which form loops that connect, and in some cases form part of, the b-sheet structure.
  • the CDRs in each chain are held together in close proximity by the framework regions in the order FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 and, with the CDRs from the other antibody chains, contribute to the formation of the target binding site of antibodies (see Rabat et al ., Sequences of Proteins of Immunological Interest, National Institute of Health, Bethesda,
  • an agent as described herein such as a CXCR4 antagonist (e.g ., plerixafor or a variant thereof) and/or a CXCR2 agonist (e.g., Gro-b or a variant or truncation thereof, such as Gro-b T) can be administered to a subject over a period of time, for example, by intravenous or subcutaneous injection.
  • An agent is considered to have“completed administration” once the prescribed dosage of the agent has been administered to the subject in its entirety.
  • agents are considered to have“completed administration” once the prescribed dosages of all agents in a particular regimen have been administered to the subject in their entirety.
  • the terms“conservative mutation,”“conservative substitution,” or “conservative amino acid substitution” refer to a substitution of one or more amino acids for one or more different amino acids that exhibit similar physicochemical properties, such as polarity, electrostatic charge, and steric volume. These properties are summarized for each of the twenty naturally-occurring amino acids in TABLE 1 below.
  • conservative amino acid families include, e.g., (i) G, A, V, L, I, P, and M; (ii) D and E; (iii) C, S and T; (iv) H, K and R; (v) N and Q; and (vi) F, Y and W.
  • a conservative mutation or substitution is therefore one that substitutes one amino acid for a member of the same amino acid family (e.g ., a substitution of Ser for Thr or Lys for Arg).
  • CRU competitive repopulating unit
  • the term“donor” refers to a subject, such as a mammalian subject (e.g., a human subject) from which one or more cells are isolated prior to administration of the cells, or progeny thereof, into a recipient.
  • the one or more cells may be, for example, a population of hematopoietic stem or progenitor cells.
  • the term“diabody” refers to a bivalent antibody containing two polypeptide chains, in which each polypeptide chain includes V H and V L domains joined by a linker that is too short (e.g, a linker composed of five amino acids) to allow for
  • the term“triabody” refers to trivalent antibodies containing three peptide chains, each of which contains one V H domain and one V L domain joined by a linker that is exceedingly short (e.g, a linker composed of 1-2 amino acids) to permit intramolecular association of V H and V L domains within the same peptide chain.
  • peptides configured in this way typically trimerize so as to position the V H and V L domains of neighboring peptide chains spatially proximal to one another (see, for example, Holliger et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-48).
  • the term“disrupt” with respect to a gene refers to preventing the formation of a functional gene product.
  • a gene product is functional only if it fulfills its normal (wild-type) functions.
  • Disruption of the gene prevents expression of a functional factor encoded by the gene and comprises an insertion, deletion, or substitution of one or more bases in a sequence encoded by the gene and/or a promoter and/or an operator that is necessary for expression of the gene in the animal.
  • the disrupted gene may be disrupted by, e.g, removal of at least a portion of the gene from a genome of the animal, alteration of the gene to prevent expression of a functional factor encoded by the gene, an interfering RNA, or expression of a dominant negative factor by an exogenous gene.
  • Materials and methods of genetically modifying hematopoietic stem/progenitor cells are detailed in US 8,518,701; US 2010/0251395; and US 2012/0222143, the disclosures of each of which are incorporated herein by reference in their entirety (in case of conflict, the instant specification is controlling).
  • Various techniques known in the art can be used to inactivate genes to make knock out animals and/or to introduce nucleic acid constructs into animals to produce founder animals and to make animal lines, in which the knockout or nucleic acid construct is integrated into the genome.
  • Such techniques include, without limitation, pronuclear microinjection (U.S. Pat. No. 4,873,191), retrovirus mediated gene transfer into germ lines (Van der Putten et al. (1985) Proc. Natl. Acad. Sci. USA, 82:6148-6152), gene targeting into embryonic stem cells (Thompson et al. (1989) Cell, 56:313-321), electroporation of embryos (Lo (1983 )Mol. Cell.
  • An animal that is genomically modified is an animal wherein all of its cells have the genetic modification, including its germ line cells.
  • the animals may be inbred and progeny that are genomically modified may be selected.
  • Cloning for example, may be used to make a mosaic animal if its cells are modified at the blastocyst state, or genomic modification can take place when a single-cell is modified. Animals that are modified so they do not sexually mature can be homozygous or heterozygous for the modification, depending on the specific approach that is used. If a particular gene is inactivated by a knock out modification, homozygosity would normally be required. If a particular gene is inactivated by an RNA interference or dominant negative strategy, then heterozygosity is often adequate.
  • a“dual variable domain immunoglobulin” refers to an antibody that combines the target-binding variable domains of two monoclonal antibodies via linkers to create a tetravalent, dual-targeting single agent (see, for example, Gu et al. (2012) Meth. Enzymol., 502:25-41).
  • the term“endogenous” describes a substance, such as a molecule, cell, tissue, or organ (e.g ., a hematopoietic stem cell or a cell of hematopoietic lineage, such as a megakaryocyte, thrombocyte, platelet, erythrocyte, mast cell, myeoblast, basophil, neutrophil, eosinophil, microglial cell, granulocyte, monocyte, osteoclast, antigen-presenting cell, macrophage, dendritic cell, natural killer cell, T-lymphocyte, or B-lymphocyte) that is found naturally in a particular organism, such as a human patient.
  • a hematopoietic stem cell or a cell of hematopoietic lineage such as a megakaryocyte, thrombocyte, platelet, erythrocyte, mast cell, myeoblast, basophil, neutrophil, eosinophil, microglial cell, granulocyte, monocyte
  • the term“engraftment potential” is used to refer to the ability of hematopoietic stem and progenitor cells to repopulate a tissue, whether such cells are naturally circulating or are provided by transplantation.
  • the term encompasses all events surrounding or leading up to engraftment, such as tissue homing of cells and colonization of cells within the tissue of interest.
  • the engraftment efficiency or rate of engraftment can be evaluated or quantified using any clinically acceptable parameter as known to those of skill in the art and can include, for example, assessment of competitive repopulating units (CRU); incorporation or expression of a marker in tissue(s) into which stem cells have homed, colonized, or become engrafted; or by evaluation of the progress of a subject through disease progression, survival of hematopoietic stem and progenitor cells, or survival of a recipient.
  • Engraftment can also be determined by measuring white blood cell counts in peripheral blood during a post-transplant period. Engraftment can also be assessed by measuring recovery of marrow cells by donor cells in a bone marrow aspirate sample.
  • exogenous describes a substance, such as a molecule, cell, tissue, or organ (e.g ., a hematopoietic stem cell or a cell of hematopoietic lineage, such as a megakaryocyte, thrombocyte, platelet, erythrocyte, mast cell, myeoblast, basophil, neutrophil, eosinophil, microglial cell, granulocyte, monocyte, osteoclast, antigen-presenting cell, macrophage, dendritic cell, natural killer cell, T-lymphocyte, or B-lymphocyte) that is not found naturally in a particular organism, such as a human patient.
  • Exogenous substances include those that are provided from an external source to an organism or to cultured matter extracted therefrom.
  • framework region or“FW region” includes amino acid residues that are adjacent to the CDRs of an antibody or antigen -binding fragment thereof.
  • FW region residues may be present in, for example, human antibodies, humanized antibodies, monoclonal antibodies, antibody fragments, Fab fragments, single chain antibody fragments, scFv fragments, antibody domains, and bispecific antibodies, among others.
  • hematopoietic progenitor cells includes pluripotent cells capable of differentiating into several cell types of the hematopoietic system, including, without limitation, granulocytes, monocytes, erythrocytes, megakaryocytes, B-cells and T- cells, among others. Hematopoietic progenitor cells are committed to the hematopoietic cell lineage and generally do not self-renew. Hematopoietic progenitor cells can be identified, for example, by expression patterns of cell surface antigens, and include cells having the following immunophenotype: Lin KLS + Flk2 CD34 + .
  • Hematopoietic progenitor cells include short-term hematopoietic stem cells, multi-potent progenitor cells, common myeloid progenitor cells, granulocyte-monocyte progenitor cells, and megakaryocyte-erythrocyte progenitor cells.
  • the presence of hematopoietic progenitor cells can be determined functionally, for example, by detecting colony -forming unit cells, e.g ., in complete methylcellulose assays, or phenotypically through the detection of cell surface markers using flow cytometry and cell sorting assays described herein and known in the art.
  • HSCs hematopoietic stem cells
  • granulocytes e.g, promyelocytes, neutrophils, eosinophils, basophils
  • erythrocytes e.g, reticulocytes, erythrocytes
  • thrombocytes e.g, megakaryoblasts, platelet producing megakaryocytes, platelets
  • monocytes e.g, monocytes, macrophages
  • dendritic cells e.g, NK cells, B-cells and T-cells
  • lymphocytes e.g, NK cells, B-cells and T-cells.
  • CD34 + cells are immature cells that express the CD34 cell surface marker. In humans,
  • CD34 + cells are believed to include a subpopulation of cells with the stem cell properties defined above, whereas in mice, HSCs are CD34-.
  • HSCs also refer to long term repopulating HSCs (LT-HSC) and short term repopulating HSCs (ST-HSC).
  • LT-HSCs and ST-HSCs are differentiated, based on functional potential and on cell surface marker expression.
  • human HSCs are CD34 + , CD38 , CD45RA , CD90 + , CD49F + , and lin (negative for mature lineage markers including CD2, CD3, CD4, CD7, CD8, CD 10, CD11B, CD 19, CD20, CD56, CD235A).
  • bone marrow LT-HSCs are CD34-, SCA- 1+, C-kit+, CD135-, Slamfl/CDl50+, CD48-, and lin- (negative for mature lineage markers including Terl l9, CDl lb, Grl, CD3, CD4, CD8, B220, IL7ra), whereas ST-HSCs are CD34 + , SCA-l + , C-kit + , CD135 , Slamfl/CDl50 + , and lin (negative for mature lineage markers including Terl l9, CDl lb, Grl, CD3, CD4, CD8, B220, IL7ra).
  • ST- HSCs are less quiescent and more proliferative than LT-HSCs under homeostatic conditions.
  • LT-HSC have greater self-renewal potential (i.e., they survive throughout adulthood, and can be serially transplanted through successive recipients), whereas ST-HSCs have limited self-renewal (i.e., they survive for only a limited period of time, and do not possess serial transplantation potential). Any of these HSCs can be used in the methods described herein.
  • ST-HSCs are particularly useful because they are highly proliferative and thus, can more quickly give rise to differentiated progeny.
  • hematopoietic stem cell functional potential refers to the functional properties of hematopoietic stem cells which include 1) multi -potency (which refers to the ability to differentiate into multiple different blood lineages including, but not limited to, granulocytes (e.g ., promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g., reticulocytes, erythrocytes), thrombocytes (e.g, megakaryoblasts, platelet producing megakaryocytes, platelets), monocytes (e.g, monocytes, macrophages), dendritic cells, microglia, osteoclasts, and lymphocytes (e.g, NK cells, B-cells and T-cells), 2) self- renewal (which refers to the ability of hematopoietic stem cells to give rise to daughter cells that have equivalent potential as the mother cell, and further that this
  • multi -potency which refers to the
  • MHC Major histocompatibility complex antigens
  • HLA human leukocyte antigens
  • MHC/HLA antigens are target molecules that are recognized by T cells and NK cells as being derived from the same source of hematopoietic stem cells as the immune effector cells ("self) or as being derived from another source of hematopoietic reconstituting cells ("non- self).
  • HLA class I and HLA class II Two main classes of HLA antigens are recognized: HLA class I and HLA class II.
  • HLA class I antigens (A, B, and C in humans) render each cell recognizable as "self”
  • HLA class II antigens DR, DP, and DQ in humans
  • MHC class I A, B and C
  • MHC class II DP, DQ and DR
  • HLA-B genes B5, and Bw4l
  • Allelic gene products differ in one or more amino acids in the a and/or b domain(s).
  • Large panels of specific antibodies or nucleic acid reagents are used to type HLA haplotypes of individuals, using leukocytes that express class I and class II molecules.
  • the genes commonly used for HLA typing are the six MHC Class I and Class II proteins, two alleles for each of HLA- A; HLA-B and HLA-DR.
  • the HLA genes are clustered in a "super-locus" present on chromosome position 6p2l, which encodes the six classical transplantation HLA genes and at least 132 protein coding genes that have important roles in the regulation of the immune system as well as some other fundamental molecular and cellular processes.
  • the complete locus measures roughly 3.6 Mb, with at least 224 gene loci.
  • haplotypes i.e. the set of alleles present on a single chromosome, which is inherited from one parent, tend to be inherited as a group.
  • the set of alleles inherited from each parent forms a haplotype, in which some alleles tend to be associated together. Identifying a patient's haplotypes can help predict the probability of finding matching donors and assist in developing a search strategy, because some alleles and haplotypes are more common than others and they are distributed at different frequencies in different racial and ethnic groups.
  • HLA-matched refers to a donor-recipient pair in which none of the HLA antigens are mismatched between the donor and recipient, such as a donor providing a hematopoietic stem cell graft to a recipient in need of hematopoietic stem cell transplant therapy.
  • HLA-matched ⁇ i.e., where all of the 6 alleles are matched) donor- recipient pairs have a decreased risk of graft rejection, as endogenous T cells and NK cells are less likely to recognize the incoming graft as foreign, and are thus less likely to mount an immune response against the transplant.
  • HLA-mismatched refers to a donor-recipient pair in which at least one HLA antigen, in particular with respect to HLA-A, HLA-B and HLA-DR, is mismatched between the donor and recipient, such as a donor providing a hematopoietic stem cell graft to a recipient in need of hematopoietic stem cell transplant therapy.
  • HLA-A, HLA-B and HLA-DR HLA-mismatched
  • HLA-mismatched donor-recipient pairs may have an increased risk of graft rejection relative to HLA-matched donor-recipient pairs, as endogenous T cells and NK cells are more likely to recognize the incoming graft as foreign in the case of an HLA-mismatched donor-recipient pair, and such T cells and NK cells are thus more likely to mount an immune response against the transplant.
  • human antibody refers to an antibody in which
  • a human antibody can be produced in a human cell (for example, by recombinant expression) or by a non-human animal or a prokaryotic or eukaryotic cell that is capable of expressing functionally rearranged human immunoglobulin (such as heavy chain and/or light chain) genes.
  • a human antibody is a single chain antibody, it can include a linker peptide that is not found in native human antibodies.
  • an Fv can contain a linker peptide, such as two to about eight glycine or other amino acid residues, which connects the variable region of the heavy chain and the variable region of the light chain.
  • linker peptides are considered to be of human origin.
  • Human antibodies can be made by a variety of methods known in the art including phage display methods using antibody libraries derived from human immunoglobulin sequences. Human antibodies can also be produced using transgenic mice that are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes (see, for example, PCT Publication Nos. WO
  • the term“humanized” antibody refers to a non-human antibody that contains minimal sequences derived from non-human immunoglobulin.
  • a humanized antibody contains substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non human immunoglobulin. All or substantially all of the FW regions may also be those of a human immunoglobulin sequence.
  • the humanized antibody can also contain at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin consensus sequence.
  • Fc immunoglobulin constant region
  • patients that are“in need of’ a hematopoietic stem cell transplant include patients that exhibit a defect or deficiency in one or more blood cell types, as well as patients having a stem cell disorder, autoimmune disease, cancer, or other pathology described herein.
  • Hematopoietic stem cells generally exhibit 1) multi-potency, and can thus differentiate into multiple different blood lineages including, but not limited to, granulocytes (e.g ., promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g, reticulocytes, erythrocytes), thrombocytes (e.g, megakaryoblasts, platelet producing megakaryocytes, platelets), monocytes (e.g ., monocytes, macrophages), dendritic cells, microglia, osteoclasts, and lymphocytes (e.g., NK cells, B-cells and T-cells), 2) self-renewal, and can thus give rise to daughter cells that have equivalent potential as the mother cell, and 3) the ability to be reintroduced into a transplant recipient whereupon they home to the hematopoietic stem cell niche and re-establish productive and sustained hema
  • Hematopoietic stem cells can thus be administered to a patient defective or deficient in one or more cell types of the hematopoietic lineage in order to re-constitute the defective or deficient population of cells in vivo.
  • the patient may be suffering from cancer, and the deficiency may be caused by administration of a chemotherapeutic agent or other medicament that depletes, either selectively or non-specifically, the cancerous cell population.
  • the patient may be suffering from a hemoglobinopathy (e.g, a non-malignant hemoglobinopathy), such as sickle cell anemia, thalassemia, Fanconi anemia, aplastic anemia, and Wiskott-Aldrich syndrome.
  • a hemoglobinopathy e.g, a non-malignant hemoglobinopathy
  • the subject may be one that is suffering from adenosine deaminase severe combined immunodeficiency (ADA SCID), HIV/AIDS, metachromatic leukodystrophy, Diamond-Blackfan anemia, and Schwachman-Diamond syndrome.
  • ADA SCID adenosine deaminase severe combined immunodeficiency
  • the subject may have or be affected by an inherited blood disorder (e.g, sickle cell anemia) or an autoimmune disorder. Additionally or alternatively, the subject may have or be affected by a malignancy, such as neuroblastoma or a hematologic cancer.
  • the subject may have a leukemia, lymphoma, or myeloma.
  • the subject has acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia, multiple myeloma, diffuse large B-cell lymphoma, or non-Hodgkin’s lymphoma. In some embodiments, the subject has
  • the subject has an autoimmune disease, such as scleroderma, multiple sclerosis, ulcerative colitis, Crohn’s disease, Type 1 diabetes, or another autoimmune pathology described herein.
  • the subject is in need of chimeric antigen receptor T-cell (CART) therapy.
  • the subject has or is otherwise affected by a metabolic storage disorder.
  • the subject may suffer or otherwise be affected by a metabolic disorder selected from the group consisting of glycogen storage diseases, mucopolysaccharidoses, Gaucher's Disease, Hurlers Disease,
  • sphingolipidoses metachromatic leukodystrophy, or any other diseases or disorders which may benefit from the treatments and therapies disclosed herein and including, without limitation, severe combined immunodeficiency, Wi scott- Aldrich syndrome, hyper immunoglobulin M (IgM) syndrome, Chediak-Higashi disease, hereditary lymphohistiocytosis, osteopetrosis, osteogenesis imperfecta, storage diseases, thalassemia major, sickle cell disease, systemic sclerosis, systemic lupus erythematosus, multiple sclerosis, juvenile rheumatoid arthritis and those diseases, or disorders described in "Bone Marrow Transplantation for Non-Malignant Disease," ASH Education Book, 1 :319-338 (2000), the disclosure of which is incorporated herein by reference in its entirety as it pertains to pathologies that may be treated by administration of hematopoietic stem cell transplant therapy.
  • IgM hyper immunoglobulin M
  • a patient“in need of’ a hematopoietic stem cell transplant may one that is or is not suffering from one of the foregoing pathologies, but nonetheless exhibits a reduced level (e.g ., as compared to that of an otherwise healthy subject) of one or more endogenous cell types within the hematopoietic lineage, such as megakaryocytes, thrombocytes, platelets, erythrocytes, mast cells, myeoblasts, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, osteoclasts, antigen-presenting cells, macrophages, dendritic cells, natural killer cells, T-lymphocytes, and B -lymphocytes.
  • endogenous cell types within the hematopoietic lineage such as megakaryocytes, thrombocytes, platelets, erythrocytes, mast cells, myeoblasts, basophils, neutrophils, e
  • FACS fluorescence activated cell sorting
  • leukocyte refers to a heterogeneous group of nucleated blood cell types, and excludes erythrocytes and platelets. Leukocytes can be divided into two general groups: polymorphonucleocytes, which include neutrophils, eosinophils, and basophils, and mononucleocytes, which include lymphocytes and monocytes.
  • Polymorphonucleocytes contain many cytoplasmic granules and a multilobed nucleus and include the following: neutrophils, which are generally amoeboid in shape, phagocytic, and stain with both basic and acidic dyes, and eosinophils and basophils, which contain cytoplasmic granules that stain with acidic dyes and with basic dyes, respectively.
  • neutrophils which are generally amoeboid in shape, phagocytic, and stain with both basic and acidic dyes
  • eosinophils and basophils which contain cytoplasmic granules that stain with acidic dyes and with basic dyes, respectively.
  • lymphocyte refers to a mononuclear leukocyte that is involved in the mounting of an immune response.
  • lymphocytes include B lymphocytes, T lymphocytes, and NK cells.
  • the terms“mobilize” and“mobilization” refer to processes by which a population of hematopoietic stem or progenitor cells is released from a stem cell niche, such as the bone marrow of a subject, into circulation in the peripheral blood. Mobilization of hematopoietic stem and progenitor cells can be monitored, for example, by assessing the quantity or concentration of hematopoietic stem or progenitor cells in a peripheral blood sample isolated from a subject.
  • the peripheral blood sample may be withdrawn from the subject, and the quantity or concentration of hematopoietic stem or progenitor cells in the peripheral blood sample may subsequently be assessed, following the administration of a hematopoietic stem or progenitor cell mobilization regimen to the subject.
  • the mobilization regimen may include, for example, a CXCR4 antagonist, such as a CXCR4 antagonist described herein ( e.g ., plerixafor or a variant thereof), and a CXCR2 agonist, such as a CXCR2 agonist described herein (e.g., Gro-b or a variant thereof, such as a truncation of Gro-b, for example, Gro-b T).
  • a CXCR4 antagonist such as a CXCR4 antagonist described herein (e.g ., plerixafor or a variant thereof)
  • a CXCR2 agonist such as a CXCR2 agonist described herein (e.g., Gro-b or
  • administration of the mobilization regimen may be compared to the quantity or concentration of hematopoietic stem or progenitor cells in a peripheral blood sample isolated from the subject prior to administration of the mobilization regimen.
  • An observation that the quantity or concentration of hematopoietic stem or progenitor cells has increased in the peripheral blood of the subject following administration of the mobilization regimen is an indication that the subject is responding to the mobilization regimen, and that hematopoietic stem and progenitor cells have been released from one or more stem cell niches, such as the bone marrow, into peripheral blood circulation.
  • HSCs are CD34 + , CD38 , CD45RA , CD90 + , CD49F + , and lin- (negative for mature lineage markers including CD2, CD3, CD4, CD7, CD8, CD10, CD11B, CD19, CD20, CD56, CD235A).
  • Additional methods for determining the quantity or concentration of hematopoietic stem or progenitor cells in a peripheral blood sample isolated from a subject include assays that quantify the number of colony-forming units (CFUs) in the sample, which is a measure of the quantity of viable hematopoietic stem or progenitor cells that, upon incubation with an appropriate culture medium, give rise to an individual population of hematopoietic stem or progenitor cells.
  • CFUs colony-forming units
  • the term“mobilizing amount” refers to a quantity of one or more agents, such as a quantity of a CXCR4 antagonist and/or a CXCR2 agonist described herein (In some embodiments, a quantity of plerixafor, or a variant thereof, and/or Gro-b, or a variant thereof, such as a truncation of Gro-b, for example, Gro-b T) that mobilizes a population of hematopoietic stem or progenitor cells upon administration to a subject, such as a mammalian subject ( e.g ., a human subject).
  • a mammalian subject e.g ., a human subject
  • Exemplary mobilizing amounts of these agents include amounts sufficient to effectuate the release of a population of, for example, from about 20 to about 40 CD34 + cells/pL of peripheral blood, such as from about 21 to about 39 CD34 + cells/pL of peripheral blood, about 22 to about 38 CD34 + cells/pL of peripheral blood, about 23 to about 37 CD34 + cells/pL of peripheral blood, about 24 to about 36 CD34 + cells/pL of peripheral blood, about 25 to about 35 CD34 + cells/pL of peripheral blood, about 26 to about 34 CD34 + cells/pL of peripheral blood, about 27 to about 33 CD34 + cells/pL of peripheral blood, about 28 to about 32 CD34 + cells/pL of peripheral blood, or about 29 to about 31 CD34 + cells/pL of peripheral blood (e.g., about 20 CD34 + cells/pL of peripheral blood, 21 CD34 + cells/pL of peripheral blood, 22 CD34 + cells/pL of peripheral blood, 23 CD34 + cells/pL of peripheral blood, 24, CD34 + cells/pL of
  • mobilizing amounts of a CXCR2 agonist include from about 50 pg/kg of recipient to about 1 mg/kg of recipient, such as from about 50 pg/kg to about 300 pg/kg, 100 pg/kg to about 250 pg/kg, or about 150 pg/kg.
  • Mobilizing amounts of a CXCR4 antagonist, such as plerixafor or a pharmaceutically acceptable salt thereof include from about 50 pg/kg of recipient to about 500 pg/kg of recipient, such as from about 200 pg/kg to about 300 pg/kg, or about 240 pg/kg.
  • the term“monoclonal antibody” refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.
  • a monocyte refers to a CDl4 + and CD34- peripheral blood mononuclear cell (PBMC), which is generally capable of differentiating into a macrophage and/or dendritic cell upon activation by one or more foreign substances, such as, a microbial product.
  • a monocyte may express elevated levels of the CD 14 surface antigen marker, and may express at least one biomarker selected from CD64, CD93, CD 180, CD328 (also known as sialic acid-binding Ig-like lectin 7 or Siglec7), and CD329 (sialic acid-binding Ig-like lectin 9 or Siglec9), as well as the peanut agglutinin protein (PNA).
  • PBMC peripheral blood mononuclear cell
  • a“peptide” refers to a single-chain polyamide containing a plurality of amino acid residues, such as naturally-occurring and/or non-natural amino acid residues, that are consecutively bound by amide bonds.
  • Examples of peptides include shorter fragments of full-length proteins, such as full-length naturally-occurring proteins.
  • the term“recipient” refers to a patient that receives a transplant, such as a transplant containing a population of hematopoietic stem cells.
  • the transplanted cells administered to a recipient may be, e.g ., autologous, syngeneic, or allogeneic cells.
  • sample refers to a specimen (e.g, blood, blood component (e.g, serum or plasma), urine, saliva, amniotic fluid, cerebrospinal fluid, tissue (e.g, placental or dermal), pancreatic fluid, chorionic villus sample, and cells) taken from a subject.
  • a sample may be, for example, withdrawn peripheral blood from a donor that is undergoing or has undergone a hematopoietic stem or progenitor cell mobilization regimen described herein.
  • scFv refers to a single chain Fv antibody in which the variable domains of the heavy chain and the light chain from an antibody have been joined to form one chain.
  • scFv fragments contain a single polypeptide chain that includes the variable region of an antibody light chain (V L ) (e.g, CDR-L1, CDR-L2, and/or CDR-L3) and the variable region of an antibody heavy chain (V H ) (e.g, CDR-H1, CDR-H2, and/or CDR-H3) separated by a linker.
  • V L variable region of an antibody light chain
  • V H variable region of an antibody heavy chain
  • the linker that joins the V L and V H regions of a scFv fragment can be a peptide linker composed of proteinogenic amino acids.
  • linkers can be used to so as to increase the resistance of the scFv fragment to proteolytic degradation (for example, linkers containing D-amino acids), in order to enhance the solubility of the scFv fragment (for example, hydrophilic linkers such as polyethylene glycol-containing linkers or polypeptides containing repeating glycine and serine residues), to improve the biophysical stability of the molecule (for example, a linker containing cysteine residues that form intramolecular or intermolecular disulfide bonds), or to attenuate the immunogenicity of the scFv fragment (for example, linkers containing glycosylation sites).
  • linkers containing D-amino acids for example, hydrophilic linkers such as polyethylene glycol-containing linkers or polypeptides containing repeating glycine and serine residues
  • hydrophilic linkers such as polyethylene glycol-containing linkers or polypeptides containing repeating glycine and serine residues
  • variable regions of the scFv molecules described herein can be modified such that they vary in amino acid sequence from the antibody molecule from which they were derived.
  • nucleotide or amino acid substitutions leading to conservative substitutions or changes at amino acid residues can be made (e.g ., in CDR and/or framework residues) so as to preserve or enhance the ability of the scFv to bind to the antigen recognized by the corresponding antibody.
  • stem cell disorder broadly refers to any disease, disorder, or condition that may be treated or cured by engrafting or transplanting a population of hematopoietic stem or progenitor cells in a target tissue within a patient.
  • Type I diabetes has been shown to be cured by hematopoietic stem cell transplant, along with various other disorders.
  • Exemplary diseases that can be treated by infusion of hematopoietic stem or progenitor cells into a patient are sickle cell anemia, thalassemias, Fanconi anemia, aplastic anemia, Wiskott-Aldrich syndrome, ADA SCID, HIV/AIDS, metachromatic leukodystrophy, Diamond-Blackfan anemia, and Schwachman-Diamond syndrome.
  • Additional diseases that may be treated by transplantation of hematopoietic stem and progenitor cells as described herein include blood disorders (e.g., sickle cell anemia) and autoimmune disorders, such as scleroderma, multiple sclerosis, ulcerative colitis, and Crohn’s disease.
  • Additional diseases that may be treated using hematopoietic stem and progenitor cell transplant therapy include cancer, such as a cancer described herein.
  • Exemplary stem cell disorders are malignancies, such as a neuroblastoma or a hematologic cancers, such as leukemia, lymphoma, and myeloma.
  • the cancer may be acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia, multiple myeloma, diffuse large B-cell lymphoma, or non-Hodgkin’s lymphoma.
  • Additional diseases treatable using hematopoietic stem or progenitor cell transplant therapy include myelodysplastic syndrome.
  • the patient has or is otherwise affected by a metabolic storage disorder.
  • the patient may suffer or otherwise be affected by a metabolic disorder selected from the group consisting of glycogen storage diseases, mucopolysaccharidoses, Gaucher's Disease, Hurlers Disease, sphingolipidoses,
  • metachromatic leukodystrophy or any other diseases or disorders which may benefit from the treatments and therapies disclosed herein and including, without limitation, severe combined immunodeficiency, Wi scott- Aldrich syndrome, hyper immunoglobulin M (IgM) syndrome, Chediak-Higashi disease, hereditary lymphohistiocytosis, osteopetrosis, osteogenesis imperfecta, storage diseases, thalassemia major, sickle cell disease, systemic sclerosis, systemic lupus erythematosus, multiple sclerosis, juvenile rheumatoid arthritis and those diseases, or disorders described in“Bone Marrow Transplantation for Non-Malignant Disease,” ASH Education Book, 1 :319-338 (2000), the disclosure of which is incorporated herein by reference in its entirety as it pertains to pathologies that may be treated by administration of hematopoietic stem or progenitor cell transplant therapy.
  • IgM hyper immunoglobulin M
  • stem cell niche refers to a microenvironment within a donor, such as a mammalian donor (e.g ., a human donor) in which endogenous hematopoietic stem or progenitor cells reside.
  • a mammalian donor e.g ., a human donor
  • An exemplary stem cell niche is bone marrow tissue.
  • the terms“subject” and“patient” refer to an organism, such as a human, that receives treatment for a particular disease or condition as described herein.
  • a patient such as a human patient, that is in need of hematopoietic stem cell transplantation may receive treatment that includes a population of hematopoietic stem cells so as to treat a stem cell disorder, such as a cancer, autoimmune disease, or metabolic disorder described herein.
  • the hematopoietic stem cells that are transplanted into the patient may be, for example, a population of hematopoietic stem cells that has been mobilized and withdrawn from a donor in accordance with the compositions and methods described herein.
  • the hematopoietic stem cells that are transplanted into the patient may be mobilized within a donor by administration of a CXCR4 antagonist and/or a CXCR2 agonist to the donor.
  • the term“transfection” refers to any of a wide variety of techniques commonly used for the introduction of exogenous DNA into a prokaryotic or eukaryotic host cell, such as electroporation, lipofection, calcium- phosphate precipitation, DEAE- dextran transfection and the like.
  • the terms“treat” or“treatment” refer to therapeutic treatment, in which the object is to prevent or slow down (lessen) an undesired physiological change or disorder or to promote a beneficial phenotype in the patient being treated.
  • Beneficial or desired clinical results include, but are not limited to, promoting the engraftment of exogenous hematopoietic cells in a patient following hematopoietic stem or progenitor cell transplant therapy.
  • the benefits include a more rapid engraftment of transplanted cells, e.g., neutrophils and platelets.
  • neutrophil recovery occurs within about 5-20 days post- transplant, about 5-15 days post-transplant, about 5-10 days post-transplant, about 7-12 days post-transplant, about 8-12 days post transplant, about 9-15 days post-transplant, about 10-15 days post-transplant, or about 10 days post-transplant.
  • platelet recovery occurs within about 10-20 days post-transplant, about 10-15 days post-transplant, about 15-20 days post-transplant, about 12-18 days post transplant, about 12-17 days post transplant, about 13-18 days post-transplant, about 12-17 days post-transplant, or about 15 days post-transplant.
  • Additional beneficial results include an increase in the cell count or relative concentration of hematopoietic stem cells in a patient in need of a hematopoietic stem or progenitor cell transplant following administration of an exogenous hematopoietic stem or progenitor cell graft to the patient.
  • Beneficial results of therapy described herein may also include an increase in the cell count or relative
  • hematopoietic lineage such as a megakaryocyte, thrombocyte, platelet, erythrocyte, mast cell, myeoblast, basophil, neutrophil, eosinophil, microglial cell, granulocyte, monocyte, osteoclast, antigen-presenting cell, macrophage, dendritic cell, natural killer cell, T-lymphocyte, or B-lymphocyte, following and subsequent hematopoietic stem cell transplant therapy.
  • Additional beneficial results may include the reduction in quantity of a disease-causing cell population, such as a population of cancer cells or autoimmune cells.
  • variants and“derivative” are used interchangeably and refer to naturally-occurring, synthetic, and semi-synthetic analogues of a compound, peptide, protein, or other substance described herein.
  • a variant or derivative of a compound, peptide, protein, or other substance described herein may retain or improve upon the biological activity of the original material.
  • vector includes a nucleic acid vector, such as a plasmid, a
  • DMA vector a plasmid, a RNA vector, virus, or other suitable replicon.
  • Expression vectors described herein may contain a polynucleotide sequence as well as, for example, additional sequence elements used for the expression of proteins and/or the integration of these polynucleotide sequences into the genome of a mammalian cell.
  • Certain vectors that can be used for the expression of peptides and proteins, such as those described herein, include plasmids that contain regulatory sequences, such as promoter and enhancer regions, which direct gene transcription.
  • Suitable vectors for expression of peptides and proteins described herein contain polynucleotide sequences that enhance the rate of translation of these genes or improve the stability or nuclear export of the mRNA that results from gene transcription. These sequence elements may include, for example, 5’ and 3’ untranslated regions and a polyadenylation signal site in order to direct efficient transcription of the gene carried on the expression vector.
  • the expression vectors described herein may also contain a polynucleotide encoding a marker for selection of cells that contain such a vector. Examples of a suitable marker include genes that encode resistance to antibiotics, such as ampicillin, chloramphenicol, kanamycin, and nourseothricin.
  • alkyl refers to a straight- or branched-chain alkyl group having, for example, from 1 to 20 carbon atoms in the chain.
  • alkyl groups include methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and the like.
  • alkylene refers to a straight- or branched-chain divalent alkyl group. The divalent positions may be on the same or different atoms within the alkyl chain. Examples of alkylene include methylene, ethylene, propylene, isopropylene, and the like.
  • heteroalkyl refers to a straight or branched-chain alkyl group having, for example, from 1 to 20 carbon atoms in the chain, and further containing one or more heteroatoms (e.g ., oxygen, nitrogen, or sulfur, among others) in the chain.
  • heteroatoms e.g ., oxygen, nitrogen, or sulfur, among others
  • heteroalkyl ene refers to a straight- or branched-chain divalent heteroalkyl group.
  • the divalent positions may be on the same or different atoms within the heteroalkyl chain.
  • the divalent positions may be one or more heteroatoms.
  • alkenyl refers to a straight- or branched-chain alkenyl group having, for example, from 2 to 20 carbon atoms in the chain.
  • alkenyl groups include vinyl, propenyl, isopropenyl, butenyl, tert-butyl enyl, hexenyl, and the like.
  • alkenylene refers to a straight- or branched-chain divalent alkenyl group. The divalent positions may be on the same or different atoms within the alkenyl chain. Examples of alkenylene include ethenylene, propenylene, isopropenylene, butenylene, and the like.
  • heteroalkenyl refers to a straight- or branched-chain alkenyl group having, for example, from 2 to 20 carbon atoms in the chain, and further containing one or more heteroatoms (e.g ., oxygen, nitrogen, or sulfur, among others) in the chain.
  • heteroalkenylene refers to a straight- or branched-chain divalent heteroalkenyl group.
  • the divalent positions may be on the same or different atoms within the heteroalkenyl chain.
  • the divalent positions may be one or more heteroatoms.
  • alkynyl refers to a straight- or branched-chain alkynyl group having, for example, from 2 to 20 carbon atoms in the chain.
  • alkynyl groups include propargyl, butynyl, pentynyl, hexynyl, and the like.
  • alkynylene refers to a straight- or branched-chain divalent alkynyl group.
  • the divalent positions may be on the same or different atoms within the alkynyl chain.
  • heteroalkynyl refers to a straight- or branched-chain alkynyl group having, for example, from 2 to 20 carbon atoms in the chain, and further containing one or more heteroatoms (e.g., oxygen, nitrogen, or sulfur, among others) in the chain.
  • heteroalkynylene refers to a straight- or branched-chain divalent heteroalkynyl group.
  • the divalent positions may be on the same or different atoms within the heteroalkynyl chain.
  • the divalent positions may be one or more heteroatoms.
  • cycloalkyl refers to a monocyclic, or fused, bridged, or spiro polycyclic ring structure that is saturated and has, for example, from 3 to 12 carbon ring atoms.
  • cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[3. l.0]hexane, and the like.
  • cycloalkylene refers to a divalent cycloalkyl group.
  • the divalent positions may be on the same or different atoms within the ring structure.
  • examples of cycloalkylene include cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, and the like.
  • heterocycloalkyl refers to a monocyclic, or fused, bridged, or spiro polycyclic ring structure that is saturated and has, for example, from 3 to 12 ring atoms per ring structure selected from carbon atoms and heteroatoms selected from, e.g ., nitrogen, oxygen, and sulfur, among others.
  • the ring structure may contain, for example, one or more oxo groups on carbon, nitrogen, or sulfur ring members.
  • heterocycloalkylene refers to a divalent heterocyclolalkyl group.
  • the divalent positions may be on the same or different atoms within the ring structure.
  • aryl refers to a monocyclic or multicyclic aromatic ring system containing, for example, from 6 to 19 carbon atoms.
  • Aryl groups include, but are not limited to, phenyl, fluorenyl, naphthyl, and the like. The divalent positions may be one or more heteroatoms.
  • arylene refers to a divalent aryl group.
  • the divalent positions may be on the same or different atoms.
  • heteroaryl refers to a monocyclic heteroaromatic, or a bicyclic or a tricyclic fused-ring heteroaromatic group.
  • Heteroaryl groups include pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, l,2,3-triazolyl, l,2,4-triazolyl, l,2,3-oxadiazolyl, l,2,4-oxadia-zolyl, l,2,5-oxadiazolyl, 1,3,4- oxadiazolyl, l,3,4-triazinyl, l,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, [2,3-dihydro]benzofuryl, [2,3-dihydro]benzofuryl,
  • the term“heteroarylene” refers to a divalent heteroaryl group.
  • the divalent positions may be on the same or different atoms.
  • the divalent positions may be one or more heteroatoms.
  • the foregoing chemical moieties such as“alkyl”,“alkylene”,“heteroalkyl”,“heteroalkylene”, “alkenyl”,“alkenylene”,“heteroalkenyl”,“heteroalkenylene”,“alkynyl”,“alkynylene”, “heteroalkynylene”,“cycloalkyl”,“cycloalkylene”,“heterocyclolalkyl”, heterocycloalkylene”,“aryl,”“arylene”,“heteroaryl”, and“heteroarylene” groups can optionally be substituted.
  • the term“optionally substituted” refers to a compound or moiety containing one or more (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) substituents, as permitted by the valence of the compound or moiety or a site thereof, such as a substituent selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkyl aryl, alkyl heteroaryl, alkyl cycloalkyl, alkyl heterocycloalkyl, amino, ammonium, acyl, acyloxy, acylamino, aminocarbonyl, alkoxycarbonyl, ureido, carbamate, aryl, heteroaryl, sulfmyl, sulfonyl, alkoxy, sulfanyl, halogen, carboxy, trihalomethyl, cyano, hydroxy, mercapto, nitro, and the like.
  • substitution may include situations in which neighboring substituents have undergone ring closure, such as ring closure of vicinal functional substituents, to form, for example, lactams, lactones, cyclic anhydrides, acetals, hemiacetals, thioacetals, aminals, and hemiaminals, formed by ring closure, for example, to furnish a protecting group.
  • ring closure such as ring closure of vicinal functional substituents, to form, for example, lactams, lactones, cyclic anhydrides, acetals, hemiacetals, thioacetals, aminals, and hemiaminals, formed by ring closure, for example, to furnish a protecting group.
  • the present invention is based, in part, on the discovery that hematopoietic stem and progenitor cells can be mobilized by administering particular doses of a CXCR2 agonist, such as Gro-b, Gro-b T, or a variant thereof, optionally in combination with a CXCR4 antagonist to a mammalian donor (e.g ., a human donor) while reducing the mobilization of other cell types, such as leukocytes, neutrophils, lymphocytes, and monocytes.
  • a CXCR2 agonist such as Gro-b, Gro-b T, or a variant thereof
  • This property is particularly beneficial in the context of hematopoietic stem cell transplant therapy, as hematopoietic stem cells that are mobilized and isolated from a donor using the compositions and method described herein have reduced quantities of cell types that are undesirable for administration to a human patient suffering from a stem cell disorder.
  • CXCR2 agonists such as Gro-b, Gro-b T, or a variant thereof, when administered intravenously at a dose of from about 50 pg/kg to about 1 mg/kg, preferably from about 100 pg/kg to about 250 pg/kg, and even more preferably at a dose of about 150 pg/kg, exhibit the ability to rapidly mobilize hematopoietic stem and progenitor cells in a donor (e.g ., a mammalian donor, such as a human donor) while reducing the mobilization of other cells of the hematopoietic lineage that may be undesirable for infusion into a patient (e.g., a mammalian patient, such as a human patient) that is undergoing hematopoietic stem cell transplant therapy.
  • hematopoietic stem cells mobilized in a donor by administration of a CXCR2 agonist, such as Gro-b, Gro-b T, or a variant thereof, and optionally, a CXCR4 antagonist, such as plerixafor or a pharmaceutically acceptable salt thereof, are suitable for release for ex vivo expansion and/or for therapeutic use one may acquire an input value for each of one or more parameters set forth in TABLE 2 that characterize a sample of peripheral blood of the donor.
  • the one or more parameters may be compared to the corresponding reference criterion for each parameter, and if the reference criterion is satisfied by the ample of hematopoietic stem cells, the cells isolated from the donor may be released for expansion ex vivo and/or for infusion into a patient for therapeutic use (e.g, for the treatment of one or more stem cell disorders described herein).
  • a donor e.g ., a mammalian donor, such as a human donor
  • parameters for determining whether a population of hematopoietic stem cells obtained from a donor one may select one or more input parameters listed in TABLE 2.
  • a donor e.g ., a mammalian donor, such as a human donor
  • the parameters used for determining whether a population of hematopoietic stem cells obtained from a donor are a combination of parameters as set forth in any one of TABLES 3-6, below.
  • Exemplary CXCR2 agonists that may be used in conjunction with the compositions and methods described herein are Gro-b and variants thereof.
  • Gro-b also referred to as growth-regulated protein b, chemokine (C-X-C motif) ligand 2 (CXCL2), and macrophage inflammatory protein 2-a (MIP2-a)
  • CXCL2 chemokine ligand 2
  • MIP2-a macrophage inflammatory protein 2-a
  • MMP9 may induce mobilization of hematopoietic stem and progenitor cells from stem cell niches, such as the bone marrow, to circulating peripheral blood by stimulating the degradation of proteins such as stem cell factor, its corresponding receptor, CD117, and CXCL12, all of which generally maintain hematopoietic stem and progenitor cells immobilized in bone marrow.
  • exemplary CXCR2 agonists that may be used in conjunction with the compositions and methods described herein are truncated forms of Gro-b, such as those that feature a deletion at the N-terminus of Gro-b of from 1 to 8 amino acids (e.g, peptides that feature an N-terminal deletion of 1 amino acids, 2 amino acids, 3 amino acids, 4 amino acids, 5 amino acids, 6 amino acids, 7 amino acids, or 8 amino acids).
  • CXCR2 agonists that may be used in conjunction with the compositions and methods described herein include Gro-b T, which is characterized by a deletion of the first four amino acids from the N-terminus of Gro-b.
  • Gro-b T exhibits particularly advantageous biological properties, such as the ability to induce hematopoietic stem and progenitor cell mobilization with a potency superior to that of Gro-b by multiple orders of magnitude.
  • Gro-b and Gro-b T are described, for example, in US Patent No. 6,080,398, the disclosure of which is incorporated herein by reference in its entirety.
  • exemplary CXCR2 agonists that may be used in conjunction with the compositions and methods described herein are variants of Gro-b containing an aspartic acid residue in place of the asparagine residue at position 69 of SEQ ID NO: 1.
  • This peptide referred to herein as Gro-b N69D, retains the hematopoietic stem and progenitor cell- mobilizing functionality of Gro-b, yet induces this effect with a superior potency.
  • CXCR2 agonists that may be used with the compositions and methods described herein include variants of Gro-b T containing an aspartic acid residue in place of the asparagine residue at position 65 of SEQ ID NO: 2.
  • This peptide referred to herein as Gro-b T N65D, not only retains hematopoietic stem and progenitor cell-mobilizing capacity, but exhibits a potency that is substantially greater than that of Gro-b T.
  • Gro-b N69D and Gro-b T N65D are described, for example, in US Patent No. 6,447,766, the disclosure of which is incorporated herein by reference in its entirety.
  • CXCR2 agonists that may be used in conjunction with the compositions and methods described herein include other variants of Gro-b, such as peptides that have one or more amino acid substitutions, insertions, and/or deletions relative to Gro-b.
  • CXCR2 agonists that may be used in conjunction with the compositions and methods described herein include peptides having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1 ( e.g ., a peptide having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1).
  • the amino acid sequence of the CXCR2 agonist differs from that of SEQ ID NO: 1 only by way of one or more conservative amino acid substitutions. In some embodiments, in some embodiments, the amino acid sequence of the CXCR2 agonist differs from that of SEQ ID NO: 1 by no more than 20, no more than 15, no more than 10, no more than 5, or no more than 1 nonconservative amino acid substitutions.
  • CXCR2 agonists useful in conjunction with the compositions and methods described herein are variants of Gro-b T, such as peptides that have one or more amino acid substitutions, insertions, and/or deletions relative to Gro-b T.
  • the CXCR2 agonist may be a peptide having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 2 ( e.g ., a peptide having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2).
  • the amino acid sequence of the CXCR2 agonist differs from that of SEQ ID NO: 2 only by way of one or more conservative amino acid
  • the amino acid sequence of the CXCR2 agonist differs from that of SEQ ID NO: 2 by no more than 20, no more than 15, no more than 10, no more than 5, or no more than 1 nonconservative amino acid substitutions.
  • CXCR2 agonists useful in conjunction with the compositions and methods described herein are variants of Gro-b N69D, such as peptides that have one or more amino acid substitutions, insertions, and/or deletions relative to Gro-b N69D.
  • the CXCR2 agonist may be a peptide having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 3 (e.g., a peptide having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3).
  • the amino acid sequence of the CXCR2 agonist differs from that of SEQ ID NO: 3 only by way of one or more conservative amino acid
  • the amino acid sequence of the CXCR2 agonist differs from that of SEQ ID NO: 3 by no more than 20, no more than 15, no more than 10, no more than 5, or no more than 1 nonconservative amino acid substitutions.
  • CXCR2 agonists useful in conjunction with the compositions and methods described herein are variants of Gro-b T N65D, such as peptides that have one or more amino acid substitutions, insertions, and/or deletions relative to Gro-b T N65D.
  • the CXCR2 agonist may be a peptide having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 4 ( e.g ., a peptide having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4).
  • the amino acid sequence of the CXCR2 agonist differs from that of SEQ ID NO: 4 only by way of one or more conservative amino acid substitutions. In some embodiments, in some embodiments, the amino acid sequence of the CXCR2 agonist differs from that of SEQ ID NO: 4 by no more than 20, no more than 15, no more than 10, no more than 5, or no more than 1 nonconservative amino acid
  • the CXCR2 agonist is an antibody or antigen-binding fragment thereof that binds CXCR2 and activates CXCR2 signal transduction.
  • the CXCR2 agonist may be an antibody or antigen-binding fragment thereof that binds the same epitope on CXCR2 as Gro-b or a variant or truncation thereof, such as Gro-b T, as assessed, for example, by way of a competitive CXCR2 binding assay.
  • the CXCR2 agonist is an antibody or an antigen-binding fragment thereof that competes with Gro-b or a variant or truncation thereof, such as Gro-b T, for binding to CXCR2.
  • the antibody or antigen-binding fragment thereof is selected from the group consisting of a monoclonal antibody or antigen binding fragment thereof, a polyclonal antibody or antigen-binding fragment thereof, a humanized antibody or antigen-binding fragment thereof, a bispecific antibody or antigen binding fragment thereof, a dual-variable immunoglobulin domain, a single-chain Fv molecule (scFv), a diabody, a triabody, a nanobody, an antibody-like protein scaffold, a Fv fragment, a Fab fragment, a F(ab’) 2 molecule, and a tandem di-scFv.
  • the antibody has an isotype selected from the group consisting of IgG, IgA, IgM, IgD, and IgE.
  • the peptidic CXCR2 agonists described herein, such as Gro-b, Gro-b T, and variants thereof, may be prepared synthetically, for instance, using solid phase peptide synthesis techniques.
  • Systems and processes for performing solid phase peptide synthesis include those that are known in the art and have been described, for instance, in US Patent Nos. 9,169,287; 9,388,212; 9,206,222; 6,028,172; and 5,233,044, among others, the disclosures of each of which are incorporated herein by reference as they pertain to protocols and techniques for the synthesis of peptides on solid support.
  • Solid phase peptide synthesis is a process in which amino acid residues are added to peptides that have been immobilized on a solid support, such as a polymeric resin (e.g ., a hydrophilic resin, such as a polyethylene-glycol-containing resin, or hydrophobic resin, such as a polystyrene-based resin).
  • a polymeric resin e.g ., a hydrophilic resin, such as a polyethylene-glycol-containing resin, or hydrophobic resin, such as a polystyrene-based resin.
  • Peptides such as those containing protecting groups at amino, hydroxy, thiol, and carboxy substituents, among others, may be bound to a solid support such that the peptide is effectively immobilized on the solid support.
  • the peptides may be bound to the solid support via their C termini, thereby immobilizing the peptides for subsequent reaction in at a resin-liquid interface.
  • the process of adding amino acid residues to immobilized peptides can include exposing a deprotection reagent to the immobilized peptides to remove at least a portion of the protection groups from at least a portion of the immobilized peptides.
  • the deprotection reagent exposure step can be configured, for instance, such that side-chain protection groups are preserved, while N-terminal protection groups are removed.
  • an exemplary amino protecting contains a fluorenylmethyloxycarbonyl (Fmoc) substituent.
  • a deprotection reagent containing a strongly basic substance, such as piperidine e.g., a piperidine solution in an appropriate organic solvent, such as dimethyl formamide (DMF)
  • a strongly basic substance such as piperidine
  • DMF dimethyl formamide
  • Other protecting groups suitable for the protection of amino substituents include, for instance, the tert-butyloxy carbonyl (Boc) moiety.
  • a deprotection reagent comprising a strong acid, such as trifluoroacetic acid (TFA) may be exposed to immobilized peptides containing a Boc-protected amino substituent so as to remove the Boc protecting group by an ionization process.
  • peptides can be protected and deprotected at specific sites, such as at one or more side-chains or at the N- or C -terminus of an immobilized peptide so as to append chemical functionality regioselectively at one or more of these positions.
  • This can be used, for instance, to derivatize a side-chain of an immobilized peptide, or to synthesize a peptide, e.g, from the C-terminus to the N- terminus.
  • the process of adding amino acid residues to immobilized peptides can include, for instance, exposing protected, activated amino acids to the immobilized peptides such that at least a portion of the activated amino acids are bonded to the immobilized peptides to form newly-bonded amino acid residues.
  • the peptides may be exposed to activated amino acids that react with the deprotected N-termini of the peptides so as to elongate the peptide chain by one amino acid.
  • Amino acids can be activated for reaction with the deprotected peptides by reaction of the amino acid with an agent that enhances the electrophilicity of the backbone carbonyl carbon of the amino acid.
  • phosphonium and uronium salts can, in the presence of a tertiary base ( e.g .,
  • DIPEA diisopropylethylamine
  • TEA triethylamine
  • Other reagents can be used to help prevent racemization that may be induced in the presence of a base.
  • These reagents include carbodiimides (for example, DCC or WSCDI) with an added auxiliary nucleophile (for example, l-hy dr oxy-benzotri azole (HOBt), l-hydroxy-azabenzotriazole (HO At), or HOSu) or derivatives thereof.
  • TBTU Another reagent that can be utilized to prevent racemization is TBTU.
  • These types of compounds can also increase the rate of carbodiimide-mediated couplings, as well as prevent dehydration of Asn and Gln residues.
  • Typical additional reagents include also bases such as N,N-diisopropylethylamine (DIPEA), triethylamine (TEA) or N- methylmorpholine (NMM).
  • DIPEA N,N-diisopropylethylamine
  • TEA triethylamine
  • NMM N- methylmorpholine
  • the solid phase peptide synthesis techniques described above, synthetic Gro-b, Gro-b T, and variants thereof that may be used in conjunction with the compositions and methods described herein may have a purity of, e.g., at least about 95% relative to the deamidated versions of these peptides (i.e., contain less than 5% of the corresponding deamidated peptide).
  • synthetic Gro- b, Gro-b T, and variants thereof that may be used in conjunction with the compositions and methods described herein may have a purity of about 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.99%, or more, relative to the deamidated versions of these peptides (e.g ., the Asn69 deamidated version of SEQ ID NO: 1 or the Asn65 deamidated version of SEQ ID NO: 2).
  • synthetic Gro-b, Gro-b T, and variants thereof may have, for instance, a purity of from about 95% to about 99.99%, such as a purity of from about 95% to about 99.99%, about 96% to about 99.99%, about 97% to about 99.99%, about 98% to about 99.99%, about 99% to about 99.99%, about 99.9% to about 99.99%, about 95% to about 99.5%, about 96% to about 99.5%, about 95% to about 99%, or about 97% to about 99% relative to the deamidated versions of these peptides (e.g., the Asn69 deamidated version of SEQ ID NO: 1 or the Asn65 deamidated version of SEQ ID NO: 2).
  • the deamidated versions of these peptides e.g., the Asn69 deamidated version of SEQ ID NO: 1 or the Asn65 deamidated version of SEQ ID NO: 2.
  • CXCR4 antagonists for use in conjunction with the compositions and methods described herein are compounds represented by formula (I)
  • A includes a monocyclic or bicyclic fused ring system including at least one nitrogen atom and B is H or a substituent of from 1 to 20 atoms; and wherein Z’ is:
  • linker is a bond, optionally substituted alkylene (e.g ., optionally substituted Ci- C 6 alkylene), optionally substituted heteroalkylene (e.g., optionally substituted Ci-C 6 heteroalkyl ene), optionally substituted alkenyl ene (e.g, optionally substituted C 2 -C 6 alkenyl ene), optionally substituted heteroalkenylene (e.g, optionally substituted C 2 -C 6 heteroalkenyl ene), optionally substituted alkynylene (e.g, optionally substituted C 2 -C 6 alkynylene), optionally substituted heteroalkynylene (e.g, optionally substituted C 2 -C 6 heteroalkynylene), optionally substituted cycloalkylene, optionally substituted alkylene (e.g ., optionally substituted Ci- C 6 alkylene), optionally substituted heteroalkylene (e.g., optionally substituted Ci-C 6 heteroalky
  • heterocycloalkyl ene optionally substituted arylene, or optionally substituted heteroaryl ene.
  • Z and Z’ may each independently a cyclic polyamine containing from 9 to 32 ring members, of which from 2 to 8 are nitrogen atoms separated from one another by 2 or more carbon atoms. In some embodiments, Z and Z’ are identical substituents. As an example, Z may be a cyclic polyamine including from 10 to 24 ring members. In some embodiments, Z may be a cyclic polyamine that contains 14 ring members. In some embodiments, Z includes 4 nitrogen atoms. In some embodiments, Z is 1,4,8,11 -tetraazocyclotetradecane.
  • the linker is represented by formula (ID)
  • ring D is an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted cycloalkyl group, or an optionally substituted
  • X and Y are each independently optionally substituted alkylene (e.g, optionally substituted Ci-C 6 alkylene), optionally substituted heteroalkylene (e.g, optionally substituted Ci-C 6 heteroalkylene), optionally substituted alkenyl ene (e.g, optionally substituted C 2 -C 6 alkenyl ene), optionally substituted heteroalkenylene (e.g, optionally substituted C 2 -C 6 heteroalkenylene), optionally substituted alkynylene (e.g, optionally substituted C 2 -C 6 alkynylene), or optionally substituted heteroalkynylene (e.g, optionally substituted C 2 -C 6 heteroalkynylene).
  • optionally substituted alkylene e.g, optionally substituted Ci-C 6 alkylene
  • optionally substituted heteroalkylene e.g, optionally substituted Ci-C 6 heteroalkylene
  • optionally substituted alkenyl ene e.g
  • the linker may be represented by formula (IE) wherein ring D is an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted cycloalkyl group, or an optionally substituted
  • X and Y are each independently optionally substituted alkyl ene (e.g ., optionally substituted Ci-C 6 alkyl ene), optionally substituted heteroalkylene (e.g., optionally substituted Ci-C 6 heteroalkyl ene), optionally substituted C 2 -C 6 alkenyl ene (e.g, optionally substituted C 2 -C 6 alkenyl ene), optionally substituted heteroalkenylene (e.g, optionally substituted C 2 -C 6 heteroalkenyl ene), optionally substituted alkynylene (e.g, optionally substituted C 2 -C 6 alkynylene), or optionally substituted heteroalkynylene (e.g, optionally substituted C 2 -C 6 heteroalkynylene).
  • optionally substituted alkyl ene e.g ., optionally substituted Ci-C 6 alkyl ene
  • optionally substituted heteroalkylene e.g.
  • X and Y are each independently optionally substituted Ci-C 6 alkylene. In some embodiments, X and Y are identical substituents. In some embodiments, X and Y may be each be methylene, ethylene, n-propylene, n-butylene, n-pentylene, or n-hexylene groups. In some embodiments, X and Y are each methylene groups.
  • the linker may be, for example, l,3-phenylene, 2,6-pyridine, 3,5-pyridine, 2,5- thiophene, 4,4'-(2,2'-bipyrimidine), 2,9-(l,l0-phenanthroline), or the like.
  • the linker is 1, 4-phenyl ene-bis-(m ethyl ene).
  • CXCR4 antagonists useful in conjunction with the compositions and methods described herein include plerixafor (also referred to herein as“AMD3100” and“Mozibil”), or a pharmaceutically acceptable salt thereof, represented by formula (II), 1,1 '-[1,4- phenylenebis(m ethylene)] -bis- 1 ,4,8, 11 -tetra-azacyclotetradecane.
  • CXCR4 antagonists that may be used in conjunction with the compositions and methods described herein include variants of plerixafor, such as a compound described in US Patent No. 5,583, 131, the disclosure of which is incorporated herein by reference as it pertains to CXCR4 antagonists.
  • the CXCR4 antagonist may be a compound selected from the group consisting of: l,r-[l,3-phenylenebis(methylene)]-bis- 1,4,8, 1 l-tetra-azacyclotetradecane; l,r-[l,4-phenylene-bis-(methylene)]-bis-l,4,8,l 1- tetraazacyclotetradecane; bis-zinc or bis-copper complex of l,l'-[l,4-phenylene-bis- (methylene)]-bis-l,4,8, 1 l-tetraazacyclotetradecane; 1,1 '-[3,3 '-biphenylene-bis-(methylene)]- bis-l,4,8,l l-tetraazacyclotetradecane; 11,11 '-[l,4-phenylene-bis-(methylene)]-bis-l,4,7,l 1- tetraazacyclotetradecane
  • the CXCR4 antagonist is a compound described in US 2006/0035829, the disclosure of which is incorporated herein by reference as it pertains to CXCR4 antagonists.
  • the CXCR4 antagonist may be a compound selected from the group consisting of: 3,7,l l,l7-tetraazabicyclo(l3.3.l)heptadeca- l(l7),l3,l5-triene;
  • the CXCR4 antagonist may be a compound described in WO 2001/044229, the disclosure of which is incorporated herein by reference as it pertains to CXCR4 antagonists.
  • the CXCR4 antagonist may be a compound selected from the group consisting of: N-[4-(l l-fluoro-l, 4, 7-triazacyclotetradecanyl)-l, 4-phenyl enebis(methylene)]- 2-(aminomethyl)pyridine; N-[4-(l 1,1 l-difluoro-l,4,7-triazacyclotetradecanyl)-l,4- phenylenebis(methylene)]-2-(aminomethyl)pyridine; N-[4-(l,4,7-triazacyclotetradecan-2- onyl)-l,4-phenylenebis(methylene)]-2-(aminomethyl)pyridine; N-[l2-(5-oxa-l,9- di
  • CXCR4 antagonists useful in conjunction with the compositions and methods described herein include compounds described in WO 2000/002870, the disclosure of which is incorporated herein by reference as it pertains to CXCR4 antagonists.
  • the CXCR4 antagonist may be a compound selected from the group consisting of: N-[l,4,8, 1 l-tetraazacycl otetra-decanyl-l, 4-phenyl enebis-(m ethyl ene)]-2- (aminomethyl)pyridine; N-[l,4,8, 1 l-tetraazacycl otetra-decanyl-l, 4- phenylenebis(methylene)]-N-methyl-2-(aminomethyl)pyridine; N-[l,4,8,l 1- tetraazacyclotetra-decanyl-l,4-phenylenebis(methylene)]-4-(aminomethyl)pyridine; N- [l,4,8,l
  • the CXCR4 antagonist is a compound selected from the group consisting of: l-[2,6-dimethoxypyrid-4-yl(methylene)]-l,4,8,l l-tetraazacyclotetradecane; 1- [2-chloropyrid-4-yl(methylene)]-l,4,8,l l-tetraazacyclotetradecane; l-[2,6-dimethylpyrid-4- yl(methylene)]-l,4,8,l l-tetraazacyclotetradecane; l-[2-methylpyrid-4-yl(methylene)]- 1,4, 8,1 l-tetraazacyclotetradecane; l-[2,6-dichloropyrid-4-yl(methylene)]-l,4,8,l 1- tetraazacyclotetradecane; l-[2-chloropyrid-5-yl(methylene)]
  • the CXCR4 antagonist is a compound described in US Patent No. 5,698,546, the disclosure of which is incorporated herein by reference as it pertains to CXCR4 antagonists.
  • the CXCR4 antagonist may be a compound selected from the group consisting of: 7,7'-[l,4-phenylene-bis(methylene)]bis-3,7, 11,17- tetraazabicyclo[ 13.3.1 Jheptadeca- 1 (17), 13 , 15-triene; 7,7 '-[ 1 , 4-phenyl ene- bis(methylene)]bis[l5-chloro-3,7,l l,l7-tetraazabicyclo [l3.3.
  • the CXCR4 antagonist is a compound described in US Patent No. 5,021,409, the disclosure of which is incorporated herein by reference as it pertains to CXCR4 antagonists.
  • the CXCR4 antagonist may be a compound selected from the group consisting of: 2,2'-bicyclam, 6,6'-bicyclam; 3,3 '-(bis-l,5,9, 13- tetraaza cyclohexadecane); 3,3'-(bis-l,5,8,l l,l4-pentaazacyclohexadecane); methylene (or polymethylene) di-l-N-l,4,8,l l-tetraaza cyclotetradecane; 3,3 '-bis-l,5,9, 13- tetraazacyclohexadecane; 3,3'-bis-l,5,8,l l,l4-pentaazacyclohexadecane; 5,5'-bis-bis-
  • the CXCR4 antagonist is a compound described in WO 2000/056729, the disclosure of which is incorporated herein by reference as it pertains to CXCR4 antagonists.
  • the CXCR4 antagonist may be a compound selected from the group consisting of: N-(2-pyridinylmethyl)-N'-(6,7,8,9-tetrahydro-5H- cyclohepta[b]pyridin-9-yl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(5, 6,7,8- tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(6,7-dihydro- 5H-cyclopenta[b]pyridin-7-yl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'- (l,2,3,4
  • CXCR4 antagonists that may be used to in conjunction with the compositions and methods described herein include those described in WO 2001/085196, WO 1999/050461, WO 2001/094420, and WO 2003/090512, the disclosures of each of which are incorporated herein by reference as they pertain to compounds that inhibit CXCR4 activity or expression.
  • hematopoietic and progenitor cells Prior to infusion into a patient, hematopoietic and progenitor cells may be expanded ex vivo , for example, by contacting the cells with an aryl hydrocarbon receptor antagonist.
  • Aryl hydrocarbon receptor antagonists useful in conjunction with the compositions and methods described herein include those described in US Patent No. 9,580,426, the disclosure of which is incorporated herein by reference in its entirety.
  • aryl hydrocarbon receptor antagonists include those represented by formula (III)
  • L is selected from— NR 5a (CH 2 ) 2-3 ,— NR 5a (CH 2 ) 2 NR 5b— — NR 5a (CH 2 ) 2 S— ,—
  • R 5a and R 5b are independently selected from hydrogen and Ci -4 alkyl;
  • Ri is selected from thiophenyl, lH-benzoimidazolyl, isoquinolinyl, lH-imidazopyridinyl, benzothiophenyl, pyrimidinyl, pyridinyl, pyrazinyl, pyridazinyl, and thiazolyl; In some embodiments, wherein the thiophenyl, lH-benzoimidazolyl, isoquinolinyl, 1H- imidazopyridinyl, benzothiophenyl, pyrimidinyl, pyridinyl, pyrazinyl, pyridazinyl, or thiazolyl of Ri can be optionally substituted by 1 to 3 radicals independently selected from cyano, hydroxy, C l-4 alkyl, Ci -4 alkoxy, halo, halo- sub stituted-C l- alkyl, halo- sub stituted-C
  • R 8a and R 8b are independently selected from hydrogen and Ci -4 alkyl;
  • R 2 is selected from— S(0) 2 NR 6a R6 b ,— NR a C(0)R 6b— ,— NR 6a C(0)NR 6b Rr,c, phenyl, 1H- pyrrol opyri din-3 -yl, lH-pyrrolopyridin-5-yl, lH-indolyl thiophenyl, pyridinyl, lH-l,2,4- triazolyl, 2-oxoimidazolidinyl, lH-pyrazolyl, 2-oxo-2,3-dihydro-lH-benzoimidazolyl and lH-indazolyl; wherein R 6a , R f , b and R 6c are independently selected from hydrogen and Ci.
  • Rv a and R 7b are independently selected from hydrogen and Ci -4 alkyl;
  • R 3 is selected from hydrogen, Ci- alkyl and biphenyl
  • Rr is selected from C M O alkyl, prop-l-en-2-yl, cyclohexyl, cyclopropyl, 2-(2-oxopyrrolidin-l- yl)ethyl, oxetan-2-yl, oxetan-3-yl, benzhydryl, tetrahydro-2H-pyran-2-yl, tetrahydro-2H- pyran-3-yl, phenyl, tetrahydrofuran-3-yl, and benzyl, (4-pentylphenyl)(phenyl)methyl and 1- (l-(2-oxo-6,9, l2-trioxa-3-azatetradecan-l4-yl)-lH-l,2,3-triazol-4-yl)ethyl wherein said alkyl, cyclopropyl, cyclohexyl, 2-(2-oxopyrrolidin-l-yl)
  • aryl hydrocarbon receptor antagonists useful in conjunction with the compositions and methods described herein include SR-l, represented by formula (1), below.
  • Peptides and proteins described herein can be expressed in host cells, for example, by delivering to the host cell a nucleic acid encoding the corresponding peptide or protein.
  • CXCR2 agonists such as Gro-b, Gro-b T, Gro-b N69D, Gro-b T N65D, and variants thereof
  • Peptides and proteins described herein can be expressed in host cells, for example, by delivering to the host cell a nucleic acid encoding the corresponding peptide or protein.
  • the sections that follow describe a variety of techniques that can be used for the purposes of introducing nucleic acids encoding peptides and proteins described herein to a host cell for the purposes of recombinant expression.
  • Techniques that can be used to introduce a polynucleotide, such as nucleic acid encoding a CXCR2 agonist, such as Gro-b, Gro-b T, Gro-b N69D, Gro-b T N65D, or a variant thereof, into a cell e.g ., a mammalian cell, such as a human cell
  • a cell e.g ., a mammalian cell, such as a human cell
  • electroporation can be used to permeabilize mammalian cells (e.g., human cells) by the application of an electrostatic potential to the cell of interest.
  • Mammalian cells such as human cells, subjected to an external electric field in this manner are subsequently predisposed to the uptake of exogenous nucleic acids. Electroporation of mammalian cells is described in detail, e.g., in Chu et al. ( 1987) Nucleic Acids Research 15: 1311, the disclosure of which is incorporated herein by reference. A similar technique,
  • NucleofectionTM utilizes an applied electric field in order to stimulate the uptake of exogenous polynucleotides into the nucleus of a eukaryotic cell. NucleofectionTM and protocols useful for performing this technique are described in detail, e.g, in Distler el al. (2005) Experimental Dermatology 14:315, as well as in US 2010/0317114, the disclosures of each of which are incorporated herein by reference.
  • Additional techniques useful for the transfection of host cells for the purposes of recombinant peptide and protein expression include the squeeze-poration methodology. This technique induces the rapid mechanical deformation of cells in order to stimulate the uptake of exogenous DNA through membranous pores that form in response to the applied stress. This technology is advantageous in that a vector is not required for delivery of nucleic acids into a cell, such as a human cell. Squeeze-poration is described in detail, e.g ., in Sharei et al. (2013) Journal of Visualized Experiments 8l :e50980, the disclosure of which is incorporated herein by reference.
  • Lipofection represents another technique useful for transfection of cells. This method involves the loading of nucleic acids into a liposome, which often presents cationic functional groups, such as quaternary or protonated amines, towards the liposome exterior. This promotes electrostatic interactions between the liposome and a cell due to the anionic nature of the cell membrane, which ultimately leads to uptake of the exogenous nucleic acids, for example, by direct fusion of the liposome with the cell membrane or by endocytosis of the complex. Lipofection is described in detail, for example, in US Patent No. 7,442,386, the disclosure of which is incorporated herein by reference.
  • Similar techniques that exploit ionic interactions with the cell membrane to provoke the uptake of foreign nucleic acids include contacting a cell with a cationic polymer-nucleic acid complex.
  • exemplary cationic molecules that associate with polynucleotides so as to impart a positive charge favorable for interaction with the cell membrane are activated dendrimers (described, e.g. , in Dennig (2003) Topics in Current Chemistry 228:227, the disclosure of which is incorporated herein by reference) and diethylaminoethyl (DEAE)-dextran, the use of which as a transfection agent is described in detail, for example, in Gulick et al. (1997) Current Protocols in
  • Magnetic beads are another tool that can be used to transfect cells in a mild and efficient manner, as this methodology utilizes an applied magnetic field in order to direct the uptake of nucleic acids. This technology is described in detail, for example, in US 2010/0227406, the disclosure of which is incorporated herein by reference.
  • Another useful tool for inducing the uptake of exogenous nucleic acids by cells is laserfection, a technique that involves exposing a cell to electromagnetic radiation of a particular wavelength in order to gently permeabilize the cells and allow polynucleotides to penetrate the cell membrane. This technique is described in detail, e.g. , in Rhodes el al. (2007) Methods in Cell Biology 82:309, the disclosure of which is incorporated herein by reference.
  • Microvesicles represent another potential vehicle that can be used to introduce a nucleic acid encoding a peptide or protein described herein into a host cell for the purpose of recombinant expression.
  • microvesicles that have been induced by the co-overexpression of the glycoprotein VSV-G with, e.g ., a genome-modifying protein, such as a nuclease can be used to efficiently deliver proteins into a cell that subsequently catalyze the site-specific cleavage of an endogenous polynucleotide sequence so as to prepare the genome of the cell for the covalent incorporation of a polynucleotide of interest, such as a gene or regulatory sequence.
  • a genome-modifying protein such as a nuclease
  • Viral genomes provide a rich source of vectors that can be used for the efficient delivery of exogenous nucleic acids encoding peptides and proteins described herein, such as CXCR2 agonists, including Gro-b, Gro-b T, Gro-b N69D, Gro-b T N65D, and variants thereof, into host cells for the purpose of recombinant expression.
  • Viral genomes are particularly useful vectors for gene delivery because the polynucleotides contained within such genomes may be incorporated into the genome of a cell, for example, by way of generalized or specialized transduction. These processes may occur as part of the natural replication cycle of a viral vector, and may not require added proteins or reagents in order to induce gene integration.
  • viral vectors that may be used to introduce a nucleic acid molecule encoding a peptide or protein described herein into a host cell for recombinant expression include parvovirus, such as adeno-associated virus (AAV), retrovirus, adenovirus (e.g, Ad5, Ad26, Ad34, Ad35, and Ad48), coronavirus, negative strand RNA viruses such as orthomyxovirus (e.g, influenza virus), rhabdovirus (e.g, rabies and vesicular stomatitis virus), paramyxovirus (e.g.
  • AAV adeno-associated virus
  • retrovirus e.g, Ad5, Ad26, Ad34, Ad35, and Ad48
  • coronavirus e.g, Ad5
  • negative strand RNA viruses such as orthomyxovirus (e.g, influenza virus), rhabdovirus (e.g, rabies and vesicular stomatitis virus), paramyxo
  • RNA viruses such as picomavirus and alphavirus
  • double stranded DNA viruses including adenovirus, herpesvirus (e.g, Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g, vaccinia, modified vaccinia Ankara (MV A), fowlpox and canarypox).
  • herpesvirus e.g, Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus
  • poxvirus e.g, vaccinia, modified vaccinia Ankara (MV A), fowlpox and canarypox.
  • viruses useful for delivering polynucleotides encoding peptides and proteins described herein to host cells for recombinant expression purposes include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis vims, for example.
  • retroviruses include avian leukosis-sarcoma, mammalian C-type, B-type viruses, D-type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their replication, In Fundamental Virology, Third Edition, B. N. Fields, et al.
  • murine leukemia viruses include murine leukemia viruses, murine sarcoma viruses, mouse mammary tumor vims, bovine leukemia vims, feline leukemia vims, feline sarcoma vims, avian leukemia vims, human T-cell leukemia vims, baboon endogenous vims, Gibbon ape leukemia vims, Mason Pfizer monkey vims, simian immunodeficiency vims, simian sarcoma vims, Rous sarcoma vims and lentivimses.
  • vectors are described, for example, in ETS Patent No. 5,801,030, the disclosure of which is incorporated herein by reference as it pertains to viral vectors for use in gene delivery and recombinant protein and peptide expression.
  • hematopoietic stem cell transplant therapy can be administered to a subject in need of treatment so as to populate or repopulate one or more blood cell types, such as a blood cell lineage that is deficient or defective in a patient suffering from a stem cell disorder.
  • Hematopoietic stem and progenitor cells exhibit multi-potency, and can thus differentiate into multiple different blood lineages including, but not limited to, granulocytes (e.g ., promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g, reticulocytes, erythrocytes), thrombocytes (e.g, megakaryoblasts, platelet producing megakaryocytes, platelets), monocytes (e.g, monocytes, macrophages), dendritic cells, microglia, osteoclasts, and lymphocytes (e.g, NK cells, B-cells and T-cells).
  • granulocytes e.g ., promyelocytes, neutrophils, eosinophils, basophils
  • erythrocytes e.g, reticulocytes, erythrocytes
  • thrombocytes e.g
  • Hematopoietic stem cells are additionally capable of self-renewal, and can thus give rise to daughter cells that have equivalent potential as the mother cell, and also feature the capacity to be reintroduced into a transplant recipient whereupon they home to the hematopoietic stem cell niche and re- establish productive and sustained hematopoiesis.
  • hematopoietic stem and progenitor cells represent a useful therapeutic modality for the treatment of a wide array of disorders in which a patient has a deficiency or defect in a cell type of the hematopoietic lineage.
  • the deficiency or defect may be caused, for example, by depletion of a population of endogenous cells of the hematopoietic system due to administration of a chemotherapeutic agent (e.g, in the case of a patient suffering from a cancer, such as a hematologic cancer described herein).
  • the deficiency or defect may be caused, for example, by depletion of a population of endogenous hematopoietic cells due to the activity of self-reactive immune cells, such as T lymphocytes or B lymphocytes that cross-react with self antigens ( e.g ., in the case of a patient suffering from an autoimmune disorder, such as an autoimmune disorder described herein).
  • the deficiency or defect in cellular activity may be caused by aberrant expression of an enzyme (e.g., in the case of a patient suffering from various metabolic disorders, such as a metabolic disorder described herein).
  • hematopoietic stem cells can be administered to a patient defective or deficient in one or more cell types of the hematopoietic lineage in order to re-constitute the defective or deficient population of cells in vivo , thereby treating the pathology associated with the defect or depletion in the endogenous blood cell population.
  • Hematopoietic stem and progenitor cells can be used to treat, e.g, a non-malignant hemoglobinopathy (e.g, a hemoglobinopathy selected from the group consisting of sickle cell anemia, thalassemia, Fanconi anemia, aplastic anemia, and Wiskott-Aldrich syndrome).
  • a CXCR4 antagonist and/or a CXCR2 agonist may be administered to a donor, such as a donor identified as likely to exhibit release of a population of hematopoietic stem and progenitor cells from a stem cell niche, such as the bone marrow, into circulating peripheral blood in response to such treatment.
  • the hematopoietic stem and progenitor cells thus mobilized may then be withdrawn from the donor and administered to a patient, where the cells may home to a hematopoietic stem cell niche and re-constitute a population of cells that are damaged or deficient in the patient.
  • hematopoietic stem and progenitor cells can be used to treat an immunodeficiency, such as a congenital immunodeficiency.
  • an immunodeficiency such as a congenital immunodeficiency.
  • the compositions and methods described herein can be used to treat an acquired immunodeficiency (e.g, an acquired immunodeficiency selected from the group consisting of HIV and AIDS).
  • an acquired immunodeficiency e.g, an acquired immunodeficiency selected from the group consisting of HIV and AIDS.
  • a CXCR4 antagonist and/or a CXCR2 agonist may be administered to a donor, such as a donor identified as likely to exhibit release of a population of hematopoietic stem and progenitor cells from a stem cell niche, such as the bone marrow, into circulating peripheral blood in response to such treatment.
  • Hematopoietic stem and progenitor cells thus mobilized may then be withdrawn from the donor and administered to a patient, where the cells may home to a hematopoietic stem cell niche and re-constitute a population of immune cells (e.g, T lymphocytes, B lymphocytes, NK cells, or other immune cells) that are damaged or deficient in the patient.
  • a metabolic disorder e.g, a metabolic disorder selected from the group consisting of glycogen storage diseases, mucopolysaccharidoses, Gaucher's Disease, Hurlers Disease, sphingolipidoses, and metachromatic leukodystrophy.
  • a CXCR4 antagonist and/or a CXCR2 agonist may be administered to a donor, such as a donor identified as likely to exhibit release of a population of hematopoietic stem and progenitor cells from a stem cell niche, such as the bone marrow, into circulating peripheral blood in response to such treatment.
  • the hematopoietic stem and progenitor cells thus mobilized may then be withdrawn from the donor and administered to a patient, where the cells may home to a hematopoietic stem cell niche and re-constitute a population of hematopoietic cells that are damaged or deficient in the patient.
  • hematopoietic stem or progenitor cells can be used to treat a malignancy or proliferative disorder, such as a hematologic cancer or
  • a CXCR4 antagonist and/or a CXCR2 agonist may be administered to a donor, such as a donor identified as likely to exhibit release of a population of hematopoietic stem and progenitor cells from a stem cell niche, such as the bone marrow, into circulating peripheral blood in response to such treatment.
  • hematopoietic stem and progenitor cells thus mobilized may then be withdrawn from the donor and administered to a patient, where the cells may home to a hematopoietic stem cell niche and re-constitute a population of cells that are damaged or deficient in the patient, such as a population of hematopoietic cells that is damaged or deficient due to the administration of one or more chemotherapeutic agents to the patient.
  • hematopoietic stem or progenitor cells may be infused into a patient in order to repopulate a population of cells depleted during cancer cell eradication, such as during systemic chemotherapy.
  • Exemplary hematological cancers that can be treated by way of administration of hematopoietic stem and progenitor cells in accordance with the compositions and methods described herein are acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia, multiple myeloma, diffuse large B-cell lymphoma, and non-Hodgkin’s lymphoma, as well as other cancerous conditions, including neuroblastoma.
  • Hematopoietic stem or progenitor cells mobilized to the peripheral blood of a subject may be withdrawn (e.g, harvested or collected) from the subject by any suitable technique.
  • the hematopoietic stem or progenitor cells may be withdrawn by a blood draw.
  • hematopoietic stem or progenitor cells mobilized to a subject’s peripheral blood as contemplated herein may be harvested (i.e., collected) using apheresis.
  • apheresis may be used to enrich a donor’s blood with mobilized hematopoietic stem or progenitor cells.
  • Additional diseases that can be treated by the administration of hematopoietic stem and progenitor cells to a patient include, without limitation, adenosine deaminase deficiency and severe combined immunodeficiency, hyper immunoglobulin M syndrome, Chediak- Higashi disease, hereditary lymphohistiocytosis, osteopetrosis, osteogenesis imperfecta, storage diseases, thalassemia major, systemic sclerosis, systemic lupus erythematosus, multiple sclerosis, and juvenile rheumatoid arthritis.
  • hematopoietic stem and progenitor cells can be used to treat autoimmune disorders.
  • transplanted hematopoietic stem and progenitor cells may home to a stem cell niche, such as the bone marrow, and establish productive hematopoiesis. This, in turn, can re-constitute a population of cells depleted during autoimmune cell eradication, which may occur due to the activity of self-reactive lymphocytes (e.g ., self-reactive T lymphocytes and/or self-reactive B lymphocytes).
  • self-reactive lymphocytes e.g ., self-reactive T lymphocytes and/or self-reactive B lymphocytes.
  • autoimmune diseases that can be treated by way of administering
  • hematopoietic stem and progenitor cells to a patient include, without limitation, psoriasis, psoriatic arthritis, Type 1 diabetes mellitus (Type 1 diabetes), rheumatoid arthritis (RA), human systemic lupus (SLE), multiple sclerosis (MS), inflammatory bowel disease (IBD), lymphocytic colitis, acute disseminated encephalomyelitis (ADEM), Addison's disease, alopecia universalis, ankylosing spondylitis, antiphospholipid antibody syndrome (APS), aplastic anemia, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune lymphoproliferative syndrome (ALPS), autoimmune oophoritis, Balo disease, Behcet's disease, bullous pemphigoid, cardiomyopathy, Chagas' disease, chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, Crohn'
  • Kawasaki's disease lichen planus, Lyme disease, Meniere disease, mixed connective tissue disease (MCTD), myasthenia gravis, neuromyotonia, opsoclonus myoclonus syndrome (OMS), optic neuritis, Ord's thyroiditis, pemphigus vulgaris, pernicious anemia,
  • MCTD mixed connective tissue disease
  • OMS opsoclonus myoclonus syndrome
  • optic neuritis Ord's thyroiditis
  • pemphigus vulgaris pernicious anemia
  • polychondritis polymyositis and dermatomyositis, primary biliary cirrhosis, polyarteritis nodosa, polyglandular syndromes, polymyalgia rheumatica, primary agammaglobulinemia, Raynaud phenomenon, Reiter' s syndrome, rheumatic fever, sarcoidosis, scleroderma, Sjogren's syndrome, stiff person syndrome, Takayasu's arteritis, temporal arteritis (also known as "giant cell arteritis"), ulcerative colitis, collagenous colitis, uveitis, vasculitis, vitiligo, vulvodynia ("vulvar vestibulitis”), and Wegener' s granulomatosis.
  • a method of harvesting hematopoietic stem cells from a human subject comprises administering a CXCR2 agonist and a CXCR4 antagonist to the human subject and harvesting the hematopoietic stem cells from peripheral blood of the human subject.
  • a method of transplanting hematopoietic stem cells into a human patient in need thereof comprises administering a CXCR2 agonist and a CXCR4 antagonist to a hematopoietic stem cell donor, harvesting the hematopoietic stem cells from peripheral blood of the donor, and transplanting the harvested hematopoietic stem cells into the patient.
  • the patient is the donor.
  • withdrawn hematopoietic stem or progenitor cells may be re-infused into the patient, such that the cells may subsequently home hematopoietic tissue and establish productive hematopoiesis, thereby populating or repopulating a line of cells that is defective or deficient in the patient (e.g ., a population of megakaryocytes, thrombocytes, platelets, erythrocytes, mast cells, myeoblasts, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, osteoclasts, antigen- presenting cells, macrophages, dendritic cells, natural killer cells, T-lymphocytes, and B- lymphocytes).
  • the transplanted hematopoietic stem or progenitor cells are least likely to undergo graft rejection, as the infused cells are derived from the patient and
  • the patient and the donor may be distinct.
  • the patient and the donor are related, and may, for example, be HLA-matched.
  • HLA-matched donor-recipient pairs have a decreased risk of graft rejection, as endogenous T cells and NK cells within the transplant recipient are less likely to recognize the incoming hematopoietic stem or progenitor cell graft as foreign, and are thus less likely to mount an immune response against the transplant.
  • Exemplary HLA-matched donor-recipient pairs are donors and recipients that are genetically related, such as familial donor-recipient pairs ( e.g ., sibling donor-recipient pairs).
  • the patient and the donor are HLA-mismatched, which occurs when at least one HLA antigen, in particular with respect to HLA-A, HLA-B and HLA-DR, is mismatched between the donor and recipient.
  • HLA-mismatched occurs when at least one HLA antigen, in particular with respect to HLA-A, HLA-B and HLA-DR, is mismatched between the donor and recipient.
  • one haplotype may be matched between the donor and recipient, and the other may be mismatched.
  • CD34 dim cells are particularly useful, in part because CD34 dim cells are capable of suppressing alloreactive T lymphocyte proliferation when administered to a recipient, thereby reducing the risk of graft vs. host disease (GVHD).
  • GVHD graft vs. host disease
  • administration of a CXCR2 agonist and a CXCR4 antagonist according to the methods disclosed herein mobilizes hematopoietic stem cells comprising CD34 dim cells from the bone marrow of a donor into peripheral blood.
  • the CD34 dim cells are present in a higher amount in the peripheral blood as compared to peripheral blood from an unmobilized mammal.
  • the CD34 dim cells are present in a higher amount in the peripheral blood than if the hematopoietic stem cells were mobilized using the CXCR4 antagonist alone.
  • the methods disclosed herein are useful in performing an allogeneic hematopoietic stem cell transplant in a patient in need thereof.
  • the method can include infusing into the patient a therapeutically effective amount of allogeneic
  • the method includes administering to the donor (i) a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof at a dose of from about 50 pg/kg to about 1,000 pg/kg and (ii) a CXCR4 antagonist.
  • CD34 dim cells have been shown to increase overall survival (OS), decrease non-relapse mortality (NRM, i.e., the time to death without relapse/recurrence), and lower the risk of infection (e.g ., cytomegalovirus (CMV) infection) in a patient having a standard risk disease receiving an allogenic hematopoietic cell transplant.
  • OS overall survival
  • NAM non-relapse mortality
  • CMV cytomegalovirus
  • the methods of treating a stem cell disorder in a human patient disclosed herein can include infusing into the patient a therapeutically effective amount of the hematopoietic stem cells mobilized by any one of the methods disclosed herein, wherein the mobilized hematopoietic stem cells comprise CD34 dim cells, and wherein the treatment results in increased OS, decreased NRM, and/or lowered risk of infection (e.g., CMV infection).
  • a therapeutically effective amount of the hematopoietic stem cells mobilized by any one of the methods disclosed herein wherein the mobilized hematopoietic stem cells comprise CD34 dim cells
  • the treatment results in increased OS, decreased NRM, and/or lowered risk of infection (e.g., CMV infection).
  • the methods described herein can be used in preventing, reducing the risk of developing, or reducing the severity of a post-transplant infection in a patient in need thereof.
  • the method can include infusing into the patient a therapeutically effective amount of hematopoietic stem cells, wherein the hematopoietic stem cells were mobilized from bone marrow of a human donor into peripheral blood of the human donor according to the methods described herein, for example, administering to the human donor (i) a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof at a dose of from about 50 pg/kg to about 1,000 pg/kg and (ii) a CXCR4 antagonist.
  • the infection is a CMV infection.
  • the disclosure relates to a method of preventing, reducing the risk of developing, or reducing the severity of graft versus host disease (GVHD) in a patient in need thereof, wherein the method includes infusing into the patient a therapeutically effective amount of hematopoietic stem cells, wherein the hematopoietic stem cells were mobilized from bone marrow of a mammalian donor into peripheral blood by the methods described herein, e.g, including administering to the mammalian donor a CXCR2 agonist and a CXCR4 antagonist.
  • GVHD graft versus host disease
  • the hematopoietic stem and progenitor cells mobilized from the bone marrow of a donor into peripheral blood comprise at least 1%, at least 2% at least 5% at least 10%, at least 15%, at least 20% or at least 20% or more CD34 dim cells as compared to peripheral blood from an unmobilized mammal.
  • the hematopoietic stem and progenitor cells mobilized from the bone marrow of a donor into peripheral blood comprise at from about 1% to about 5%, from about 1% to about 10%, from about 1% to about 15%, from about 1% to about 20%, from about 2% to about 25%, 2% to about 5%, from about 2% to about 10%, from about 2% to about 15%, from about 2% to about 20%, from about 2% to about 25%, from about 5% to about 10%, from about 5% to about 15%, from about 5% to about 20%, from about 5% to about 25%, from about 10% to about 15%, from about 10% to about 20%, from about 10% to about 25%, from about 15% to about 20%, from about 15% to about 20%, from about 15% to about 25% CD34 dim cells as compared to peripheral blood from an unmobilized mammal.
  • the hematopoietic stem and progenitor cells mobilized from the bone marrow of a donor into peripheral blood comprise at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least lO-fold, at least 11 -fold, at least 12-fold, at least 13 -fold, at least 14-fold, at least 15-fold, at least 20-fold, at least 30-fold, at least 50-fold more CD34 dim cells as compared to peripheral blood from an unmobilized mammal.
  • the hematopoietic stem and progenitor cells mobilized from the bone marrow of a donor into peripheral blood comprise between about 1.5-fold and 30-fold, between about 5-fold and about 25-fold, between about lO-fold and about 20-fold, or between about l2-fold and about l7-fold more CD34 dim cells as compared to peripheral blood from an unmobilized mammal.
  • the hematopoietic stem and progenitor cells mobilized from the bone marrow of a donor into peripheral blood comprise at least 1%, at least 2% at least 5% at least 10%, at least 15%, at least 20% or at least 20% or more CD34 dim cells than if the hematopoietic stem cells were mobilized using the CXCR4 antagonist alone.
  • the hematopoietic stem and progenitor cells mobilized from the bone marrow of a donor into peripheral blood comprise at from about 1% to about 5%, from about 1% to about 10%, from about 1% to about 15%, from about 1% to about 20%, from about 2% to about 25%, 2% to about 5%, from about 2% to about 10%, from about 2% to about 15%, from about 2% to about 20%, from about 2% to about 25%, from about 5% to about 10%, from about 5% to about 15%, from about 5% to about 20%, from about 5% to about 25%, from about 10% to about 15%, from about 10% to about 20%, from about 10% to about 25%, from about 15% to about 20%, from about 15% to about 20%, from about 15% to about 25% CD34 dim cells than if the hematopoietic stem cells were mobilized using the CXCR4 antagonist alone.
  • the hematopoietic stem and progenitor cells mobilized from the bone marrow of a donor into peripheral blood comprise at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least lO-fold, at least 11 -fold, at least 12-fold, at least 13 -fold, at least 14-fold, at least 15-fold, at least 20-fold, at least 30-fold, at least 50-fold more CD34 dim cells than if the hematopoietic stem cells were mobilized using the CXCR4 antagonist alone.
  • the hematopoietic stem and progenitor cells mobilized from the bone marrow of a donor into peripheral blood comprise between about 1.5-fold and 30-fold, between about 5-fold and about 25-fold, between about lO-fold and about 20-fold, or between about l2-fold and about 17-fold more CD34 dim cells than if the hematopoietic stem cells were mobilized using the CXCR4 antagonist alone.
  • hematopoietic stem cells obtained from a donor may be genetically modified, for example, by disrupting an endogenous gene. This strategy can be used, for example, to silence the expression of one or more major
  • CRISPR clustered regularly interspaced short palindromic repeats
  • Cas9 Cas9 nuclease
  • Polynucleotides containing these foreign sequences and the repeat-spacer elements of the CRISPR locus are in turn transcribed in a host cell to create a guide RNA, which can subsequently anneal to a target sequence and localize the Cas9 nuclease to this site.
  • highly site-specific cas9-mediated DNA cleavage can be engendered in a foreign polynucleotide because the interaction that brings cas9 within close proximity of the target DNA molecule is governed by RNA:DNA hybridization.
  • RNA:DNA hybridization As a result, one can theoretically design a CRISPR/Cas system to cleave any target DNA molecule of interest. This technique has been exploited in order to edit eukaryotic genomes (Hwang et al. (2013) Nature
  • Biotechnology 31 :227 the disclosure of which is incorporated herein by reference
  • CRISPR/Cas to modulate gene expression has been described in, e.g. , US 8,697,359, the disclosure of which is incorporated herein by reference.
  • Alternative methods for site-specifically cleaving genomic DNA prior to the incorporation of a gene of interest in a hematopoietic stem cell include the use of zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs).
  • ZFNs zinc finger nucleases
  • TALENs transcription activator-like effector nucleases
  • these enzymes do not contain a guiding polynucleotide to localize to a specific target sequence. Target specificity is instead controlled by DNA binding domains within these enzymes.
  • ZFNs and TALENs in genome editing applications is described, e.g. , in Urnov et al. (2010) Nature Reviews Genetics 11 :636; and in Joung et al. (2013) Nature Reviews Molecular Cell Biology 14:49, the disclosure of both of which are incorporated herein by reference.
  • Additional genome editing techniques that can be used to incorporate polynucleotides encoding target genes into the genome of a hematopoietic stem cell include the use of ARCUSTM meganucleases that can be rationally designed so as to site-specifically cleave genomic DNA.
  • ARCUSTM meganucleases that can be rationally designed so as to site-specifically cleave genomic DNA.
  • the use of these enzymes for the incorporation of genes encoding target genes into the genome of a mammalian cell is advantageous in view of the defined structure- activity relationships that have been established for such enzymes.
  • meganucleases can be modified at certain amino acid positions in order to create nucleases that selectively cleave DNA at desired locations, enabling the site-specific incorporation of a target gene into the nuclear DNA of a hematopoietic stem cell.
  • These single-chain nucleases have been described extensively in, e.g. , US 8,021,867 and US 8,445,251, the disclosures of each of which are incorporated herein by reference.
  • the two agents may be administered to the donor concurrently.
  • the two agents may be administered to the donor concurrently.
  • the CXCR4 antagonist and the CXCR2 agonist may be co-formulated with one another and administered in the same pharmaceutical composition.
  • the CXCR4 antagonist and the CXCR2 agonist may be formulated in distinct pharmaceutical compositions and administered separately but simultaneously to the donor.
  • the CXCR4 antagonist is administered to the donor prior to administration of the CXCR2 agonist.
  • the CXCR4 antagonist may be administered to the donor from about 30 minutes to about 180 minutes prior to administration of the CXCR2 agonist, such as from about 40 minutes to about 160 minutes, about 50 minutes to about 150 minutes, about 60 minutes to about 140 minutes, about 70 minutes to about 130 minutes, about 60 minutes to about 120 minutes, about 70 minutes to about 110 minutes, or about 80 minutes to about 100 minutes ( e.g ., about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 75 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 105 minutes, about 110 minutes, about 115 minutes, about 120 minutes, about 125 minutes, about 130 minutes, about 135 minutes, about 140 minutes, about 145 minutes, about 150 minutes, about 155 minutes, about 160 minutes, about 165 minutes,
  • the CXCR4 antagonist is administered to the donor from about 30 minutes to about 60 minutes prior to administration of the CXCR2 agonist (e.g., about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, or about 60 minutes prior to administration of the CXCR2 agonist). In some embodiments, the CXCR4 antagonist may be administered to the donor about 45 minutes prior to administration of the CXCR2 agonist.
  • Isolation of the population of hematopoietic stem or progenitor cells may commence from about 10 minutes to about 60 minutes following completion of the administration of the CXCR4 antagonist and the CXCR2 agonist (e.g, about 10 minutes to about 1.9 hours, about 20 minutes to about 1.8 hours, about 25 minutes to about 1.7 hours, about 30 minutes to about 1.6 hours, about 40 minutes to about 1.5 hours (e.g, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, or about 120 minutes following completion of the administration of the CXCR4 antagonist and the CXCR2 agonist).
  • the CXCR4 antagonist and the CXCR2 agonist e.g, about 10 minutes to about 1.9 hours, about 20 minutes to about 1.8 hours, about 25 minutes to about 1.7 hours, about 30 minutes to about 1.6 hours, about 40 minutes to about 1.5 hours (e.g, about 10 minutes, about 15 minutes, about 20 minutes,
  • isolation of the population of hematopoietic stem or progenitor cells may commence from about 10 minutes to about 20 minutes following completion of the administration of the CXCR4 antagonist and the CXCR2 agonist (e.g, about 10 minutes, about 11 minutes, about 12 minutes, about 13 minutes, about 14 minutes, about 15 minutes, about 16 minutes, about 17 minutes, about 18 minutes, about 19 minutes, or about 20 minutes following completion of the administration of the CXCR4 antagonist and the CXCR2 agonist). In some embodiments, isolation of the population of hematopoietic stem or progenitor cells commences about 15 minutes following completion of the administration of the CXCR4 antagonist and the CXCR2 agonist.
  • the population of hematopoietic stem or progenitor cells is isolated from the donor over a period of from about 15 minutes to about 6 hours, such as from about 20 minutes to about 4.5 hours, about 30 minutes to about 4 hours, about 40 minutes to about 3.5 hours, about 50 minutes to about 3 hours, or about 1 hour to about 2 hours ( e.g ., over a period of about 15 minutes, about 20 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 75 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 105 minutes, about 110 minutes, about 115 minutes, about 120 minutes, about 180 minutes, about 240 minutes, about 300 minutes, or about 360 minutes).
  • the population of hematopoietic stem and progenitor cells may be isolated from the donor over a period of from about 30 minutes to about 1 hour (e.g., over a period of about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, or about 60 minutes).
  • the hematopoietic stem or progenitor cells may be harvested by apheresis. In some embodiments, the hematopoietic stem or progenitor cells may be harvested by drawing peripheral blood from the donor (i.e., subject).
  • the CXCR4 antagonists and CXCR2 agonists described herein may be administered to a patient by a variety of routes, such as intravenously, subcutaneously, intramuscularly, or parenterally.
  • routes such as intravenously, subcutaneously, intramuscularly, or parenterally.
  • the most suitable route for administration in any given case will depend on the particular agent administered, the patient, pharmaceutical formulation methods,
  • the CXCR2 agonist e.g, Gro-b, Gro-b T, or a variant thereof
  • the CXCR2 agonist may be administered to a donor intravenously.
  • CXCR2 agonists such as those described herein, rapidly give rise to populations of cells that are enriched in CD34 + CD90 + CD45RA cells (hematopoietic stem cells), and reduce the mobilization of other cell types, such as leukocytes, neutrophils, lymphocytes, and monocytes. This property is described in further detail in Example 1, below.
  • the CXCR2 agonists and CXCR4 antagonists contemplated herein may each be formulated into a pharmaceutical composition for administration to a subject, such as a mammalian subject (e.g ., a human subject).
  • a subject such as a mammalian subject (e.g ., a human subject).
  • contemplated herein are pharmaceutical compositions comprising a CXCR2 agonist and/or a CXCR4 antagonist, in admixture with one or more suitable diluents, carriers, and/or excipients.
  • Pharmaceutical compositions may include sterile aqueous suspensions.
  • a pharmaceutical composition may be administered to a subject, such as a human subject, alone or in combination with pharmaceutically acceptable carriers, the proportion of which may be determined by the quantity of active pharmaceutical ingredient (i.e., CXCR2 agonist and/or a CXCR4 antagonist), chosen route of administration, and standard pharmaceutical practice.
  • active pharmaceutical ingredient i.e., CXCR2 agonist and/or a CXCR4 antagonist
  • Contemplated CXCR2 agonists and CXCR4 antagonists may be administered to a subject, such as a mammalian subject (e.g., a human subject), by one or more routes of administration.
  • a subject such as a mammalian subject (e.g., a human subject)
  • contemplated CXCR2 agonists and CXCR4 antagonists may be administered to a subject by intravenous, intraperitoneal, intramuscular, intraarterial, or subcutaneous infusion, among others.
  • Contemplated CXCR2 agonists and CXCR4 antagonists may be administered to a subject in one or more doses.
  • a CXCR2 agonist and/or CXCR4 antagonist may be administered as a single dose or in two, three, four, five, or more doses.
  • subsequent doses may be provided during the same day or one or more days, weeks, months, or years following the initial dose.
  • contemplated CXCR2 agonists and CXCR4 antagonists described herein may be administered to a subject, such as a human subject one or more times daily, weekly, monthly, or yearly, depending on such factors as, for instance, the subject's age, body weight, sex, the subject’s diet, and the subject’s excretion rate.
  • the contemplated CXCR2 agonists and CXCR4 antagonists are each administered in a single dose once per day.
  • Hematopoietic stem or progenitor cells and pharmaceutical compositions described herein may be administered to a subject in one or more doses. When multiple doses are administered, subsequent doses may be provided one or more days, weeks, months, or years following the initial dose.
  • the hematopoietic stem cells and pharmaceutical compositions described herein may be administered to a subject, such as a human subject suffering from one or more diseases, conditions, or disorders described herein, one or more times daily, weekly, monthly, or yearly, depending on such factors as, for instance, the subject's age, body weight, sex, severity of the diseases being treated, the subject’s diet, and the subject’s excretion rate.
  • Example 1 The effects of Gro-b T on the mobilization of hematopoietic stem cells in mice and Rhesus monkeys
  • hematopoietic stem and progenitor cells for both autologous and allogeneic transplantation.
  • the most common clinical hematopoietic stem cell mobilization protocol is five days of Filgrastim (G-CSF). This regimen requires daily injections, has been associated with bone pain and often results in unpredictably low yields. A rapid mobilization method that ideally only required a single treatment and had robust and predictable kinetics would be a significant improvement over the current standard of care.
  • a unique CXCR2 agonist, Gro-b T induces rapid mobilization of stem and progenitor cells 15 minutes after a single injection.
  • CRU competitive repopulating units
  • FIG. 2A shows the pharmacokinetic profile of various dosages of Gro-b T when administered intravenously to Rhesus monkeys.
  • FIG. 2B shows the pharmacokinetic profile of various dosages of Gro-b T when administered subcutaneously to Rhesus monkeys. In all experiments, Gro-b T was administered to subjects concurrently with plerixafor.
  • CD34 + cells mobilized in response to Gro- b T + AMD3100 are enriched for primitive CD34 + CD90+ CD45RA- stem and progenitor cells.
  • the data shown in FIGS. 9 and 10 include the percentage of whole blood accounted for by CD34 + CD90 + CD45RA hematopoietic stem and progenitor cells for each treatment group. Absolute numbers and fold change in CD34 + CD90 + CD45RA cells per pL of peripheral blood are shown.
  • Data shown in FIGS. 9 and 10 are expressed as mean ⁇ SEM and represent 5 animals per group. Statistical significance was determined based on 2-way ANOVA with post-hoc Dunnett’s multiple comparisons test (* p ⁇ 0.05. **p ⁇ 0.01, *** p ⁇
  • Gro-b T and AMD3100 mobilizes hematopoietic stem and progenitor cells with colony forming potential.
  • the number of CFET per mL of peripheral blood was enumerated after seven days of culture in methylcellulose.
  • Data shown in FIG. 11 are expressed as mean ⁇ SEM and represent 3-5 animals per group. Statistical significance was determined based on 2-way ANOVA with post-hoc Dunnett’s multiple comparisons test (* p ⁇ 0.05).
  • the ratio of MMP-9 to TIMP-l is additionally elevated following treatment with Gro-b T and AMD3100 (FIGS. 12-14).

Abstract

The invention provides compositions and methods useful for mobilizing populations of hematopoietic stem and progenitor cells within a donor, as well as for determining whether samples of mobilized cells are suitable for release for ex vivo expansion and/or therapeutic use. In accordance with the compositions and methods described herein, mobilized hematopoietic stem and progenitor cells can be withdrawn from a donor and administered to a patient for the treatment of various stem cell disorders, including hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. In certain embodiments, the compositions and methods described herein lead to the mobilization of a population of CD34dim cells that have immunosuppressive effects and that can reduce the incidence of graft vs. host disease.

Description

DOSING REGIMENS FOR THE MOBILIZATION
OF HEMATOPOIETIC STEM AND PROGENITOR CELLS
Cross Reference to Related Applications
[0001] This application claims the benefit of and priority to U.S. Application No.
15/834,017, filed on December 6, 2017, U.S. Provisional Patent Application No. 62/596,056, filed on December 7, 2017, U.S. Application No. 16/101,676, filed on August 13, 2018, U.S. Provisional Patent Application No. 62/753,656, filed on October 31, 2018, and U.S.
Provisional Patent Application No. 62/773,954, filed on November 30, 2018, the disclosure of each of which is hereby incorporated by reference in its entirety.
Field of the Invention
[0002] The invention relates to the mobilization of hematopoietic stem and progenitor cells from a donor, such as a human donor, and to the treatment of patients suffering from various pathologies, such as blood diseases, metabolic disorders, cancers, and autoimmune diseases, among others.
Background of the Invention
[0003] Despite advances in the medicinal arts, there remains a demand for treating pathologies of the hematopoietic system, such as diseases of a particular blood cell, metabolic disorders, cancers, and autoimmune conditions, among others. While hematopoietic stem cells have significant therapeutic potential, a limitation that has hindered their use in the clinic has been the difficulty associated with releasing hematopoietic stem cells from the bone marrow into the peripheral blood of a donor, from which the hematopoietic stem cells may be isolated for infusion into a patient.
[0004] A further limitation is that up to 80% of mobilized peripheral blood (mPB) allogeneic recipients will experience graft-versus-host disease (GVHD). Despite the higher levels of CD3+ T cells in mPB grafts compared to bone marrow transplants, the level of acute GVHD observed following transplant of HLA-matched mPB is comparable to HLA-matched bone marrow. One explanation is that G-CSF mobilized grafts contain myeloid-derived suppressor cells (MDSCs) possessing potent immunosuppressive properties capable of inhibiting T cell proliferation in vitro. The percentage of MDSCs is variable in grafts mobilized with G-CSF, and clinical data suggest that patients transplanted with mPB grafts that contain higher numbers of MDSCs may have better outcomes including lower rates of acute GVHD
(Vendramin et al. , (2014) BBMT 20(l2):2049-2055).
[0005] Accordingly, there is currently a need for compositions and methods for promoting the mobilization of hematopoietic stem and progenitor cells, and particularly for methods of identifying populations of mobilized cells that are suitable for therapeutic use. There is also a need for compositions and methods for promoting the mobilization of hematopoietic stem and progenitor cells that consistently produce higher numbers of MDSCs than do prior art methods.
Summary of the Invention
[0006] The present invention provides compositions and methods for mobilizing
hematopoietic stem and progenitor cells in a subject. For example, the subject may be a hematopoietic stem and progenitor cell donor (z.e., a donor), such as a mammalian donor, and particularly a human donor. The invention additionally provides compositions and methods for the treatment of disorders, such as stem cell disorders, in a patient, such as a human patient. Using the compositions and methods described herein, a C-X-C chemokine receptor type 2 (CXCR2) agonist, such as Gro-b or a variant thereof, such as a truncated form of Gro- b (e.g, Gro-b T), as described herein, optionally in combination with a C-X-C chemokine receptor type 4 (CXCR4) antagonist, such as l,r-[l,4-phenylenebis(methylene)]-bis- 1,4,8, 1 l-tetra-azacyclotetradecane or a variant thereof, may be administered to a subject in amounts sufficient to mobilize hematopoietic stem and progenitor cells. Significantly, the compositions and methods described herein may be used to mobilize hematopoietic stem and progenitor cells from a stem cell niche within a donor, such as a human donor, into the circulating peripheral blood of the donor while reducing the mobilization of other cells of the hematopoietic lineage, such as white blood cells, neutrophils, lymphocytes, and monocytes. The compositions and methods described herein thus enable the selective mobilization of hematopoietic stem and progenitor cells in a donor, which may then be isolated from a donor for therapeutic use.
[0007] In some embodiments, the hematopoietic stem or progenitor cells may be mobilized from the bone marrow of the donor to the peripheral blood, from which the hematopoietic stem or progenitor cells may be collected and/or isolated. Upon collection of the mobilized cells, the withdrawn hematopoietic stem or progenitor cells may then be infused into a patient, which may be the donor or another subject, such as a subject that is HLA-matched to the donor, for the treatment of one or more pathologies of the hematopoietic system. In some embodiments, the withdrawn hematopoietic stem or progenitor cells are first expanded ex vivo prior to infusion of these cells, and/or progeny thereof, into the patient. The
compositions and methods described herein provide the important clinical benefit of enabling the production of populations of cells that are enriched in hematopoietic stem cells relative to other cell types, such as leukocytes, neutrophils, and monocytes. Thus, the populations of mobilized hematopoietic stem and progenitor cells produced using the compositions and methods described herein are particularly suitable for hematopoietic stem cell transplantation therapy, optionally preceded by ex vivo expansion in order to increase the quantity of hematopoietic stem and progenitor cells available for infusion into a patient.
[0008] Further, the methods described herein provide the advantage of inhibiting
leukocytosis in the donor. Leukocytosis may lead to adverse effects such as splenic rupture, renal dysfunction, acute febrile noninfectious pneumonitis (i.e., pulmonary toxicity), cardiovascular toxicity ( e.g ., hypercoagulation, heart attack, dyspnea, angina, arrhythmia, atherosclerotic plaque rupture due to proinflammatory actions related o high neutrophil counts), neurological disturbances (e.g., blurred vision, headache, and retinal hemorrhage), and sickle cell crisis. See, e.g, D’ Souza et al. (2008) Transfusion Medicine Reviews 22(4):280-290.
[0009] As described herein, hematopoietic stem cells are capable of differentiating into a multitude of cell types in the hematopoietic lineage and can thus be administered to a patient in order to populate or repopulate a cell type that is defective or deficient in the patient. The patient may be one, for example, that is suffering from one or more blood disorders, such as an autoimmune disease, cancer, hemoglobinopathy, or other hematopoietic pathology, and is therefore in need of hematopoietic stem cell transplantation. The invention thus provides methods of treating a variety of hematopoietic conditions, such as sickle cell anemia, thalassemia, Fanconi anemia, Wiskott-Aldrich syndrome, adenosine deaminase deficiency- severe combined immunodeficiency, metachromatic leukodystrophy, Diamond-Blackfan anemia and Schwachman-Diamond syndrome, human immunodeficiency virus infection, and acquired immune deficiency syndrome, as well as cancers and autoimmune diseases, among others. [0010] In a first aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34+ cells to leukocytes of from about 0.0008 to about 0.0021 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist. In some embodiments, the ratio of CD34+ cells to leukocytes in the sample may be about
0.00080, 0.00081, 0.00082, 0.00083, 0.00084, 0.00085, 0.00086, 0.00087, 0.00088, 0.00089, 0.00090, 0.00091, 0.00092, 0.00093, 0.00094, 0.00095, 0.00096, 0.00097, 0.00098, 0.00099, 0.00100, 0.00101, 0.00102, 0.00103, 0.00104, 0.00105, 0.00106, 0.00107, 0.00108, 0.00109, 0.00110, 0.00111, 0.00112, 0.00113, 0.00114, 0.00115, 0.00116, 0.00117, 0.00118, 0.00119, 0.00120, 0.00121, 0.00122, 0.00123, 0.00124, 0.00125, 0.00126, 0.00127, 0.00128, 0.00129, 0.00130, 0.00131, 0.00132, 0.00133, 0.00134, 0.00135, 0.00136, 0.00137, 0.00138, 0.00139, 0.00140, 0.00141, 0.00142, 0.00143, 0.00144, 0.00145, 0.00146, 0.00147, 0.00148, 0.00149, 0.00150, 0.00151, 0.00152, 0.00153, 0.00154, 0.00155, 0.00156, 0.00157, 0.00158, 0.00159, 0.00160, 0.00161, 0.00162, 0.00163, 0.00164, 0.00165, 0.00166, 0.00167, 0.00168, 0.00169, 0.00170, 0.00171, 0.00172, 0.00173, 0.00174, 0.00175, 0.00176, 0.00178, 0.00179, 0.00180, 0.00181, 0.00182, 0.00183, 0.00184, 0.00185, 0.00186, 0.00187, 0.00188, 0.00189, 0.00190, 0.00191, 0.00192, 0.00193, 0.00194, 0.00195, 0.00196, 0.00197, 0.00198, 0.00199, 0.00200, 0.00201, 0.00202, 0.00203, 0.00204, 0.00205, 0.00206, 0.00207, 0.00208, 0.00209, 0.00210, 0.00211, 0.00212, 0.00213, 0.00214, 0.00215, 0.00216, 0.00217, 0.00218, 0.00219, 0.00220, 0.00221, 0.00222, 0.00223, 0.00224, or 0.00225. In some embodiments, the ratio of CD34 cells to leukocytes in the sample is from about 0.0009 to about 0.002, about 0.001 to about
0.0019, about 0.0011 to about 0.0018, about 0.0012 to about 0.0017, about 0.0013 to about 0.0016, or about 0.0014 to about 0.0015. In some embodiments, the ratio of CD34+ cells to leukocytes in the sample is from about 0.0010 to about 0.0018, such as a ratio of
hematopoietic stem cells to leukocytes in the sample of about 0.00100, 0.00101, 0.00102,
0.00103, 0.00104, 0.00105, 0.00106, 0.00107, 0.00108, 0.00109, 0.00110, 0.00111, 0.00112, 0.00113, 0.00114, 0.00115, 0.00116, 0.00117, 0.00118, 0.00119, 0.00120, 0.00121, 0.00122, 0.00123, 0.00124, 0.00125, 0.00126, 0.00127, 0.00128, 0.00129, 0.00130, 0.00131, 0.00132, 0.00133, 0.00134, 0.00135, 0.00136, 0.00137, 0.00138, 0.00139, 0.00140, 0.00141, 0.00142, 0.00143, 0.00144, 0.00145, 0.00146, 0.00147, 0.00148, 0.00149, 0.00150, 0.00151, 0.00152, 0.00153, 0.00154, 0.00155, 0.00156, 0.00157, 0.00158, 0.00159, 0.00160, 0.00161, 0.00162, 0.00163, 0.00164, 0.00165, 0.00166, 0.00167, 0.00168, 0.00169, 0.00170, 0.00171, 0.00172, 0.00173, 0.00174, 0.00175, 0.00176, 0.00178, 0.00179, or 0.00180. In some embodiments, the ratio of CD34+ cells to leukocytes in the sample is from about 0.0012 to about 0.0016, such as a ratio of CD34+ cells to leukocytes in the sample of about 0.00120, 0.00121,
0.00122, 0.00123, 0.00124, 0.00125, 0.00126, 0.00127, 0.00128, 0.00129, 0.00130, 0.00131,
0.00132, 0.00133, 0.00134, 0.00135, 0.00136, 0.00137, 0.00138, 0.00139, 0.00140, 0.00141,
0.00142, 0.00143, 0.00144, 0.00145, 0.00146, 0.00147, 0.00148, 0.00149, 0.00150, 0.00151,
0.00152, 0.00153, 0.00154, 0.00155, 0.00156, 0.00157, 0.00158, 0.00159, or 0.00160. In some embodiments, the ratio of CD34+ cells to leukocytes in the sample is about 0.0014.
[0011] In another aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34+ cells relative to leukocytes by a ratio of from about 3.40: 1 to about 6.90: 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist. In some embodiments, the peripheral blood of the donor may be enriched with CD34+ cells relative to leukocytes by a ratio of about 3.40:1, 3.45:1, 3.50:1, 3.55:1, 3.60:1, 3.65:1, 3.70:1, 3.75:1, 3.80:1, 3.85:1, 3.90:1, 3.95:1, 4.00:1, 4.05:1, 4.10:1, 4.15:1, 4.20:1, 4.25:1, 4.30:1, 4.35:1, 4.40:1, 4.45:1,
4.50:1, 4.55:1, 4.60:1, 4.65:1, 4.70:1, 4.75:1, 4.80:1, 4.85:1, 4.90:1, 4.95:1, 5.00:1, 5.05:1,
5.10:1, 5.15:1, 5.20:1, 5.25:1, 5.30:1, 5.35:1, 5.40:1, 5.45:1, 5.50:1, 5.55:1, 5.60:1, 5.65:1,
5.70:1, 5.75:1, 5.80:1, 5.85:1, 5.90:1, 5.95:1, 6.00:1, 6.05:1, 6.10:1, 6.15:1, 6.20:1, 6.25:1,
6.30:1, 6.35:1, 6.40:1, 6.45:1, 6.50:1, 6.55:1, 6.60:1, 6.65:1, 6.70:1, 6.75:1, 6.80:1, 6.85:1, or
6.90: 11. In some embodiments, the peripheral blood of the donor is enriched with CD34+ cells relative to leukocytes by a ratio of from about 3.5:1 to about 6.8:1, about 3.6:1 to about 6.7:1, about 3.8:1 to about 6.6:1, about 3.9:1 to about 6.5:1, about 4:1 to about 6.4:1, about 4.1:1 to about 6.3:1, about 4.2:1 to about 6.2:1, about 4.3:1 to about 6.1:1, about 4.4:1 to about 6:1, about 4.5:1 to about 6:1, about 4.6:1 to about 5.9:1, about 4.7:1 to about 5.8:1, or about 4.8:1 to about 5.7:1. In some embodiments, the peripheral blood of the donor is enriched with CD34+ cells relative to leukocytes by a ratio of about from about 4.0: 1 to about 6.0:1, such as a ratio of about 4.00:1, 4.05:1, 4.10:1, 4.15:1, 4.20:1, 4.25:1, 4.30:1, 4.35:1, 4.40:1, 4.45:1, 4.50:1, 4.55:1, 4.60:1, 4.65:1, 4.70:1, 4.75:1, 4.80:1, 4.85:1, 4.90:1, 4.95:1, 5.00: 1, 5.05: 1, 5.10: 1, 5.15: 1, 5.20: 1, 5.25: 1, 5.30: 1, 5.35: 1, 5.40: 1, 5.45: 1, 5.50: 1, 5.55: 1, 5.60: 1, 5.65: 1, 5.70: 1, 5.75: 1, 5.80: 1, 5.85: 1, 5.90: 1, 5.95: 1, or 6.00: 1. In some
embodiments, the peripheral blood of the donor is enriched with CD34+ cells relative to leukocytes by a ratio of about from about 4.5: 1 to about 5.5: 1, such as a ratio of about 4.50: 1, 4.55: 1, 4.60: 1, 4.65: 1, 4.70: 1, 4.75: 1, 4.80: 1, 4.85: 1, 4.90: 1, 4.95: 1, 5.00: 1, 5.05: 1, 5.10: 1, 5.15: 1, 5.20: 1, 5.25: 1, 5.30: 1, 5.35: 1, 5.40: 1, 5.45: 1, or 5.50. In some embodiments, the peripheral blood of the donor is enriched with CD34+ cells relative to leukocytes by a ratio of about 5.1 : 1.
[0012] In another aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ cells of at least about 38,000 cells/ml, such as a density of CD34+ cells of from about 38,000 cells/ml to about 100,000 cells/ml, about 40,000 cells/ml to about 90,000 cells/ml, about 50,000 cells/ml to about 80,000 cells/ml, or about 60,000 cells/ml to about 70,000 cells/ml (e.g., about 38,00 cells/ml, 39,000 cells/ml, 40,000 cells/ml, 41,000 cells/ml, 42,000 cells/ml, 43,000 cells/ml, 44,000 cells/ml, 45,000 cells/ml, 46,000 cells/ml, 47,000 cells/ml, 48,000 cells/ml, 49,000 cells/ml, 50,000 cells/ml, 51,000 cells/ml, 52,000 cells/ml, 53,000 cells/ml, 54,000 cells/ml, 55,000 cells/ml, 56,000 cells/ml, 57,000 cells/ml, 58,000 cells/ml, 59,000 cells/ml, 60,000 cells/ml, 61,000 cells/ml, 62,000 cells/ml, 63,000 cells/ml, 64,000 cells/ml, 65,000 cells/ml, 66,000 cells/ml, 67,000 cells/ml, 68,000 cells/ml, 69,000 cells/ml, 70,000 cells/ml, 71,000 cells/ml, 72,000 cells/ml, 73,000 cells/ml, 74,000 cells/ml, 75,000 cells/ml, 76,000 cells/ml, 77,000 cells/ml, 78,000 cells/ml, 79,000 cells/ml, 80,000 cells/ml, 81,000 cells/ml, 82,000 cells/ml, 83,000 cells/ml, 84,000 cells/ml, 85,000 cells/ml, 86,000 cells/ml, 87,000 cells/ml, 88,000 cells/ml, 89,000 cells/ml, 90,000 cells/ml, 91,000 cells/ml, 92,000 cells/ml, 93,000 cells/ml, 94,000 cells/ml, 95,000 cells/ml, 96,000 cells/ml, 97,000 cells/ml, 98,000 cells/ml, 99,000 cells/ml, 100,000 cells/ml, or more), and having a density of leukocytes of no more than about 5.3 x 107 cells/ml, such as a density of leukocytes of about 2.3 x 107 cells/ml to about 5.3 x 107 cells/ml, about 2.5 x 107 cells/ml to about 5.1 x 107 cells/ml, 2.9 x 107 cells/ml to about 4.5 x 107 cells/ml, about 3 x 107 cells/ml to about 4 x 107 cells/ml (e.g, 5.3 x 107 cells/ml, 5.2 x 107 cells/ml, 5.1 x 107 cells/ml, 5 x 107 cells/ml, 4.9 x 107 cells/ml, 4.8 x 107 cells/ml, 4.7 x 107 cells/ml, 4.6 x 107 cells/ml, 4.5 x 107 cells/ml, 4.4 x 107 cells/ml, 4.3 x 107 cells/ml 4.2 x 107 cells/ml, 4.1 x 107 cells/ml 4 x 107 cells/ml, 3.9 x 107 cells/ml, 3.8 x 107 cells/ml, 3.7 x 107 cells/ml, 3.6 x 107 cells/ml, 3.5 x 107 cells/ml, 3.4 x 107 cells/ml, 3.3 x 107 cells/ml, 3.2 x 107 cells/ml, 3.1 x 107 cells/ml, 3 x 107 cells/ml, 2.9 x 107 cells/ml, 2.8 x 107 cells/ml, 2.7 x 107 cells/ml, 2.6 x 107 cells/ml, 2.5 x 107 cells/ml, 2.4 x 107 cells/ml, 2.3 x 107 cells/ml, or less). In some embodiments, the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ cells of from about 38,000 cells/ml to about 100,000 cells/ml, and having a density of leukocytes of from about 2.3 x 107 cells/ml to about 5.3 x 107 cells/ml. In some embodiments, the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ cells of from about 40,000 cells/ml to about 80,000 cells/ml, and having a density of leukocytes of from about 2.5 x 107 cells/ml to about 5 x 107 cells/ml. In some embodiments, the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ cells of from about 50,000 cells/ml to about 90,000 cells/ml, and having a density of leukocytes of from about 3 x 107 cells/ml to about 4 x 107 cells/ml.
[0013] In a further aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34+ cells to neutrophils of from about 0.0018 to about 0.0058 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist. In some embodiments, the ratio of CD34+ cells to neutrophils in the sample may be about
0.00180, 0.00181, 0.00182, 0.00183, 0.00184, 0.00185, 0.00186, 0.00187, 0.00188, 0.00189, 0.00190, 0.00191, 0.00192, 0.00193, 0.00194, 0.00195, 0.00196, 0.00197, 0.00198, 0.00199, 0.00200, 0.00201, 0.00202, 0.00203, 0.00204, 0.00205, 0.00206, 0.00207, 0.00208, 0.00209, 0.00210, 0.00211, 0.00212, 0.00213, 0.00214, 0.00215, 0.00216, 0.00217, 0.00218, 0.00219, 0.00220, 0.00221, 0.00222, 0.00223, 0.00224, 0.00225, 0.00226, 0.00227, 0.00228, 0.00229, 0.00230, 0.00231, 0.00232, 0.00233, 0.00234, 0.00235, 0.00236, 0.00237, 0.00238, 0.00239, 0.00240, 0.00241, 0.00242, 0.00243, 0.00244, 0.00245, 0.00246, 0.00247, 0.00248, 0.00249, 0.00250, 0.00251, 0.00252, 0.00253, 0.00254, 0.00255, 0.00256, 0.00257, 0.00258, 0.00259, 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266, 0.00267, 0.00268, 0.00269, 0.00270, 0.00271, 0.00272, 0.00273, 0.00274, 0.00275, 0.00276, 0.00277, 0.00278, 0.00279, 0.00280, 0.00281, 0.00282, 0.00283, 0.00284, 0.00285, 0.00286, 0.00287, 0.00288, 0.00289, 0.00290, 0.00291, 0.00292, 0.00293, 0.00294, 0.00295, 0.00296, 0.00297, 0.00298, 0.00299, 0.00300, 0.00300, 0.00301, 0.00302, 0.00303, 0.00304, 0.00305, 0.00306, 0.00307, 0.00308, 0.00309, 0.00310, 0.00311, 0.00312, 0.00313, 0.00314, 0.00315, 0.00316, 0.00317, 0.00318, 0.00319, 0.00320, 0.00321, 0.00322, 0.00323, 0.00324, 0.00325, 0.00326, 0.00327, 0.00328, 0.00329, 0.00330, 0.00331, 0.00332, 0.00333, 0.00334, 0.00335, 0.00336, 0.00337, 0.00338, 0.00339, 0.00340, 0.00341, 0.00342, 0.00343, 0.00344, 0.00345, 0.00346, 0.00347, 0.00348, 0.00349, 0.00350, 0.00351, 0.00352, 0.00353, 0.00354, 0.00355, 0.00356, 0.00357, 0.00358, 0.00359, 0.00360, 0.00361, 0.00362, 0.00363, 0.00364, 0.00365, 0.00366, 0.00367, 0.00368, 0.00369, 0.00370, 0.00371, 0.00372, 0.00373, 0.00374, 0.00375, 0.00376, 0.00377, 0.00378, 0.00379, 0.00380, 0.00381, 0.00382, 0.00383, 0.00384, 0.00385, 0.00386, 0.00387, 0.00388, 0.00389, 0.00390, 0.00391, 0.00392, 0.00393, 0.00394, 0.00395, 0.00396, 0.00397, 0.00398, 0.00399, 0.00400, 0.00401, 0.00402, 0.00403, 0.00404, 0.00405, 0.00406, 0.00407, 0.00408, 0.00409, 0.00410, 0.00411, 0.00412, 0.00413, 0.00414, 0.00415, 0.00416, 0.00417, 0.00418, 0.00419, 0.00420, 0.00421, 0.00422, 0.00423, 0.00424, 0.00425, 0.00426, 0.00427, 0.00428, 0.00429, 0.00430, 0.00431, 0.00432, 0.00433, 0.00434, 0.00435, 0.00436, 0.00437, 0.00438, 0.00439, 0.00440, 0.00441, 0.00442, 0.00443, 0.00444, 0.00445, 0.00446, 0.00447, 0.00448, 0.00449, 0.00450, 0.00451, 0.00452, 0.00453, 0.00454, 0.00455, 0.00456, 0.00457, 0.00458, 0.00459, 0.00460, 0.00461, 0.00462, 0.00463, 0.00464, 0.00465, 0.00466, 0.00467, 0.00468, 0.00469, 0.00470, 0.00471, 0.00472, 0.00473, 0.00474, 0.00475, 0.00476, 0.00477, 0.00478, 0.00479, 0.00480, 0.00481, 0.00482, 0.00483, 0.00484, 0.00485, 0.00486, 0.00487, 0.00488, 0.00489, 0.00490, 0.00491, 0.00492, 0.00493, 0.00494, 0.00495, 0.00496, 0.00497, 0.00498, 0.00499, 0.00500, 0.00501, 0.00502, 0.00503, 0.00504, 0.00505, 0.00506, 0.00507, 0.00508, 0.00509, 0.00510, 0.00511, 0.00512, 0.00513, 0.00514, 0.00515, 0.00516, 0.00517, 0.00518, 0.00519, 0.00520, 0.00521, 0.00522, 0.00523, 0.00524, 0.00525, 0.00526, 0.00527, 0.00528, 0.00529, 0.00530, 0.00531, 0.00532, 0.00533, 0.00534, 0.00535, 0.00536, 0.00537, 0.00538, 0.00539, 0.00540, 0.00541, 0.00542, 0.00543, 0.00544, 0.00545, 0.00546, 0.00547, 0.00548, 0.00549, 0.00550, 0.00551, 0.00552, 0.00553, 0.00554, 0.00555, 0.00556, 0.00557, 0.00558, 0.00559, 0.00560, 0.00561, 0.00562, 0.00563, 0.00564, 0.00565, 0.00566, 0.00567, 0.00568, 0.00569, 0.00570, 0.00571, 0.00572, 0.00573, 0.00574, 0.00575, 0.00576, 0.00577, 0.00578,
0.00579, or 0.00580. In some embodiments, the ratio of CD34+ cells to neutrophils in the sample is from about 0.002 to about 0.0056, about 0.0022 to about 0.0054, about 0.0024 to about 0.0052, about 0.0026 to about 0.005, about 0.0028 to about 0.0048, or about 0.003 to about 0.0046. In some embodiments, the ratio of CD34+ cells to neutrophils in the sample is from about 0.0026 to about 0.0046, such as a ratio of CD34+ cells to neutrophils in the sample of about 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266, 0.00267, 0.00268, 0.00269, 0.00270, 0.00271, 0.00272, 0.00273, 0.00274, 0.00275, 0.00276, 0.00277,
0.00278, 0.00279, 0.00280, 0.00281, 0.00282, 0.00283, 0.00284, 0.00285, 0.00286, 0.00287,
0.00288, 0.00289, 0.00290, 0.00291, 0.00292, 0.00293, 0.00294, 0.00295, 0.00296, 0.00297,
0.00298, 0.00299, 0.00300, 0.00300, 0.00301, 0.00302, 0.00303, 0.00304, 0.00305, 0.00306,
0.00307, 0.00308, 0.00309, 0.00310, 0.00311, 0.00312, 0.00313, 0.00314, 0.00315, 0.00316,
0.00317, 0.00318, 0.00319, 0.00320, 0.00321, 0.00322, 0.00323, 0.00324, 0.00325, 0.00326,
0.00327, 0.00328, 0.00329, 0.00330, 0.00331, 0.00332, 0.00333, 0.00334, 0.00335, 0.00336,
0.00337, 0.00338, 0.00339, 0.00340, 0.00341, 0.00342, 0.00343, 0.00344, 0.00345, 0.00346,
0.00347, 0.00348, 0.00349, 0.00350, 0.00351, 0.00352, 0.00353, 0.00354, 0.00355, 0.00356,
0.00357, 0.00358, 0.00359, 0.00360, 0.00361, 0.00362, 0.00363, 0.00364, 0.00365, 0.00366,
0.00367, 0.00368, 0.00369, 0.00370, 0.00371, 0.00372, 0.00373, 0.00374, 0.00375, 0.00376,
0.00377, 0.00378, 0.00379, 0.00380, 0.00381, 0.00382, 0.00383, 0.00384, 0.00385, 0.00386,
0.00387, 0.00388, 0.00389, 0.00390, 0.00391, 0.00392, 0.00393, 0.00394, 0.00395, 0.00396,
0.00397, 0.00398, 0.00399, 0.00400, 0.00401, 0.00402, 0.00403, 0.00404, 0.00405, 0.00406,
0.00407, 0.00408, 0.00409, 0.00410, 0.00411, 0.00412, 0.00413, 0.00414, 0.00415, 0.00416,
0.00417, 0.00418, 0.00419, 0.00420, 0.00421, 0.00422, 0.00423, 0.00424, 0.00425, 0.00426,
0.00427, 0.00428, 0.00429, 0.00430, 0.00431, 0.00432, 0.00433, 0.00434, 0.00435, 0.00436,
0.00437, 0.00438, 0.00439, 0.00440, 0.00441, 0.00442, 0.00443, 0.00444, 0.00445, 0.00446,
0.00447, 0.00448, 0.00449, 0.00450, 0.00451, 0.00452, 0.00453, 0.00454, 0.00455, 0.00456,
0.00457, 0.00458, 0.00459, or 0.00460. In some embodiments, the ratio of CD34+ cells to neutrophils in the sample is about 0.0036.
[0014] In an additional aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34+ cells relative to neutrophils by a ratio of from about 2.1 : 1 to about 8.1 : 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist. In some embodiments, the peripheral blood of the donor may be enriched with CD34+ cells relative to neutrophils by a ratio of about 2.10:1, 2.15:1, 2.20:1, 2.25:1, 2.30:1, 2.35:1, 2.40:1, 2.45:1, 2.50:1, 2.55:1, 2.60:1, 2.65:1, 2.70:1, 2.75:1, 2.80:1, 2.85:1, 2.90:1, 2.95:1, 3.00:1, 3.05:1, 3.10:1, 3.15:1,
3.20:1, 3.25:1, 3.30:1, 3.35:1, 3.40:1, 3.45:1, 3.50:1, 3.55:1, 3.60:1, 3.65:1, 3.70:1, 3.75:1,
3.80:1, 3.85:1, 3.90:1, 3.95:1, 4.00:1, 4.05:1, 4.10:1, 4.15:1, 4.20:1, 4.25:1, 4.30:1, 4.35:1,
4.40:1, 4.45:1, 4.50:1, 4.55:1, 4.60:1, 4.65:1, 4.70:1, 4.75:1, 4.80:1, 4.85:1, 4.90:1, 4.95:1,
5.00:1, 5.05:1, 5.10:1, 5.15:1, 5.20:1, 5.25:1, 5.30:1, 5.35:1, 5.40:1, 5.45:1, 5.50:1, 5.55:1,
5.60:1, 5.65:1, 5.70:1, 5.75:1, 5.80:1, 5.85:1, 5.90:1, 5.95:1, 6.00:1, 6.05:1, 6.10:1, 6.15:1,
6.20:1, 6.25:1, 6.30:1, 6.35:1, 6.40:1, 6.45:1, 6.50:1, 6.55:1, 6.60:1, 6.65:1, 6.70:1, 6.75:1,
6.80:1, 6.85:1, 6.90:1, 6.95:1, 7.00:1, 7.05:1, 7.10:1, 7.15:1, 7.20:1, 7.25:1, 7.30:1, 7.35:1,
7.40:1, 7.45:1, 7.50:1, 7.55:1, 7.60:1, 7.65:1, 7.70:1, 7.75:1, 7.80:1, 7.85:1, 7.90:1, 7.95:1, or
8.00: 1. In some embodiments, the peripheral blood of the donor is enriched with CD34+ cells relative to neutrophils by a ratio of from about 2.5:1 to about 7:1, about 2.6: 1 to about 6.9:1, about 2.7:1 to about 6.8:1, about 2.8:1 to about 6.7:1, about 2.9:1 to about 6.6:1, about 3:1 to about 6.5:1, about 3.2:1 to about 6.4:1, about 3.3:1 to about 6.3:1, about 3.4:1 to about 6.2:1, or about 3.5 : 1 to about 6.1:1 In some embodiments, the peripheral blood of the donor is enriched with CD34+ cells relative to neutrophils by a ratio of from about from about 5.4: 1 to about 7.4:1, such as a ratio of about 5.40:1, 5.45:1, 5.50:1, 5.55:1, 5.60:1, 5.65:1, 5.70:1, 5.75:1, 5.80:1, 5.85:1, 5.90:1, 5.95:1, 6.00:1, 6.05:1, 6.10:1, 6.15:1, 6.20:1, 6.25:1, 6.30:1,
6.35:1, 6.40:1, 6.45:1, 6.50:1, 6.55:1, 6.60:1, 6.65:1, 6.70:1, 6.75:1, 6.80:1, 6.85:1, 6.90:1,
6.95:1, 7.00:1, 7.05:1, 7.10:1, 7.15:1, 7.20:1, 7.25:1, 7.30:1, 7.35:1, or 7.40:1. In some embodiments, the peripheral blood of the donor is enriched with CD34+ cells relative to neutrophils by a ratio of about 6.4:1.
[0015] In yet another aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34+ cells to lymphocytes of from about 0.0021 to about 0.0094 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist.
In some embodiments, the ratio of CD34+ cells to lymphocytes in the sample may be about 0.00210, 0.00211, 0.00212, 0.00213, 0.00214, 0.00215, 0.00216, 0.00217, 0.00218, 0.00219,
0.00220, 0.00221, 0.00222, 0.00223, 0.00224, 0.00225, 0.00226, 0.00227, 0.00228, 0.00229,
0.00230, 0.00231, 0.00232, 0.00233, 0.00234, 0.00235, 0.00236, 0.00237, 0.00238, 0.00239,
0.00240, 0.00241, 0.00242, 0.00243, 0.00244, 0.00245, 0.00246, 0.00247, 0.00248, 0.00249, 0.00250, 0.00251, 0.00252, 0.00253, 0.00254, 0.00255, 0.00256, 0.00257, 0.00258, 0.00259, 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266, 0.00267, 0.00268, 0.00269, 0.00270, 0.00271, 0.00272, 0.00273, 0.00274, 0.00275, 0.00276, 0.00277, 0.00278, 0.00279, 0.00280, 0.00281, 0.00282, 0.00283, 0.00284, 0.00285, 0.00286, 0.00287, 0.00288, 0.00289, 0.00290, 0.00291, 0.00292, 0.00293, 0.00294, 0.00295, 0.00296, 0.00297, 0.00298, 0.00299, 0.00300, 0.00300, 0.00301, 0.00302, 0.00303, 0.00304, 0.00305, 0.00306, 0.00307, 0.00308, 0.00309, 0.00310, 0.00311, 0.00312, 0.00313, 0.00314, 0.00315, 0.00316, 0.00317, 0.00318, 0.00319, 0.00320, 0.00321, 0.00322, 0.00323, 0.00324, 0.00325, 0.00326, 0.00327, 0.00328, 0.00329, 0.00330, 0.00331, 0.00332, 0.00333, 0.00334, 0.00335, 0.00336, 0.00337, 0.00338, 0.00339, 0.00340, 0.00341, 0.00342, 0.00343, 0.00344, 0.00345, 0.00346, 0.00347, 0.00348, 0.00349, 0.00350, 0.00351, 0.00352, 0.00353, 0.00354, 0.00355, 0.00356, 0.00357, 0.00358, 0.00359, 0.00360, 0.00361, 0.00362, 0.00363, 0.00364, 0.00365, 0.00366, 0.00367, 0.00368, 0.00369, 0.00370, 0.00371, 0.00372, 0.00373, 0.00374, 0.00375, 0.00376, 0.00377, 0.00378, 0.00379, 0.00380, 0.00381, 0.00382, 0.00383, 0.00384, 0.00385, 0.00386, 0.00387, 0.00388, 0.00389, 0.00390, 0.00391, 0.00392, 0.00393, 0.00394, 0.00395, 0.00396, 0.00397, 0.00398, 0.00399, 0.00400, 0.00401, 0.00402, 0.00403, 0.00404, 0.00405, 0.00406, 0.00407, 0.00408, 0.00409, 0.00410, 0.00411, 0.00412, 0.00413, 0.00414, 0.00415, 0.00416, 0.00417, 0.00418, 0.00419, 0.00420, 0.00421, 0.00422, 0.00423, 0.00424, 0.00425, 0.00426, 0.00427, 0.00428, 0.00429, 0.00430, 0.00431, 0.00432, 0.00433, 0.00434, 0.00435, 0.00436, 0.00437, 0.00438, 0.00439, 0.00440, 0.00441, 0.00442, 0.00443, 0.00444, 0.00445, 0.00446, 0.00447, 0.00448, 0.00449, 0.00450, 0.00451, 0.00452, 0.00453, 0.00454, 0.00455, 0.00456, 0.00457, 0.00458, 0.00459, 0.00460, 0.00461, 0.00462, 0.00463, 0.00464, 0.00465, 0.00466, 0.00467, 0.00468, 0.00469, 0.00470, 0.00471, 0.00472, 0.00473, 0.00474, 0.00475, 0.00476, 0.00477, 0.00478, 0.00479, 0.00480, 0.00481, 0.00482, 0.00483, 0.00484, 0.00485, 0.00486, 0.00487, 0.00488, 0.00489, 0.00490, 0.00491, 0.00492, 0.00493, 0.00494, 0.00495, 0.00496, 0.00497, 0.00498, 0.00499, 0.00500, 0.00501, 0.00502, 0.00503, 0.00504, 0.00505, 0.00506, 0.00507, 0.00508, 0.00509, 0.00510, 0.00511, 0.00512, 0.00513, 0.00514, 0.00515, 0.00516, 0.00517, 0.00518, 0.00519, 0.00520, 0.00521, 0.00522, 0.00523, 0.00524, 0.00525, 0.00526, 0.00527, 0.00528, 0.00529, 0.00530, 0.00531, 0.00532, 0.00533, 0.00534, 0.00535, 0.00536, 0.00537, 0.00538, 0.00539, 0.00540, 0.00541, 0.00542, 0.00543, 0.00544, 0.00545, 0.00546, 0.00547, 0.00548, 0.00549, 0.00550, 0.00551, 0.00552, 0.00553, 0.00554, 0.00555, 0.00556, 0.00557, 0.00558, 0.00559, 0.00560, 0.00561, 0.00562, 0.00563, 0.00564, 0.00565, 0.00566, 0.00567, 0.00568, 0.00569, 0.00570, 0.00571, 0.00572, 0.00573, 0.00574, 0.00575, 0.00576, 0.00577, 0.00578, 0.00579, 0.00580, 0.00581, 0.00582, 0.00583, 0.00584, 0.00585, 0.00586, 0.00587, 0.00588, 0.00589, 0.00590, 0.00591, 0.00592, 0.00593, 0.00594, 0.00595, 0.00596, 0.00597, 0.00598, 0.00599, 0.00600, 0.00601, 0.00602, 0.00603, 0.00604, 0.00605, 0.00606, 0.00607, 0.00608, 0.00609, 0.00610, 0.00611, 0.00612, 0.00613, 0.00614, 0.00615, 0.00616, 0.00617, 0.00618, 0.00619, 0.00620, 0.00621, 0.00622, 0.00623, 0.00624, 0.00625, 0.00626, 0.00627, 0.00628, 0.00629, 0.00630, 0.00631, 0.00632, 0.00633, 0.00634, 0.00635, 0.00636, 0.00637, 0.00638, 0.00639, 0.00640, 0.00641, 0.00642, 0.00643, 0.00644, 0.00645, 0.00646, 0.00647, 0.00648, 0.00649, 0.00650, 0.00651, 0.00652, 0.00653, 0.00654, 0.00655, 0.00656, 0.00657, 0.00658, 0.00659, 0.00660, 0.00661, 0.00662, 0.00663, 0.00664, 0.00665, 0.00666, 0.00667, 0.00668, 0.00669, 0.00670, 0.00671, 0.00672, 0.00673, 0.00674, 0.00675, 0.00676, 0.00677, 0.00678, 0.00679, 0.00680, 0.00681, 0.00682, 0.00683, 0.00684, 0.00685, 0.00686, 0.00687, 0.00688, 0.00689, 0.00690, 0.00691, 0.00692, 0.00693, 0.00694, 0.00695, 0.00696, 0.00697, 0.00698, 0.00699, 0.00700, 0.00701, 0.00702, 0.00703, 0.00704, 0.00705, 0.00706, 0.00707, 0.00708, 0.00709, 0.00710, 0.00711, 0.00712, 0.00713, 0.00714, 0.00715, 0.00716, 0.00717, 0.00718, 0.00719, 0.00720, 0.00721, 0.00722, 0.00723, 0.00724, 0.00725, 0.00726, 0.00727, 0.00728, 0.00729, 0.00730, 0.00731, 0.00732, 0.00733, 0.00734, 0.00735, 0.00736, 0.00737, 0.00738, 0.00739, 0.00740, 0.00741, 0.00742, 0.00743, 0.00744, 0.00745, 0.00746, 0.00747, 0.00748, 0.00749, 0.00750, 0.00751, 0.00752, 0.00753, 0.00754, 0.00755, 0.00756, 0.00757, 0.00758, 0.00759, 0.00760, 0.00761, 0.00762, 0.00763, 0.00764, 0.00765, 0.00766, 0.00767, 0.00768, 0.00769, 0.00770, 0.00771, 0.00772, 0.00773, 0.00774, 0.00775, 0.00776, 0.00777, 0.00778, 0.00779, 0.00780, 0.00781, 0.00782, 0.00783, 0.00784, 0.00785, 0.00786, 0.00787, 0.00788, 0.00789, 0.00790, 0.00791, 0.00792, 0.00793, 0.00794, 0.00795, 0.00796, 0.00797, 0.00798, 0.00799, 0.00800, 0.00801, 0.00802, 0.00803, 0.00804, 0.00805, 0.00806, 0.00807, 0.00808, 0.00809, 0.00810, 0.00811, 0.00812, 0.00813, 0.00814, 0.00815, 0.00816, 0.00817, 0.00818, 0.00819, 0.00820, 0.00821, 0.00822, 0.00823, 0.00824, 0.00825, 0.00826, 0.00827, 0.00828, 0.00829, 0.00830, 0.00831, 0.00832, 0.00833, 0.00834, 0.00835, 0.00836, 0.00837, 0.00838, 0.00839, 0.00840, 0.00841, 0.00842, 0.00843, 0.00844, 0.00845, 0.00846, 0.00847, 0.00848, 0.00849, 0.00850, 0.00851, 0.00852, 0.00853, 0.00854, 0.00855, 0.00856, 0.00857, 0.00858, 0.00859, 0.00860, 0.00861, 0.00862, 0.00863, 0.00864, 0.00865, 0.00866, 0.00867, 0.00868, 0.00869, 0.00870, 0.00871, 0.00872, 0.00873, 0.00874, 0.00875, 0.00876, 0.00877, 0.00878, 0.00879, 0.00880, 0.00881, 0.00882, 0.00883, 0.00884, 0.00885, 0.00886, 0.00887, 0.00888, 0.00889, 0.00890, 0.00891, 0.00892, 0.00893, 0.00894, 0.00895, 0.00896, 0.00897, 0.00898, 0.00899, 0.00900, 0.00901, 0.00902, 0.00903, 0.00904, 0.00905, 0.00906, 0.00907, 0.00908, 0.00909, 0.00910, 0.00911, 0.00912, 0.00913, 0.00914, 0.00915, 0.00916, 0.00917, 0.00918,
0.00919, 0.00920, 0.00921, 0.00922, 0.00923, 0.00924, 0.00925, 0.00926, 0.00927, 0.00928,
0.00929, 0.00930, 0.00931, 0.00932, 0.00933, 0.00934, 0.00935, 0.00936, 0.00937, 0.00938,
0.00939, or 0.00940. In some embodiments, the ratio of CD34+ cells to lymphocytes in the sample is from about 0.0022 to about 0.0093, about 0.0023 to about 0.0092, about 0.0024 to about 0.0091, about 0.003 to about 0.0085, about 0.0035 to about 0.0075, or about 0.0045 to about 0.0065. In some embodiments, the ratio of CD34+ cells to lymphocytes in the sample is from about 0.0025 to about 0.0035, such as a ratio of CD34+ cells to lymphocytes in the sample of about 0.00250, 0.00251, 0.00252, 0.00253, 0.00254, 0.00255, 0.00256, 0.00257, 0.00258, 0.00259, 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266, 0.00267,
0.00268, 0.00269, 0.00270, 0.00271, 0.00272, 0.00273, 0.00274, 0.00275, 0.00276, 0.00277,
0.00278, 0.00279, 0.00280, 0.00281, 0.00282, 0.00283, 0.00284, 0.00285, 0.00286, 0.00287,
0.00288, 0.00289, 0.00290, 0.00291, 0.00292, 0.00293, 0.00294, 0.00295, 0.00296, 0.00297,
0.00298, 0.00299, 0.00300, 0.00300, 0.00301, 0.00302, 0.00303, 0.00304, 0.00305, 0.00306,
0.00307, 0.00308, 0.00309, 0.00310, 0.00311, 0.00312, 0.00313, 0.00314, 0.00315, 0.00316,
0.00317, 0.00318, 0.00319, 0.00320, 0.00321, 0.00322, 0.00323, 0.00324, 0.00325, 0.00326,
0.00327, 0.00328, 0.00329, 0.00330, 0.00331, 0.00332, 0.00333, 0.00334, 0.00335, 0.00336,
0.00337, 0.00338, 0.00339, 0.00340, 0.00341, 0.00342, 0.00343, 0.00344, 0.00345, 0.00346,
0.00347, 0.00348, 0.00349, or 0.00350. In some embodiments, the ratio of CD34+ cells to lymphocytes in the sample is about 0.0031.
[0016] In an additional aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34+ cells relative to lymphocytes by a ratio of from about 4.8: 1 to about 8.4: 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist. In some embodiments, the peripheral blood of the donor may be enriched with CD34+ cells relative to lymphocytes by a ratio of about 4.80: 1, 4.85: 1, 4.90: 1, 4.95: 1, 5.00: 1, 5.05: 1, 5.10: 1, 5.15: 1, 5.20: 1, 5.25: 1, 5.30: 1, 5.35: 1, 5.40: 1, 5.45: 1, 5.50: 1, 5.55: 1, 5.60: 1, 5.65: 1, 5.70: 1, 5.75: 1, 5.80: 1, 5.85: 1,
5.90: 1, 5.95: 1, 6.00: 1, 6.05: 1, 6.10: 1, 6.15: 1, 6.20: 1, 6.25: 1, 6.30: 1, 6.35: 1, 6.40: 1, 6.45: 1,
6.50: 1, 6.55: 1, 6.60: 1, 6.65: 1, 6.70: 1, 6.75: 1, 6.80: 1, 6.85: 1, 6.90: 1, 6.95: 1, 7.00: 1, 7.05: 1, 7.10:1, 7.15:1, 7.20:1, 7.25:1, 7.30:1, 7.35:1, 7.40:1, 7.45:1, 7.50:1, 7.55:1, 7.60:1, 7.65:1,
7.70:1, 7.75:1, 7.80:1, 7.85:1, 7.90:1, 7.95:1, 8.00:1, 8.05:1, 8.10:1, 8.15:1, 8.20:1, 8.25:1,
8.30:1, 8.35:1, or 8.40:1. In some embodiments, the peripheral blood of the donor is enriched with CD34+ cells relative to lymphocytes by a ratio of from about 5: 1 to about 7:1, about 5.5:1 to about 6.5:1, or about 5.2:1 to about 5.7:1. In some embodiments, the peripheral blood of the donor is enriched with CD34+ cells relative to lymphocytes by a ratio of from about 5.0:1 to about 6.5:1, such as a ratio of about 5.00:1, 5.05:1, 5.10:1, 5.15:1, 5.20:1, 5.25:1, 5.30:1, 5.35:1, 5.40:1, 5.45:1, 5.50:1, 5.55:1, 5.60:1, 5.65:1, 5.70:1, 5.75:1, 5.80:1,
5.85:1, 5.90:1, 5.95:1, 6.00:1, 6.05:1, 6.10:1, 6.15:1, 6.20:1, 6.25:1, 6.30:1, 6.35:1, 6.40:1,
6.45:1, or 6.50:1. In some embodiments, the peripheral blood of the donor is enriched with CD34+ cells relative to lymphocytes by a ratio of about 5.7:1.
[0017] In another aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ cells of at least about 38,000 cells/ml, such as a density of CD34+ cells of from about 38,000 cells/ml to about 100,000 cells/ml, about 40,000 cells/ml to about 90,000 cells/ml, about 50,000 cells/ml to about 80,000 cells/ml, or about 60,000 cells/ml to about 70,000 cells/ml (e.g., about 38,00 cells/ml, 39,000 cells/ml, 40,000 cells/ml, 41,000 cells/ml, 42,000 cells/ml, 43,000 cells/ml, 44,000 cells/ml, 45,000 cells/ml, 46,000 cells/ml, 47,000 cells/ml, 48,000 cells/ml, 49,000 cells/ml, 50,000 cells/ml, 51,000 cells/ml, 52,000 cells/ml, 53,000 cells/ml, 54,000 cells/ml, 55,000 cells/ml, 56,000 cells/ml, 57,000 cells/ml, 58,000 cells/ml, 59,000 cells/ml, 60,000 cells/ml, 61,000 cells/ml, 62,000 cells/ml, 63,000 cells/ml, 64,000 cells/ml, 65,000 cells/ml, 66,000 cells/ml, 67,000 cells/ml, 68,000 cells/ml, 69,000 cells/ml, 70,000 cells/ml, 71,000 cells/ml, 72,000 cells/ml, 73,000 cells/ml, 74,000 cells/ml, 75,000 cells/ml, 76,000 cells/ml, 77,000 cells/ml, 78,000 cells/ml, 79,000 cells/ml, 80,000 cells/ml, 81,000 cells/ml, 82,000 cells/ml, 83,000 cells/ml, 84,000 cells/ml, 85,000 cells/ml, 86,000 cells/ml, 87,000 cells/ml, 88,000 cells/ml, 89,000 cells/ml, 90,000 cells/ml, 91,000 cells/ml, 92,000 cells/ml, 93,000 cells/ml, 94,000 cells/ml, 95,000 cells/ml, 96,000 cells/ml, 97,000 cells/ml, 98,000 cells/ml, 99,000 cells/ml, 100,000 cells/ml, or more), and having a density of lymphocytes of no more than about 2.4 x 107 cells/ml, such as a density of lymphocytes of about 1 x 107 cells/ml to about 2.3 x 107 cells/ml, about 1.3 x 107 cells/ml to about 2.1 x l07cells/ml, or about 1.5 x 107 cells/ml to about 1.9 x 107 cells/ml (e.g, about 2.4 x 107 cells/ml, 2.3 x 107 cells/ml, 2.2 x 07 cells/ml, 2.1 x 107 cells/ml, 2 x 107 cells/ml, 1.9 x 107 cells/ml, 1.8 x 107 cells/ml, 1.7 x 107 cells/ml, 1.6 x 107 cells/ml, 1.5 x 107 cells/ml 1.4 x 107 cells/ml, 1.3 x 107 cells/ml, 1.2 x 107 cells/ml, 1.1 x 107 cells/ml, 1 x 107 cells/ml, or less, 0.9 x 107 cells/ml, 0.8 x 107 cells/ml, or less). In some embodiments, the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ cells of from about 38,000 cells/ml to about 100,000 cells/ml, and having a density of lymphocytes of from about 1 x 107 cells/ml to about 2.3 x 107 cells/ml. In some embodiments, the method includes
administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ cells of from about 40,000 cells/ml to about 80,000 cells/ml, and having a density of lymphocytes of from about 1.3 x 107 cells/ml to about 2.3 x 107 cells/ml. In some embodiments, the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ cells of from about 50,000 cells/ml to about 90,000 cells/ml, and having a density of lymphocytes of from about 1.5 x 107 cells/ml to about 2 x 107 cells/ml.
[0018] In another aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34+ cells to monocytes of from about 0.0071 to about 0.0174 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist. In some embodiments, the ratio of CD34+ cells to monocytes in the sample may be about 0.00710, 0.00711, 0.00712,
0.00713, 0.00714, 0.00715, 0.00716, 0.00717, 0.00718, 0.00719, 0.00720, 0.00721, 0.00722, 0.00723, 0.00724, 0.00725, 0.00726, 0.00727, 0.00728, 0.00729, 0.00730, 0.00731, 0.00732, 0.00733, 0.00734, 0.00735, 0.00736, 0.00737, 0.00738, 0.00739, 0.00740, 0.00741, 0.00742, 0.00743, 0.00744, 0.00745, 0.00746, 0.00747, 0.00748, 0.00749, 0.00750, 0.00751, 0.00752, 0.00753, 0.00754, 0.00755, 0.00756, 0.00757, 0.00758, 0.00759, 0.00760, 0.00761, 0.00762, 0.00763, 0.00764, 0.00765, 0.00766, 0.00767, 0.00768, 0.00769, 0.00770, 0.00771, 0.00772, 0.00773, 0.00774, 0.00775, 0.00776, 0.00777, 0.00778, 0.00779, 0.00780, 0.00781, 0.00782, 0.00783, 0.00784, 0.00785, 0.00786, 0.00787, 0.00788, 0.00789, 0.00790, 0.00791, 0.00792, 0.00793, 0.00794, 0.00795, 0.00796, 0.00797, 0.00798, 0.00799, 0.00800, 0.00801, 0.00802, 0.00803, 0.00804, 0.00805, 0.00806, 0.00807, 0.00808, 0.00809, 0.00810, 0.00811, 0.00812, 0.00813, 0.00814, 0.00815, 0.00816, 0.00817, 0.00818, 0.00819, 0.00820, 0.00821, 0.00822,
0.00823, 0.00824, 0.00825, 0.00826, 0.00827, 0.00828, 0.00829, 0.00830, 0.00831, 0.00832,
0.00833, 0.00834, 0.00835, 0.00836, 0.00837, 0.00838, 0.00839, 0.00840, 0.00841, 0.00842,
0.00843, 0.00844, 0.00845, 0.00846, 0.00847, 0.00848, 0.00849, 0.00850, 0.00851, 0.00852,
0.00853, 0.00854, 0.00855, 0.00856, 0.00857, 0.00858, 0.00859, 0.00860, 0.00861, 0.00862,
0.00863, 0.00864, 0.00865, 0.00866, 0.00867, 0.00868, 0.00869, 0.00870, 0.00871, 0.00872,
0.00873, 0.00874, 0.00875, 0.00876, 0.00877, 0.00878, 0.00879, 0.00880, 0.00881, 0.00882,
0.00883, 0.00884, 0.00885, 0.00886, 0.00887, 0.00888, 0.00889, 0.00890, 0.00891, 0.00892,
0.00893, 0.00894, 0.00895, 0.00896, 0.00897, 0.00898, 0.00899, 0.00900, 0.00901, 0.00902,
0.00903, 0.00904, 0.00905, 0.00906, 0.00907, 0.00908, 0.00909, 0.00910, 0.00911, 0.00912,
0.00913, 0.00914, 0.00915, 0.00916, 0.00917, 0.00918, 0.00919, 0.00920, 0.00921, 0.00922,
0.00923, 0.00924, 0.00925, 0.00926, 0.00927, 0.00928, 0.00929, 0.00930, 0.00931, 0.00932,
0.00933, 0.00934, 0.00935, 0.00936, 0.00937, 0.00938, 0.00939, 0.00940, 0.00941, 0.00942,
0.00943, 0.00944, 0.00945, 0.00946, 0.00947, 0.00948, 0.00949, 0.00950, 0.00951, 0.00952,
0.00953, 0.00954, 0.00955, 0.00956, 0.00957, 0.00958, 0.00959, 0.00960, 0.00961, 0.00962,
0.00963, 0.00964, 0.00965, 0.00966, 0.00967, 0.00968, 0.00969, 0.00970, 0.00971, 0.00972,
0.00973, 0.00974, 0.00975, 0.00976, 0.00977, 0.00978, 0.00979, 0.00980, 0.00981, 0.00982,
0.00983, 0.00984, 0.00985, 0.00986, 0.00987, 0.00988, 0.00989, 0.00990, 0.00991, 0.00992,
0.00993, 0.00994, 0.00995, 0.00996, 0.00997, 0.00998, 0.00999, 0.0100, 0.0101, 0.0103, 0.0104, 0.0105, 0.0106, 0.0107, 0.0108, 0.0109, 0.0110, 0.0111, 0.0112, 0.0113, 0.0114,
0.0115, 0.0116, 0.0117, 0.0118, 0.0119, 0.0120, 0.0121, 0.0122, 0.0123, 0.0124, 0.0125,
0.0126, 0.0127, 0.0128, 0.0129, 0.0130, 0.0131, 0.0132, 0.0133, 0.0134, 0.0135, 0.0136,
0.0137, 0.0138, 0.0139, 0.0140, 0.0141, 0.0142, 0.0143, 0.0144, 0.0145, 0.0146, 0.0147,
0.0148, 0.0149, 0.0150, 0.0151, 0.0152, 0.0153, 0.0154, 0.0155, 0.0156, 0.0157, 0.0158,
0.0159, 0.0160, 0.0161, 0.0162, 0.0163, 0.0164, 0.0165, 0.0166, 0.0167, 0.0168, 0.0169,
0.0170, 0.0171, 0.0172, 0.0173, or 0.0174. In some embodiments, the ratio of CD34+ cells to monocytes in the sample is from 0.008 to about 0.016, about 0.009 to about 0.015, about 0.01 to about 0.014, or about 0.011 to about 0.013. In some embodiments, the ratio of CD34+ cells to monocytes in the sample is from about 0.0100 to about 0.0140, such as a ratio of CD34+ cells to monocytes in the sample of about 0.0100, 0.0101, 0.0103, 0.0104, 0.0105, 0.0106, 0.0107, 0.0108, 0.0109, 0.0110, 0.0111, 0.0112, 0.0113, 0.0114, 0.0115, 0.0116, 0.0117, 0.0118, 0.0119, 0.0120, 0.0121, 0.0122, 0.0123, 0.0124, 0.0125, 0.0126, 0.0127, 0.0128, 0.0129, 0.0130, 0.0131, 0.0132, 0.0133, 0.0134, 0.0135, 0.0136, 0.0137, 0.0138, 0.0139, or 0.0140. In some embodiments, the ratio of CD34+ cells to monocytes in the sample is about 0.0118.
[0019] In an additional aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ cells of at least about 38,000 cells/ml, such as a density of CD34+ cells of from about 38,000 cells/ml to about 100,000 cells/ml, about 40,000 cells/ml to about 90,000 cells/ml, about 50,000 cells/ml to about 80,000 cells/ml, or about 60,000 cells/ml to about 70,000 cells/ml (e.g., about 38,00 cells/ml, 39,000 cells/ml, 40,000 cells/ml, 41,000 cells/ml, 42,000 cells/ml, 43,000 cells/ml, 44,000 cells/ml, 45,000 cells/ml, 46,000 cells/ml, 47,000 cells/ml, 48,000 cells/ml, 49,000 cells/ml, 50,000 cells/ml, 51,000 cells/ml, 52,000 cells/ml, 53,000 cells/ml, 54,000 cells/ml, 55,000 cells/ml, 56,000 cells/ml, 57,000 cells/ml, 58,000 cells/ml, 59,000 cells/ml, 60,000 cells/ml, 61,000 cells/ml, 62,000 cells/ml, 63,000 cells/ml, 64,000 cells/ml, 65,000 cells/ml, 66,000 cells/ml, 67,000 cells/ml, 68,000 cells/ml, 69,000 cells/ml, 70,000 cells/ml, 71,000 cells/ml, 72,000 cells/ml, 73,000 cells/ml, 74,000 cells/ml, 75,000 cells/ml, 76,000 cells/ml, 77,000 cells/ml, 78,000 cells/ml, 79,000 cells/ml, 80,000 cells/ml, 81,000 cells/ml, 82,000 cells/ml, 83,000 cells/ml, 84,000 cells/ml, 85,000 cells/ml, 86,000 cells/ml, 87,000 cells/ml, 88,000 cells/ml, 89,000 cells/ml, 90,000 cells/ml, 91,000 cells/ml, 92,000 cells/ml, 93,000 cells/ml, 94,000 cells/ml, 95,000 cells/ml, 96,000 cells/ml, 97,000 cells/ml, 98,000 cells/ml, 99,000 cells/ml, 100,000 cells/ml, or more), and having a density of monocytes of no more than about 6 x 106 cells/ml, such as a density of monocytes of from 3.4 x 106 cells/ml to about 5.9 x 106 cells/ml, about 3.5 x 106 cells/ml to about 5.7 x 106 cells/ml, or about 4 x 106 cells/ml to about 5 x 106 cells/ml (e.g, 5.9 x 106 cells/ml, 5.8 x 106 cells/ml, 5.7 x 106 cells/ml, 5.6 x 106 cells/ml, 5.5 x 106 cells/ml, 5.4 x 106 cells/ml, 5.3 x
106 cells/ml, 5.2 x 106 cells/ml, 5.1 x 106 cells/ml, 5 x 106 cells/ml, 4.9 x 106 cells/ml, 4.8 x
106 cells/ml, 4.7 x 106 cells/ml, 4.6 x 106 cells/ml, 4.5 x 106 cells/ml, 4.4 x 106 cells/ml, 4.3 x
106 cells/ml, 4.2 x 106 cells/ml, 4.1 x 106 cells/ml, 4 x 106 cells/ml, 3.9 x 106 cells/ml, 3.8 x
106 cells/ml, 3.7 x 106 cells/ml, 3.6 x 106 cells/ml, 3.5 x 106 cells/ml, 3.4 x 106 cells/ml, or less). In some embodiments, the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ cells of from about 38,000 cells/ml to about 100,000 cells/ml, and having a density of monocytes of from about 3.4 x 106 cells/ml to about 6 x 106 cells/ml. In some embodiments, the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ cells of from about 40,000 cells/ml to about 80,000 cells/ml, and having a density of monocytes of from about 4 x 106 cells/ml to about 5.5 x 106 cells/ml. In some embodiments, the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ cells of from about 50,000 cells/ml to about 90,000 cells/ml, and having a density of monocytes of from about 4 x 106 cells/ml to about 5 x 106 cells/ml.
[0020] In another aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34+ cells relative to monocytes by a ratio of from about 1.1 : 1 to about 2.3 : 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist. In some embodiments, the peripheral blood of the donor may be enriched with CD34+ cells relative to monocytes by a ratio of about 1.10: 1, 1.15: 1, 1.20: 1, 1.25: 1, 1.30: 1, 1.35: 1, 1.40: 1, 1.45: 1, 1.50: 1, 1.55: 1, 1.60: 1, 1.65: 1, 1.70: 1, 1.75: 1, 1.80: 1, 1.85: 1, 1.90: 1, 1.95: 1, 2.00: 1, 2.05: 1, 2.10: 1, 2.15: 1, 2.20: 1, 2.25: 1, or 2.30: 1. In some embodiments, the peripheral blood of the donor is enriched with CD34+ cells relative to monocytes by a ratio of about from about 1.3 : 1 to about 1.9: 1, such as a ratio of about 1.30: 1, 1.35: 1, 1.40: 1, 1.45: 1, 1.50: 1, 1.55: 1, 1.60: 1, 1.65: 1, 1.70: 1, 1.75: 1, 1.80: 1, 1.85: 1, or 1.90: 1.
[0021] In another aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a frequency of CD34+ cells of from about 0.051% to about 0.140% in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist.
In some embodiments, the population of cells may have a frequency of CD34+ cells of about
0.051%, 0.052%, 0.053%, 0.054%, 0.055%, 0.056%, 0.057%, 0.058%, 0.059%, 0.060%,
0.061%, 0.062%, 0.063%, 0.064%, 0.065%, 0.066%, 0.067%, 0.068%, 0.069%, 0.070%,
0.071%, 0.072%, 0.073%, 0.074%, 0.075%, 0.076%, 0.077%, 0.078%, 0.079%, 0.080%, 0.081%, 0.082%, 0.083%, 0.084%, 0.085%, 0.086%, 0.087%, 0.088%, 0.089%, 0.090%, 0.091%, 0.092%, 0.093%, 0.094%, 0.095%, 0.096%, 0.097%, 0.098%, 0.099%, 0.100%, 0.101%, 0.102%, 0.103%, 0.104%, 0.105%, 0.106%, 0.107%, 0.108%, 0.109%, 0.110%, 0.111%, 0.112%, 0.113%, 0.114%, 0.115%, 0.116%, 0.117%, 0.118%, 0.119%, 0.120%, 0.121%, 0.122%, 0.123%, 0.124%, 0.125%, 0.126%, 0.127%, 0.128%, 0.129%, 0.130%, 0.131%, 0.132%, 0.133%, 0.134%, 0.135%, 0.136%, 0.137%, 0.138%, 0.139%, or 0.140%.
In some embodiments, the population of cells has a frequency of CD34+ cells of from about 0.050% to about 0.120%, about 0.060% to about 0.110%, or about 0.080% to about 0.100%. In some embodiments, the population of cells has a frequency of CD34+ cells of from about 0.080% to about 0.120%, such as a frequency of hematopoietic stem cells of about 0.080%, 0.081%, 0.082%, 0.083%, 0.084%, 0.085%, 0.086%, 0.087%, 0.088%, 0.089%, 0.090%, 0.091%, 0.092%, 0.093%, 0.094%, 0.095%, 0.096%, 0.097%, 0.098%, 0.099%, 0.100%, 0.101%, 0.102%, 0.103%, 0.104%, 0.105%, 0.106%, 0.107%, 0.108%, 0.109%, 0.110%, 0.111%, 0.112%, 0.113%, 0.114%, 0.115%, 0.116%, 0.117%, 0.118%, 0.119%, or 0.120%.
In some embodiments, the population of cells has a frequency of CD34+ cells of about 0.097%.
[0022] In an additional aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to induce an increase in the frequency of CD34+ cells in the peripheral blood of the donor by at least 3-fold as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist (e.g., by from about 3.4-fold to about 7.1 -fold, such as by about 3.4-fold, 3.5-fold, 3.6-fold, 3.7-fold, 3.8-fold, 3.9-fold, 4.0-fold, 4. l-fold, 4.2-fold, 4.3- fold, 4.4-fold, 4.5-fold, 4.6-fold, 4.7-fold, 4.8-fold, 4.9-fold, 5.0-fold, 5. l-fold, 5.2-fold, 5.3- fold, 5.4-fold, 5.5-fold, 5.6-fold, 5.7-fold, 5.8-fold, 5.9-fold, 6.0-fold, 6. l-fold, 6.2-fold, 6.3- fold, 6.4-fold, 6.5-fold, 6.6-fold, 6.7-fold, 6.8-fold, 6.9-fold, 7.0-fold, or 7. l-fold. In some embodiments, the frequency of CD34+ cells in the peripheral blood of the donor is increased by from about 4-fold to about 7-fold, about 4.5-fold to about 6.5-fold, or about 5-fold to about 6-fold following administration of the CXCR2 agonist and CXCR4 antagonist. In some embodiments, the frequency of CD34+ cells in the peripheral blood of the donor is increased by from about 4.0-fold to about 6.0-fold following administration of the CXCR2 agonist and CXCR4 antagonist, such as by about 4.0-fold, 4.l-fold, 4.2-fold, 4.3-fold, 4.4- fold, 4.5-fold, 4.6-fold, 4.7-fold, 4.8-fold, 4.9-fold, 5.0-fold, 5.l-fold, 5.2-fold, 5.3-fold, 5.4- fold, 5.5-fold, 5.6-fold, 5.7-fold, 5.8-fold, 5.9-fold, or 6.0-fold. In some embodiments, the frequency of CD34+ cells in the peripheral blood of the donor is increased by about 4.8-fold.
[0023] In a further aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34+ CD90+ CD45RA cells to leukocytes of from about 0.0003 to about 0.0016 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to leukocytes in the sample may be about 0.00030, 0.00031, 0.00032, 0.00033, 0.00034,
0.00035, 0.00036, 0.00037, 0.00038, 0.00039, 0.00040, 0.00041, 0.00042, 0.00043, 0.00044, 0.00045, 0.00046, 0.00047, 0.00048, 0.00049, 0.00050, 0.00051, 0.00052, 0.00053, 0.00054, 0.00055, 0.00056, 0.00057, 0.00058, 0.00059, 0.00060, 0.00061, 0.00062, 0.00063, 0.00064, 0.00065, 0.00066, 0.00067, 0.00068, 0.00069, 0.00070, 0.00071, 0.00072, 0.00073, 0.00074, 0.00075, 0.00076, 0.00077, 0.00078, 0.00079, 0.00080, 0.00081, 0.00082, 0.00083, 0.00084, 0.00085, 0.00086, 0.00087, 0.00088, 0.00089, 0.00090, 0.00091, 0.00092, 0.00093, 0.00094, 0.00095, 0.00096, 0.00097, 0.00098, 0.00099, 0.00100, 0.00101, 0.00102, 0.00103, 0.00104, 0.00105, 0.00106, 0.00107, 0.00108, 0.00109, 0.00110, 0.00111, 0.00112, 0.00113, 0.00114, 0.00115, 0.00116, 0.00117, 0.00118, 0.00119, 0.00120, 0.00121, 0.00122, 0.00123, 0.00124, 0.00125, 0.00126, 0.00127, 0.00128, 0.00129, 0.00130, 0.00131, 0.00132, 0.00133, 0.00134, 0.00135, 0.00136, 0.00137, 0.00138, 0.00139, 0.00140, 0.00141, 0.00142, 0.00143, 0.00144, 0.00145, 0.00146, 0.00147, 0.00148, 0.00149, 0.00150, 0.00151, 0.00152, 0.00153, 0.00154, 0.00155, 0.00156, 0.00157, 0.00158, 0.00159, or 0.00160. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to leukocytes in the sample is from about 0.0008 to about 0.0010. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to leukocytes in the sample is from about 0.0006 to about 0.0012, such as a ratio of hematopoietic stem cells to leukocytes in the sample of about 0.00060, 0.00061, 0.00062, 0.00063, 0.00064, 0.00065, 0.00066, 0.00067, 0.00068, 0.00069, 0.00070, 0.00071, 0.00072, 0.00073, 0.00074, 0.00075, 0.00076, 0.00077, 0.00078, 0.00079, 0.00080, 0.00081, 0.00082, 0.00083, 0.00084, 0.00085, 0.00086, 0.00087, 0.00088, 0.00089, 0.00090, 0.00091, 0.00092, 0.00093, 0.00094, 0.00095, 0.00096, 0.00097, 0.00098, 0.00099, 0.00100, 0.00101, 0.00102, 0.00103, 0.00104, 0.00105, 0.00106, 0.00107, 0.00108, 0.00109, 0.00110, 0.00111, 0.00112, 0.00113, 0.00114, 0.00115, 0.00116, 0.00117, 0.00118, 0.00119, or 0.00120. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to leukocytes in the sample is about 0.0009.
[0024] In another aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34+ CD90+ CD45RA cells relative to leukocytes by a ratio of from about 5.5:1 to about 26.9: 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist. In some embodiments, the peripheral blood of the donor may be enriched with CD34+ CD90+
CD45RA cells relative to leukocytes by a ratio of about 5.50:1, 5.55:1, 5.60:1, 5.65:1, 5.70:1, 5.75:1, 5.80:1, 5.85:1, 5.90:1, 5.95:1, 6.00:1, 6.05:1, 6.10:1, 6.15:1, 6.20:1, 6.25:1, 6.30:1,
6.35:1, 6.40:1, 6.45:1, 6.50:1, 6.55:1, 6.60:1, 6.65:1, 6.70:1, 6.75:1, 6.80:1, 6.85:1, 6.90:1,
6.95:1, 7.00:1, 7.05:1, 7.10:1, 7.15:1, 7.20:1, 7.25:1, 7.30:1, 7.35:1, 7.40:1, 7.45:1, 7.50:1,
7.55:1, 7.60:1, 7.65:1, 7.70:1, 7.75:1, 7.80:1, 7.85:1, 7.90:1, 7.95:1, 8.00:1, 8.05:1, 8.10:1,
8.15:1, 8.20:1, 8.25:1, 8.30:1, 8.35:1, 8.40:1, 8.45:1, 8.50:1, 8.55:1, 8.60:1, 8.65:1, 8.70:1,
8.75:1, 8.80:1, 8.85:1, 8.90:1, 8.95:1, 9.00:1, 9.05:1, 9.10:1, 9.15:1, 9.20:1, 9.25:1, 9.30:1,
9.35:1, 9.40:1, 9.45:1, 9.50:1, 9.55:1, 9.60:1, 9.65:1, 9.70:1, 9.75:1, 9.80:1, 9.85:1, 9.90:1,
9.95:1, 10.00:1, 10.05:1, 10.10:1, 10.15:1, 10.20:1, 10.25:1, 10.30:1, 10.35:1, 10.40:1,
10.45:1, 10.50:1, 10.55:1, 10.60:1, 10.65:1, 10.70:1, 10.75:1, 10.80:1, 10.85:1, 10.90:1,
10.95:1, 11.00:1, 11.05:1, 11.10:1, 11.15:1, 11.20:1, 11.25:1, 11.30:1, 11.35:1, 11.40:1,
11.45:1, 11.50:1, 11.55:1, 11.60:1, 11.65:1, 11.70:1, 11.75:1, 11.80:1, 11.85:1, 11.90:1,
11.95:1, 12.00:1, 12.05:1, 12.10:1, 12.15:1, 12.20:1, 12.25:1, 12.30:1, 12.35:1, 12.40:1,
12.45:1, 12.50:1, 12.55:1, 12.60:1, 12.65:1, 12.70:1, 12.75:1, 12.80:1, 12.85:1, 12.90:1,
12.95:1, 13.00:1, 13.05:1, 13.10:1, 13.15:1, 13.20:1, 13.25:1, 13.30:1, 13.35:1, 13.40:1,
13.45:1, 13.50:1, 13.55:1, 13.60:1, 13.65:1, 13.70:1, 13.75:1, 13.80:1, 13.85:1, 13.90:1,
13.95:1, 14.00:1, 14.05:1, 14.10:1, 14.15:1, 14.20:1, 14.25:1, 14.30:1, 14.35:1, 14.40:1,
14.45:1, 14.50:1, 14.55:1, 14.60:1, 14.65:1, 14.70:1, 14.75:1, 14.80:1, 14.85:1, 14.90:1,
14.95:1, 15.00:1, 15.05:1, 15.10:1, 15.15:1, 15.20:1, 15.25:1, 15.30:1, 15.35:1, 15.40:1,
15.45:1, 15.50:1, 15.55:1, 15.60:1, 15.65:1, 15.70:1, 15.75:1, 15.80:1, 15.85:1, 15.90:1,
15.95:1, 16.00:1, 16.05:1, 16.10:1, 16.15:1, 16.20:1, 16.25:1, 16.30:1, 16.35:1, 16.40:1, 16.45:1, 16.50:1, 16.55:1, 16.60:1, 16.65:1, 16.70:1, 16.75:1, 16.80:1, 16.85:1, 16.90:1,
16.95:1, 17.00:1, 17.05:1, 17.10:1, 17.15:1, 17.20:1, 17.25:1, 17.30:1, 17.35:1, 17.40:1,
17.45:1, 17.50:1, 17.55:1, 17.60:1, 17.65:1, 17.70:1, 17.75:1, 17.80:1, 17.85:1, 17.90:1,
17.95:1, 18.00:1, 18.05:1, 18.10:1, 18.15:1, 18.20:1, 18.25:1, 18.30:1, 18.35:1, 18.40:1,
18.45:1, 18.50:1, 18.55:1, 18.60:1, 18.65:1, 18.70:1, 18.75:1, 18.80:1, 18.85:1, 18.90:1,
18.95:1, 19.00:1, 19.05:1, 19.10:1, 19.15:1, 19.20:1, 19.25:1, 19.30:1, 19.35:1, 19.40:1,
19.45:1, 19.50:1, 19.55:1, 19.60:1, 19.65:1, 19.70:1, 19.75:1, 19.80:1, 19.85:1, 19.90:1,
19.95:1, 20.00:1, 20.05:1, 20.10:1, 20.15:1, 20.20:1, 20.25:1, 20.30:1, 20.35:1, 20.40:1,
20.45:1, 20.50:1, 20.55:1, 20.60:1, 20.65:1, 20.70:1, 20.75:1, 20.80:1, 20.85:1, 20.90:1,
20.95:1, 21.00:1, 21.05:1, 21.10:1, 21.15:1, 21.20:1, 21.25:1, 21.30:1, 21.35:1, 21.40:1,
21.45:1, 21.50:1, 21.55:1, 21.60:1, 21.65:1, 21.70:1, 21.75:1, 21.80:1, 21.85:1, 21.90:1,
21.95:1, 22.00:1, 22.05:1, 22.10:1, 22.15:1, 22.20:1, 22.25:1, 22.30:1, 22.35:1, 22.40:1,
22.45:1, 22.50:1, 22.55:1, 22.60:1, 22.65:1, 22.70:1, 22.75:1, 22.80:1, 22.85:1, 22.90:1,
22.95:1, 23.00, 23.05:1, 23.10:1, 23.15:1, 23.20:1, 23.25:1, 23.30:1, 23.35:1, 23.40:1,
23.45:1, 23.50:1, 23.55:1, 23.60:1, 23.65:1, 23.70:1, 23.75:1, 23.80:1, 23.85:1, 23.90:1,
23.95:1, 24.00:1, 24.05:1, 24.10:1, 24.15:1, 24.20:1, 24.25:1, 24.30:1, 24.35:1, 24.40:1,
24.45:1, 24.50:1, 24.55:1, 24.60:1, 24.65:1, 24.70:1, 24.75:1, 24.80:1, 24.85:1, 24.90:1,
24.95:1, 25.05:1, 25.10:1, 25.15:1, 25.20:1, 25.25:1, 25.30:1, 25.35:1, 25.40:1, 25.45:1,
25.50:1, 25.55:1, 25.60:1, 25.65:1, 25.70:1, 25.75:1, 25.80:1, 25.85:1, 25.90:1, 25.95:1,
26.00:1, 26.05:1, 26.10:1, 26.15:1, 26.20:1, 26.25:1, 26.30:1, 26.35:1, 26.40:1, 26.45:1,
26.50:1, 26.55:1, 26.60:1, 26.65:1, 26.70:1, 26.75:1, 26.80:1, 26.85:1, 26.90:1, or 26.95:1. In some embodiments, the peripheral blood of the donor is enriched with CD34+ CD90+ CD45RA cells relative to leukocytes by a ratio of about from about 5.5:1 to about 6.5:1, such asaratio of about 5.50:1, 5.55:1, 5.60:1, 5.65:1, 5.70:1, 5.75:1, 5.80:1, 5.85:1, 5.90:1, 5.95:1, 6.00:1, 6.05:1, 6.10:1, 6.15:1, 6.20:1, 6.25:1, 6.30:1, 6.35:1, 6.40:1, 6.45:1, or 6.50:1. In some embodiments, the peripheral blood of the donor is enriched with CD34+ CD90+ CD45RA cells relative to leukocytes by a ratio of about 6.0:1.
[0025] In another aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ CD90+ CD45RA cells of at least about 16,000 cells/ml, such as a density of from about 20,000 cells/ml to about 75,000 cells/ml, about 25,000 cells/ml to about 70,000 cells/ml, about 30,000 cells/ml to about 65,000 cells/ml, about 35,000 cells/ml to about 60,000 cells/ml, about 40,000 cells/ml to about 55,000 cells/ml, or about 45,000 cells/ml to about 50,000 cells/ml ( e.g ., about 16,000 cells/ml, 17,000 cells/ml, 18,000 cells/ml, 19,000 cells/ml, 20,000 cells/ml, 21,000 cells/ml, 22,000 cells/ml, 23,000 cells/ml, 24,000 cells/ml, 25,000 cells/ml, 26,000 cells/ml, 27,000 cells/ml, 28,000 cells/ml, 29,000 cells/ml, 30,000 cells/ml, 31,000 cells/ml, 32,000 cells/ml, 33,000 cells/ml, 34,000 cells/ml, 35,000 cells/ml, 36,000 cells/ml, 37,000 cells/ml, 38,000 cells/ml, 39,000 cells/ml, 40,000 cells/ml, 41,000 cells/ml, 42,000 cells/ml, 43,000 cells/ml, 44,000 cells/ml, 45,000 cells/ml, 46,000 cells/ml, 47,000 cells/ml, 48,000 cells/ml, 49,000 cells/ml, 50,000 cells/ml, 51,000 cells/ml, 52,000 cells/ml, 53,000 cells/ml, 54,000 cells/ml, 55,000 cells/ml, 56,000 cells/ml, 57,000 cells/ml, 58,000 cells/ml, 59,000 cells/ml, 60,000 cells/ml, 61,000 cells/ml, 62,000 cells/ml, 63,000 cells/ml, 64,000 cells/ml, 65,000 cells/ml, 66,000 cells/ml, 67,000 cells/ml, 68,000 cells/ml, 69,000 cells/ml, 70,000 cells/ml, 71,000 cells/ml, 72,000 cells/ml, 73,000 cells/ml, 74,000 cells/ml, 75,000 cells/ml, 76,000 cells/ml, 77,000 cells/ml, or more), and having a density of leukocytes of no more than about 5.3 x 107 cells/ml, such as a density of leukocytes of about 2.3 x 107 cells/ml to about 5.3 x 107 cells/ml, about 2.5 x 107 cells/ml to about 5.1 x 107 cells/ml, 2.9 x 107 cells/ml to about 4.5 x 107 cells/ml, about 3 x 107 cells/ml to about 4 x 107 cells/ml (e.g., 5.3 x 107 cells/ml, 5.2 x 107 cells/ml, 5.1 x 107 cells/ml, 5 x 107 cells/ml, 4.9 x 107 cells/ml, 4.8 x 107 cells/ml, 4.7 x 107 cells/ml, 4.6 x 107 cells/ml, 4.5 x 107 cells/ml, 4.4 x 107 cells/ml, 4.3 x 107 cells/ml 4.2 x 107 cells/ml, 4.1 x 107 cells/ml 4 x 107 cells/ml, 3.9 x 107 cells/ml, 3.8 x 107 cells/ml, 3.7 x 107 cells/ml, 3.6 x 107 cells/ml, 3.5 x 107 cells/ml, 3.4 x 107 cells/ml, 3.3 x 107 cells/ml, 3.2 x 107 cells/ml, 3.1 x 107 cells/ml, 3 x 107 cells/ml, 2.9 x 107 cells/ml, 2.8 x 107 cells/ml, 2.7 x 107 cells/ml, 2.6 x 107 cells/ml, 2.5 x 107 cells/ml, 2.4 x 107 cells/ml, 2.3 x 107 cells/ml, or less). In some embodiments, the method includes
administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ CD90+ CD45RA cells of from about 20,000 cells/ml to about 75,000 cells/ml, and having a density of leukocytes of from about 2.3 x 107 cells/ml to about 5.3 x 107 cells/ml. In some embodiments, the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ CD90+ CD45RA cells of from about 30,000 cells/ml to about 60,000 cells/ml, and having a density of leukocytes of from about 2.5 x 107 cells/ml to about 5 x 107 cells/ml. In some embodiments, the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ CD90+ CD45RA cells of from about 40,000 cells/ml to about 50,000 cells/ml, and having a density of leukocytes of from about 3 x 107 cells/ml to about 4 x 107 cells/ml.
[0026] In a further aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34+ CD90+ CD45RA cells to neutrophils of from about 0.0007 to about 0.0043 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to neutrophils in the sample may be about 0.00070, 0.00071, 0.00072, 0.00073, 0.00074,
0.00075, 0.00076, 0.00077, 0.00078, 0.00079, 0.00080, 0.00081, 0.00082, 0.00083, 0.00084, 0.00085, 0.00086, 0.00087, 0.00088, 0.00089, 0.00090, 0.00091, 0.00092, 0.00093, 0.00094, 0.00095, 0.00096, 0.00097, 0.00098, 0.00099, 0.00100, 0.00101, 0.00102, 0.00103, 0.00104, 0.00105, 0.00106, 0.00107, 0.00108, 0.00109, 0.00110, 0.00111, 0.00112, 0.00113, 0.00114, 0.00115, 0.00116, 0.00117, 0.00118, 0.00119, 0.00120, 0.00121, 0.00122, 0.00123, 0.00124, 0.00125, 0.00126, 0.00127, 0.00128, 0.00129, 0.00130, 0.00131, 0.00132, 0.00133, 0.00134, 0.00135, 0.00136, 0.00137, 0.00138, 0.00139, 0.00140, 0.00141, 0.00142, 0.00143, 0.00144, 0.00145, 0.00146, 0.00147, 0.00148, 0.00149, 0.00150, 0.00151, 0.00152, 0.00153, 0.00154, 0.00155, 0.00156, 0.00157, 0.00158, 0.00159, 0.00160, 0.00161, 0.00162, 0.00163, 0.00164, 0.00165, 0.00166, 0.00167, 0.00168, 0.00169, 0.00170, 0.00171, 0.00172, 0.00173, 0.00174, 0.00175, 0.00176, 0.00177, 0.00178, 0.00179, 0.00180, 0.00181, 0.00182, 0.00183, 0.00184, 0.00185, 0.00186, 0.00187, 0.00188, 0.00189, 0.00190, 0.00191, 0.00192, 0.00193, 0.00194, 0.00195, 0.00196, 0.00197, 0.00198, 0.00199, 0.00200, 0.00201, 0.00202, 0.00203, 0.00204, 0.00205, 0.00206, 0.00207, 0.00208, 0.00209, 0.00210, 0.00211, 0.00212, 0.00213, 0.00214, 0.00215, 0.00216, 0.00217, 0.00218, 0.00219, 0.00220, 0.00221, 0.00222, 0.00223, 0.00224, 0.00225, 0.00226, 0.00227, 0.00228, 0.00229, 0.00230, 0.00231, 0.00232, 0.00233, 0.00234, 0.00235, 0.00236, 0.00237, 0.00238, 0.00239, 0.00240, 0.00241, 0.00242, 0.00243, 0.00244, 0.00245, 0.00246, 0.00247, 0.00248, 0.00249, 0.00250, 0.00251, 0.00252, 0.00253, 0.00254, 0.00255, 0.00256, 0.00257, 0.00258, 0.00259, 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266, 0.00267, 0.00268, 0.00269, 0.00270, 0.00271, 0.00272, 0.00273, 0.00274, 0.00275, 0.00276, 0.00277, 0.00278, 0.00279, 0.00280, 0.00281, 0.00282, 0.00283, 0.00284, 0.00285, 0.00286, 0.00287, 0.00288, 0.00289, 0.00290, 0.00291, 0.00292, 0.00293, 0.00294, 0.00295, 0.00296, 0.00297, 0.00298, 0.00299, 0.00300, 0.00300, 0.00301, 0.00302, 0.00303, 0.00304, 0.00305, 0.00306, 0.00307, 0.00308, 0.00309, 0.00310, 0.00311, 0.00312, 0.00313, 0.00314, 0.00315, 0.00316, 0.00317, 0.00318, 0.00319, 0.00320, 0.00321, 0.00322, 0.00323, 0.00324, 0.00325, 0.00326, 0.00327, 0.00328, 0.00329, 0.00330, 0.00331, 0.00332, 0.00333, 0.00334, 0.00335, 0.00336, 0.00337, 0.00338, 0.00339, 0.00340, 0.00341, 0.00342, 0.00343, 0.00344, 0.00345, 0.00346, 0.00347, 0.00348, 0.00349, 0.00350, 0.00351, 0.00352, 0.00353, 0.00354, 0.00355, 0.00356, 0.00357, 0.00358, 0.00359, 0.00360, 0.00361, 0.00362, 0.00363, 0.00364, 0.00365, 0.00366, 0.00367, 0.00368, 0.00369, 0.00370, 0.00371, 0.00372, 0.00373, 0.00374, 0.00375, 0.00376, 0.00377, 0.00378, 0.00379, 0.00380, 0.00381, 0.00382, 0.00383, 0.00384, 0.00385, 0.00386, 0.00387, 0.00388, 0.00389, 0.00390, 0.00391, 0.00392, 0.00393, 0.00394, 0.00395, 0.00396, 0.00397, 0.00398, 0.00399, 0.00400, 0.00401, 0.00402, 0.00403, 0.00404, 0.00405, 0.00406, 0.00407, 0.00408, 0.00409, 0.00410, 0.00411, 0.00412, 0.00413, 0.00414, 0.00415, 0.00416, 0.00417, 0.00418, 0.00419, 0.00420, 0.00421, 0.00422, 0.00423, 0.00424, 0.00425, 0.00426, 0.00427, 0.00428, 0.00429, or 0.00430. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to neutrophils in the sample is from about 0.002 to about 0.003. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to neutrophils in the sample is from about 0.0014 to about 0.0034, such as a ratio of CD34+ CD90+
CD45RA cells to neutrophils in the sample of about 0.00140, 0.00141, 0.00142, 0.00143,
0.00144, 0.00145, 0.00146, 0.00147, 0.00148, 0.00149, 0.00150, 0.00151, 0.00152, 0.00153, 0.00154, 0.00155, 0.00156, 0.00157, 0.00158, 0.00159, 0.00160, 0.00161, 0.00162, 0.00163, 0.00164, 0.00165, 0.00166, 0.00167, 0.00168, 0.00169, 0.00170, 0.00171, 0.00172, 0.00173, 0.00174, 0.00175, 0.00176, 0.00177, 0.00178, 0.00179, 0.00180, 0.00181, 0.00182, 0.00183, 0.00184, 0.00185, 0.00186, 0.00187, 0.00188, 0.00189, 0.00190, 0.00191, 0.00192, 0.00193, 0.00194, 0.00195, 0.00196, 0.00197, 0.00198, 0.00199, 0.00200, 0.00201, 0.00202, 0.00203, 0.00204, 0.00205, 0.00206, 0.00207, 0.00208, 0.00209, 0.00210, 0.00211, 0.00212, 0.00213, 0.00214, 0.00215, 0.00216, 0.00217, 0.00218, 0.00219, 0.00220, 0.00221, 0.00222, 0.00223, 0.00224, 0.00225, 0.00226, 0.00227, 0.00228, 0.00229, 0.00230, 0.00231, 0.00232, 0.00233, 0.00234, 0.00235, 0.00236, 0.00237, 0.00238, 0.00239, 0.00240, 0.00241, 0.00242, 0.00243, 0.00244, 0.00245, 0.00246, 0.00247, 0.00248, 0.00249, 0.00250, 0.00251, 0.00252, 0.00253, 0.00254, 0.00255, 0.00256, 0.00257, 0.00258, 0.00259, 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266, 0.00267, 0.00268, 0.00269, 0.00270, 0.00271, 0.00272, 0.00273, 0.00274, 0.00275, 0.00276, 0.00277, 0.00278, 0.00279, 0.00280, 0.00281, 0.00282, 0.00283, 0.00284, 0.00285, 0.00286, 0.00287, 0.00288, 0.00289, 0.00290, 0.00291, 0.00292, 0.00293, 0.00294, 0.00295, 0.00296, 0.00297, 0.00298, 0.00299, 0.00300, 0.00300, 0.00301, 0.00302,
0.00303, 0.00304, 0.00305, 0.00306, 0.00307, 0.00308, 0.00309, 0.00310, 0.00311, 0.00312,
0.00313, 0.00314, 0.00315, 0.00316, 0.00317, 0.00318, 0.00319, 0.00320, 0.00321, 0.00322,
0.00323, 0.00324, 0.00325, 0.00326, 0.00327, 0.00328, 0.00329, 0.00330, 0.00331, 0.00332,
0.00333, 0.00334, 0.00335, 0.00336, 0.00337, 0.00338, 0.00339, or 0.00340. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to neutrophils in the sample is about 0.0024.
[0027] In an additional aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34+ CD90+ CD45RA cells relative to neutrophils by a ratio of from about 3.5:1 to about 22.0: 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist. In some embodiments, the peripheral blood of the donor may be enriched with CD34+ CD90+ CD45RA cells relative to neutrophils by a ratio of about 3.50:1, 3.55:1, 3.60:1, 3.65:1, 3.70:1, 3.75:1, 3.80:1, 3.85:1, 3.90:1, 3.95:1, 4.00:1, 4.05:1, 4.10:1, 4.15:1, 4.20:1, 4.25:1,
4.30:1, 4.35:1, 4.40:1, 4.45:1, 4.50:1, 4.55:1, 4.60:1, 4.65:1, 4.70:1, 4.75:1, 4.80:1, 4.85:1,
4.90:1, 4.95:1, 5.00:1, 5.05:1, 5.10:1, 5.15:1, 5.20:1, 5.25:1, 5.30:1, 5.35:1, 5.40:1, 5.45:1,
5.50:1, 5.55:1, 5.60:1, 5.65:1, 5.70:1, 5.75:1, 5.80:1, 5.85:1, 5.90:1, 5.95:1, 6.00:1, 6.05:1,
6.10:1, 6.15:1, 6.20:1, 6.25:1, 6.30:1, 6.35:1, 6.40:1, 6.45:1, 6.50:1, 6.55:1, 6.60:1, 6.65:1,
6.70:1, 6.75:1, 6.80:1, 6.85:1, 6.90:1, 6.95:1, 7.00:1, 7.05:1, 7.10:1, 7.15:1, 7.20:1, 7.25:1,
7.30:1, 7.35:1, 7.40:1, 7.45:1, 7.50:1, 7.55:1, 7.60:1, 7.65:1, 7.70:1, 7.75:1, 7.80:1, 7.85:1,
7.90:1, 7.95:1, 8.00:1, 8.05:1, 8.10:1, 8.15:1, 8.20:1, 8.25:1, 8.30:1, 8.35:1, 8.40:1, 8.45:1,
8.50:1, 8.55:1, 8.60:1, 8.65:1, 8.70:1, 8.75:1, 8.80:1, 8.85:1, 8.90:1, 8.95:1, 9.00:1, 9.05:1,
9.10:1, 9.15:1, 9.20:1, 9.25:1, 9.30:1, 9.35:1, 9.40:1, 9.45:1, 9.50:1, 9.55:1, 9.60:1, 9.65:1,
9.70:1, 9.75:1, 9.80:1, 9.85:1, 9.90:1, 9.95:1, 10.00:1, 10.05:1, 10.10:1, 10.15:1, 10.20:1, 10.25:1, 10.30:1, 10.35:1, 10.40:1, 10.45:1, 10.50:1, 10.55:1, 10.60:1, 10.65:1, 10.70:1,
10.75:1, 10.80:1, 10.85:1, 10.90:1, 10.95:1, 11.00:1, 11.05:1, 11.10:1, 11.15:1, 11.20:1,
11.25:1, 11.30:1, 11.35:1, 11.40:1, 11.45:1, 11.50:1, 11.55:1, 11.60:1, 11.65:1, 11.70:1,
11.75:1, 11.80:1, 11.85:1, 11.90:1, 11.95:1, 12.00:1, 12.05:1, 12.10:1, 12.15:1, 12.20:1,
12.25:1, 12.30:1, 12.35:1, 12.40:1, 12.45:1, 12.50:1, 12.55:1, 12.60:1, 12.65:1, 12.70:1, 12.75:1, 12.80:1, 12.85:1, 12.90:1, 12.95:1, 13.00:1, 13.05:1, 13.10:1, 13.15:1, 13.20:1,
13.25:1, 13.30:1, 13.35:1, 13.40:1, 13.45:1, 13.50:1, 13.55:1, 13.60:1, 13.65:1, 13.70:1,
13.75:1, 13.80:1, 13.85:1, 13.90:1, 13.95:1, 14.00:1, 14.05:1, 14.10:1, 14.15:1, 14.20:1,
14.25:1, 14.30:1, 14.35:1, 14.40:1, 14.45:1, 14.50:1, 14.55:1, 14.60:1, 14.65:1, 14.70:1,
14.75:1, 14.80:1, 14.85:1, 14.90:1, 14.95:1, 15.00:1, 15.05:1, 15.10:1, 15.15:1, 15.20:1,
15.25:1, 15.30:1, 15.35:1, 15.40:1, 15.45:1, 15.50:1, 15.55:1, 15.60:1, 15.65:1, 15.70:1,
15.75:1, 15.80:1, 15.85:1, 15.90:1, 15.95:1, 16.00:1, 16.05:1, 16.10:1, 16.15:1, 16.20:1,
16.25:1, 16.30:1, 16.35:1, 16.40:1, 16.45:1, 16.50:1, 16.55:1, 16.60:1, 16.65:1, 16.70:1,
16.75:1, 16.80:1, 16.85:1, 16.90:1, 16.95:1, 17.00:1, 17.05:1, 17.10:1, 17.15:1, 17.20:1,
17.25:1, 17.30:1, 17.35:1, 17.40:1, 17.45:1, 17.50:1, 17.55:1, 17.60:1, 17.65:1, 17.70:1,
17.75:1, 17.80:1, 17.85:1, 17.90:1, 17.95:1, 18.00:1, 18.05:1, 18.10:1, 18.15:1, 18.20:1,
18.25:1, 18.30:1, 18.35:1, 18.40:1, 18.45:1, 18.50:1, 18.55:1, 18.60:1, 18.65:1, 18.70:1,
18.75:1, 18.80:1, 18.85:1, 18.90:1, 18.95:1, 19.00:1, 19.05:1, 19.10:1, 19.15:1, 19.20:1,
19.25:1, 19.30:1, 19.35:1, 19.40:1, 19.45:1, 19.50:1, 19.55:1, 19.60:1, 19.65:1, 19.70:1,
19.75:1, 19.80:1, 19.85:1, 19.90:1, 19.95:1,20.00:1,20.05:1,20.10:1,20.15:1,20.20:1, 20.25:1, 20.30:1, 20.35:1, 20.40:1, 20.45:1, 20.50:1, 20.55:1, 20.60:1, 20.65:1, 20.70:1,
20.75:1, 20.80:1, 20.85:1, 20.90:1, 20.95:1, 21.00:1, 21.05:1, 21.10:1, 21.15:1, 21.20:1,
21.25:1, 21.30:1, 21.35:1, 21.40:1, 21.45:1, 21.50:1, 21.55:1, 21.60:1, 21.65:1, 21.70:1,
21.75:1, 21.80:1, 21.85:1, 21.90:1, 21.95:1, or 22.00:1. In some embodiments, the peripheral blood of the donor is enriched with CD34+ CD90+ CD45RA cells relative to neutrophils by a ratio of about from about 7.0:1 to about 10:1. In some embodiments, the peripheral blood of the donor is enriched with CD34+ CD90+ CD45RA cells relative to neutrophils by a ratio of from about 7.00:1 to about 9.00:1, such as a ratio of about 7.00:1, 7.05:1, 7.10:1, 7.15:1, 7.20:1, 7.25:1, 7.30:1, 7.35:1, 7.40:1, 7.45:1, 7.50:1, 7.55:1, 7.60:1, 7.65:1, 7.70:1, 7.75:1,
7.80:1, 7.85:1, 7.90:1, 7.95:1, 8.00:1, 8.05:1, 8.10:1, 8.15:1, 8.20:1, 8.25:1, 8.30:1, 8.35:1,
8.40:1, 8.45:1, 8.50:1, 8.55:1, 8.60:1, 8.65:1, 8.70:1, 8.75:1, 8.80:1, 8.85:1, 8.90:1, 8.95:1, or
9.00: 1. In some embodiments, the peripheral blood of the donor is enriched with CD34+ CD90+ CD45RA cells relative to neutrophils by a ratio of about 8.2:1.
[0028] In another aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ CD90+ CD45RA cells of at least about 16,000 cells/ml, such as a density of from about 20,000 cells/ml to about 75,000 cells/ml, about 25,000 cells/ml to about 70,000 cells/ml, about 30,000 cells/ml to about 65,000 cells/ml, about 35,000 cells/ml to about 60,000 cells/ml, about 40,000 cells/ml to about 55,000 cells/ml, or about 45,000 cells/ml to about 50,000 cells/ml ( e.g ., about 16,000 cells/ml, 17,000 cells/ml, 18,000 cells/ml, 19,000 cells/ml, 20,000 cells/ml, 21,000 cells/ml, 22,000 cells/ml, 23,000 cells/ml, 24,000 cells/ml, 25,000 cells/ml, 26,000 cells/ml, 27,000 cells/ml, 28,000 cells/ml, 29,000 cells/ml, 30,000 cells/ml, 31,000 cells/ml, 32,000 cells/ml, 33,000 cells/ml, 34,000 cells/ml, 35,000 cells/ml, 36,000 cells/ml, 37,000 cells/ml, 38,000 cells/ml, 39,000 cells/ml, 40,000 cells/ml, 41,000 cells/ml, 42,000 cells/ml, 43,000 cells/ml, 44,000 cells/ml, 45,000 cells/ml, 46,000 cells/ml, 47,000 cells/ml, 48,000 cells/ml, 49,000 cells/ml, 50,000 cells/ml, 51,000 cells/ml, 52,000 cells/ml, 53,000 cells/ml, 54,000 cells/ml, 55,000 cells/ml, 56,000 cells/ml, 57,000 cells/ml, 58,000 cells/ml, 59,000 cells/ml, 60,000 cells/ml, 61,000 cells/ml, 62,000 cells/ml, 63,000 cells/ml, 64,000 cells/ml, 65,000 cells/ml, 66,000 cells/ml, 67,000 cells/ml, 68,000 cells/ml, 69,000 cells/ml, 70,000 cells/ml, 71,000 cells/ml, 72,000 cells/ml, 73,000 cells/ml, 74,000 cells/ml, 75,000 cells/ml, 76,000 cells/ml, 77,000 cells/ml, or more), and having a density of neutrophils of no more than about 2.5 x 107 cells/ml, such as a density of neutrophils of about 1 x 107 cells/ml to about 2.5 x 107 cells/ml, about 1.3 x 107 cells/ml to about 2 x l07cells/ml, or about 1.5 x l07cells/ml to about 1.9 x 107 cells/ml (e.g., about 2.5 x 107 cells/ml, 2.4 x 107 cells/ml, 2.3 x 107 cells/ml, 2.2 x 07 cells/ml, 2.1 x 107 cells/ml, 2 x 107 cells/ml, 1.9 x 107 cells/ml, 1.8 x 107 cells/ml, 1.7 x 107 cells/ml, 1.6 x 107 cells/ml, 1.5 x 107 cells/ml 1.4 x 107 cells/ml, 1.3 x 107 cells/ml, 1.2 x 107 cells/ml, 1.1 x 107 cells/ml, 1 x 107 cells/ml, or less). In some embodiments, the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ CD90+ CD45RA cells of from about 20,000 cells/ml to about 75,000 cells/ml, and having a density of neutrophils of from about 1 x 107 cells/ml to about 2.5 x 107 cells/ml. In some embodiments, the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ CD90+ CD45RA cells of from about 30,000 cells/ml to about 60,000 cells/ml, and having a density of neutrophils of from about 1.3 x 107 cells/ml to about 2.3 x 107 cells/ml.
In some embodiments, the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ CD90+ CD45RA cells of from about 40,000 cells/ml to about 50,000 cells/ml, and having a density of neutrophils of from about 1.5 x 107 cells/ml to about 2 x 107 cells/ml. [0029] In yet another aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34+ CD90+ CD45RA cells to lymphocytes of from about 0.0008 to about 0.0069 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to lymphocytes in the sample may be about 0.00080, 0.00081, 0.00082, 0.00083, 0.00084,
0.00085, 0.00086, 0.00087, 0.00088, 0.00089, 0.00090, 0.00091, 0.00092, 0.00093, 0.00094, 0.00095, 0.00096, 0.00097, 0.00098, 0.00099, 0.00100, 0.00101, 0.00102, 0.00103, 0.00104, 0.00105, 0.00106, 0.00107, 0.00108, 0.00109, 0.00110, 0.00111, 0.00112, 0.00113, 0.00114, 0.00115, 0.00116, 0.00117, 0.00118, 0.00119, 0.00120, 0.00121, 0.00122, 0.00123, 0.00124, 0.00125, 0.00126, 0.00127, 0.00128, 0.00129, 0.00130, 0.00131, 0.00132, 0.00133, 0.00134, 0.00135, 0.00136, 0.00137, 0.00138, 0.00139, 0.00140, 0.00141, 0.00142, 0.00143, 0.00144, 0.00145, 0.00146, 0.00147, 0.00148, 0.00149, 0.00150, 0.00151, 0.00152, 0.00153, 0.00154, 0.00155, 0.00156, 0.00157, 0.00158, 0.00159, 0.00160, 0.00161, 0.00162, 0.00163, 0.00164, 0.00165, 0.00166, 0.00167, 0.00168, 0.00169, 0.00170, 0.00171, 0.00172, 0.00173, 0.00174, 0.00175, 0.00176, 0.00178, 0.00179, 0.00180, 0.00181, 0.00182, 0.00183, 0.00184, 0.00185, 0.00186, 0.00187, 0.00188, 0.00189, 0.00190, 0.00191, 0.00192, 0.00193, 0.00194, 0.00195, 0.00196, 0.00197, 0.00198, 0.00199, 0.00200, 0.00201, 0.00202, 0.00203, 0.00204, 0.00205, 0.00206, 0.00207, 0.00208, 0.00209, 0.00210, 0.00211, 0.00212, 0.00213, 0.00214, 0.00215, 0.00216, 0.00217, 0.00218, 0.00219, 0.00220, 0.00221, 0.00222, 0.00223, 0.00224, 0.00225, 0.00226, 0.00227, 0.00228, 0.00229, 0.00230, 0.00231, 0.00232, 0.00233, 0.00234, 0.00235, 0.00236, 0.00237, 0.00238, 0.00239, 0.00240, 0.00241, 0.00242, 0.00243, 0.00244, 0.00245, 0.00246, 0.00247, 0.00248, 0.00249, 0.00250, 0.00251, 0.00252, 0.00253, 0.00254, 0.00255, 0.00256, 0.00257, 0.00258, 0.00259, 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266, 0.00267, 0.00268, 0.00269, 0.00270, 0.00271, 0.00272, 0.00273, 0.00274, 0.00275, 0.00276, 0.00278, 0.00279, 0.00280, 0.00281, 0.00282, 0.00283, 0.00284, 0.00285, 0.00286, 0.00287, 0.00288, 0.00289, 0.00290, 0.00291, 0.00292, 0.00293, 0.00294, 0.00295, 0.00296, 0.00297, 0.00298, 0.00299, 0.00300, 0.00301, 0.00302, 0.00303, 0.00304, 0.00305, 0.00306, 0.00307, 0.00308, 0.00309, 0.00310, 0.00311, 0.00312, 0.00313, 0.00314, 0.00315, 0.00316, 0.00317, 0.00318, 0.00319, 0.00320, 0.00321, 0.00322, 0.00323, 0.00324, 0.00325, 0.00326, 0.00327, 0.00328, 0.00329, 0.00330, 0.00331, 0.00332, 0.00333, 0.00334, 0.00335, 0.00336, 0.00337, 0.00338, 0.00339, 0.00340, 0.00341, 0.00342, 0.00343, 0.00344, 0.00345, 0.00346, 0.00347, 0.00348, 0.00349, 0.00350, 0.00351, 0.00352, 0.00353, 0.00354, 0.00355, 0.00356, 0.00357, 0.00358, 0.00359, 0.00360, 0.00361, 0.00362, 0.00363, 0.00364, 0.00365, 0.00366, 0.00367, 0.00368, 0.00369, 0.00370, 0.00371, 0.00372, 0.00373, 0.00374, 0.00375, 0.00376, 0.00378, 0.00379, 0.00380, 0.00381, 0.00382, 0.00383, 0.00384, 0.00385, 0.00386, 0.00387, 0.00388, 0.00389, 0.00390, 0.00391, 0.00392, 0.00393, 0.00394, 0.00395, 0.00396, 0.00397, 0.00398, 0.00399, 0.00401, 0.00402, 0.00403, 0.00404, 0.00405, 0.00406, 0.00407, 0.00408, 0.00409, 0.00410, 0.00411, 0.00412, 0.00413, 0.00414, 0.00415, 0.00416, 0.00417, 0.00418, 0.00419, 0.00420, 0.00421, 0.00422, 0.00423, 0.00424, 0.00425, 0.00426, 0.00427, 0.00428, 0.00429, 0.00430, 0.00431, 0.00432, 0.00433, 0.00434, 0.00435, 0.00436, 0.00437, 0.00438, 0.00439, 0.00440, 0.00441, 0.00442, 0.00443, 0.00444, 0.00445, 0.00446, 0.00447, 0.00448, 0.00449, 0.00450, 0.00451, 0.00452, 0.00453, 0.00454, 0.00455, 0.00456, 0.00457, 0.00458, 0.00459, 0.00460, 0.00461, 0.00462, 0.00463, 0.00464, 0.00465, 0.00466, 0.00467, 0.00468, 0.00469, 0.00470, 0.00471, 0.00472, 0.00473, 0.00474, 0.00475, 0.00476, 0.00478, 0.00479, 0.00480, 0.00481, 0.00482, 0.00483, 0.00484, 0.00485, 0.00486, 0.00487, 0.00488, 0.00489, 0.00490, 0.00491, 0.00492, 0.00493, 0.00494, 0.00495, 0.00496, 0.00497, 0.00498, 0.00499, 0.00500, 0.00501, 0.00502, 0.00503, 0.00504, 0.00505, 0.00506, 0.00507, 0.00508, 0.00509, 0.00510, 0.00511, 0.00512, 0.00513, 0.00514, 0.00515, 0.00516, 0.00517, 0.00518, 0.00519, 0.00520, 0.00521, 0.00522, 0.00523, 0.00524, 0.00525, 0.00526, 0.00527, 0.00528, 0.00529, 0.00530, 0.00531, 0.00532, 0.00533, 0.00534, 0.00535, 0.00536, 0.00537, 0.00538, 0.00539, 0.00540, 0.00541, 0.00542, 0.00543, 0.00544, 0.00545, 0.00546, 0.00547, 0.00548, 0.00549, 0.00550, 0.00551, 0.00552, 0.00553, 0.00554, 0.00555, 0.00556, 0.00557, 0.00558, 0.00559, 0.00560, 0.00561, 0.00562, 0.00563, 0.00564, 0.00565, 0.00566, 0.00567, 0.00568, 0.00569, 0.00570, 0.00571, 0.00572, 0.00573, 0.00574, 0.00575, 0.00576, 0.00578, 0.00579, 0.00580, 0.00581, 0.00582, 0.00583, 0.00584, 0.00585, 0.00586, 0.00587, 0.00588, 0.00589, 0.00590, 0.00591, 0.00592, 0.00593, 0.00594, 0.00595, 0.00596, 0.00597, 0.00598, 0.00599, 0.00600, 0.00601, 0.00602, 0.00603, 0.00604, 0.00605, 0.00606, 0.00607, 0.00608, 0.00609, 0.00610, 0.00611, 0.00612, 0.00613, 0.00614, 0.00615, 0.00616, 0.00617, 0.00618, 0.00619, 0.00620, 0.00621, 0.00622, 0.00623, 0.00624, 0.00625, 0.00626, 0.00627, 0.00628, 0.00629, 0.00630, 0.00631, 0.00632, 0.00633, 0.00634, 0.00635, 0.00636, 0.00637, 0.00638, 0.00639, 0.00640, 0.00641, 0.00642, 0.00643, 0.00644, 0.00645, 0.00646, 0.00647, 0.00648, 0.00649, 0.00650, 0.00651, 0.00652, 0.00653, 0.00654, 0.00655, 0.00656, 0.00657, 0.00658, 0.00659, 0.00660, 0.00661, 0.00662, 0.00663, 0.00664, 0.00665, 0.00666, 0.00667, 0.00668, 0.00669, 0.00670, 0.00671, 0.00672, 0.00673, 0.00674, 0.00675, 0.00676, 0.00678, 0.00679, 0.00680, 0.00681, 0.00682, 0.00683, 0.00684, 0.00685, 0.00686, 0.00687, 0.00688, 0.00689, or 0.00690. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to lymphocytes in the sample is from about 0.0011 to about 0.0031, such as a ratio of CD34+ CD90+ CD45RA cells to lymphocytes in the sample of about 0.00110, 0.00111, 0.00112, 0.00113, 0.00114, 0.00115, 0.00116, 0.00117, 0.00118, 0.00119, 0.00120, 0.00121, 0.00122, 0.00123, 0.00124, 0.00125,
0.00126, 0.00127, 0.00128, 0.00129, 0.00130, 0.00131, 0.00132, 0.00133, 0.00134, 0.00135,
0.00136, 0.00137, 0.00138, 0.00139, 0.00140, 0.00141, 0.00142, 0.00143, 0.00144, 0.00145,
0.00146, 0.00147, 0.00148, 0.00149, 0.00150, 0.00151, 0.00152, 0.00153, 0.00154, 0.00155,
0.00156, 0.00157, 0.00158, 0.00159, 0.00160, 0.00161, 0.00162, 0.00163, 0.00164, 0.00165,
0.00166, 0.00167, 0.00168, 0.00169, 0.00170, 0.00171, 0.00172, 0.00173, 0.00174, 0.00175,
0.00176, 0.00178, 0.00179, 0.00180, 0.00181, 0.00182, 0.00183, 0.00184, 0.00185, 0.00186,
0.00187, 0.00188, 0.00189, 0.00190, 0.00191, 0.00192, 0.00193, 0.00194, 0.00195, 0.00196,
0.00197, 0.00198, 0.00199, 0.00200, 0.00201, 0.00202, 0.00203, 0.00204, 0.00205, 0.00206,
0.00207, 0.00208, 0.00209, 0.00210, 0.00211, 0.00212, 0.00213, 0.00214, 0.00215, 0.00216,
0.00217, 0.00218, 0.00219, 0.00220, 0.00221, 0.00222, 0.00223, 0.00224, 0.00225, 0.00226,
0.00227, 0.00228, 0.00229, 0.00230, 0.00231, 0.00232, 0.00233, 0.00234, 0.00235, 0.00236,
0.00237, 0.00238, 0.00239, 0.00240, 0.00241, 0.00242, 0.00243, 0.00244, 0.00245, 0.00246,
0.00247, 0.00248, 0.00249, 0.00250, 0.00251, 0.00252, 0.00253, 0.00254, 0.00255, 0.00256,
0.00257, 0.00258, 0.00259, 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266,
0.00267, 0.00268, 0.00269, 0.00270, 0.00271, 0.00272, 0.00273, 0.00274, 0.00275, 0.00276,
0.00278, 0.00279, 0.00280, 0.00281, 0.00282, 0.00283, 0.00284, 0.00285, 0.00286, 0.00287,
0.00288, 0.00289, 0.00290, 0.00291, 0.00292, 0.00293, 0.00294, 0.00295, 0.00296, 0.00297,
0.00298, 0.00299, 0.00300, 0.00301, 0.00302, 0.00303, 0.00304, 0.00305, 0.00306, 0.00307,
0.00308, 0.00309, or 0.00310. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to lymphocytes in the sample is about 0.0021.
[0030] In an additional aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34+ CD90+ CD45RA cells relative to lymphocytes by a ratio of from about 5.6: 1 to about 37.0: 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist. In some embodiments, the peripheral blood of the donor may be enriched with CD34+ CD90+ CD45RA cells relative to lymphocytes by a ratio of about 5.60:1, 5.65:1, 5.70:1, 5.75:1,
5.80:1, 5.85:1, 5.90:1, 5.95:1, 6.00:1, 6.05:1 , 6.10:1, 6.15:1, 6.20:1, 6.25:1, 6.30:1, 6.35:1, 6.40:1, 6.45:1, 6.50:1, 6.55:1, 6.60:1, 6.65:1 , 6.70:1, 6.75:1, 6.80:1, 6.85:1, 6.90:1, 6.95:1, 7.00:1, 7.05:1, 7.10:1, 7.15:1, 7.20:1, 7.25:1 , 7.30:1, 7.35:1, 7.40:1, 7.45:1, 7.50:1, 7.55:1, 7.60:1, 7.65:1, 7.70:1, 7.75:1, 7.80:1, 7.85:1 , 7.90:1, 7.95:1, 8.00:1, 8.05:1, 8.10:1, 8.15:1, 8.20:1, 8.25:1, 8.30:1, 8.35:1, 8.40:1, 8.45:1 , 8.50:1, 8.55:1, 8.60:1, 8.65:1, 8.70:1, 8.75:1, 8.80:1, 8.85:1, 8.90:1, 8.95:1, 9.00:1, 9.05:1 , 9.10:1, 9.15:1, 9.20:1, 9.25:1, 9.30:1, 9.35:1, 9.40:1, 9.45:1, 9.50:1, 9.55:1, 9.60:1, 9.65:1 , 9.70:1, 9.75:1, 9.80:1, 9.85:1, 9.90:1, 9.95:1, 10.00:1, 10.05:1, 10.10:1, 10.15:1, 10.20:1, 10.25:1, 10.30:1, 10.35: 1, 10.40:1, 10.45:1, 10.50:1, 10.55:1, 10.60:1, 10.65:1, 10.70:1, 10.75:1, 10.80:1, 10.85: 1, 10.90:1, 10.95:1, 11.00:1, 11.05:1, 11.10:1, 11.15:1, 11.20:1, 11.25:1, 11.30:1, 11.35: 1, 11.40:1, 11.45:1, 11.50:1, 11.55:1, 11.60:1, 11.65:1, 11.70:1, 11.75:1, 11.80:1, 11.85: 1, 11.90:1, 11.95:1, 12.00:1, 12.05:1, 12.10:1, 12.15:1, 12.20:1, 12.25:1, 12.30:1, 12.35: 1, 12.40:1, 12.45:1, 12.50:1, 12.55:1, 12.60:1, 12.65:1, 12.70:1, 12.75:1, 12.80:1, 12.85: 1, 12.90:1, 12.95:1, 13.00:1, 13.05:1, 13.10:1, 13.15:1, 13.20:1, 13.25:1, 13.30:1, 13.35: 1, 13.40:1, 13.45:1, 13.50:1, 13.55:1, 13.60:1, 13.65:1, 13.70:1, 13.75:1, 13.80:1, 13.85: 1, 13.90:1, 13.95:1, 14.00:1, 14.05:1, 14.10:1, 14.15:1, 14.20:1, 14.25:1, 14.30:1, 14.35 1, 14.40:1, 14.45:1, 14.50:1, 14.55:1, 14.60:1, 14.65:1, 14.70:1, 14.75:1, 14.80:1, 14.85 1, 14.90:1, 14.95:1, 15.00:1, 15.05:1, 15.10:1, 15.15:1, 15.20:1, 15.25:1, 15.30:1, 15.35 1, 15.40:1, 15.45:1, 15.50:1, 15.55:1, 15.60:1, 15.65:1, 15.70:1, 15.75:1, 15.80:1, 15.85 1, 15.90:1, 15.95:1, 16.00:1, 16.05:1, 16.10:1, 16.15:1, 16.20:1, 16.25:1, 16.30:1, 16.35 1, 16.40:1, 16.45:1, 16.50:1, 16.55:1, 16.60:1, 16.65:1, 16.70:1, 16.75:1, 16.80:1, 16.85 1, 16.90:1, 16.95:1, 17.00:1, 17.05:1, 17.10:1, 17.15:1, 17.20:1, 17.25:1, 17.30:1, 17.35 1, 17.40:1, 17.45:1, 17.50:1, 17.55:1, 17.60:1, 17.65:1, 17.70:1, 17.75:1, 17.80:1, 17.85 1, 17.90:1, 17.95:1, 18.00:1, 18.05:1, 18.10:1, 18.15:1, 18.20:1, 18.25:1, 18.30:1, 18.35 1, 18.40:1, 18.45:1, 18.50:1, 18.55:1, 18.60:1, 18.65:1, 18.70:1, 18.75:1, 18.80:1, 18.85 1, 18.90:1, 18.95:1, 19.00:1, 19.05:1, 19.10:1, 19.15:1, 19.20:1, 19.25:1, 19.30:1, 19.35 1, 19.40:1, 19.45:1, 19.50:1, 19.55:1, 19.60:1, 19.65:1, 19.70:1, 19.75:1, 19.80:1, 19.85 1, 19.90:1, 19.95:1, 20.00:1, 20.05:1, 20.10:1, 20.15:1, 20.20:1, 20.25:1, 20.30:1, 20.35 1, 20.40:1, 20.45:1, 20.50:1, 20.55:1, 20.60:1, 20.65:1, 20.70:1, 20.75:1, 20.80:1, 20.85 1, 20.90:1, 20.95:1, 21.00:1, 21.05:1, 21.10:1, 21.15:1, 21.20:1, 21.25:1, 21.30:1, 21.35 1, 21.40:1, 21.45:1, 21.50:1, 21.55:1, 21.60:1, 21.65:1, 21.70:1, 21.75:1, 21.80:1, 21.85:1, 21.90:1, 21.95:1,
22.00:1, 22.05:1, 22.10:1, 22.15:1, 22.20:1, 22.25:1, 22.30:1, 22.35:1, 22.40:1, 22.45:1,
22.50:1, 22.55:1, 22.60:1, 22.65:1, 22.70:1, 22.75:1, 22.80:1, 22.85:1, 22.90:1, 22.95:1,
23.00, 23.05:1, 23.10:1, 23.15:1, 23.20:1, 23.25:1, 23.30:1, 23.35:1, 23.40:1, 23.45:1,
23.50:1, 23.55:1, 23.60:1, 23.65:1, 23.70:1, 23.75:1, 23.80:1, 23.85:1, 23.90:1, 23.95:1, 24.00:1, 24.05:1, 24.10:1, 24.15:1, 24.20:1, 24.25:1, 24.30:1, 24.35:1, 24.40:1, 24.45:1, 24.50:1, 24.55:1, 24.60:1, 24.65:1, 24.70:1, 24.75:1, 24.80:1, 24.85:1, 24.90:1, 24.95:1, 25.05:1, 25.10:1, 25.15:1, 25.20:1, 25.25:1, 25.30:1, 25.35:1, 25.40:1, 25.45:1, 25.50:1, 25.55:1, 25.60:1, 25.65:1, 25.70:1, 25.75:1, 25.80:1, 25.85:1, 25.90:1, 25.95:1, 26.00:1, 26.05:1, 26.10:1, 26.15:1, 26.20:1, 26.25:1, 26.30:1, 26.35:1, 26.40:1, 26.45:1, 26.50:1, 26.55:1, 26.60:1, 26.65:1, 26.70:1, 26.75:1, 26.80:1, 26.85:1, 26.90:1, 26.95:1, 27.00:1, 27.05:1, 27.10:1, 27.15:1, 27.20:1, 27.25:1, 27.30:1, 27.35:1, 27.40:1, 27.45:1, 27.50:1, 27.55:1, 27.60:1, 27.65:1, 27.70:1, 27.75:1, 27.80:1, 27.85:1, 27.90:1, 27.95:1, 28.00:1, 28.05:1, 28.10:1, 28.15:1, 28.20:1, 28.25:1, 28.30:1, 28.35:1, 28.40:1, 28.45:1, 28.50:1, 28.55:1, 28.60:1, 28.65:1, 28.70:1, 28.75:1, 28.80:1, 28.85:1, 28.90:1, 28.95:1, 29.00:1, 29.05:1, 29.10:1, 29.15:1, 29.20:1, 29.25:1, 29.30:1, 29.35:1, 29.40:1, 29.45:1, 29.50:1, 29.55:1, 29.60:1, 29.65:1, 29.70:1, 29.75:1, 29.80:1, 29.85:1, 29.90:1, 29.95:1, 30.00:1, 30.05:1, 30.10:1, 30.15:1, 30.20:1, 30.25:1, 30.30:1, 30.35:1, 30.40:1, 30.45:1, 30.50:1, 30.55:1, 30.60:1, 30.65:1, 30.70:1, 30.75:1, 30.80:1, 30.85:1, 30.90:1, 30.95:1, 31.00:1, 31.05:1, 31.10:1, 31.15:1, 31.20:1, 31.25:1, 31.30:1, 31.35:1, 31.40:1, 31.45:1, 31.50:1, 31.55:1, 31.60:1, 31.65:1, 31.70:1, 31.75:1, 31.80:1, 31.85:1, 31.90:1, 31.95:1, 32.00:1, 32.05:1, 32.10:1, 32.15:1, 32.20:1, 32.25:1, 32.30:1, 32.35:1, 32.40:1, 32.45:1, 32.50:1, 32.55:1, 32.60:1, 32.65:1, 32.70:1, 32.75:1, 32.80:1, 32.85:1, 32.90:1, 32.95:1, 33.00:1, 33.05:1, 33.10:1, 33.15:1, 33.20:1, 33.25:1, 33.30:1, 33.35:1, 33.40:1, 33.45:1, 33.50:1, 33.55:1, 33.60:1, 33.65:1, 33.70:1, 33.75:1, 33.80:1, 33.85:1, 33.90:1, 33.95:1, 34.00:1, 34.05:1, 34.10:1, 34.15:1, 34.20:1, 34.25:1, 34.30:1, 34.35:1, 34.40:1, 34.45:1, 34.50:1, 34.55:1, 34.60:1, 34.65:1, 34.70:1, 34.75:1, 34.80:1, 34.85:1, 34.90:1, 34.95:1, 35.00:1, 35.05:1, 35.10:1, 35.15:1, 35.20:1, 35.25:1, 35.30:1, 35.35:1, 35.40:1, 35.45:1, 35.50:1, 35.55:1, 35.60:1, 35.65:1, 35.70:1, 35.75:1, 35.80:1, 35.85:1, 35.90:1, 35.95:1, 36.00:1, 36.05:1, 36.10:1, 36.15:1, 36.20:1, 36.25:1, 36.30:1, 36.35:1, 36.40:1, 36.45:1, 36.50:1, 36.55:1, 36.60:1, 36.65:1, 36.70:1, 36.75:1, 36.80:1, 36.85:1, 36.90:1, 36.95:1, or 37.00. In some embodiments, the peripheral blood of the donor is enriched with CD34+ CD90+
CD45RA cells relative to lymphocytes by a ratio of about from about 8.0: 1 to about 10.0:1, such as a ratio of about 8.00: 1, 8.05: 1, 8.10: 1, 8.15: 1, 8.20: 1, 8.25: 1, 8.30: 1, 8.35: 1, 8.40: 1,
8.45: 1, 8.50: 1, 8.55: 1, 8.60: 1, 8.65: 1, 8.70: 1, 8.75: 1, 8.80: 1, 8.85: 1, 8.90: 1, 8.95: 1, 9.00: 1,
9.05: 1, 9.10: 1, 9.15: 1, 9.20: 1, 9.25: 1, 9.30: 1, 9.35: 1, 9.40: 1, 9.45: 1, 9.50: 1, 9.55: 1, 9.60: 1,
9.65: 1, 9.70: 1, 9.75: 1, 9.80: 1, 9.85: 1, 9.90: 1, 9.95: 1, or 10.00: 1. In some embodiments, the peripheral blood of the donor is enriched with CD34+ CD90+ CD45RA cells relative to lymphocytes by a ratio of about 9.3 : 1.
[0031] In another aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ CD90+ CD45RA cells of at least about 16,000 cells/ml, such as a density of from about 20,000 cells/ml to about 75,000 cells/ml, about 25,000 cells/ml to about 70,000 cells/ml, about 30,000 cells/ml to about 65,000 cells/ml, about 35,000 cells/ml to about 60,000 cells/ml, about 40,000 cells/ml to about 55,000 cells/ml, or about 45,000 cells/ml to about 50,000 cells/ml (e.g., about 16,000 cells/ml, 17,000 cells/ml, 18,000 cells/ml, 19,000 cells/ml, 20,000 cells/ml, 21,000 cells/ml, 22,000 cells/ml, 23,000 cells/ml, 24,000 cells/ml, 25,000 cells/ml, 26,000 cells/ml, 27,000 cells/ml, 28,000 cells/ml, 29,000 cells/ml, 30,000 cells/ml, 31,000 cells/ml, 32,000 cells/ml, 33,000 cells/ml, 34,000 cells/ml, 35,000 cells/ml, 36,000 cells/ml, 37,000 cells/ml, 38,000 cells/ml, 39,000 cells/ml, 40,000 cells/ml, 41,000 cells/ml, 42,000 cells/ml, 43,000 cells/ml, 44,000 cells/ml, 45,000 cells/ml, 46,000 cells/ml, 47,000 cells/ml, 48,000 cells/ml, 49,000 cells/ml, 50,000 cells/ml, 51,000 cells/ml, 52,000 cells/ml, 53,000 cells/ml, 54,000 cells/ml, 55,000 cells/ml, 56,000 cells/ml, 57,000 cells/ml, 58,000 cells/ml, 59,000 cells/ml, 60,000 cells/ml, 61,000 cells/ml, 62,000 cells/ml, 63,000 cells/ml, 64,000 cells/ml, 65,000 cells/ml, 66,000 cells/ml, 67,000 cells/ml, 68,000 cells/ml, 69,000 cells/ml, 70,000 cells/ml, 71,000 cells/ml, 72,000 cells/ml, 73,000 cells/ml, 74,000 cells/ml, 75,000 cells/ml, 76,000 cells/ml, 77,000 cells/ml, or more), and having a density of lymphocytes of no more than about 2.4 x 107 cells/ml, such as a density of lymphocytes of about 1 x 107 cells/ml to about 2.3 x 107 cells/ml, about 1.3 x 107 cells/ml to about 2.1 x l07cells/ml, or about 1.5 x 107 cells/ml to about 1.9 x 107 cells/ml (e.g, about 2.4 x 107 cells/ml, 2.3 x 107 cells/ml, 2.2 x 07 cells/ml, 2.1 x 107 cells/ml, 2 x 107 cells/ml, 1.9 x 107 cells/ml, 1.8 x 107 cells/ml, 1.7 x 107 cells/ml, 1.6 x 107 cells/ml, 1.5 x 107 cells/ml 1.4 x 107 cells/ml, 1.3 x 107 cells/ml, 1.2 x 107 cells/ml, 1.1 x 107 cells/ml, 1 x 107 cells/ml, or less, 0.9 x 107 cells/ml, 0.8 x 107 cells/ml, or less). In some embodiments, the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ CD90+ CD45RA cells of from about 20,000 cells/ml to about 75,000 cells/ml, and having a density of lymphocytes of from about 1 x 107 cells/ml to about 2.3 x 107 cells/ml. In some embodiments, the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ CD90+ CD45RA cells of from about 30,000 cells/ml to about 60,000 cells/ml, and having a density of lymphocytes of from about 1.3 x 107 cells/ml to about 2.3 x 107 cells/ml. In some embodiments, the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ CD90+ CD45RA cells of from about 40,000 cells/ml to about 50,000 cells/ml, and having a density of lymphocytes of from about 1.5 x 107 cells/ml to about 2 x 107 cells/ml.
[0032] In another aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34+ CD90+ CD45Ra cells to monocytes of from about 0.0028 to about 0.0130 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to monocytes in the sample may be about 0.00280. 0.00281. 0.00282. 0.00283. 0.00284. 0.00285. 0.00286. 0.00287. 0.00288
0.00289, 0.00290, 0.00291, 0.00292, 0.00293, 0.00294, 0.00295, 0.00296, 0.00297, 0.00298, 0.00299, 0.00300, 0.00301, 0.00302, 0.00303, 0.00304, 0.00305, 0.00306, 0.00307, 0.00308, 0.00309, 0.00310, 0.00311, 0.00312, 0.00313, 0.00314, 0.00315, 0.00316, 0.00317, 0.00318, 0.00319, 0.00320, 0.00321, 0.00322, 0.00323, 0.00324, 0.00325, 0.00326, 0.00327, 0.00328, 0.00329, 0.00330, 0.00331, 0.00332, 0.00333, 0.00334, 0.00335, 0.00336, 0.00337, 0.00338, 0.00339, 0.00340, 0.00341, 0.00342, 0.00343, 0.00344, 0.00345, 0.00346, 0.00347, 0.00348, 0.00349, 0.00350, 0.00351, 0.00352, 0.00353, 0.00354, 0.00355, 0.00356, 0.00357, 0.00358, 0.00359, 0.00360, 0.00361, 0.00362, 0.00363, 0.00364, 0.00365, 0.00366, 0.00367, 0.00368, 0.00369, 0.00370, 0.00371, 0.00372, 0.00373, 0.00374, 0.00375, 0.00376, 0.00378, 0.00379, 0.00380, 0.00381, 0.00382, 0.00383, 0.00384, 0.00385, 0.00386, 0.00387, 0.00388, 0.00389, 0.00390, 0.00391, 0.00392, 0.00393, 0.00394, 0.00395, 0.00396, 0.00397, 0.00398, 0.00399, 0.00401, 0.00402, 0.00403, 0.00404, 0.00405, 0.00406, 0.00407, 0.00408, 0.00409, 0.00410, 0.00411, 0.00412, 0.00413, 0.00414, 0.00415, 0.00416, 0.00417, 0.00418, 0.00419, 0.00420, 0.00421, 0.00422, 0.00423, 0.00424, 0.00425, 0.00426, 0.00427, 0.00428, 0.00429, 0.00430, 0.00431, 0.00432, 0.00433, 0.00434, 0.00435, 0.00436, 0.00437, 0.00438, 0.00439, 0.00440, 0.00441, 0.00442, 0.00443, 0.00444, 0.00445, 0.00446, 0.00447, 0.00448, 0.00449, 0.00450, 0.00451, 0.00452, 0.00453, 0.00454, 0.00455, 0.00456, 0.00457, 0.00458, 0.00459, 0.00460, 0.00461, 0.00462, 0.00463, 0.00464, 0.00465, 0.00466, 0.00467, 0.00468, 0.00469, 0.00470, 0.00471, 0.00472, 0.00473, 0.00474, 0.00475, 0.00476, 0.00478, 0.00479, 0.00480, 0.00481, 0.00482, 0.00483, 0.00484, 0.00485, 0.00486, 0.00487, 0.00488, 0.00489, 0.00490, 0.00491, 0.00492, 0.00493, 0.00494, 0.00495, 0.00496, 0.00497, 0.00498, 0.00499, 0.00500, 0.00501, 0.00502, 0.00503, 0.00504, 0.00505, 0.00506, 0.00507, 0.00508, 0.00509, 0.00510, 0.00511, 0.00512, 0.00513, 0.00514, 0.00515, 0.00516, 0.00517, 0.00518, 0.00519, 0.00520, 0.00521, 0.00522, 0.00523, 0.00524, 0.00525, 0.00526, 0.00527, 0.00528, 0.00529, 0.00530, 0.00531, 0.00532, 0.00533, 0.00534, 0.00535, 0.00536, 0.00537, 0.00538, 0.00539, 0.00540, 0.00541, 0.00542, 0.00543, 0.00544, 0.00545, 0.00546, 0.00547, 0.00548, 0.00549, 0.00550, 0.00551, 0.00552, 0.00553, 0.00554, 0.00555, 0.00556, 0.00557, 0.00558, 0.00559, 0.00560, 0.00561, 0.00562, 0.00563, 0.00564, 0.00565, 0.00566, 0.00567, 0.00568, 0.00569, 0.00570, 0.00571, 0.00572, 0.00573, 0.00574, 0.00575, 0.00576, 0.00578, 0.00579, 0.00580, 0.00581, 0.00582, 0.00583, 0.00584, 0.00585, 0.00586, 0.00587, 0.00588, 0.00589, 0.00590, 0.00591, 0.00592, 0.00593, 0.00594, 0.00595, 0.00596, 0.00597, 0.00598, 0.00599, 0.00600, 0.00601, 0.00602, 0.00603, 0.00604, 0.00605, 0.00606, 0.00607, 0.00608, 0.00609, 0.00610, 0.00611, 0.00612, 0.00613, 0.00614, 0.00615, 0.00616, 0.00617, 0.00618, 0.00619, 0.00620, 0.00621, 0.00622, 0.00623, 0.00624, 0.00625, 0.00626, 0.00627, 0.00628, 0.00629, 0.00630, 0.00631, 0.00632, 0.00633, 0.00634, 0.00635, 0.00636, 0.00637, 0.00638, 0.00639, 0.00640, 0.00641, 0.00642, 0.00643, 0.00644, 0.00645, 0.00646, 0.00647, 0.00648, 0.00649, 0.00650, 0.00651, 0.00652, 0.00653, 0.00654, 0.00655, 0.00656, 0.00657, 0.00658, 0.00659, 0.00660, 0.00661, 0.00662, 0.00663, 0.00664, 0.00665, 0.00666, 0.00667, 0.00668, 0.00669, 0.00670, 0.00671, 0.00672, 0.00673, 0.00674, 0.00675, 0.00676, 0.00678, 0.00679, 0.00680, 0.00681, 0.00682, 0.00683, 0.00684, 0.00685, 0.00686, 0.00687, 0.00688, 0.00689, 0.00690, 0.00691, 0.00692, 0.00693, 0.00694, 0.00695, 0.00696, 0.00697, 0.00698, 0.00699, 0.00700, 0.00701, 0.00702, 0.00703, 0.00704, 0.00705, 0.00706, 0.00707, 0.00708, 0.00709, 0.00710, 0.00711, 0.00712, 0.00713, 0.00714, 0.00715, 0.00716, 0.00717, 0.00718, 0.00719, 0.00720, 0.00721, 0.00722, 0.00723, 0.00724, 0.00725, 0.00726, 0.00727, 0.00728, 0.00729, 0.00730, 0.00731, 0.00732, 0.00733, 0.00734, 0.00735, 0.00736, 0.00737, 0.00738, 0.00739, 0.00740, 0.00741, 0.00742, 0.00743, 0.00744, 0.00745, 0.00746, 0.00747, 0.00748, 0.00749, 0.00750, 0.00751, 0.00752, 0.00753, 0.00754, 0.00755, 0.00756, 0.00757, 0.00758, 0.00759, 0.00760, 0.00761, 0.00762, 0.00763, 0.00764, 0.00765, 0.00766, 0.00767, 0.00768, 0.00769, 0.00770, 0.00771, 0.00772, 0.00773, 0.00774, 0.00775, 0.00776, 0.00777, 0.00778, 0.00779, 0.00780, 0.00781, 0.00782, 0.00783, 0.00784, 0.00785, 0.00786, 0.00787, 0.00788, 0.00789, 0.00790, 0.00791, 0.00792, 0.00793, 0.00794, 0.00795, 0.00796, 0.00797, 0.00798, 0.00799, 0.00800, 0.00801, 0.00802, 0.00803, 0.00804, 0.00805, 0.00806, 0.00807, 0.00808, 0.00809, 0.00810, 0.00811, 0.00812, 0.00813, 0.00814, 0.00815, 0.00816, 0.00817, 0.00818, 0.00819, 0.00820, 0.00821, 0.00822, 0.00823, 0.00824, 0.00825, 0.00826, 0.00827, 0.00828, 0.00829, 0.00830, 0.00831, 0.00832, 0.00833, 0.00834, 0.00835, 0.00836, 0.00837, 0.00838, 0.00839, 0.00840, 0.00841, 0.00842, 0.00843, 0.00844, 0.00845, 0.00846, 0.00847, 0.00848, 0.00849, 0.00850, 0.00851, 0.00852, 0.00853, 0.00854, 0.00855, 0.00856, 0.00857, 0.00858, 0.00859, 0.00860, 0.00861, 0.00862, 0.00863, 0.00864, 0.00865, 0.00866, 0.00867, 0.00868, 0.00869, 0.00870, 0.00871, 0.00872, 0.00873, 0.00874, 0.00875, 0.00876, 0.00877, 0.00878, 0.00879, 0.00880, 0.00881, 0.00882, 0.00883, 0.00884, 0.00885, 0.00886, 0.00887, 0.00888, 0.00889, 0.00890, 0.00891, 0.00892, 0.00893, 0.00894, 0.00895, 0.00896, 0.00897, 0.00898, 0.00899, 0.00900, 0.00901, 0.00902, 0.00903, 0.00904, 0.00905, 0.00906, 0.00907, 0.00908, 0.00909, 0.00910, 0.00911, 0.00912, 0.00913, 0.00914, 0.00915, 0.00916, 0.00917, 0.00918, 0.00919, 0.00920, 0.00921, 0.00922, 0.00923, 0.00924, 0.00925, 0.00926, 0.00927, 0.00928, 0.00929, 0.00930, 0.00931, 0.00932, 0.00933, 0.00934, 0.00935, 0.00936, 0.00937, 0.00938, 0.00939, 0.00940, 0.00941, 0.00942, 0.00943, 0.00944, 0.00945, 0.00946, 0.00947, 0.00948, 0.00949, 0.00950, 0.00951, 0.00952, 0.00953, 0.00954, 0.00955, 0.00956, 0.00957, 0.00958, 0.00959, 0.00960, 0.00961, 0.00962, 0.00963, 0.00964, 0.00965, 0.00966, 0.00967, 0.00968, 0.00969, 0.00970, 0.00971, 0.00972, 0.00973, 0.00974, 0.00975, 0.00976, 0.00977, 0.00978, 0.00979, 0.00980, 0.00981, 0.00982, 0.00983, 0.00984, 0.00985, 0.00986, 0.00987, 0.00988, 0.00989, 0.00990, 0.00991, 0.00992, 0.00993, 0.00994, 0.00995, 0.00996, 0.00997, 0.00998, 0.00999, 0.0100, 0.0101, 0.0103, 0.0104, 0.0105, 0.0106, 0.0107, 0.0108, 0.0109, 0.0110, 0.0111, 0.0112, 0.0113, 0.0114, 0.0115, 0.0116, 0.0117, 0.0118, 0.0119, 0.0120, 0.0121, 0.0122, 0.0123, 0.0124, 0.0125, 0.0126, 0.0127, 0.0128, 0.0129, or 0.0130. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to monocytes in the sample is from about 0.0063 to about 0.0083, such as a ratio of CD34+ CD90+ CD45RA cells to monocytes in the sample of about 0.00630, 0.00631, 0.00632, 0.00633, 0.00634, 0.00635, 0.00636, 0.00637, 0.00638, 0.00639, 0.00640, 0.00641, 0.00642, 0.00643, 0.00644, 0.00645, 0.00646, 0.00647, 0.00648, 0.00649, 0.00650, 0.00651, 0.00652, 0.00653, 0.00654, 0.00655, 0.00656, 0.00657, 0.00658, 0.00659, 0.00660, 0.00661, 0.00662, 0.00663, 0.00664, 0.00665, 0.00666, 0.00667, 0.00668, 0.00669, 0.00670, 0.00671, 0.00672, 0.00673, 0.00674, 0.00675, 0.00676, 0.00678, 0.00679, 0.00680, 0.00681, 0.00682, 0.00683, 0.00684, 0.00685, 0.00686, 0.00687, 0.00688, 0.00689, 0.00690, 0.00691, 0.00692, 0.00693, 0.00694, 0.00695, 0.00696, 0.00697, 0.00698, 0.00699, 0.00700, 0.00701, 0.00702, 0.00703, 0.00704, 0.00705, 0.00706, 0.00707, 0.00708, 0.00709, 0.00710, 0.00711, 0.00712, 0.00713, 0.00714, 0.00715, 0.00716, 0.00717, 0.00718, 0.00719, 0.00720, 0.00721, 0.00722, 0.00723, 0.00724, 0.00725, 0.00726, 0.00727, 0.00728, 0.00729, 0.00730, 0.00731, 0.00732, 0.00733, 0.00734, 0.00735, 0.00736, 0.00737, 0.00738, 0.00739, 0.00740, 0.00741, 0.00742, 0.00743, 0.00744, 0.00745, 0.00746, 0.00747, 0.00748, 0.00749, 0.00750, 0.00751, 0.00752, 0.00753, 0.00754, 0.00755, 0.00756, 0.00757, 0.00758, 0.00759, 0.00760, 0.00761, 0.00762, 0.00763, 0.00764, 0.00765, 0.00766, 0.00767, 0.00768, 0.00769, 0.00770, 0.00771, 0.00772, 0.00773, 0.00774, 0.00775, 0.00776, 0.00777, 0.00778, 0.00779, 0.00780, 0.00781, 0.00782, 0.00783, 0.00784, 0.00785, 0.00786, 0.00787, 0.00788, 0.00789, 0.00790, 0.00791, 0.00792, 0.00793, 0.00794, 0.00795, 0.00796, 0.00797, 0.00798, 0.00799, 0.00800, 0.00801, 0.00802, 0.00803, 0.00804, 0.00805, 0.00806, 0.00807, 0.00808, 0.00809, 0.00810, 0.00811, 0.00812, 0.00813, 0.00814, 0.00815, 0.00816, 0.00817, 0.00818, 0.00819, 0.00820, 0.00821, 0.00822, 0.00823, 0.00824, 0.00825, 0.00826, 0.00827, 0.00828, 0.00829, 0.00830. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to monocytes in the sample is about 0.0073.
[0033] In an additional aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34+ CD90+ CD45RA cells relative to monocytes by a ratio of from about 1.5: 1 to about 8.5: 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist. In some embodiments, the peripheral blood of the donor may be enriched with CD34+ CD90+ CD45RA cells relative to monocytes by a ratio of about 1.50: 1, 1.55: 1, 1.60: 1, 1.65: 1,
1.70: 1, 1.75: 1, 1.80: 1, 1.85: 1, 1.90: 1, 1.95: 1, 2.00: 1, 2.05: 1, 2.10:1, 2.15: 1, 2.20: 1, 2.25: 1,
2.30: 1, 2.35: 1, 2.40: 1, 2.45: 1, 2.50: 1, 2.55: 1, 2.60: 1, 2.65: 1, 2.70:1, 2.75: 1, 2.80: 1, 2.85: 1,
2.90: 1, 2.95: 1, 3.00: 1, 3.05: 1, 3.10: 1, 3.15: 1, 3.20: 1, 3.25: 1, 3.30:1, 3.35: 1, 3.40: 1, 3.45: 1,
3.50: 1, 3.55: 1, 3.60: 1, 3.65: 1, 3.70: 1, 3.75: 1, 3.80: 1, 3.85: 1, 3.90:1, 3.95: 1, 4.00: 1, 4.05: 1, 4.10:1, 4.15:1, 4.20:1, 4.25:1, 4.30:1, 4.35:1, 4.40:1, 4.45:1, 4.50:1, 4.55:1, 4.60:1, 4.65:1, 4.70:1, 4.75:1, 4.80:1, 4.85:1, 4.90:1, 4.95:1, 5.00:1, 5.05:1, 5.10:1, 5.15:1, 5.20:1, 5.25:1, 5.30:1, 5.35:1, 5.40:1, 5.45:1, 5.50:1, 5.55:1, 5.60:1, 5.65:1, 5.70:1, 5.75:1, 5.80:1, 5.85:1, 5.90:1, 5.95:1, 6.00:1, 6.05:1, 6.10:1, 6.15:1, 6.20:1, 6.25:1, 6.30:1, 6.35:1, 6.40:1, 6.45:1, 6.50:1, 6.55:1, 6.60:1, 6.65:1, 6.70:1, 6.75:1, 6.80:1, 6.85:1, 6.90:1, 6.95:1, 7.00:1, 7.05:1, 7.10:1, 7.15:1, 7.20:1, 7.25:1, 7.30:1, 7.35:1, 7.40:1, 7.45:1, 7.50:1, 7.55:1, 7.60:1, 7.65:1, 7.70:1, 7.75:1, 7.80:1, 7.85:1, 7.90:1, 7.95:1, 8.00:1, 8.05:1, 8.10:1, 8.15:1, 8.20:1, 8.25:1, 8.30:1, 8.35:1, 8.40:1, 8.45:1, or 8.50:1. In some embodiments, the peripheral blood of the donor is enriched with CD34+ CD90+ CD45RA cells relative to monocytes by a ratio of about 1.9:1.
[0034] In another aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ CD90+ CD45RA cells of at least about 16,000 cells/ml, such as a density of from about 20,000 cells/ml to about 75,000 cells/ml, about 25,000 cells/ml to about 70,000 cells/ml, about 30,000 cells/ml to about 65,000 cells/ml, about 35,000 cells/ml to about 60,000 cells/ml, about 40,000 cells/ml to about 55,000 cells/ml, or about 45,000 cells/ml to about 50,000 cells/ml (e.g., about 16,000 cells/ml, 17,000 cells/ml, 18,000 cells/ml, 19,000 cells/ml, 20,000 cells/ml, 21,000 cells/ml, 22,000 cells/ml, 23,000 cells/ml, 24,000 cells/ml, 25,000 cells/ml, 26,000 cells/ml, 27,000 cells/ml, 28,000 cells/ml, 29,000 cells/ml, 30,000 cells/ml, 31,000 cells/ml, 32,000 cells/ml, 33,000 cells/ml, 34,000 cells/ml, 35,000 cells/ml, 36,000 cells/ml, 37,000 cells/ml, 38,000 cells/ml, 39,000 cells/ml, 40,000 cells/ml, 41,000 cells/ml, 42,000 cells/ml, 43,000 cells/ml, 44,000 cells/ml, 45,000 cells/ml, 46,000 cells/ml, 47,000 cells/ml, 48,000 cells/ml, 49,000 cells/ml, 50,000 cells/ml, 51,000 cells/ml, 52,000 cells/ml, 53,000 cells/ml, 54,000 cells/ml, 55,000 cells/ml, 56,000 cells/ml, 57,000 cells/ml, 58,000 cells/ml, 59,000 cells/ml, 60,000 cells/ml, 61,000 cells/ml, 62,000 cells/ml, 63,000 cells/ml, 64,000 cells/ml, 65,000 cells/ml, 66,000 cells/ml, 67,000 cells/ml, 68,000 cells/ml, 69,000 cells/ml, 70,000 cells/ml, 71,000 cells/ml, 72,000 cells/ml, 73,000 cells/ml, 74,000 cells/ml, 75,000 cells/ml, 76,000 cells/ml, 77,000 cells/ml, or more), and having a density of monocytes of no more than about 6 x 106 cells/ml, such as a density of monocytes of from 3.4 x 106 cells/ml to about 5.9 x 106 cells/ml, about 3.5 x 106 cells/ml to about 5.7 x 106 cells/ml, or about 4 x 106 cells/ml to about 5 x 106 cells/ml (e.g, 5.9 x 106 cells/ml, 5.8 x 106 cells/ml, 5.7 x 106 cells/ml, 5.6 x 106 cells/ml, 5.5 x 106 cells/ml, 5.4 x 106 cells/ml, 5.3 x 106 cells/ml,
5.2 x 106 cells/ml, 5.1 x 106 cells/ml, 5 x 106 cells/ml, 4.9 x 106 cells/ml, 4.8 x 106 cells/ml,
4.7 x 106 cells/ml, 4.6 x 106 cells/ml, 4.5 x 106 cells/ml, 4.4 x 106 cells/ml, 4.3 x 106 cells/ml,
4.2 x 106 cells/ml, 4.1 x 106 cells/ml, 4 x 106 cells/ml, 3.9 x 106 cells/ml, 3.8 x 106 cells/ml,
3.7 x 106 cells/ml, 3.6 x 106 cells/ml, 3.5 x 106 cells/ml, 3.4 x 106 cells/ml, or less). In some embodiments, the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ CD90+ CD45RA cells of from about 20,000 cells/ml to about 75,000 cells/ml, and having a density of monocytes of from about 3.4 x 106 cells/ml to about 6 x 106 cells/ml. In some embodiments, the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ CD90+ CD45RA cells of from about 30,000 cells/ml to about 60,000 cells/ml, and having a density of monocytes of from about 4 x 106 cells/ml to about 5.5 x 106 cells/ml. In some embodiments, the method includes administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a density of CD34+ CD90+ CD45RA cells of from about 40,000 cells/ml to about 50,000 cells/ml, and having a density of monocytes of from about 4 x 106 cells/ml to about 5 x 106 cells/ml.
[0035] In another aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34+ CD90+ CD45RA cells to CD34+ cells of from about 0.393 to about 0.745 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to CD34+ cells in the sample may be about 0.393, 0.394, 0.395, 0.396, 0.397, 0.398, 0.399, 0.401, 0.402, 0.403, 0.404, 0.405, 0.406, 0.407, 0.408, 0.409, 0.410, 0.411, 0.412, 0.413, 0.414, 0.415, 0.416, 0.417, 0.418,
0.419, 0.420, 0.421, 0.422, 0.423, 0.424, 0.425, 0.426, 0.427, 0.428, 0.429, 0.430, 0.431,
0.432, 0.433, 0.434, 0.435, 0.436, 0.437, 0.438, 0.439, 0.440, 0.441, 0.442, 0.443, 0.444,
0.445, 0.446, 0.447, 0.448, 0.449, 0.450, 0.451, 0.452, 0.453, 0.454, 0.455, 0.456, 0.457,
0.458, 0.459, 0.460, 0.461, 0.462, 0.463, 0.464, 0.465, 0.466, 0.467, 0.468, 0.469, 0.470,
0.471, 0.472, 0.473, 0.474, 0.475, 0.476, 0.478, 0.479, 0.480, 0.481, 0.482, 0.483, 0.484,
0.485, 0.486, 0.487, 0.488, 0.489, 0.490, 0.491, 0.492, 0.493, 0.494, 0.495, 0.496, 0.497,
0.498, 0.499, 0.500, 0.501, 0.502, 0.503, 0.504, 0.505, 0.506, 0.507, 0.508, 0.509, 0.510, 0.511, 0.512, 0.513, 0.514, 0.515, 0.516, 0.517, 0.518, 0.519, 0.520, 0.521, 0.522, 0.523,
0.524, 0.525, 0.526, 0.527, 0.528, 0.529, 0.530, 0.531, 0.532, 0.533, 0.534, 0.535, 0.536,
0.537, 0.538, 0.539, 0.540, 0.541, 0.542, 0.543, 0.544, 0.545, 0.546, 0.547, 0.548, 0.549,
0.550, 0.551, 0.552, 0.553, 0.554, 0.555, 0.556, 0.557, 0.558, 0.559, 0.560, 0.561, 0.562,
0.563, 0.564, 0.565, 0.566, 0.567, 0.568, 0.569, 0.570, 0.571, 0.572, 0.573, 0.574, 0.575,
0.576, 0.578, 0.579, 0.580, 0.581, 0.582, 0.583, 0.584, 0.585, 0.586, 0.587, 0.588, 0.589,
0.590, 0.591, 0.592, 0.593, 0.594, 0.595, 0.596, 0.597, 0.598, 0.599, 0.600, 0.601, 0.602,
0.603, 0.604, 0.605, 0.606, 0.607, 0.608, 0.609, 0.610, 0.611, 0.612, 0.613, 0.614, 0.615,
0.616, 0.617, 0.618, 0.619, 0.620, 0.621, 0.622, 0.623, 0.624, 0.625, 0.626, 0.627, 0.628,
0.629, 0.630, 0.631, 0.632, 0.633, 0.634, 0.635, 0.636, 0.637, 0.638, 0.639, 0.640, 0.641,
0.642, 0.643, 0.644, 0.645, 0.646, 0.647, 0.648, 0.649, 0.650, 0.651, 0.652, 0.653, 0.654,
0.655, 0.656, 0.657, 0.658, 0.659, 0.660, 0.661, 0.662, 0.663, 0.664, 0.665, 0.666, 0.667,
0.668, 0.669, 0.670, 0.671, 0.672, 0.673, 0.674, 0.675, 0.676, 0.678, 0.679, 0.680, 0.681,
0.682, 0.683, 0.684, 0.685, 0.686, 0.687, 0.688, 0.689, 0.690, 0.691, 0.692, 0.693, 0.694,
0.695, 0.696, 0.697, 0.698, 0.699, 0.700, 0.701, 0.702, 0.703, 0.704, 0.705, 0.706, 0.707,
0.708, 0.709, 0.710, 0.711, 0.712, 0.713, 0.714, 0.715, 0.716, 0.717, 0.718, 0.719, 0.720,
0.721, 0.722, 0.723, 0.724, 0.725, 0.726, 0.727, 0.728, 0.729, 0.730, 0.731, 0.732, 0.733,
0.734, 0.735, 0.736, 0.737, 0.738, 0.739, 0.740, 0.741, 0.742, 0.743, 0.744, or 0.745. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to CD34+ cells in the sample is from about 0.625 to about 0.725, such as a ratio of CD34+ CD90+ CD45RA cells to CD34+ cells in the sample of about 0.625, 0.626, 0.627, 0.628, 0.629, 0.630, 0.631, 0.632, 0.633, 0.634, 0.635, 0.636, 0.637, 0.638, 0.639, 0.640, 0.641, 0.642, 0.643, 0.644, 0.645, 0.646, 0.647,
0.648, 0.649, 0.650, 0.651, 0.652, 0.653, 0.654, 0.655, 0.656, 0.657, 0.658, 0.659, 0.660,
0.661, 0.662, 0.663, 0.664, 0.665, 0.666, 0.667, 0.668, 0.669, 0.670, 0.671, 0.672, 0.673,
0.674, 0.675, 0.676, 0.678, 0.679, 0.680, 0.681, 0.682, 0.683, 0.684, 0.685, 0.686, 0.687,
0.688, 0.689, 0.690, 0.691, 0.692, 0.693, 0.694, 0.695, 0.696, 0.697, 0.698, 0.699, 0.700,
0.701, 0.702, 0.703, 0.704, 0.705, 0.706, 0.707, 0.708, 0.709, 0.710, 0.711, 0.712, 0.713,
0.714, 0.715, 0.716, 0.717, 0.718, 0.719, 0.720, 0.721, 0.722, 0.723, 0.724, or 0.725. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to CD34+ cells in the sample is about 0.676.
[0036] In an additional aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34+ CD90+ CD45RA cells relative to CD34+ cells by a ratio of from about 1.1 : 1 to about 4.8:1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist. In some embodiments, the peripheral blood of the donor may be enriched with CD34+ CD90+ CD45RA cells relative to monocytes by a ratio of about 1.10:1, 1.15:1, 1.20:1, 1.25:1,
1.30:1, 1.35:1, 1.40:1, 1.45:1, 1.50:1, 1.55:1, 1.60:1, 1.65:1, 1.70:1, 1.75:1, 1.80:1, 1.85:1,
1.90:1, 1.95:1, 2.00:1, 2.05:1, 2.10:1, 2.15:1, 2.20:1, 2.25:1, 2.30:1, 2.35:1, 2.40:1, 2.45:1,
2.50:1, 2.55:1, 2.60:1, 2.65:1, 2.70:1, 2.75:1, 2.80:1, 2.85:1, 2.90:1, 2.95:1, 3.00:1, 3.05:1,
3.10:1, 3.15:1, 3.20:1, 3.25:1, 3.30:1, 3.35:1, 3.40:1, 3.45:1, 3.50:1, 3.55:1, 3.60:1, 3.65:1,
3.70:1, 3.75:1, 3.80:1, 3.85:1, 3.90:1, 3.95:1, 4.00:1, 4.05:1, 4.10:1, 4.15:1, 4.20:1, 4.25:1,
4.30:1, 4.35:1, 4.40:1, 4.45:1, 4.50:1, 4.55:1, 4.60:1, 4.65:1, 4.70:1, 4.75:1, or 4.80:1. In some embodiments, the peripheral blood of the donor is enriched with CD34+ CD90+ CD45RA cells relative to CD34+ cells by a ratio of about 1.2:1.
[0037] In another aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a frequency of CD34+ CD90+ CD45RA cells of from about 0.020% to about 0.110% in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist. In some embodiments, the population of cells may have a frequency of CD34+ CD90+ CD45RA cells of about 0.020%, 0.021%, 0.022%, 0.023%, 0.024%, 0.025%, 0.026%, 0.027%, 0.028%, 0.029%, 0.030%, 0.031%, 0.032%, 0.033%, 0.034%, 0.035%, 0.036%, 0.037%, 0.038%, 0.039%, 0.040%, 0.041%, 0.042%, 0.043%, 0.044%, 0.045%, 0.046%, 0.047%, 0.048%, 0.049%, 0.050%, 0.051%, 0.052%, 0.053%, 0.054%, 0.055%, 0.056%, 0.057%, 0.058%, 0.059%, 0.060%, 0.061%, 0.062%, 0.063%, 0.064%, 0.065%, 0.066%, 0.067%, 0.068%, 0.069%, 0.070%, 0.071%, 0.072%, 0.073%, 0.074%, 0.075%, 0.076%, 0.077%, 0.078%, 0.079%, 0.080%, 0.081%, 0.082%, 0.083%, 0.084%, 0.085%, 0.086%, 0.087%, 0.088%, 0.089%, 0.090%, 0.091%, 0.092%, 0.093%, 0.094%, 0.095%, 0.096%, 0.097%, 0.098%, 0.099%, 0.100%, 0.101%, 0.102%, 0.103%, 0.104%, 0.105%, 0.106%, 0.107%, 0.108%, 0.109%, or 0.110%. In some embodiments, the population of cells has a frequency of CD34+ CD90+ CD45RA cells of from about 0.046% to about 0.086%, such as a frequency of hematopoietic stem cells of about 0.046%, 0.047%, 0.048%, 0.049%, 0.050%, 0.051%, 0.052%, 0.053%, 0.054%, 0.055%, 0.056%, 0.057%, 0.058%, 0.059%,
0.060%, 0.061%, 0.062%, 0.063%, 0.064%, 0.065%, 0.066%, 0.067%, 0.068%, 0.069%,
0.070%, 0.071%, 0.072%, 0.073%, 0.074%, 0.075%, 0.076%, 0.077%, 0.078%, 0.079%,
0.080%, 0.081%, 0.082%, 0.083%, 0.084%, 0.085%, or 0.086%. In some embodiments, the population of cells has a frequency of CD34+ CD90+ CD45RA cells of about 0.066%.
[0038] In an additional aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor ( e.g ., a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to induce an increase in the frequency of CD34+ CD90+ CD45RA cells in the peripheral blood of the donor by at least 3-fold as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist (e.g., by from about 5.1 -fold to about 25.7-fold, such as by about 5. l-fold, 5.2-fold, 5.3-fold, 5.4-fold, 5.5-fold, 5.6-fold, 5.7- fold, 5.8-fold, 5.9-fold, 6.0-fold, 6. l-fold, 6.2-fold, 6.3-fold, 6.4-fold, 6.5-fold, 6.6-fold, 6.7- fold, 6.8-fold, 6.9-fold, 7.0-fold, 7.1 -fold, 7.2-fold, 7.3-fold, 7.4-fold, 7.5-fold, 7.6-fold, 7.7- fold, 7.8-fold, 7.9-fold, 8.0-fold, 8.1 -fold, 8.2-fold, 8.3-fold, 8.4-fold, 8.5-fold, 8.6-fold, 8.7- fold, 8.8-fold, 8.9-fold, 9.0-fold, 9.1 -fold, 9.2-fold, 9.3-fold, 9.4-fold, 9.5-fold, 9.6-fold, 9.7- fold, 9.8-fold, 9.9-fold, lO.O-fold, lO. l-fold, l0.2-fold, l0.3-fold, l0.4-fold, l0.5-fold, 10.6- fold, 10.7-fold, 10.8-fold, l0.9-fold, l l .O-fold, l l . l-fold, 11.2-fold, 11.3-fold, 11.4-fold,
11.5-fold, 11.6-fold, 11.7-fold, 11.8-fold, 11.9-fold, l2.0-fold, l2. l-fold, l2.2-fold, l2.3-fold,
12.4-fold, 12.5-fold, l2.6-fold, l2.7-fold, l2.8-fold, l2.9-fold, l3.0-fold, l3. l-fold, l3.2-fold,
13.3-fold, 13.4-fold, 13.5-fold, l3.6-fold, 13.7-fold, 13.8-fold, 13.9-fold, l4.0-fold, l4. l-fold, 14.2-fold, 14.3-fold, l4.4-fold, l4.5-fold, l4.6-fold, l4.7-fold, l4.8-fold, l4.9-fold, l5.0-fold, 15.1 -fold, 15.2-fold, l5.3-fold, l5.4-fold, 15.5-fold, l5.6-fold, 15.7-fold, 15.8-fold, l5.9-fold, 16.0-fold, 16.1 -fold, l6.2-fold, l6.3-fold, l6.4-fold, l6.5-fold, l6.6-fold, l6.7-fold, l6.8-fold, 16.9-fold, l7.0-fold, l7. l-fold, l7.2-fold, l7.3-fold, l7.4-fold, l7.5-fold, l7.6-fold, l7.7-fold, 17.8-fold, 17.9-fold, l8.0-fold, l8. l-fold, l8.2-fold, l8.3-fold, l8.4-fold, 18.5-fold, l8.6-fold, 18.7-fold, 18.8-fold, l8.9-fold, l9.0-fold, l9. l-fold, l9.2-fold, l9.3-fold, l9.4-fold, l9.5-fold,
19.6-fold, 19.7-fold, l9.8-fold, l9.9-fold, 20.0-fold, 20. l-fold, 20.2-fold, 20.3-fold, 20.4-fold,
20.5-fold, 20.6-fold, 20.7-fold, 20.8-fold, 20.9-fold, 2l .0-fold, 2l . l-fold, 21.2-fold, 21.3-fold,
21.4-fold, 21.5-fold, 21.6-fold, 21.7-fold, 21.8-fold, 21.9-fold, 22.0-fold, 22. l-fold, 22.2-fold, 22.3-fold, 22.4-fold, 22.5-fold, 22.6-fold, 22.7-fold, 22.8-fold, 22.9-fold, 23.0-fold, 23. l-fold, 23.2-fold, 23.3-fold, 23.4-fold, 23.5-fold, 23.6-fold, 23.7-fold, 23.8-fold, 23.9-fold, 24.0-fold, 24.1 -fold, 24.2-fold, 24.3-fold, 24.4-fold, 24.5-fold, 24.6-fold, 24.7-fold, 24.8-fold, 24.9-fold, 25.0-fold, 25.1 -fold, 25.2-fold, 25.3-fold, 25.4-fold, 25.5-fold, 25.6-fold, or 25.7-fold. In some embodiments, the frequency of CD34+ CD90+ CD45RA cells in the peripheral blood of the donor is increased by from about 5.1 -fold to about 7.1 -fold following administration of the CXCR2 agonist and CXCR4 antagonist, such as by about 5. l-fold, 5.2-fold, 5.3-fold, 5.4- fold, 5.5-fold, 5.6-fold, 5.7-fold, 5.8-fold, 5.9-fold, 6.0-fold, 6. l-fold, 6.2-fold, 6.3-fold, 6.4- fold, 6.5-fold, 6.6-fold, 6.7-fold, 6.8-fold, 6.9-fold, 7.0-fold, or 7. l-fold. In some
embodiments, the frequency of CD34+ CD90+ CD45RA cells in the peripheral blood of the donor is increased by about 5.8-fold.
[0039] In another aspect, the invention features a method of mobilizing a population of hematopoietic stem cells, from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor mobilizing amounts of a CXCR2 agonist and a CXCR4 antagonist; acquiring an input value for each of one or more parameters in TABLE 2 characterizing a sample of peripheral blood of the donor, and releasing the sample for ex vivo expansion of the hematopoietic stem cells or for use in the treatment of one or more stem cell disorders in a mammalian patient if the input value for each of the one or more parameters meets the corresponding reference criterion for each of the one or more parameters. In some embodiments, the one or more reference parameters are a set of parameters listed in any one of TABLES 3-6 herein.
[0040] In some embodiments of any of the above aspects of the invention, the sample is isolated from the donor at from about 3 hours to about 5 hours following administration of the CXCR2 agonist and CXCR4 antagonist ( e.g ., at about 3 hours, 3.1 hours, 3.2 hours, 3.3 hours, 3.4 hours, 3.5 hours, 3.6 hours, 3.7 hours, 3.8 hours, 3.9 hours, 4.0 hours, 4.1 hours,
4.2 hours, 4.3 hours, 4.4 hours, 4.5 hours, 4.6 hours, 4.7 hours, 4.8 hours, 4.9 hours, or 5.0 hours following administration of the CXCR2 agonist and CXCR4 antagonist). In some embodiments, the sample is isolated from the donor at about 4 hours following administration of the CXCR2 agonist and CXCR4 antagonist.
[0041] In some embodiments of any of the above aspects of the invention, the CXCR2 agonist is Gro-b T or a variant thereof. In some embodiments, the CXCR2 agonist may be a peptide having at least about 85% (e.g., at least about 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the CXCR2 agonist is a peptide having from about 85% to 100% sequence identity to the amino acid sequence of SEQ ID NO: 2, such as a peptide having from about 86% to about 100%, from about 87% to about 99%, about 88% to about 98%, about 89%, to about 97%, about 90% to about 96%, or about 91% to about 95% sequence identity to the amino acid sequence of SEQ ID NO: 2. In some embodiments, the CXCR2 agonist is a peptide having an amino acid sequence that differs from that of SEQ ID NO: 2 only by way of one or more conservative amino acid substitutions ( e.g ., only by way of from 1 to 10 conservative amino acid substitutions, from 1 to 5 conservative amino acid substitutions, or from 1 to 3 conservative amino acid substitutions, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative amino acid substitutions). In some embodiments, the CXCR2 agonist is Gro-b T. In some embodiments, the Gro-b T is not covalently modified. In some embodiments, the Gro-b T is not covalently modified with a polyalkylene glycol moiety, such as a polyethylene glycol moiety.
[0042] In some embodiments of any of the above aspects of the invention, the CXCR2 agonist is Gro-b or a variant thereof. In some embodiments, the CXCR2 agonist may be a peptide having at least about 85% (e.g., about 85%, 90%, 95%, 96%, 97%, 98%, 99%, or more) sequence identity to the amino acid sequence of SEQ ID NO: 1. In some
embodiments, the CXCR2 agonist is a peptide having from about 85% to 100% sequence identity to the amino acid sequence of SEQ ID NO: 1, such as a peptide having from about 86% to about 100%, from about 87% to about 99%, about 88% to about 98%, about 89%, to about 97%, about 90% to about 96%, or about 91% to about 95% sequence identity to the amino acid sequence of SEQ ID NO: 1. In some embodiments, the CXCR2 agonist is a peptide having an amino acid sequence that differs from that of SEQ ID NO: 1 only by way of one or more conservative amino acid substitutions (e.g, only by way of from 1 to 10 conservative amino acid substitutions, from 1 to 5 conservative amino acid substitutions, or from 1 to 3 conservative amino acid substitutions, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative amino acid substitutions). In some embodiments, the CXCR2 agonist is Gro-b. In some embodiments, the Gro-b T is not covalently modified. In some embodiments, the Gro-b is not covalently modified with a polyalkylene glycol moiety, such as a polyethylene glycol moiety.
[0043] In some embodiments, the CXCR2 agonist (e.g, Gro-b or Gro-b T, such as unmodified Gro-b or Gro-b T) is administered to the donor at a dose of from about 50 pg/kg to about 1 mg/kg, such as a dose of about 50 pg/kg, 55 pg/kg, 60 pg/kg, 65 pg/kg, 70 pg/kg, 75 pg/kg, 80 pg/kg, 85 pg/kg, 90 pg/kg, 95 pg/kg, 100 pg/kg, 105 pg/kg, 1 10 pg/kg, 115 gg/kg, 120 pg/kg, 125 pg/kg, 130 pg/kg, 135 pg/kg, 140 pg/kg, 145 pg/kg, 150 pg/kg, 155 gg/kg, 160 pg/kg, 165 pg/kg, 170 pg/kg, 175 pg/kg, 180 pg/kg, 185 pg/kg, 190 pg/kg, 195 gg/kg, 200 pg/kg, 205 pg/kg, 210 pg/kg, 215 pg/kg, 220 pg/kg, 225 pg/kg, 230 pg/kg, 235 gg/kg, 240 pg/kg, 245 pg/kg, 250 pg/kg, 255 pg/kg, 260 pg/kg, 265 pg/kg, 270 pg/kg, 275 gg/kg, 280 pg/kg, 285 pg/kg, 290 pg/kg, 295 pg/kg, 300 pg/kg, 305 pg/kg, 310 pg/kg, 315 gg/kg, 320 pg/kg, 325 pg/kg, 330 pg/kg, 335 pg/kg, 340 pg/kg, 345 pg/kg, 350 pg/kg, 355 gg/kg, 360 pg/kg, 365 pg/kg, 370 pg/kg, 375 pg/kg, 380 pg/kg, 400 pg/kg, 405 pg/kg, 410 gg/kg, 415 pg/kg, 425 pg/kg, 430 pg/kg, 435 pg/kg, 440 pg/kg, 445 pg/kg, 450 pg/kg, 210 gg/kg, 300 pg/kg, 400 pg/kg, 405 pg/kg, 410 pg/kg, 415 pg/kg, 420 pg/kg, 425 pg/kg, 430 gg/kg, 435 pg/kg, 440 pg/kg, 445 pg/kg, 450 pg/kg, 455 pg/kg, 460 pg/kg, 465 pg/kg, 470 gg/kg, 475 pg/kg, 480 pg/kg, 485 pg/kg, 490 pg/kg, 495 pg/kg, 500 pg/kg, 505 pg/kg, 510 gg/kg, 505 pg/kg, 515 pg/kg, 520 pg/kg, 525 pg/kg, 530 pg/kg, 545 pg/kg, 550 pg/kg, 555 gg/kg, 560 pg/kg, 565 pg/kg, 570 pg/kg, 575 pg/kg, 580 pg/kg, 585 pg/kg, 590 pg/kg, 595 gg/kg, 600 pg/kg, 605 pg/kg, 610 pg/kg, 615 pg/kg, 620 pg/kg, 625 pg/kg, 630 pg/kg, 635 gg/kg, 640 pg/kg, 645 pg/kg, 650 pg/kg, 655 pg/kg, 660 pg/kg, 665 pg/kg, 670 pg/kg, 675 gg/kg, 680 pg/kg, 685 pg/kg, 690 pg/kg, 695 pg/kg, 700 pg/kg, 705 pg/kg, 710 pg/kg, 715 gg/kg, 720 pg/kg, 725 pg/kg, 730 pg/kg, 735 pg/kg, 740 pg/kg, 745 pg/kg, 750 pg/kg, 755 gg/kg, 760 pg/kg, 765 pg/kg, 770 pg/kg, 775 pg/kg, 780 pg/kg, 785 pg/kg, 790 pg/kg, 795 gg/kg, 800 pg/kg, 805 pg/kg, 810 pg/kg, 815 pg/kg, 820 pg/kg, 825 pg/kg, 830 pg/kg, 835 gg/kg, 840 pg/kg, 845 pg/kg, 850 pg/kg, 855 pg/kg, 860 pg/kg, 865 pg/kg, 870 pg/Kg, 875 gg/kg, 880 pg/kg, 885 pg/kg, 890 pg/kg, 895 pg/kg, 900 pg/kg, 905 pg/kg, 910 pg/kg, 915 gg/kg, 920 pg/kg, 925 pg/kg, 930 pg/kg, 935 pg/kg, 940 pg/kg, 945 pg/kg, 950 pg/kg, 955 gg/kg, 960 pg/kg, 965 pg/kg, 970 pg/kg, 975 pg/kg, 980 pg/kg, 985 pg/kg, 990 pg/kg, 995 pg/kg, or 1,000 pg/kg. In some embodiments, the CXCR2 agonist (e.g, Gro-b or Gro-b T, such as unmodified Gro-b or Gro-b T) is administered to the donor at a dose of from about 50 gg/kg to about 300 gg/kg, such as a dose of from about 100 gg/kg to about 250 gg/kg, or from about 125 gg/kg to about 225 gg/kg. In some embodiments, the CXCR2 agonist (e.g, Gro-b or Gro-b T, such as unmodified Gro-b or Gro-b T) is administered to the donor at a dose of about 150 gg/kg.
[0044] In another aspect, the invention features a method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor (e.g, a human donor) into peripheral blood, the method including administering to the donor a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof at a dose of from about 50 pg/kg to about 1 mg/kg (e.g., a dose of 50 pg/kg, 55 pg/kg, 60 pg/kg, 65 pg/kg, 70 pg/kg, 75 pg/kg, 80 pg/kg, 85 pg/kg, 90 pg/kg, 95 pg/kg, 100 pg/kg, 105 pg/kg, 110 pg/kg,
115 pg/kg, 120 pg/kg, 125 pg/kg, 130 kg/kg, 135 pg/kg, 140 pg/kg, 145 pg/kg, 150 kg/kg, 155 pg/kg, 160 pg/kg, 165 pg/kg, 170 gg/kg, 175 pg/kg, 180 pg/kg, 185 pg/kg, 190 kg/kg, 195 pg/kg, 200 pg/kg, 205 pg/kg, 210 gg/kg, 215 pg/kg, 220 pg/kg, 225 pg/kg, 230 gg/kg, 235 pg/kg, 240 pg/kg, 245 pg/kg, 250 gg/kg, 255 pg/kg, 260 pg/kg, 265 pg/kg, 270 gg/kg, 275 pg/kg, 280 pg/kg, 285 pg/kg, 290 gg/kg, 295 pg/kg, 300 pg/kg, 305 pg/kg, 310 gg/kg, 315 pg/kg, 320 pg/kg, 325 pg/kg, 330 gg/kg, 335 pg/kg, 340 pg/kg, 345 pg/kg, 350 gg/kg, 355 pg/kg, 360 pg/kg, 365 pg/kg, 370 gg/kg, 375 pg/kg, 380 pg/kg, 400 pg/kg, 405 gg/kg, 410 pg/kg, 415 pg/kg, 425 pg/kg, 430 gg/kg, 435 pg/kg, 440 pg/kg, 445 pg/kg, 450 gg/kg, 210 pg/kg, 300 pg/kg, 400 pg/kg, 405 gg/kg, 410 pg/kg, 415 pg/kg, 420 pg/kg, 425 gg/kg, 430 pg/kg, 435 pg/kg, 440 pg/kg, 445 gg/kg, 450 pg/kg, 455 pg/kg, 460 pg/kg, 465 gg/kg, 470 pg/kg, 475 pg/kg, 480 pg/kg, 485 gg/kg, 490 pg/kg, 495 pg/kg, 500 pg/kg, 505 gg/kg, 510 pg/kg, 505 pg/kg, 515 pg/kg, 520 gg/kg, 525 pg/kg, 530 pg/kg, 545 pg/kg, 550 gg/kg, 555 pg/kg, 560 pg/kg, 565 pg/kg, 570 gg/kg, 575 pg/kg, 580 pg/kg, 585 pg/kg, 590 gg/kg, 595 pg/kg, 600 pg/kg, 605 pg/kg, 610 gg/kg, 615 pg/kg, 620 pg/kg, 625 pg/kg, 630 gg/kg, 635 pg/kg, 640 pg/kg, 645 pg/kg, 650 gg/kg, 655 pg/kg, 660 pg/kg, 665 pg/kg, 670 gg/kg, 675 pg/kg, 680 pg/kg, 685 pg/kg, 690 gg/kg, 695 pg/kg, 700 pg/kg, 705 pg/kg, 710 gg/kg, 715 pg/kg, 720 pg/kg, 725 pg/kg, 730 gg/kg, 735 pg/kg, 740 pg/kg, 745 pg/kg, 750 gg/kg, 755 pg/kg, 760 pg/kg, 765 pg/kg, 770 gg/kg, 775 pg/kg, 780 pg/kg, 785 pg/kg, 790 gg/kg, 795 pg/kg, 800 pg/kg, 805 pg/kg, 810 gg/kg, 815 pg/kg, 820 pg/kg, 825 pg/kg, 830 gg/kg, 835 pg/kg, 840 pg/kg, 845 pg/kg, 850 gg/kg, 855 pg/kg, 860 pg/kg, 865 pg/kg, 870 gg/Kg, 875 pg/kg, 880 pg/kg, 885 pg/kg, 890 gg/kg, 895 pg/kg, 900 pg/kg, 905 pg/kg, 910 gg/kg, 915 pg/kg, 920 pg/kg, 925 pg/kg, 930 gg/kg, 935 pg/kg, 940 pg/kg, 945 pg/kg, 950 gg/kg, 955 pg/kg, 960 pg/kg, 965 pg/kg, 970 gg/kg, 975 pg/kg, 980 pg/kg, 985 pg/kg, 990 pg/kg, 995 pg/kg, or 1,000 pg/kg). In some embodiments, the method further includes
administering a CXCR4 antagonist to the donor.
[0045] In some embodiments of any of the above aspects of the invention, the CXCR2 agonist ( e.g ., Gro-b or Gro-b T, such as unmodified Gro-b or Gro-b T) is administered to the donor at a dose of from about 50 pg/kg to about 300 pg/kg, such as a dose of about 50 pg/kg, 55 pg/kg, 60 pg/kg, 65 pg/kg, 70 pg/kg, 75 pg/kg, 80 pg/kg, 85 pg/kg, 90 pg/kg, 95 pg/kg, 100 pg/kg, 105 pg/kg, 110 pg/kg, 115 pg/kg, 120 pg/kg, 125 pg/kg, 130 pg/kg, 135 pg/kg,
140 pg/kg, 145 pg/kg, 150 pg/kg, 155 pg/kg, 160 pg/kg, 165 pg/kg, 170 pg/kg, 175 pg/kg,
180 pg/kg, 185 pg/kg, 190 pg/kg, 195 pg/kg, 200 pg/kg, 205 pg/kg, 210 pg/kg, 215 pg/kg,
220 pg/kg, 225 pg/kg, 230 pg/kg, 235 pg/kg, 240 pg/kg, 245 pg/kg, 250 pg/kg, 255 pg/kg,
260 pg/kg, 265 pg/kg, 270 pg/kg, 275 pg/kg, 280 pg/kg, 285 pg/kg, 290 pg/kg, 295 pg/kg, or
300 pg/kg.
[0046] In some embodiments of any of the above aspects of the invention, the CXCR2 agonist ( e.g ., Gro-b or Gro-b T, such as unmodified Gro-b or Gro-b T) is administered to the donor at a dose of from about 100 pg/kg to about 250 pg/kg, such as a dose of about 100 gg/kg, 105 pg/kg, 110 pg/kg, 115 pg/kg, 120 pg/kg, 125 pg/kg, 130 pg/kg, 135 pg/kg, 140 gg/kg, 145 pg/kg, 150 pg/kg, 155 pg/kg, 160 pg/kg, 165 pg/kg, 170 pg/kg, 175 pg/kg, 180 gg/kg, 185 pg/kg, 190 pg/kg, 195 gg/kg, 200 gg/kg, 205 gg/kg, 210 gg/kg, 215 gg/kg, 220 gg/kg, 225 gg/kg, 230 gg/kg, 235 gg/kg, 240 gg/kg, 245 gg/kg, or 250 gg/kg.
[0047] In some embodiments of any of the above aspects of the invention, the CXCR2 agonist (e.g., Gro-b or Gro-b T, such as unmodified Gro-b or Gro-b T) is administered to the donor at a dose of about 150 pg/kg. For example, in some embodiments, the CXCR2 agonist (e.g, Gro-b or Gro-b T, such as unmodified Gro-b or Gro-b T) is administered to the donor at a dose of from about 50 pg/kg per day to about 1 mg/kg per day, such as a dose of about 50 pg/kg per day, 55 pg/kg per day, 60 pg/kg per day, 65 pg/kg per day, 70 pg/kg per day, 75 pg/kg per day, 80 pg/kg per day, 85 pg/kg per day, 90 pg/kg per day, 95 pg/kg per day, 100 pg/kg per day, 105 pg/kg per day, 110 pg/kg per day, 115 pg/kg per day, 120 pg/kg per day, 125 pg/kg per day, 130 pg/kg per day, 135 pg/kg per day, 140 pg/kg per day, 145 pg/kg per day, 150 pg/kg per day, 155 pg/kg per day, 160 pg/kg per day, 165 pg/kg per day, 170 pg/kg per day, 175 pg/kg per day, 180 pg/kg per day, 185 pg/kg per day, 190 pg/kg per day, 195 pg/kg per day, 200 pg/kg per day, 205 pg/kg per day, 210 pg/kg per day, 215 pg/kg per day, 220 pg/kg per day, 225 pg/kg per day, 230 pg/kg per day, 235 pg/kg per day, 240 pg/kg per day, 245 pg/kg per day, 250 pg/kg per day, 255 pg/kg per day, 260 pg/kg per day, 265 pg/kg per day, 270 pg/kg per day, 275 pg/kg per day, 280 pg/kg per day, 285 pg/kg per day, 290 pg/kg per day, 295 pg/kg per day, 300 pg/kg per day, 305 pg/kg per day, 310 pg/kg per day, 315 pg/kg per day, 320 pg/kg per day, 325 pg/kg per day, 330 pg/kg per day, 335 pg/kg per day, 340 pg/kg per day, 345 pg/kg per day, 350 pg/kg per day, 355 pg/kg per day, 360 pg/kg per day, 365 pg/kg per day, 370 pg/kg per day, 375 pg/kg per day, 380 pg/kg per day, 400 pg/kg per day, 405 pg/kg per day, 410 pg/kg per day, 415 pg/kg per day, 425 pg/kg per day, 430 m /1< per day, 435 pg/kg per day, 440 pg/kg per day, 445 pg/kg per day, 450 pg/kg per day, 210 pg/kg per day, 300 pg/kg per day, 400 pg/kg per day, 405 pg/kg per day, 410 pg/kg per day, 415 pg/kg per day, 420 pg/kg per day, 425 pg/kg per day, 430 pg/kg per day, 435 pg/kg per day, 440 pg/kg per day, 445 pg/kg per day, 450 pg/kg per day, 455 pg/kg per day, 460 pg/kg per day, 465 pg/kg per day, 470 pg/kg per day, 475 pg/kg per day, 480 pg/kg per day, 485 pg/kg per day, 490 pg/kg per day, 495 pg/kg per day, 500 pg/kg per day, 505 pg/kg per day, 510 pg/kg per day, 505 pg/kg per day, 515 pg/kg per day, 520 pg/kg per day, 525 pg/kg per day, 530 pg/kg per day, 545 pg/kg per day, 550 pg/kg per day, 555 pg/kg per day, 560 pg/kg per day, 565 pg/kg per day, 570 pg/kg per day, 575 pg/kg per day, 580 pg/kg per day, 585 pg/kg per day, 590 pg/kg per day, 595 pg/kg per day, 600 pg/kg per day, 605 pg/kg per day, 610 pg/kg per day, 615 pg/kg per day, 620 pg/kg per day, 625 pg/kg per day, 630 pg/kg per day, 635 pg/kg per day, 640 pg/kg per day, 645 pg/kg per day, 650 pg/kg per day, 655 pg/kg per day, 660 pg/kg per day, 665 pg/kg per day, 670 pg/kg per day, 675 pg/kg per day, 680 pg/kg per day, 685 pg/kg per day, 690 pg/kg per day, 695 pg/kg per day, 700 pg/kg per day, 705 pg/kg per day, 710 pg/kg per day, 715 pg/kg per day, 720 pg/kg per day, 725 pg/kg per day, 730 pg/kg per day, 735 pg/kg per day, 740 pg/kg per day, 745 pg/kg per day, 750 pg/kg per day, 755 pg/kg per day, 760 pg/kg per day, 765 pg/kg per day, 770 pg/kg per day, 775 pg/kg per day, 780 pg/kg per day, 785 pg/kg per day, 790 pg/kg per day, 795 pg/kg per day, 800 pg/kg per day, 805 pg/kg per day, 810 pg/kg per day, 815 pg/kg per day, 820 pg/kg per day, 825 pg/kg per day, 830 pg/kg per day, 835 pg/kg per day, 840 pg/kg per day, 845 pg/kg per day, 850 pg/kg per day, 855 pg/kg per day, 860 pg/kg per day, 865 pg/kg per day, 870 pg/kg per day, 875 pg/kg per day, 880 pg/kg per day, 885 pg/kg per day, 890 pg/kg per day, 895 pg/kg per day, 900 pg/kg per day, 905 pg/kg per day, 910 pg/kg per day, 915 pg/kg per day, 920 pg/kg per day, 925 pg/kg per day, 930 pg/kg per day, 935 pg/kg per day, 940 pg/kg per day, 945 pg/kg per day, 950 pg/kg per day, 955 pg/kg per day, 960 pg/kg per day, 965 pg/kg per day, 970 pg/kg per day, 975 pg/kg per day, 980 pg/kg per day, 985 pg/kg per day, 990 pg/kg per day, 995 pg/kg per day, or 1,000 pg/kg per day. In some
embodiments, the CXCR2 agonist ( e.g ., Gro-b or Gro-b T, such as unmodified Gro-b or Gro- b T) is administered to the donor at a dose of from about 50 pg/kg per day to about 300 pg/kg per day, such as a dose of from about 100 pg/kg per day to about 250 pg/kg per day, or from about 125 pg/kg per day to about 225 pg/kg per day, or from about 125 pg/kg per day to about 175 pg/kg per day. In some embodiments, the CXCR2 agonist (e.g., Gro-b or Gro-b T, such as unmodified Gro-b or Gro-b T) is administered to the donor at a dose of about 150 pg/kg per day. In some embodiments, the CXCR2 agonist may be administered as a single dose. In other embodiments, the CXCR2 agonist may be administered as two or more doses.
[0048] In some embodiments, a human equivalent dose (HED) may be derived from animal dosage data using a conversion factor. For example, Nair and Jacob, ./. Basic Clin. Pharma. (2016) 7:27-31 disclose methods extrapolation of dose between species. For instance, in one non-limiting example, HED may be derived from rhesus monkey dose by multiplying the rhesus monkey dose by about 0.324.
[0049] In some embodiments of any of the above aspects of the invention, the CXCR2 agonist ( e.g ., Gro-b or Gro-b T, such as unmodified Gro-b or Gro-b T) is administered intravenously to the donor.
[0050] In some embodiments of any of the above aspects of the invention, the CXCR4 antagonist is a compound represented by formula (I)
Z - linker - Z’ (I)
or a pharmaceutically acceptable salt thereof, wherein Z is:
(i) a cyclic polyamine containing from 9 to 32 ring members, wherein from 2 to 8 of the ring members are nitrogen atoms separated from one another by 2 or more carbon atoms; or
(ii) an amine represented by formula (IA)
Figure imgf000051_0001
wherein A includes a monocyclic or bicyclic fused ring system including at least one nitrogen atom and B is H or a substituent of from 1 to 20 atoms;
and wherein Z’ is:
(i) a cyclic polyamine containing from 9 to 32 ring members, wherein from 2 to 8 of the ring members are nitrogen atoms separated from one another by 2 or more carbon atoms;
(ii) an amine represented by formula (IB)
Figure imgf000052_0001
wherein A’ includes a monocyclic or bicyclic fused ring system including at least one nitrogen atom and B’ is H or a substituent of from 1 to 20 atoms; or
(iii) a substituent represented by formula (IC)
N(R) - (CR2)n - X (IC)
wherein each R is independently H or Ci-C6 alkyl, n is 1 or 2, and X is an aryl or heteroaryl group or a mercaptan;
wherein the linker is a bond, optionally substituted Ci-C6 alkyl ene, optionally substituted Ci-C6 heteroalkylene, optionally substituted C2-C6 alkenylene, optionally substituted C2-C6 heteroalkenylene, optionally substituted C2-C6 alkynylene, optionally substituted C2-C6 heteroalkynylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, or optionally substituted heteroaryl ene.
[0051] In some embodiments, Z and Z’ are each independently a cyclic polyamine containing from 9 to 32 ring members, of which from 2 to 8 are nitrogen atoms separated from one another by 2 or more carbon atoms. Z and Z’ may be identical substituents. In some embodiments, Z and/or Z’ is a cyclic polyamine including from 10 to 24 ring members, such as a cyclic polyamine including 14 ring members. In some embodiments, Z includes 4 nitrogen atoms. Z and/or Z’ may be, for example, 1,4,8, 1 l-tetraazocy cl otetradecane.
[0052] In some embodiments, the linker is represented by formula (ID)
Figure imgf000052_0002
wherein ring D is an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted cycloalkyl group, or an optionally substituted heterocycloalkyl group; and
X and Y are each independently optionally substituted Ci-C6 alkylene, optionally substituted Ci-C6 heteroalkylene, optionally substituted C2-C6 alkenylene, optionally substituted C2-C6 heteroalkenylene, optionally substituted C2-C6 alkynylene, or optionally substituted C2-C6 heteroalkynylene.
In some embodiments, the linker is represented by formula (IE)
Figure imgf000053_0001
wherein ring D is an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted cycloalkyl group, or an optionally substituted heterocycloalkyl group; and
X and Y are each independently optionally substituted Ci-C6 alkylene, optionally substituted Ci-C6 heteroalkylene, optionally substituted C2-C6 alkenylene, optionally substituted C2-C6 heteroalkenylene, optionally substituted C2-C6 alkynylene, or optionally substituted C2-C6 heteroalkynylene.
[0053] In some embodiments, X and Y are each independently optionally substituted Ci-C6 alkylene. In some embodiments, X and Y are identical substituents, such as identical alkylene substituents ( e.g ., methylene, ethylene, propylene, or butylene substituents).
[0054] In some embodiments, the CXCR4 antagonist is plerixafor or a pharmaceutically acceptable salt thereof. In some embodiments, the CXCR4 antagonist (e.g., plerixafor or a pharmaceutically acceptable salt thereof) is administered subcutaneously to the donor. In some embodiments, the CXCR4 antagonist (e.g, plerixafor or a pharmaceutically acceptable salt thereof) is administered to the donor at a dose of from about 50 gg/kg to about 500 m /1< , such as a dose of about 50 mm/1<m, 55 mm/1<m, 60 mm/1<m, 65 mm/1<m, 70 mm/1<m, 75 mm/1<m, 80 gg/kg, 85 mm/kg, 90 mm/kg, 95 gg/kg, 100 gg/kg, 105 gg/kg, 1 10 gg/kg, 1 15 gg/kg, 120 gg/kg, 125 gg/kg, 130 gg/kg, 135 gg/kg, 140 gg/kg, 145 gg/kg, 150 gg/kg, 155 gg/kg, 160 gg/kg, 165 gg/kg, 170 gg/kg, 175 gg/kg, 180 gg/kg, 185 gg/kg, 190 gg/kg, 195 gg/kg, 200 gg/kg, 205 gg/kg, 210 gg/kg, 215 gg/kg, 220 gg/kg, 225 gg/kg, 230 gg/kg, 235 gg/kg, 240
Pg/kg, 245 mm/kg, 250 gg/kg, 255 gg/kg, 260 gg/kg, 265 gg/kg, 270 gg/kg, 275 gg/kg, 280 gg/kg, 285 gg/kg, 290 gg/kg, 295 gg/kg, 300 gg/kg, 305 gg/kg, 310 gg/kg, 315 gg/kg, 320 gg/kg, 325 gg/kg, 330 gg/kg, 335 gg/kg, 340 gg/kg, 345 gg/kg, 350 gg/kg, 355 gg/kg, 360 gg/kg, 365 gg/kg, 370 gg/kg, 375 gg/kg, 380 gg/kg, 385 gg/kg, 390 gg/kg, 395 gg/kg, 400 gg/kg, 405 gg/kg, 410 gg/kg, 415 gg/kg, 420 gg/kg, 425 gg/kg, 430 gg/kg, 435 gg/kg, 440 gg/kg, 445 gg/kg, 450 gg/kg, 455 gg/kg, 460 gg/kg, 465 gg/kg, 470 gg/kg, 475 gg/kg, 480 gg/kg, 485 gg/kg, 490 gg/kg, 495 gg/kg, or 500 gg/kg. In some embodiments, the CXCR4 antagonist ( e.g ., plerixafor or a pharmaceutically acceptable salt thereof) is administered to the donor at a dose of from about 200 gg/kg to about 300 gg/kg, such as a dose of about 240 hg/kg.
[0055] For example, in some embodiments, the CXCR4 antagonist (e.g., plerixafor or a pharmaceutically acceptable salt thereof) is administered to the donor at a dose of from about 50 gg/kg per day to about 500 gg/kg per day, such as a dose of about 50 gg/kg per day, 55 gg/kg per day, 60 gg/kg per day, 65 gg/kg per day, 70 gg/kg per day, 75 gg/kg per day, 80 gg/kg per day, 85 gg/kg per day, 90 gg/kg per day, 95 gg/kg per day, 100 gg/kg per day, 105 gg/kg per day, 110 gg/kg per day, 115 gg/kg per day, 120 gg/kg per day, 125 gg/kg per day, 130 gg/kg per day, 135 gg/kg per day, 140 gg/kg per day, 145 gg/kg per day, 150 gg/kg per day, 155 gg/kg per day, 160 gg/kg per day, 165 gg/kg per day, 170 gg/kg per day, 175 gg/kg per day, 180 gg/kg per day, 185 gg/kg per day, 190 gg/kg per day, 195 gg/kg per day, 200 gg/kg per day, 205 gg/kg per day, 210 gg/kg per day, 215 gg/kg per day, 220 gg/kg per day, 225 gg/kg per day, 230 gg/kg per day, 235 gg/kg per day, 240 gg/kg per day, 245 gg/kg per day, 250 gg/kg per day, 255 gg/kg per day, 260 gg/kg per day, 265 gg/kg per day, 270 gg/kg per day, 275 gg/kg per day, 280 gg/kg per day, 285 gg/kg per day, 290 gg/kg per day, 295 gg/kg per day, 300 gg/kg per day, 305 gg/kg per day, 310 gg/kg per day, 315 gg/kg per day, 320 gg/kg per day, 325 gg/kg per day, 330 gg/kg per day, 335 gg/kg per day, 340 gg/kg per day, 345 gg/kg per day, 350 gg/kg per day, 355 gg/kg per day, 360 gg/kg per day, 365 gg/kg per day, 370 gg/kg per day, 375 gg/kg per day, 380 gg/kg per day, 385 gg/kg per day, 390 gg/kg per day, 395 gg/kg per day, 400 gg/kg per day, 405 gg/kg per day, 410 gg/kg per day, 415 gg/kg per day, 420 gg/kg per day, 425 gg/kg per day, 430 gg/kg per day, 435 gg/kg per day, 440 gg/kg per day, 445 gg/kg per day, 450 gg/kg per day, 455 gg/kg per day, 460 gg/kg per day, 465 gg/kg per day, 470 gg/kg per day, 475 gg/kg per day, 480 gg/kg per day, 485 gg/kg per day, 490 gg/kg per day, 495 gg/kg per day, or 500 gg/kg per day. In some embodiments, the CXCR4 antagonist (e.g, plerixafor or a pharmaceutically acceptable salt thereof) is administered to the donor at a dose of from about 200 gg/kg per day to about 300 gg/kg per day, such as a dose of about 240 gg/kg per day. In some embodiments, the CXCR4 antagonist may be administered as a single dose. In other embodiments, the CXCR4 antagonist may be administered as two or more doses.
[0056] In some embodiments of any of the above aspects of the invention, the CXCR2 agonist and the CXCR4 antagonist are administered to the donor concurrently. In some embodiments, the CXCR4 antagonist is administered to the donor prior to administration of the CXCR2 agonist. In some embodiments, the CXCR4 antagonist may be administered to the donor from about 1 minute to about 180 minutes prior to administration of the CXCR2 agonist, such as from about 15 minutes to about 180 minutes, about 30 minutes to about 180 minutes, about 40 minutes to about 160 minutes, about 50 minutes to about 150 minutes, about 60 minutes to about 140 minutes, about 70 minutes to about 130 minutes, about 60 minutes to about 120 minutes, about 70 minutes to about 110 minutes, or about 80 minutes to about 100 minutes ( e.g ., about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 75 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 105 minutes, about 110 minutes, about 115 minutes, about 120 minutes, about 125 minutes, about 130 minutes, about 135 minutes, about 140 minutes, about 145 minutes, about 150 minutes, about 155 minutes, about 160 minutes, about 165 minutes, about 170 minutes, about 175 minutes, or about 180 minutes prior to administration of the CXCR2 agonist). In some embodiments, the CXCR4 antagonist is administered to the donor from about 30 minutes to about 60 minutes prior to administration of the CXCR2 agonist (e.g., about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, or about 60 minutes prior to administration of the CXCR2 agonist). In some embodiments, the CXCR4 antagonist may be administered to the donor about 45 minutes prior to administration of the CXCR2 agonist.
[0057] In a further aspect, the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor (e.g, a human donor), wherein the ratio of CD34+ cells to leukocytes in the population is from about 0.0008 to about 0.0021. In some embodiments, the ratio of CD34+ cells to leukocytes may be about 0.00080, 0.00081, 0.00082, 0.00083, 0.00084, 0.00085, 0.00086, 0.00087, 0.00088, 0.00089, 0.00090, 0.00091, 0.00092, 0.00093, 0.00094, 0.00095, 0.00096,
0.00097, 0.00098, 0.00099, 0.00100, 0.00101, 0.00102, 0.00103, 0.00104, 0.00105, 0.00106,
0.00107, 0.00108, 0.00109, 0.00110, 0.00111, 0.00112, 0.00113, 0.00114, 0.00115, 0.00116,
0.00117, 0.00118, 0.00119, 0.00120, 0.00121, 0.00122, 0.00123, 0.00124, 0.00125, 0.00126,
0.00127, 0.00128, 0.00129, 0.00130, 0.00131, 0.00132, 0.00133, 0.00134, 0.00135, 0.00136,
0.00137, 0.00138, 0.00139, 0.00140, 0.00141, 0.00142, 0.00143, 0.00144, 0.00145, 0.00146,
0.00147, 0.00148, 0.00149, 0.00150, 0.00151, 0.00152, 0.00153, 0.00154, 0.00155, 0.00156,
0.00157, 0.00158, 0.00159, 0.00160, 0.00161, 0.00162, 0.00163, 0.00164, 0.00165, 0.00166, 0.00167, 0.00168, 0.00169, 0.00170, 0.00171, 0.00172, 0.00173, 0.00174, 0.00175, 0.00176,
0.00178, 0.00179, 0.00180, 0.00181, 0.00182, 0.00183, 0.00184, 0.00185, 0.00186, 0.00187,
0.00188, 0.00189, 0.00190, 0.00191, 0.00192, 0.00193, 0.00194, 0.00195, 0.00196, 0.00197,
0.00198, 0.00199, 0.00200, 0.00201, 0.00202, 0.00203, 0.00204, 0.00205, 0.00206, 0.00207,
0.00208, 0.00209, 0.00210, 0.00211, 0.00212, 0.00213, 0.00214, 0.00215, 0.00216, 0.00217,
0.00218, 0.00219, 0.00220, 0.00221, 0.00222, 0.00223, 0.00224, or 0.00225. In some embodiments, the ratio of CD34+ cells to leukocytes is from about 0.0010 to about 0.0018, such as a ratio of CD34+ cells to leukocytes of about 0.00100, 0.00101, 0.00102, 0.00103, 0.00104, 0.00105, 0.00106, 0.00107, 0.00108, 0.00109, 0.00110, 0.00111, 0.00112, 0.00113,
0.00114, 0.00115, 0.00116, 0.00117, 0.00118, 0.00119, 0.00120, 0.00121, 0.00122, 0.00123,
0.00124, 0.00125, 0.00126, 0.00127, 0.00128, 0.00129, 0.00130, 0.00131, 0.00132, 0.00133,
0.00134, 0.00135, 0.00136, 0.00137, 0.00138, 0.00139, 0.00140, 0.00141, 0.00142, 0.00143,
0.00144, 0.00145, 0.00146, 0.00147, 0.00148, 0.00149, 0.00150, 0.00151, 0.00152, 0.00153,
0.00154, 0.00155, 0.00156, 0.00157, 0.00158, 0.00159, 0.00160, 0.00161, 0.00162, 0.00163,
0.00164, 0.00165, 0.00166, 0.00167, 0.00168, 0.00169, 0.00170, 0.00171, 0.00172, 0.00173,
0.00174, 0.00175, 0.00176, 0.00178, 0.00179, or 0.00180. In some embodiments, the ratio of CD34+ cells to leukocytes is about 0.0014.
[0058] In an additional aspect, the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor ( e.g ., a human donor), wherein the ratio of CD34+ cells to neutrophils in the population is from about 0.0018 to about 0.0058. In some embodiments, the ratio of CD34+ cells to neutrophils may be about 0.00180, 0.00181, 0.00182, 0.00183, 0.00184, 0.00185, 0.00186, 0.00187, 0.00188, 0.00189, 0.00190, 0.00191, 0.00192, 0.00193, 0.00194, 0.00195, 0.00196,
0.00197, 0.00198, 0.00199, 0.00200, 0.00201, 0.00202, 0.00203, 0.00204, 0.00205, 0.00206,
0.00207, 0.00208, 0.00209, 0.00210, 0.00211, 0.00212, 0.00213, 0.00214, 0.00215, 0.00216,
0.00217, 0.00218, 0.00219, 0.00220, 0.00221, 0.00222, 0.00223, 0.00224, 0.00225, 0.00226,
0.00227, 0.00228, 0.00229, 0.00230, 0.00231, 0.00232, 0.00233, 0.00234, 0.00235, 0.00236,
0.00237, 0.00238, 0.00239, 0.00240, 0.00241, 0.00242, 0.00243, 0.00244, 0.00245, 0.00246,
0.00247, 0.00248, 0.00249, 0.00250, 0.00251, 0.00252, 0.00253, 0.00254, 0.00255, 0.00256,
0.00257, 0.00258, 0.00259, 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266,
0.00267, 0.00268, 0.00269, 0.00270, 0.00271, 0.00272, 0.00273, 0.00274, 0.00275, 0.00276,
0.00277, 0.00278, 0.00279, 0.00280, 0.00281, 0.00282, 0.00283, 0.00284, 0.00285, 0.00286,
0.00287, 0.00288, 0.00289, 0.00290, 0.00291, 0.00292, 0.00293, 0.00294, 0.00295, 0.00296, 0.00297, 0.00298, 0.00299, 0.00300, 0.00300, 0.00301 0.00302, 0.00303, 0.00304, 0.00305, 0.00306, 0.00307, 0.00308, 0.00309, 0.00310, 0.00311 0.00312, 0.00313, 0.00314, 0.00315, 0.00316, 0.00317, 0.00318, 0.00319, 0.00320, 0.00321 0.00322, 0.00323, 0.00324, 0.00325, 0.00326, 0.00327, 0.00328, 0.00329, 0.00330, 0.00331 0.00332, 0.00333, 0.00334, 0.00335, 0.00336, 0.00337, 0.00338, 0.00339, 0.00340, 0.00341 0.00342, 0.00343, 0.00344, 0.00345, 0.00346, 0.00347, 0.00348, 0.00349, 0.00350, 0.00351 0.00352, 0.00353, 0.00354, 0.00355, 0.00356, 0.00357, 0.00358, 0.00359, 0.00360, 0.00361 0.00362, 0.00363, 0.00364, 0.00365, 0.00366, 0.00367, 0.00368, 0.00369, 0.00370, 0.00371 0.00372, 0.00373, 0.00374, 0.00375, 0.00376, 0.00377, 0.00378, 0.00379, 0.00380, 0.00381 0.00382, 0.00383, 0.00384, 0.00385, 0.00386, 0.00387, 0.00388, 0.00389, 0.00390, 0.00391 0.00392, 0.00393, 0.00394, 0.00395, 0.00396, 0.00397, 0.00398, 0.00399, 0.00400, 0.00401 0.00402, 0.00403, 0.00404, 0.00405, 0.00406, 0.00407, 0.00408, 0.00409, 0.00410, 0.00411 0.00412, 0.00413, 0.00414, 0.00415, 0.00416, 0.00417, 0.00418, 0.00419, 0.00420, 0.00421 0.00422, 0.00423, 0.00424, 0.00425, 0.00426, 0.00427, 0.00428, 0.00429, 0.00430, 0.00431 0.00432, 0.00433, 0.00434, 0.00435, 0.00436, 0.00437, 0.00438, 0.00439, 0.00440, 0.00441 0.00442, 0.00443, 0.00444, 0.00445, 0.00446, 0.00447, 0.00448, 0.00449, 0.00450, 0.00451 0.00452, 0.00453, 0.00454, 0.00455, 0.00456, 0.00457, 0.00458, 0.00459, 0.00460, 0.00461 0.00462, 0.00463, 0.00464, 0.00465, 0.00466, 0.00467, 0.00468, 0.00469, 0.00470, 0.00471 0.00472, 0.00473, 0.00474, 0.00475, 0.00476, 0.00477, 0.00478, 0.00479, 0.00480, 0.00481 0.00482, 0.00483, 0.00484, 0.00485, 0.00486, 0.00487, 0.00488, 0.00489, 0.00490, 0.00491 0.00492, 0.00493, 0.00494, 0.00495, 0.00496, 0.00497, 0.00498, 0.00499, 0.00500, 0.00501 0.00502, 0.00503, 0.00504, 0.00505, 0.00506, 0.00507, 0.00508, 0.00509, 0.00510, 0.00511 0.00512, 0.00513, 0.00514, 0.00515, 0.00516, 0.00517, 0.00518, 0.00519, 0.00520, 0.00521 0.00522, 0.00523, 0.00524, 0.00525, 0.00526, 0.00527, 0.00528, 0.00529, 0.00530, 0.00531 0.00532, 0.00533, 0.00534, 0.00535, 0.00536, 0.00537, 0.00538, 0.00539, 0.00540, 0.00541 0.00542, 0.00543, 0.00544, 0.00545, 0.00546, 0.00547, 0.00548, 0.00549, 0.00550, 0.00551 0.00552, 0.00553, 0.00554, 0.00555, 0.00556, 0.00557, 0.00558, 0.00559, 0.00560, 0.00561 0.00562, 0.00563, 0.00564, 0.00565, 0.00566, 0.00567, 0.00568, 0.00569, 0.00570, 0.00571 0.00572, 0.00573, 0.00574, 0.00575, 0.00576, 0.00577, 0.00578, 0.00579, or 0.00580. In some embodiments, the ratio of CD34 cells to neutrophils is from about 0.0026 to about 0.0046, such as a ratio of CD34+ cells to neutrophils of about 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266, 0.00267, 0.00268, 0.00269, 0.00270, 0.00271, 0.00272, 0.00273, 0.00274, 0.00275, 0.00276, 0.00277, 0.00278, 0.00279, 0.00280, 0.00281, 0.00282, 0.00283, 0.00284, 0.00285, 0.00286, 0.00287, 0.00288, 0.00289, 0.00290, 0.00291, 0.00292 0.00293, 0.00294, 0.00295, 0.00296, 0.00297, 0.00298, 0.00299, 0.00300, 0.00300, 0.00301 0.00302, 0.00303, 0.00304, 0.00305, 0.00306, 0.00307, 0.00308, 0.00309, 0.00310, 0.00311 0.00312, 0.00313, 0.00314, 0.00315, 0.00316, 0.00317, 0.00318, 0.00319, 0.00320, 0.00321 0.00322, 0.00323, 0.00324, 0.00325, 0.00326, 0.00327, 0.00328, 0.00329, 0.00330, 0.00331 0.00332, 0.00333, 0.00334, 0.00335, 0.00336, 0.00337, 0.00338, 0.00339, 0.00340, 0.00341 0.00342, 0.00343, 0.00344, 0.00345, 0.00346, 0.00347, 0.00348, 0.00349, 0.00350, 0.00351 0.00352, 0.00353, 0.00354, 0.00355, 0.00356, 0.00357, 0.00358, 0.00359, 0.00360, 0.00361 0.00362, 0.00363, 0.00364, 0.00365, 0.00366, 0.00367, 0.00368, 0.00369, 0.00370, 0.00371 0.00372, 0.00373, 0.00374, 0.00375, 0.00376, 0.00377, 0.00378, 0.00379, 0.00380, 0.00381 0.00382, 0.00383, 0.00384, 0.00385, 0.00386, 0.00387, 0.00388, 0.00389, 0.00390, 0.00391 0.00392, 0.00393, 0.00394, 0.00395, 0.00396, 0.00397, 0.00398, 0.00399, 0.00400, 0.00401 0.00402, 0.00403, 0.00404, 0.00405, 0.00406, 0.00407, 0.00408, 0.00409, 0.00410, 0.00411 0.00412, 0.00413, 0.00414, 0.00415, 0.00416, 0.00417, 0.00418, 0.00419, 0.00420, 0.00421 0.00422, 0.00423, 0.00424, 0.00425, 0.00426, 0.00427, 0.00428, 0.00429, 0.00430, 0.00431: 0.00432, 0.00433, 0.00434, 0.00435, 0.00436, 0.00437, 0.00438, 0.00439, 0.00440, 0.00441 0.00442, 0.00443, 0.00444, 0.00445, 0.00446, 0.00447, 0.00448, 0.00449, 0.00450, 0.00451 0.00452, 0.00453, 0.00454, 0.00455, 0.00456, 0.00457, 0.00458, 0.00459, or 0.00460. In some embodiments, the ratio of CD34 cells to neutrophils is about 0.0036.
[0059] In another aspect, the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor (e.g, a human donor), wherein the ratio of CD34+ cells to lymphocytes in the population is from about 0.0021 to about 0.0094. In some embodiments, the ratio of CD34+ cells to lymphocytes may be about 0.00210, 0.00211, 0.00212, 0.00213, 0.00214, 0.00215, 0.00216,
0.00217, 0.00218, 0.00219, 0.00220, 0.00221, 0.00222, 0.00223, 0.00224, 0.00225, 0.00226, 0.00227, 0.00228, 0.00229, 0.00230, 0.00231, 0.00232, 0.00233, 0.00234, 0.00235, 0.00236, 0.00237, 0.00238, 0.00239, 0.00240, 0.00241, 0.00242, 0.00243, 0.00244, 0.00245, 0.00246, 0.00247, 0.00248, 0.00249, 0.00250, 0.00251, 0.00252, 0.00253, 0.00254, 0.00255, 0.00256, 0.00257, 0.00258, 0.00259, 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266, 0.00267, 0.00268, 0.00269, 0.00270, 0.00271, 0.00272, 0.00273, 0.00274, 0.00275, 0.00276, 0.00277, 0.00278, 0.00279, 0.00280, 0.00281, 0.00282, 0.00283, 0.00284, 0.00285, 0.00286, 0.00287, 0.00288, 0.00289, 0.00290, 0.00291, 0.00292, 0.00293, 0.00294, 0.00295, 0.00296, 0.00297, 0.00298, 0.00299, 0.00300, 0.00300, 0.00301, 0.00302, 0.00303, 0.00304, 0.00305, 0.00306, 0.00307, 0.00308, 0.00309, 0.00310, 0.00311, 0.00312, 0.00313, 0.00314, 0.00315, 0.00316, 0.00317, 0.00318, 0.00319, 0.00320, 0.00321, 0.00322, 0.00323, 0.00324, 0.00325, 0.00326, 0.00327, 0.00328, 0.00329, 0.00330, 0.00331, 0.00332, 0.00333, 0.00334, 0.00335, 0.00336, 0.00337, 0.00338, 0.00339, 0.00340, 0.00341, 0.00342, 0.00343, 0.00344, 0.00345, 0.00346, 0.00347, 0.00348, 0.00349, 0.00350, 0.00351, 0.00352, 0.00353, 0.00354, 0.00355, 0.00356, 0.00357, 0.00358, 0.00359, 0.00360, 0.00361, 0.00362, 0.00363, 0.00364, 0.00365, 0.00366, 0.00367, 0.00368, 0.00369, 0.00370, 0.00371, 0.00372, 0.00373, 0.00374, 0.00375, 0.00376, 0.00377, 0.00378, 0.00379, 0.00380, 0.00381, 0.00382, 0.00383, 0.00384, 0.00385, 0.00386, 0.00387, 0.00388, 0.00389, 0.00390, 0.00391, 0.00392, 0.00393, 0.00394, 0.00395, 0.00396, 0.00397, 0.00398, 0.00399, 0.00400, 0.00401, 0.00402, 0.00403, 0.00404, 0.00405, 0.00406, 0.00407, 0.00408, 0.00409, 0.00410, 0.00411, 0.00412, 0.00413, 0.00414, 0.00415, 0.00416, 0.00417, 0.00418, 0.00419, 0.00420, 0.00421, 0.00422, 0.00423, 0.00424, 0.00425, 0.00426, 0.00427, 0.00428, 0.00429, 0.00430, 0.00431, 0.00432, 0.00433, 0.00434, 0.00435, 0.00436, 0.00437, 0.00438, 0.00439, 0.00440, 0.00441, 0.00442, 0.00443, 0.00444, 0.00445, 0.00446, 0.00447, 0.00448, 0.00449, 0.00450, 0.00451, 0.00452, 0.00453, 0.00454, 0.00455, 0.00456, 0.00457, 0.00458, 0.00459, 0.00460, 0.00461, 0.00462, 0.00463, 0.00464, 0.00465, 0.00466, 0.00467, 0.00468, 0.00469, 0.00470, 0.00471, 0.00472, 0.00473, 0.00474, 0.00475, 0.00476, 0.00477, 0.00478, 0.00479, 0.00480, 0.00481, 0.00482, 0.00483, 0.00484, 0.00485, 0.00486, 0.00487, 0.00488, 0.00489, 0.00490, 0.00491, 0.00492, 0.00493, 0.00494, 0.00495, 0.00496, 0.00497, 0.00498, 0.00499, 0.00500, 0.00501, 0.00502, 0.00503, 0.00504, 0.00505, 0.00506, 0.00507, 0.00508, 0.00509, 0.00510, 0.00511, 0.00512, 0.00513, 0.00514, 0.00515, 0.00516, 0.00517, 0.00518, 0.00519, 0.00520, 0.00521, 0.00522, 0.00523, 0.00524, 0.00525, 0.00526, 0.00527, 0.00528, 0.00529, 0.00530, 0.00531, 0.00532, 0.00533, 0.00534, 0.00535, 0.00536, 0.00537, 0.00538, 0.00539, 0.00540, 0.00541, 0.00542, 0.00543, 0.00544, 0.00545, 0.00546, 0.00547, 0.00548, 0.00549, 0.00550, 0.00551, 0.00552, 0.00553, 0.00554, 0.00555, 0.00556, 0.00557, 0.00558, 0.00559, 0.00560, 0.00561, 0.00562, 0.00563, 0.00564, 0.00565, 0.00566, 0.00567, 0.00568, 0.00569, 0.00570, 0.00571, 0.00572, 0.00573, 0.00574, 0.00575, 0.00576, 0.00577, 0.00578, 0.00579, 0.00580, 0.00581, 0.00582, 0.00583, 0.00584, 0.00585, 0.00586, 0.00587, 0.00588, 0.00589, 0.00590, 0.00591, 0.00592, 0.00593, 0.00594, 0.00595, 0.00596, 0.00597, 0.00598, 0.00599, 0.00600, 0.00601, 0.00602, 0.00603, 0.00604, 0.00605, 0.00606, 0.00607, 0.00608, 0.00609, 0.00610, 0.00611, 0.00612, 0.00613, 0.00614, 0.00615, 0.00616, 0.00617, 0.00618, 0.00619, 0.00620, 0.00621, 0.00622, 0.00623, 0.00624, 0.00625, 0.00626, 0.00627, 0.00628, 0.00629, 0.00630, 0.00631, 0.00632, 0.00633, 0.00634, 0.00635, 0.00636, 0.00637, 0.00638, 0.00639, 0.00640, 0.00641 0.00642, 0.00643, 0.00644, 0.00645, 0.00646, 0.00647, 0.00648, 0.00649, 0.00650, 0.00651 0.00652, 0.00653, 0.00654, 0.00655, 0.00656, 0.00657, 0.00658, 0.00659, 0.00660, 0.00661 0.00662, 0.00663, 0.00664, 0.00665, 0.00666, 0.00667, 0.00668, 0.00669, 0.00670, 0.00671 0.00672, 0.00673, 0.00674, 0.00675, 0.00676, 0.00677, 0.00678, 0.00679, 0.00680, 0.00681 0.00682, 0.00683, 0.00684, 0.00685, 0.00686, 0.00687, 0.00688, 0.00689, 0.00690, 0.00691 0.00692, 0.00693, 0.00694, 0.00695, 0.00696, 0.00697, 0.00698, 0.00699, 0.00700, 0.00701 0.00702, 0.00703, 0.00704, 0.00705, 0.00706, 0.00707, 0.00708, 0.00709, 0.00710, 0.00711 0.00712, 0.00713, 0.00714, 0.00715, 0.00716, 0.00717, 0.00718, 0.00719, 0.00720, 0.00721 0.00722, 0.00723, 0.00724, 0.00725, 0.00726, 0.00727, 0.00728, 0.00729, 0.00730, 0.00731 0.00732, 0.00733, 0.00734, 0.00735, 0.00736, 0.00737, 0.00738, 0.00739, 0.00740, 0.00741 0.00742, 0.00743, 0.00744, 0.00745, 0.00746, 0.00747, 0.00748, 0.00749, 0.00750, 0.00751 0.00752, 0.00753, 0.00754, 0.00755, 0.00756, 0.00757, 0.00758, 0.00759, 0.00760, 0.00761 0.00762, 0.00763, 0.00764, 0.00765, 0.00766, 0.00767, 0.00768, 0.00769, 0.00770, 0.00771 0.00772, 0.00773, 0.00774, 0.00775, 0.00776, 0.00777, 0.00778, 0.00779, 0.00780, 0.00781 0.00782, 0.00783, 0.00784, 0.00785, 0.00786, 0.00787, 0.00788, 0.00789, 0.00790, 0.00791 0.00792, 0.00793, 0.00794, 0.00795, 0.00796, 0.00797, 0.00798, 0.00799, 0.00800, 0.00801 0.00802, 0.00803, 0.00804, 0.00805, 0.00806, 0.00807, 0.00808, 0.00809, 0.00810, 0.00811 0.00812, 0.00813, 0.00814, 0.00815, 0.00816, 0.00817, 0.00818, 0.00819, 0.00820, 0.00821 0.00822, 0.00823, 0.00824, 0.00825, 0.00826, 0.00827, 0.00828, 0.00829, 0.00830, 0.00831 0.00832, 0.00833, 0.00834, 0.00835, 0.00836, 0.00837, 0.00838, 0.00839, 0.00840, 0.00841 0.00842, 0.00843, 0.00844, 0.00845, 0.00846, 0.00847, 0.00848, 0.00849, 0.00850, 0.00851 0.00852, 0.00853, 0.00854, 0.00855, 0.00856, 0.00857, 0.00858, 0.00859, 0.00860, 0.00861 0.00862, 0.00863, 0.00864, 0.00865, 0.00866, 0.00867, 0.00868, 0.00869, 0.00870, 0.00871 0.00872, 0.00873, 0.00874, 0.00875, 0.00876, 0.00877, 0.00878, 0.00879, 0.00880, 0.00881 0.00882, 0.00883, 0.00884, 0.00885, 0.00886, 0.00887, 0.00888, 0.00889, 0.00890, 0.00891 0.00892, 0.00893, 0.00894, 0.00895, 0.00896, 0.00897, 0.00898, 0.00899, 0.00900, 0.00901 0.00902, 0.00903, 0.00904, 0.00905, 0.00906, 0.00907, 0.00908, 0.00909, 0.00910, 0.00911 0.00912, 0.00913, 0.00914, 0.00915, 0.00916, 0.00917, 0.00918, 0.00919, 0.00920, 0.00921 0.00922, 0.00923, 0.00924, 0.00925, 0.00926, 0.00927, 0.00928, 0.00929, 0.00930, 0.00931 0.00932, 0.00933, 0.00934, 0.00935, 0.00936, 0.00937, 0.00938, 0.00939, or 0.00940. In some embodiments, the ratio of CD34 cells to lymphocytes is from about 0.0025 to about 0.0035, such as a ratio of CD34+ cells to lymphocytes of about 0.00250, 0.00251, 0.00252, 0.00253, 0.00254, 0.00255, 0.00256, 0.00257, 0.00258, 0.00259, 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266, 0.00267, 0.00268, 0.00269, 0.00270, 0.00271, 0.00272, 0.00273, 0.00274, 0.00275, 0.00276, 0.00277, 0.00278, 0.00279, 0.00280, 0.00281, 0.00282, 0.00283, 0.00284, 0.00285, 0.00286, 0.00287, 0.00288, 0.00289, 0.00290, 0.00291, 0.00292, 0.00293, 0.00294, 0.00295, 0.00296, 0.00297, 0.00298, 0.00299, 0.00300, 0.00300, 0.00301, 0.00302, 0.00303, 0.00304, 0.00305, 0.00306, 0.00307, 0.00308, 0.00309, 0.00310, 0.00311, 0.00312, 0.00313, 0.00314, 0.00315, 0.00316, 0.00317, 0.00318, 0.00319, 0.00320, 0.00321, 0.00322, 0.00323, 0.00324, 0.00325, 0.00326, 0.00327, 0.00328, 0.00329, 0.00330, 0.00331, 0.00332, 0.00333, 0.00334, 0.00335, 0.00336, 0.00337, 0.00338, 0.00339, 0.00340, 0.00341, 0.00342, 0.00343, 0.00344, 0.00345, 0.00346, 0.00347, 0.00348, 0.00349, or 0.00350. In some embodiments, the ratio of CD34+ cells to lymphocytes is about 0.0031.
[0060] In a further aspect, the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor e.g ., a human donor), wherein the ratio of CD34+ cells to monocytes in the population is from about 0.0071 to about 0.0174. In some embodiments, the ratio of CD34+ cells to monocytes may be about 0.00710, 0.00711, 0.00712, 0.00713, 0.00714, 0.00715, 0.00716,
0.00717, 0.00718, 0.00719, 0.00720, 0.00721, 0.00722, 0.00723, 0.00724, 0.00725, 0.00726, 0.00727, 0.00728, 0.00729, 0.00730, 0.00731, 0.00732, 0.00733, 0.00734, 0.00735, 0.00736, 0.00737, 0.00738, 0.00739, 0.00740, 0.00741, 0.00742, 0.00743, 0.00744, 0.00745, 0.00746, 0.00747, 0.00748, 0.00749, 0.00750, 0.00751, 0.00752, 0.00753, 0.00754, 0.00755, 0.00756, 0.00757, 0.00758, 0.00759, 0.00760, 0.00761, 0.00762, 0.00763, 0.00764, 0.00765, 0.00766, 0.00767, 0.00768, 0.00769, 0.00770, 0.00771, 0.00772, 0.00773, 0.00774, 0.00775, 0.00776, 0.00777, 0.00778, 0.00779, 0.00780, 0.00781, 0.00782, 0.00783, 0.00784, 0.00785, 0.00786, 0.00787, 0.00788, 0.00789, 0.00790, 0.00791, 0.00792, 0.00793, 0.00794, 0.00795, 0.00796, 0.00797, 0.00798, 0.00799, 0.00800, 0.00801, 0.00802, 0.00803, 0.00804, 0.00805, 0.00806, 0.00807, 0.00808, 0.00809, 0.00810, 0.00811, 0.00812, 0.00813, 0.00814, 0.00815, 0.00816, 0.00817, 0.00818, 0.00819, 0.00820, 0.00821, 0.00822, 0.00823, 0.00824, 0.00825, 0.00826, 0.00827, 0.00828, 0.00829, 0.00830, 0.00831, 0.00832, 0.00833, 0.00834, 0.00835, 0.00836, 0.00837, 0.00838, 0.00839, 0.00840, 0.00841, 0.00842, 0.00843, 0.00844, 0.00845, 0.00846, 0.00847, 0.00848, 0.00849, 0.00850, 0.00851, 0.00852, 0.00853, 0.00854, 0.00855, 0.00856, 0.00857, 0.00858, 0.00859, 0.00860, 0.00861, 0.00862, 0.00863, 0.00864, 0.00865, 0.00866, 0.00867, 0.00868, 0.00869, 0.00870, 0.00871, 0.00872, 0.00873, 0.00874, 0.00875, 0.00876, 0.00877, 0.00878, 0.00879, 0.00880, 0.00881, 0.00882, 0.00883, 0.00884, 0.00885, 0.00886, 0.00887, 0.00888, 0.00889, 0.00890, 0.00891, 0.00892, 0.00893, 0.00894, 0.00895, 0.00896, 0.00897, 0.00898, 0.00899, 0.00900, 0.00901, 0.00902, 0.00903, 0.00904, 0.00905, 0.00906, 0.00907, 0.00908, 0.00909, 0.00910, 0.00911, 0.00912, 0.00913, 0.00914, 0.00915, 0.00916, 0.00917, 0.00918, 0.00919, 0.00920, 0.00921, 0.00922, 0.00923, 0.00924, 0.00925, 0.00926, 0.00927, 0.00928, 0.00929, 0.00930, 0.00931, 0.00932, 0.00933, 0.00934, 0.00935, 0.00936, 0.00937, 0.00938, 0.00939, 0.00940, 0.00941, 0.00942, 0.00943, 0.00944, 0.00945, 0.00946, 0.00947, 0.00948, 0.00949, 0.00950, 0.00951, 0.00952, 0.00953, 0.00954, 0.00955, 0.00956, 0.00957, 0.00958, 0.00959, 0.00960, 0.00961, 0.00962, 0.00963, 0.00964, 0.00965, 0.00966, 0.00967, 0.00968, 0.00969, 0.00970, 0.00971, 0.00972, 0.00973, 0.00974, 0.00975, 0.00976, 0.00977, 0.00978, 0.00979, 0.00980, 0.00981, 0.00982, 0.00983, 0.00984, 0.00985, 0.00986, 0.00987, 0.00988, 0.00989, 0.00990, 0.00991, 0.00992, 0.00993, 0.00994, 0.00995, 0.00996, 0.00997, 0.00998, 0.00999, 0.0100, 0.0101, 0.0103, 0.0104, 0.0105, 0.0106, 0.0107, 0.0108, 0.0109, 0.0110, 0.0111, 0.0112, 0.0113, 0.0114, 0.0115, 0.0116, 0.0117, 0.0118, 0.0119,
0.0120, 0.0121, 0.0122, 0.0123, 0.0124, 0.0125, 0.0126, 0.0127, 0.0128, 0.0129, 0.0130,
0.0131, 0.0132, 0.0133, 0.0134, 0.0135, 0.0136, 0.0137, 0.0138, 0.0139, 0.0140, 0.0141,
0.0142, 0.0143, 0.0144, 0.0145, 0.0146, 0.0147, 0.0148, 0.0149, 0.0150, 0.0151, 0.0152,
0.0153, 0.0154, 0.0155, 0.0156, 0.0157, 0.0158, 0.0159, 0.0160, 0.0161, 0.0162, 0.0163,
0.0164, 0.0165, 0.0166, 0.0167, 0.0168, 0.0169, 0.0170, 0.0171, 0.0172, 0.0173, or 0.0174.
In some embodiments, the ratio of CD34+ cells to monocytes is from about 0.0100 to about 0.0140, such as a ratio of CD34+ cells to monocytes of about 0.0100, 0.0101, 0.0103, 0.0104, 0.0105, 0.0106, 0.0107, 0.0108, 0.0109, 0.0110, 0.0111, 0.0112, 0.0113, 0.0114, 0.0115,
0.0116, 0.0117, 0.0118, 0.0119, 0.0120, 0.0121, 0.0122, 0.0123, 0.0124, 0.0125, 0.0126,
0.0127, 0.0128, 0.0129, 0.0130, 0.0131, 0.0132, 0.0133, 0.0134, 0.0135, 0.0136, 0.0137,
0.0138, 0.0139, or 0.0140. In some embodiments, the ratio of CD34+ cells to monocytes is about 0.0118.
[0061] In a further aspect, the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor e.g ., a human donor), wherein the frequency of CD34+ cells in the population is from about 0.051% to about 0.140%. In some embodiments, the population of cells may have a frequency of CD34+ cells of about 0.051%, 0.052%, 0.053%, 0.054%, 0.055%, 0.056%, 0.057%, 0.058%, 0.059%, 0.060%, 0.061%, 0.062%, 0.063%, 0.064%, 0.065%, 0.066%,
0.067%, 0.068%, 0.069%, 0.070%, 0.071%, 0.072%, 0.073%, 0.074%, 0.075%, 0.076%,
0.077%, 0.078%, 0.079%, 0.080%, 0.081%, 0.082%, 0.083%, 0.084%, 0.085%, 0.086%, 0.087%, 0.088%, 0.089%, 0.090%, 0.091%, 0.092%, 0.093%, 0.094%, 0.095%, 0.096%, 0.097%, 0.098%, 0.099%, 0.100%, 0.101%, 0.102%, 0.103%, 0.104%, 0.105%, 0.106%, 0.107%, 0.108%, 0.109%, 0.110%, 0.111%, 0.112%, 0.113%, 0.114%, 0.115%, 0.116%, 0.117%, 0.118%, 0.119%, 0.120%, 0.121%, 0.122%, 0.123%, 0.124%, 0.125%, 0.126%, 0.127%, 0.128%, 0.129%, 0.130%, 0.131%, 0.132%, 0.133%, 0.134%, 0.135%, 0.136%, 0.137%, 0.138%, 0.139%, or 0.140%. In some embodiments, the population of cells has a frequency of CD34+ cells of from about 0.080% to about 0.120%, such as a frequency of CD34+ cells of about 0.080%, 0.081%, 0.082%, 0.083%, 0.084%, 0.085%, 0.086%, 0.087%, 0.088%, 0.089%, 0.090%, 0.091%, 0.092%, 0.093%, 0.094%, 0.095%, 0.096%, 0.097%, 0.098%, 0.099%, 0.100%, 0.101%, 0.102%, 0.103%, 0.104%, 0.105%, 0.106%, 0.107%, 0.108%, 0.109%, 0.110%, 0.111%, 0.112%, 0.113%, 0.114%, 0.115%, 0.116%, 0.117%,
0.118%, 0.119%, or 0.120%. In some embodiments, the population of cells has a frequency of CD34+ cells of about 0.097%.
[0062] In a further aspect, the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor e.g ., a human donor), wherein the ratio of CD34+ CD90+ CD45RA cells to leukocytes in the population is from about 0.0003 to about 0.0016. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to leukocytes may be about 0.00030, 0.00031, 0.00032, 0.00033, 0.00034, 0.00035, 0.00036, 0.00037, 0.00038, 0.00039, 0.00040, 0.00041, 0.00042, 0.00043,
0.00044, 0.00045, 0.00046, 0.00047, 0.00048, 0.00049, 0.00050, 0.00051, 0.00052, 0.00053,
0.00054, 0.00055, 0.00056, 0.00057, 0.00058, 0.00059, 0.00060, 0.00061, 0.00062, 0.00063,
0.00064, 0.00065, 0.00066, 0.00067, 0.00068, 0.00069, 0.00070, 0.00071, 0.00072, 0.00073,
0.00074, 0.00075, 0.00076, 0.00077, 0.00078, 0.00079, 0.00080, 0.00081, 0.00082, 0.00083,
0.00084, 0.00085, 0.00086, 0.00087, 0.00088, 0.00089, 0.00090, 0.00091, 0.00092, 0.00093,
0.00094, 0.00095, 0.00096, 0.00097, 0.00098, 0.00099, 0.00100, 0.00101, 0.00102, 0.00103,
0.00104, 0.00105, 0.00106, 0.00107, 0.00108, 0.00109, 0.00110, 0.00111, 0.00112, 0.00113,
0.00114, 0.00115, 0.00116, 0.00117, 0.00118, 0.00119, 0.00120, 0.00121, 0.00122, 0.00123,
0.00124, 0.00125, 0.00126, 0.00127, 0.00128, 0.00129, 0.00130, 0.00131, 0.00132, 0.00133,
0.00134, 0.00135, 0.00136, 0.00137, 0.00138, 0.00139, 0.00140, 0.00141, 0.00142, 0.00143,
0.00144, 0.00145, 0.00146, 0.00147, 0.00148, 0.00149, 0.00150, 0.00151, 0.00152, 0.00153,
0.00154, 0.00155, 0.00156, 0.00157, 0.00158, 0.00159, or 0.00160. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to leukocytes is from about 0.0006 to about 0.0012, such as a ratio of CD34+ CD90+ CD45RA cells to leukocytes of about 0.00060, 0.00061, 0.00062, 0.00063, 0.00064, 0.00065, 0.00066, 0.00067, 0.00068, 0.00069, 0.00070,
0.00071, 0.00072, 0.00073, 0.00074, 0.00075, 0.00076, 0.00077, 0.00078, 0.00079, 0.00080,
0.00081, 0.00082, 0.00083, 0.00084, 0.00085, 0.00086, 0.00087, 0.00088, 0.00089, 0.00090,
0.00091, 0.00092, 0.00093, 0.00094, 0.00095, 0.00096, 0.00097, 0.00098, 0.00099, 0.00100,
0.00101, 0.00102, 0.00103, 0.00104, 0.00105, 0.00106, 0.00107, 0.00108, 0.00109, 0.00110,
0.00111, 0.00112, 0.00113, 0.00114, 0.00115, 0.00116, 0.00117, 0.00118, 0.00119, or
0.00120. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to leukocytes is about 0.0009.
[0063] In an additional aspect, the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor ( e.g ., a human donor), wherein the ratio of CD34+ CD90+ CD45RA cells to neutrophils in the population is from about 0.0007 to about 0.0043. In some embodiments, the ratio of CD34 CD90+ CD45RA cells to neutrophils may be about 0.00070, 0.00071,
0.00072, 0.00073, 0.00074, 0.00075, 0.00076, 0.00077, 0.00078, 0.00079, 0.00080, 0.00081, 0.00082, 0.00083, 0.00084, 0.00085, 0.00086, 0.00087, 0.00088, 0.00089, 0.00090, 0.00091, 0.00092, 0.00093, 0.00094, 0.00095, 0.00096, 0.00097, 0.00098, 0.00099, 0.00100, 0.00101, 0.00102, 0.00103, 0.00104, 0.00105, 0.00106, 0.00107, 0.00108, 0.00109, 0.00110, 0.00111, 0.00112, 0.00113, 0.00114, 0.00115, 0.00116, 0.00117, 0.00118, 0.00119, 0.00120, 0.00121, 0.00122, 0.00123, 0.00124, 0.00125, 0.00126, 0.00127, 0.00128, 0.00129, 0.00130, 0.00131, 0.00132, 0.00133, 0.00134, 0.00135, 0.00136, 0.00137, 0.00138, 0.00139, 0.00140, 0.00141, 0.00142, 0.00143, 0.00144, 0.00145, 0.00146, 0.00147, 0.00148, 0.00149, 0.00150, 0.00151, 0.00152, 0.00153, 0.00154, 0.00155, 0.00156, 0.00157, 0.00158, 0.00159, 0.00160, 0.00161, 0.00162, 0.00163, 0.00164, 0.00165, 0.00166, 0.00167, 0.00168, 0.00169, 0.00170, 0.00171, 0.00172, 0.00173, 0.00174, 0.00175, 0.00176, 0.00177, 0.00178, 0.00179, 0.00180, 0.00181, 0.00182, 0.00183, 0.00184, 0.00185, 0.00186, 0.00187, 0.00188, 0.00189, 0.00190, 0.00191, 0.00192, 0.00193, 0.00194, 0.00195, 0.00196, 0.00197, 0.00198, 0.00199, 0.00200, 0.00201, 0.00202, 0.00203, 0.00204, 0.00205, 0.00206, 0.00207, 0.00208, 0.00209, 0.00210, 0.00211, 0.00212, 0.00213, 0.00214, 0.00215, 0.00216, 0.00217, 0.00218, 0.00219, 0.00220, 0.00221, 0.00222, 0.00223, 0.00224, 0.00225, 0.00226, 0.00227, 0.00228, 0.00229, 0.00230, 0.00231, 0.00232, 0.00233, 0.00234, 0.00235, 0.00236, 0.00237, 0.00238, 0.00239, 0.00240, 0.00241, 0.00242, 0.00243, 0.00244, 0.00245, 0.00246, 0.00247, 0.00248, 0.00249, 0.00250, 0.00251, 0.00252, 0.00253, 0.00254, 0.00255, 0.00256, 0.00257, 0.00258, 0.00259, 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266, 0.00267, 0.00268, 0.00269, 0.00270, 0.00271, 0.00272, 0.00273, 0.00274, 0.00275, 0.00276, 0.00277, 0.00278, 0.00279, 0.00280, 0.00281, 0.00282, 0.00283, 0.00284, 0.00285, 0.00286, 0.00287, 0.00288, 0.00289, 0.00290, 0.00291, 0.00292, 0.00293, 0.00294, 0.00295, 0.00296, 0.00297, 0.00298, 0.00299, 0.00300, 0.00300, 0.00301, 0.00302, 0.00303, 0.00304, 0.00305, 0.00306, 0.00307, 0.00308, 0.00309, 0.00310, 0.00311, 0.00312, 0.00313, 0.00314, 0.00315, 0.00316, 0.00317, 0.00318, 0.00319, 0.00320, 0.00321, 0.00322, 0.00323, 0.00324, 0.00325, 0.00326, 0.00327, 0.00328, 0.00329, 0.00330, 0.00331, 0.00332, 0.00333, 0.00334, 0.00335, 0.00336, 0.00337, 0.00338, 0.00339, 0.00340, 0.00341, 0.00342, 0.00343, 0.00344, 0.00345, 0.00346, 0.00347, 0.00348, 0.00349, 0.00350, 0.00351, 0.00352, 0.00353, 0.00354, 0.00355, 0.00356, 0.00357, 0.00358, 0.00359, 0.00360, 0.00361, 0.00362, 0.00363, 0.00364, 0.00365, 0.00366, 0.00367, 0.00368, 0.00369, 0.00370, 0.00371, 0.00372, 0.00373, 0.00374, 0.00375, 0.00376, 0.00377, 0.00378, 0.00379, 0.00380, 0.00381, 0.00382, 0.00383, 0.00384, 0.00385, 0.00386, 0.00387, 0.00388, 0.00389, 0.00390, 0.00391, 0.00392, 0.00393, 0.00394, 0.00395, 0.00396, 0.00397, 0.00398, 0.00399, 0.00400, 0.00401, 0.00402, 0.00403, 0.00404, 0.00405, 0.00406, 0.00407, 0.00408, 0.00409, 0.00410, 0.00411, 0.00412, 0.00413, 0.00414, 0.00415, 0.00416, 0.00417, 0.00418, 0.00419, 0.00420, 0.00421, 0.00422, 0.00423, 0.00424, 0.00425, 0.00426, 0.00427, 0.00428, 0.00429, or 0.00430. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to neutrophils is from about 0.0014 to about 0.0034, such as a ratio of CD34+ CD90+ CD45RA cells to neutrophils of about 0.00140, 0.00141, 0.00142, 0.00143, 0.00144, 0.00145, 0.00146,
0.00147, 0.00148, 0.00149, 0.00150, 0.00151, 0.00152, 0.00153, 0.00154, 0.00155, 0.00156, 0.00157, 0.00158, 0.00159, 0.00160, 0.00161, 0.00162, 0.00163, 0.00164, 0.00165, 0.00166, 0.00167, 0.00168, 0.00169, 0.00170, 0.00171, 0.00172, 0.00173, 0.00174, 0.00175, 0.00176, 0.00177, 0.00178, 0.00179, 0.00180, 0.00181, 0.00182, 0.00183, 0.00184, 0.00185, 0.00186, 0.00187, 0.00188, 0.00189, 0.00190, 0.00191, 0.00192, 0.00193, 0.00194, 0.00195, 0.00196, 0.00197, 0.00198, 0.00199, 0.00200, 0.00201, 0.00202, 0.00203, 0.00204, 0.00205, 0.00206, 0.00207, 0.00208, 0.00209, 0.00210, 0.00211, 0.00212, 0.00213, 0.00214, 0.00215, 0.00216, 0.00217, 0.00218, 0.00219, 0.00220, 0.00221, 0.00222, 0.00223, 0.00224, 0.00225, 0.00226, 0.00227, 0.00228, 0.00229, 0.00230, 0.00231, 0.00232, 0.00233, 0.00234, 0.00235, 0.00236, 0.00237, 0.00238, 0.00239, 0.00240, 0.00241, 0.00242, 0.00243, 0.00244, 0.00245, 0.00246, 0.00247, 0.00248, 0.00249, 0.00250, 0.00251, 0.00252, 0.00253, 0.00254, 0.00255, 0.00256, 0.00257, 0.00258, 0.00259, 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266, 0.00267, 0.00268, 0.00269, 0.00270, 0.00271, 0.00272, 0.00273, 0.00274, 0.00275, 0.00276, 0.00277, 0.00278, 0.00279, 0.00280, 0.00281, 0.00282, 0.00283, 0.00284, 0.00285, 0.00286, 0.00287, 0.00288, 0.00289, 0.00290, 0.00291, 0.00292, 0.00293, 0.00294, 0.00295, 0.00296,
0.00297, 0.00298, 0.00299, 0.00300, 0.00300, 0.00301, 0.00302, 0.00303, 0.00304, 0.00305,
0.00306, 0.00307, 0.00308, 0.00309, 0.00310, 0.00311, 0.00312, 0.00313, 0.00314, 0.00315,
0.00316, 0.00317, 0.00318, 0.00319, 0.00320, 0.00321, 0.00322, 0.00323, 0.00324, 0.00325,
0.00326, 0.00327, 0.00328, 0.00329, 0.00330, 0.00331, 0.00332, 0.00333, 0.00334, 0.00335,
0.00336, 0.00337, 0.00338, 0.00339, or 0.00340. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to neutrophils is about 0.0024.
[0064] In another aspect, the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor (e.g, a human donor), wherein the ratio of CD34+ CD90+ CD45RA cells to lymphocytes in the population is from about 0.0008 to about 0.0069. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to lymphocytes may be about 0.00080, 0.00081, 0.00082,
0.00083, 0.00084, 0.00085, 0.00086, 0.00087, 0.00088, 0.00089, 0.00090, 0.00091, 0.00092, 0.00093, 0.00094, 0.00095, 0.00096, 0.00097, 0.00098, 0.00099, 0.00100, 0.00101, 0.00102, 0.00103, 0.00104, 0.00105, 0.00106, 0.00107, 0.00108, 0.00109, 0.00110, 0.00111, 0.00112, 0.00113, 0.00114, 0.00115, 0.00116, 0.00117, 0.00118, 0.00119, 0.00120, 0.00121, 0.00122, 0.00123, 0.00124, 0.00125, 0.00126, 0.00127, 0.00128, 0.00129, 0.00130, 0.00131, 0.00132, 0.00133, 0.00134, 0.00135, 0.00136, 0.00137, 0.00138, 0.00139, 0.00140, 0.00141, 0.00142, 0.00143, 0.00144, 0.00145, 0.00146, 0.00147, 0.00148, 0.00149, 0.00150, 0.00151, 0.00152, 0.00153, 0.00154, 0.00155, 0.00156, 0.00157, 0.00158, 0.00159, 0.00160, 0.00161, 0.00162, 0.00163, 0.00164, 0.00165, 0.00166, 0.00167, 0.00168, 0.00169, 0.00170, 0.00171, 0.00172, 0.00173, 0.00174, 0.00175, 0.00176, 0.00178, 0.00179, 0.00180, 0.00181, 0.00182, 0.00183, 0.00184, 0.00185, 0.00186, 0.00187, 0.00188, 0.00189, 0.00190, 0.00191, 0.00192, 0.00193, 0.00194, 0.00195, 0.00196, 0.00197, 0.00198, 0.00199, 0.00200, 0.00201, 0.00202, 0.00203, 0.00204, 0.00205, 0.00206, 0.00207, 0.00208, 0.00209, 0.00210, 0.00211, 0.00212, 0.00213, 0.00214, 0.00215, 0.00216, 0.00217, 0.00218, 0.00219, 0.00220, 0.00221, 0.00222, 0.00223, 0.00224, 0.00225, 0.00226, 0.00227, 0.00228, 0.00229, 0.00230, 0.00231, 0.00232, 0.00233, 0.00234, 0.00235, 0.00236, 0.00237, 0.00238, 0.00239, 0.00240, 0.00241, 0.00242, 0.00243, 0.00244, 0.00245, 0.00246, 0.00247, 0.00248, 0.00249, 0.00250, 0.00251, 0.00252, 0.00253, 0.00254, 0.00255, 0.00256, 0.00257, 0.00258, 0.00259, 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266, 0.00267, 0.00268, 0.00269, 0.00270, 0.00271, 0.00272, 0.00273, 0.00274, 0.00275, 0.00276, 0.00278, 0.00279, 0.00280, 0.00281, 0.00282, 0.00283, 0.00284, 0.00285, 0.00286, 0.00287, 0.00288, 0.00289, 0.00290, 0.00291, 0.00292, 0.00293, 0.00294, 0.00295, 0.00296, 0.00297, 0.00298, 0.00299, 0.00300, 0.00301, 0.00302, 0.00303, 0.00304, 0.00305, 0.00306, 0.00307, 0.00308, 0.00309, 0.00310, 0.00311, 0.00312, 0.00313, 0.00314, 0.00315, 0.00316, 0.00317, 0.00318, 0.00319, 0.00320, 0.00321, 0.00322, 0.00323, 0.00324, 0.00325, 0.00326, 0.00327, 0.00328, 0.00329, 0.00330, 0.00331, 0.00332, 0.00333, 0.00334, 0.00335, 0.00336, 0.00337, 0.00338, 0.00339, 0.00340, 0.00341, 0.00342, 0.00343, 0.00344, 0.00345, 0.00346, 0.00347, 0.00348, 0.00349, 0.00350, 0.00351, 0.00352, 0.00353, 0.00354, 0.00355, 0.00356, 0.00357, 0.00358, 0.00359, 0.00360, 0.00361, 0.00362, 0.00363, 0.00364, 0.00365, 0.00366, 0.00367, 0.00368, 0.00369, 0.00370, 0.00371, 0.00372, 0.00373, 0.00374, 0.00375, 0.00376, 0.00378, 0.00379, 0.00380, 0.00381, 0.00382, 0.00383, 0.00384, 0.00385, 0.00386, 0.00387, 0.00388, 0.00389, 0.00390, 0.00391, 0.00392, 0.00393, 0.00394, 0.00395, 0.00396, 0.00397, 0.00398, 0.00399, 0.00401, 0.00402, 0.00403, 0.00404, 0.00405, 0.00406, 0.00407, 0.00408, 0.00409, 0.00410, 0.00411, 0.00412, 0.00413, 0.00414, 0.00415, 0.00416, 0.00417, 0.00418, 0.00419, 0.00420, 0.00421, 0.00422, 0.00423, 0.00424, 0.00425, 0.00426, 0.00427, 0.00428, 0.00429, 0.00430, 0.00431, 0.00432, 0.00433, 0.00434, 0.00435, 0.00436, 0.00437, 0.00438, 0.00439, 0.00440, 0.00441, 0.00442, 0.00443, 0.00444, 0.00445, 0.00446, 0.00447, 0.00448, 0.00449, 0.00450, 0.00451, 0.00452, 0.00453, 0.00454, 0.00455, 0.00456, 0.00457, 0.00458, 0.00459, 0.00460, 0.00461, 0.00462, 0.00463, 0.00464, 0.00465, 0.00466, 0.00467, 0.00468, 0.00469, 0.00470, 0.00471, 0.00472, 0.00473, 0.00474, 0.00475, 0.00476, 0.00478, 0.00479, 0.00480, 0.00481, 0.00482, 0.00483, 0.00484, 0.00485, 0.00486, 0.00487, 0.00488, 0.00489, 0.00490, 0.00491, 0.00492, 0.00493, 0.00494, 0.00495, 0.00496, 0.00497, 0.00498, 0.00499, 0.00500, 0.00501, 0.00502, 0.00503, 0.00504, 0.00505, 0.00506, 0.00507, 0.00508, 0.00509, 0.00510, 0.00511, 0.00512, 0.00513, 0.00514, 0.00515, 0.00516, 0.00517, 0.00518, 0.00519, 0.00520, 0.00521, 0.00522, 0.00523, 0.00524, 0.00525, 0.00526, 0.00527, 0.00528, 0.00529, 0.00530, 0.00531, 0.00532, 0.00533, 0.00534, 0.00535, 0.00536, 0.00537, 0.00538, 0.00539, 0.00540, 0.00541, 0.00542, 0.00543, 0.00544, 0.00545, 0.00546, 0.00547, 0.00548, 0.00549, 0.00550, 0.00551, 0.00552, 0.00553, 0.00554, 0.00555, 0.00556, 0.00557, 0.00558, 0.00559, 0.00560, 0.00561, 0.00562, 0.00563, 0.00564, 0.00565, 0.00566, 0.00567, 0.00568, 0.00569, 0.00570, 0.00571, 0.00572, 0.00573, 0.00574, 0.00575, 0.00576, 0.00578, 0.00579, 0.00580, 0.00581, 0.00582, 0.00583, 0.00584, 0.00585, 0.00586, 0.00587, 0.00588, 0.00589, 0.00590, 0.00591, 0.00592, 0.00593, 0.00594, 0.00595, 0.00596, 0.00597, 0.00598, 0.00599, 0.00600, 0.00601, 0.00602, 0.00603, 0.00604, 0.00605, 0.00606, 0.00607, 0.00608, 0.00609, 0.00610, 0.00611, 0.00612, 0.00613, 0.00614, 0.00615, 0.00616, 0.00617, 0.00618, 0.00619, 0.00620, 0.00621, 0.00622, 0.00623, 0.00624, 0.00625, 0.00626, 0.00627, 0.00628, 0.00629, 0.00630, 0.00631, 0.00632, 0.00633, 0.00634, 0.00635, 0.00636, 0.00637, 0.00638,
0.00639, 0.00640, 0.00641, 0.00642, 0.00643, 0.00644, 0.00645, 0.00646, 0.00647, 0.00648,
0.00649, 0.00650, 0.00651, 0.00652, 0.00653, 0.00654, 0.00655, 0.00656, 0.00657, 0.00658,
0.00659, 0.00660, 0.00661, 0.00662, 0.00663, 0.00664, 0.00665, 0.00666, 0.00667, 0.00668,
0.00669, 0.00670, 0.00671, 0.00672, 0.00673, 0.00674, 0.00675, 0.00676, 0.00678, 0.00679,
0.00680, 0.00681, 0.00682, 0.00683, 0.00684, 0.00685, 0.00686, 0.00687, 0.00688, 0.00689, or 0.00690. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to lymphocytes is from about 0.0011 to about 0.0031, such as a ratio of CD34+ CD90+ CD45RA cells to lymphocytes of about 0.00110, 0.00111, 0.00112, 0.00113, 0.00114, 0.00115, 0.00116, 0.00117, 0.00118, 0.00119, 0.00120, 0.00121, 0.00122, 0.00123, 0.00124, 0.00125, 0.00126,
0.00127, 0.00128, 0.00129, 0.00130, 0.00131, 0.00132, 0.00133, 0.00134, 0.00135, 0.00136,
0.00137, 0.00138, 0.00139, 0.00140, 0.00141, 0.00142, 0.00143, 0.00144, 0.00145, 0.00146,
0.00147, 0.00148, 0.00149, 0.00150, 0.00151, 0.00152, 0.00153, 0.00154, 0.00155, 0.00156,
0.00157, 0.00158, 0.00159, 0.00160, 0.00161, 0.00162, 0.00163, 0.00164, 0.00165, 0.00166,
0.00167, 0.00168, 0.00169, 0.00170, 0.00171, 0.00172, 0.00173, 0.00174, 0.00175, 0.00176,
0.00178, 0.00179, 0.00180, 0.00181, 0.00182, 0.00183, 0.00184, 0.00185, 0.00186, 0.00187,
0.00188, 0.00189, 0.00190, 0.00191, 0.00192, 0.00193, 0.00194, 0.00195, 0.00196, 0.00197,
0.00198, 0.00199, 0.00200, 0.00201, 0.00202, 0.00203, 0.00204, 0.00205, 0.00206, 0.00207,
0.00208, 0.00209, 0.00210, 0.00211, 0.00212, 0.00213, 0.00214, 0.00215, 0.00216, 0.00217,
0.00218, 0.00219, 0.00220, 0.00221, 0.00222, 0.00223, 0.00224, 0.00225, 0.00226, 0.00227,
0.00228, 0.00229, 0.00230, 0.00231, 0.00232, 0.00233, 0.00234, 0.00235, 0.00236, 0.00237,
0.00238, 0.00239, 0.00240, 0.00241, 0.00242, 0.00243, 0.00244, 0.00245, 0.00246, 0.00247,
0.00248, 0.00249, 0.00250, 0.00251, 0.00252, 0.00253, 0.00254, 0.00255, 0.00256, 0.00257,
0.00258, 0.00259, 0.00260, 0.00261, 0.00262, 0.00263, 0.00264, 0.00265, 0.00266, 0.00267,
0.00268, 0.00269, 0.00270, 0.00271, 0.00272, 0.00273, 0.00274, 0.00275, 0.00276, 0.00278,
0.00279, 0.00280, 0.00281, 0.00282, 0.00283, 0.00284, 0.00285, 0.00286, 0.00287, 0.00288,
0.00289, 0.00290, 0.00291, 0.00292, 0.00293, 0.00294, 0.00295, 0.00296, 0.00297, 0.00298,
0.00299, 0.00300, 0.00301, 0.00302, 0.00303, 0.00304, 0.00305, 0.00306, 0.00307, 0.00308,
0.00309, or 0.00310. In some embodiments, the ratio of CD34+ CD90+ CD45RA - cells to lymphocytes is about 0.0021.
[0065] In a further aspect, the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor e.g ., a human donor), wherein the ratio of CD34+ CD90+ CD45RA cells to monocytes in the population is from about 0.0028 to about 0.0130. In some embodiments, the ratio of CD34+
CD90+ CD45RA cells to monocytes may be about 0.00280, 0.00281, 0.00282, 0.00283,
0.00284, 0.00285, 0.00286, 0.00287, 0.00288, 0.00289, 0.00290, 0.00291, 0.00292, 0.00293,
0.00294, 0.00295, 0.00296, 0.00297, 0.00298, 0.00299, 0.00300, 0.00301, 0.00302, 0.00303,
0.00304, 0.00305, 0.00306, 0.00307, 0.00308, 0.00309, 0.00310, 0.00311, 0.00312, 0.00313,
0.00314, 0.00315, 0.00316, 0.00317, 0.00318, 0.00319, 0.00320, 0.00321, 0.00322, 0.00323,
0.00324, 0.00325, 0.00326, 0.00327, 0.00328, 0.00329, 0.00330, 0.00331, 0.00332, 0.00333,
0.00334, 0.00335, 0.00336, 0.00337, 0.00338, 0.00339, 0.00340, 0.00341, 0.00342, 0.00343,
0.00344, 0.00345, 0.00346, 0.00347, 0.00348, 0.00349, 0.00350, 0.00351, 0.00352, 0.00353,
0.00354, 0.00355, 0.00356, 0.00357, 0.00358, 0.00359, 0.00360, 0.00361, 0.00362, 0.00363,
0.00364, 0.00365, 0.00366, 0.00367, 0.00368, 0.00369, 0.00370, 0.00371, 0.00372, 0.00373,
0.00374, 0.00375, 0.00376, 0.00378, 0.00379, 0.00380, 0.00381, 0.00382, 0.00383, 0.00384,
0.00385, 0.00386, 0.00387, 0.00388, 0.00389, 0.00390, 0.00391, 0.00392, 0.00393, 0.00394,
0.00395, 0.00396, 0.00397, 0.00398, 0.00399, 0.00401, 0.00402, 0.00403, 0.00404, 0.00405,
0.00406, 0.00407, 0.00408, 0.00409, 0.00410, 0.00411, 0.00412, 0.00413, 0.00414, 0.00415,
0.00416, 0.00417, 0.00418, 0.00419, 0.00420, 0.00421, 0.00422, 0.00423, 0.00424, 0.00425,
0.00426, 0.00427, 0.00428, 0.00429, 0.00430, 0.00431, 0.00432, 0.00433, 0.00434, 0.00435,
0.00436, 0.00437, 0.00438, 0.00439, 0.00440, 0.00441, 0.00442, 0.00443, 0.00444, 0.00445,
0.00446, 0.00447, 0.00448, 0.00449, 0.00450, 0.00451, 0.00452, 0.00453, 0.00454, 0.00455,
0.00456, 0.00457, 0.00458, 0.00459, 0.00460, 0.00461, 0.00462, 0.00463, 0.00464, 0.00465,
0.00466, 0.00467, 0.00468, 0.00469, 0.00470, 0.00471, 0.00472, 0.00473, 0.00474, 0.00475,
0.00476, 0.00478, 0.00479, 0.00480, 0.00481, 0.00482, 0.00483, 0.00484, 0.00485, 0.00486,
0.00487, 0.00488, 0.00489, 0.00490, 0.00491, 0.00492, 0.00493, 0.00494, 0.00495, 0.00496,
0.00497, 0.00498, 0.00499, 0.00500, 0.00501, 0.00502, 0.00503, 0.00504, 0.00505, 0.00506,
0.00507, 0.00508, 0.00509, 0.00510, 0.00511, 0.00512, 0.00513, 0.00514, 0.00515, 0.00516,
0.00517, 0.00518, 0.00519, 0.00520, 0.00521, 0.00522, 0.00523, 0.00524, 0.00525, 0.00526,
0.00527, 0.00528, 0.00529, 0.00530, 0.00531, 0.00532, 0.00533, 0.00534, 0.00535, 0.00536,
0.00537, 0.00538, 0.00539, 0.00540, 0.00541, 0.00542, 0.00543, 0.00544, 0.00545, 0.00546,
0.00547, 0.00548, 0.00549, 0.00550, 0.00551, 0.00552, 0.00553, 0.00554, 0.00555, 0.00556,
0.00557, 0.00558, 0.00559, 0.00560, 0.00561, 0.00562, 0.00563, 0.00564, 0.00565, 0.00566,
0.00567, 0.00568, 0.00569, 0.00570, 0.00571, 0.00572, 0.00573, 0.00574, 0.00575, 0.00576,
0.00578, 0.00579, 0.00580, 0.00581, 0.00582, 0.00583, 0.00584, 0.00585, 0.00586, 0.00587,
0.00588, 0.00589, 0.00590, 0.00591, 0.00592, 0.00593, 0.00594, 0.00595, 0.00596, 0.00597, 0.00598, 0.00599, 0.00600, 0.00601, 0.00602, 0.00603, 0.00604, 0.00605, 0.00606, 0.00607, 0.00608, 0.00609, 0.00610, 0.00611, 0.00612, 0.00613, 0.00614, 0.00615, 0.00616, 0.00617, 0.00618, 0.00619, 0.00620, 0.00621, 0.00622, 0.00623, 0.00624, 0.00625, 0.00626, 0.00627, 0.00628, 0.00629, 0.00630, 0.00631, 0.00632, 0.00633, 0.00634, 0.00635, 0.00636, 0.00637, 0.00638, 0.00639, 0.00640, 0.00641, 0.00642, 0.00643, 0.00644, 0.00645, 0.00646, 0.00647, 0.00648, 0.00649, 0.00650, 0.00651, 0.00652, 0.00653, 0.00654, 0.00655, 0.00656, 0.00657, 0.00658, 0.00659, 0.00660, 0.00661, 0.00662, 0.00663, 0.00664, 0.00665, 0.00666, 0.00667, 0.00668, 0.00669, 0.00670, 0.00671, 0.00672, 0.00673, 0.00674, 0.00675, 0.00676, 0.00678, 0.00679, 0.00680, 0.00681, 0.00682, 0.00683, 0.00684, 0.00685, 0.00686, 0.00687, 0.00688, 0.00689, 0.00690, 0.00691, 0.00692, 0.00693, 0.00694, 0.00695, 0.00696, 0.00697, 0.00698, 0.00699, 0.00700, 0.00701, 0.00702, 0.00703, 0.00704, 0.00705, 0.00706, 0.00707, 0.00708, 0.00709, 0.00710, 0.00711, 0.00712, 0.00713, 0.00714, 0.00715, 0.00716, 0.00717, 0.00718, 0.00719, 0.00720, 0.00721, 0.00722, 0.00723, 0.00724, 0.00725, 0.00726, 0.00727, 0.00728, 0.00729, 0.00730, 0.00731, 0.00732, 0.00733, 0.00734, 0.00735, 0.00736, 0.00737, 0.00738, 0.00739, 0.00740, 0.00741, 0.00742, 0.00743, 0.00744, 0.00745, 0.00746, 0.00747, 0.00748, 0.00749, 0.00750, 0.00751, 0.00752, 0.00753, 0.00754, 0.00755, 0.00756, 0.00757, 0.00758, 0.00759, 0.00760, 0.00761, 0.00762, 0.00763, 0.00764, 0.00765, 0.00766, 0.00767, 0.00768, 0.00769, 0.00770, 0.00771, 0.00772, 0.00773, 0.00774, 0.00775, 0.00776, 0.00777, 0.00778, 0.00779, 0.00780, 0.00781, 0.00782, 0.00783, 0.00784, 0.00785, 0.00786, 0.00787, 0.00788, 0.00789, 0.00790, 0.00791, 0.00792, 0.00793, 0.00794, 0.00795, 0.00796, 0.00797, 0.00798, 0.00799, 0.00800, 0.00801, 0.00802, 0.00803, 0.00804, 0.00805, 0.00806, 0.00807, 0.00808, 0.00809, 0.00810, 0.00811, 0.00812, 0.00813, 0.00814, 0.00815, 0.00816, 0.00817, 0.00818, 0.00819, 0.00820, 0.00821, 0.00822, 0.00823, 0.00824, 0.00825, 0.00826, 0.00827, 0.00828, 0.00829, 0.00830, 0.00831, 0.00832, 0.00833, 0.00834, 0.00835, 0.00836, 0.00837, 0.00838, 0.00839, 0.00840, 0.00841, 0.00842, 0.00843, 0.00844, 0.00845, 0.00846, 0.00847, 0.00848, 0.00849, 0.00850, 0.00851, 0.00852, 0.00853, 0.00854, 0.00855, 0.00856, 0.00857, 0.00858, 0.00859, 0.00860, 0.00861, 0.00862, 0.00863, 0.00864, 0.00865, 0.00866, 0.00867, 0.00868, 0.00869, 0.00870, 0.00871, 0.00872, 0.00873, 0.00874, 0.00875, 0.00876, 0.00877, 0.00878, 0.00879, 0.00880, 0.00881, 0.00882, 0.00883, 0.00884, 0.00885, 0.00886, 0.00887, 0.00888, 0.00889, 0.00890, 0.00891, 0.00892, 0.00893, 0.00894, 0.00895, 0.00896, 0.00897, 0.00898, 0.00899, 0.00900, 0.00901, 0.00902, 0.00903, 0.00904, 0.00905, 0.00906, 0.00907, 0.00908, 0.00909, 0.00910, 0.00911, 0.00912, 0.00913, 0.00914, 0.00915, 0.00916, 0.00917, 0.00918, 0.00919, 0.00920, 0.00921, 0.00922, 0.00923, 0.00924, 0.00925, 0.00926, 0.00927, 0.00928, 0.00929, 0.00930, 0.00931, 0.00932, 0.00933, 0.00934, 0.00935, 0.00936, 0.00937, 0.00938,
0.00939, 0.00940, 0.00941, 0.00942, 0.00943, 0.00944, 0.00945, 0.00946, 0.00947, 0.00948,
0.00949, 0.00950, 0.00951, 0.00952, 0.00953, 0.00954, 0.00955, 0.00956, 0.00957, 0.00958,
0.00959, 0.00960, 0.00961, 0.00962, 0.00963, 0.00964, 0.00965, 0.00966, 0.00967, 0.00968,
0.00969, 0.00970, 0.00971, 0.00972, 0.00973, 0.00974, 0.00975, 0.00976, 0.00977, 0.00978,
0.00979, 0.00980, 0.00981, 0.00982, 0.00983, 0.00984, 0.00985, 0.00986, 0.00987, 0.00988,
0.00989, 0.00990, 0.00991, 0.00992, 0.00993, 0.00994, 0.00995, 0.00996, 0.00997, 0.00998,
0.00999, 0.0100, 0.0101, 0.0103, 0.0104, 0.0105, 0.0106, 0.0107, 0.0108, 0.0109, 0.0110, 0.0111, 0.0112, 0.0113, 0.0114, 0.0115, 0.0116, 0.0117, 0.0118, 0.0119, 0.0120, 0.0121,
0.0122, 0.0123, 0.0124, 0.0125, 0.0126, 0.0127, 0.0128, 0.0129, or 0.0130. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to monocytes is from about 0.0063 to about 0.0083, such as a ratio of CD34+ CD90+ CD45RA cells to monocytes of about
0.00630, 0.00631, 0.00632, 0.00633, 0.00634, 0.00635, 0.00636, 0.00637, 0.00638, 0.00639, 0.00640, 0.00641, 0.00642, 0.00643, 0.00644, 0.00645, 0.00646, 0.00647, 0.00648, 0.00649, 0.00650, 0.00651, 0.00652, 0.00653, 0.00654, 0.00655, 0.00656, 0.00657, 0.00658, 0.00659, 0.00660, 0.00661, 0.00662, 0.00663, 0.00664, 0.00665, 0.00666, 0.00667, 0.00668, 0.00669, 0.00670, 0.00671, 0.00672, 0.00673, 0.00674, 0.00675, 0.00676, 0.00678, 0.00679, 0.00680, 0.00681, 0.00682, 0.00683, 0.00684, 0.00685, 0.00686, 0.00687, 0.00688, 0.00689, 0.00690, 0.00691, 0.00692, 0.00693, 0.00694, 0.00695, 0.00696, 0.00697, 0.00698, 0.00699, 0.00700, 0.00701, 0.00702, 0.00703, 0.00704, 0.00705, 0.00706, 0.00707, 0.00708, 0.00709, 0.00710, 0.00711, 0.00712, 0.00713, 0.00714, 0.00715, 0.00716, 0.00717, 0.00718, 0.00719, 0.00720, 0.00721, 0.00722, 0.00723, 0.00724, 0.00725, 0.00726, 0.00727, 0.00728, 0.00729, 0.00730, 0.00731, 0.00732, 0.00733, 0.00734, 0.00735, 0.00736, 0.00737, 0.00738, 0.00739, 0.00740, 0.00741, 0.00742, 0.00743, 0.00744, 0.00745, 0.00746, 0.00747, 0.00748, 0.00749, 0.00750, 0.00751, 0.00752, 0.00753, 0.00754, 0.00755, 0.00756, 0.00757, 0.00758, 0.00759, 0.00760, 0.00761, 0.00762, 0.00763, 0.00764, 0.00765, 0.00766, 0.00767, 0.00768, 0.00769, 0.00770, 0.00771, 0.00772, 0.00773, 0.00774, 0.00775, 0.00776, 0.00777, 0.00778, 0.00779, 0.00780, 0.00781, 0.00782, 0.00783, 0.00784, 0.00785, 0.00786, 0.00787, 0.00788, 0.00789, 0.00790, 0.00791, 0.00792, 0.00793, 0.00794, 0.00795, 0.00796, 0.00797, 0.00798, 0.00799, 0.00800, 0.00801, 0.00802, 0.00803, 0.00804, 0.00805, 0.00806, 0.00807, 0.00808, 0.00809, 0.00810, 0.00811, 0.00812, 0.00813, 0.00814, 0.00815, 0.00816, 0.00817, 0.00818, 0.00819, 0.00820, 0.00821, 0.00822, 0.00823, 0.00824, 0.00825, 0.00826, 0.00827, 0.00828, 0.00829, or 0.00830. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to monocytes is about 0.0073.
[0066] In a further aspect, the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor e.g ., a human donor), wherein the ratio of CD34+ CD90+ CD45RA cells to CD34+ cells in the population is from about 0.393 to about 0.745. In some embodiments, the ratio of CD34+
CD90+ CD45RA cells to CD34+ cells may be about 0.393, 0.394, 0.395, 0.396, 0.397, 0.398,
0.399, 0.401, 0.402, 0.403, 0.404, 0.405, 0.406, 0.407, 0.408, 0.409, 0.410, 0.411, 0.412, 0.413, 0.414, 0.415, 0.416, 0.417, 0.418, 0.419, 0.420, 0.421, 0.422, 0.423, 0.424, 0.425, 0.426, 0.427, 0.428, 0.429, 0.430, 0.431, 0.432, 0.433, 0.434, 0.435, 0.436, 0.437, 0.438, 0.439, 0.440, 0.441, 0.442, 0.443, 0.444, 0.445, 0.446, 0.447, 0.448, 0.449, 0.450, 0.451, 0.452, 0.453, 0.454, 0.455, 0.456, 0.457, 0.458, 0.459, 0.460, 0.461, 0.462, 0.463, 0.464, 0.465, 0.466, 0.467, 0.468, 0.469, 0.470, 0.471, 0.472, 0.473, 0.474, 0.475, 0.476, 0.478, 0.479, 0.480, 0.481, 0.482, 0.483, 0.484, 0.485, 0.486, 0.487, 0.488, 0.489, 0.490, 0.491, 0.492, 0.493, 0.494, 0.495, 0.496, 0.497, 0.498, 0.499, 0.500, 0.501, 0.502, 0.503, 0.504, 0.505, 0.506, 0.507, 0.508, 0.509, 0.510, 0.511, 0.512, 0.513, 0.514, 0.515, 0.516, 0.517, 0.518, 0.519, 0.520, 0.521, 0.522, 0.523, 0.524, 0.525, 0.526, 0.527, 0.528, 0.529, 0.530, 0.531, 0.532, 0.533, 0.534, 0.535, 0.536, 0.537, 0.538, 0.539, 0.540, 0.541, 0.542, 0.543, 0.544, 0.545, 0.546, 0.547, 0.548, 0.549, 0.550, 0.551, 0.552, 0.553, 0.554, 0.555, 0.556, 0.557, 0.558, 0.559, 0.560, 0.561, 0.562, 0.563, 0.564, 0.565, 0.566, 0.567, 0.568, 0.569, 0.570, 0.571, 0.572, 0.573, 0.574, 0.575, 0.576, 0.578, 0.579, 0.580, 0.581, 0.582, 0.583, 0.584, 0.585, 0.586, 0.587, 0.588, 0.589, 0.590, 0.591, 0.592, 0.593, 0.594, 0.595, 0.596, 0.597, 0.598, 0.599, 0.600, 0.601, 0.602, 0.603, 0.604, 0.605, 0.606, 0.607, 0.608, 0.609, 0.610, 0.611, 0.612, 0.613, 0.614, 0.615, 0.616, 0.617, 0.618, 0.619, 0.620, 0.621, 0.622, 0.623, 0.624, 0.625, 0.626, 0.627, 0.628, 0.629, 0.630, 0.631, 0.632, 0.633, 0.634, 0.635, 0.636, 0.637, 0.638, 0.639, 0.640, 0.641, 0.642, 0.643, 0.644, 0.645, 0.646, 0.647, 0.648, 0.649, 0.650, 0.651, 0.652, 0.653, 0.654, 0.655, 0.656, 0.657, 0.658, 0.659, 0.660, 0.661, 0.662, 0.663, 0.664, 0.665, 0.666, 0.667, 0.668, 0.669, 0.670, 0.671, 0.672, 0.673, 0.674, 0.675, 0.676, 0.678, 0.679, 0.680, 0.681, 0.682, 0.683, 0.684, 0.685, 0.686, 0.687, 0.688, 0.689, 0.690, 0.691, 0.692, 0.693, 0.694, 0.695, 0.696, 0.697, 0.698, 0.699, 0.700, 0.701, 0.702, 0.703, 0.704, 0.705, 0.706, 0.707, 0.708, 0.709, 0.710, 0.711, 0.712, 0.713, 0.714, 0.715, 0.716, 0.717, 0.718, 0.719, 0.720, 0.721, 0.722, 0.723, 0.724, 0.725, 0.726, 0.727, 0.728, 0.729, 0.730, 0.731, 0.732, 0.733, 0.734, 0.735, 0.736, 0.737, 0.738, 0.739, 0.740, 0.741, 0.742, 0.743, 0.744, or 0.745. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to CD34+ cells is from about 0.625 to about 0.725, such as a ratio of CD34+ CD90+ CD45RA cells to CD34+ cells of about 0.625, 0.626, 0.627, 0.628, 0.629, 0.630, 0.631, 0.632, 0.633, 0.634, 0.635, 0.636, 0.637, 0.638, 0.639, 0.640, 0.641, 0.642, 0.643,
0.644, 0.645, 0.646, 0.647, 0.648, 0.649, 0.650, 0.651, 0.652, 0.653, 0.654, 0.655, 0.656,
0.657, 0.658, 0.659, 0.660, 0.661, 0.662, 0.663, 0.664, 0.665, 0.666, 0.667, 0.668, 0.669,
0.670, 0.671, 0.672, 0.673, 0.674, 0.675, 0.676, 0.678, 0.679, 0.680, 0.681, 0.682, 0.683,
0.684, 0.685, 0.686, 0.687, 0.688, 0.689, 0.690, 0.691, 0.692, 0.693, 0.694, 0.695, 0.696,
0.697, 0.698, 0.699, 0.700, 0.701, 0.702, 0.703, 0.704, 0.705, 0.706, 0.707, 0.708, 0.709,
0.710, 0.711, 0.712, 0.713, 0.714, 0.715, 0.716, 0.717, 0.718, 0.719, 0.720, 0.721, 0.722,
0.723, 0.724, or 0.725. In some embodiments, the ratio of CD34+ CD90+ CD45RA cells to CD34+ cells is about 0.676.
[0067] In a further aspect, the invention features a pharmaceutical composition including a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor e.g ., a human donor), wherein the frequency of CD34+ CD90+ CD45RA cells in the population is from about 0.020% to about 0.110%. In some embodiments, the population of cells may have a frequency of CD34+ CD90+ CD45RA cells of about 0.020%, 0.021%, 0.022%, 0.023%, 0.024%, 0.025%, 0.026%, 0.027%, 0.028%, 0.029%, 0.030%, 0.031%, 0.032%, 0.033%, 0.034%, 0.035%, 0.036%, 0.037%, 0.038%, 0.039%, 0.040%, 0.041%, 0.042%, 0.043%, 0.044%, 0.045%, 0.046%, 0.047%, 0.048%, 0.049%, 0.050%, 0.051%, 0.052%, 0.053%, 0.054%, 0.055%, 0.056%, 0.057%, 0.058%, 0.059%, 0.060%, 0.061%, 0.062%, 0.063%, 0.064%, 0.065%, 0.066%, 0.067%, 0.068%, 0.069%, 0.070%, 0.071%, 0.072%, 0.073%, 0.074%, 0.075%, 0.076%, 0.077%, 0.078%, 0.079%, 0.080%, 0.081%, 0.082%, 0.083%, 0.084%, 0.085%, 0.086%, 0.087%, 0.088%, 0.089%, 0.090%, 0.091%, 0.092%, 0.093%, 0.094%, 0.095%, 0.096%, 0.097%, 0.098%, 0.099%, 0.100%, 0.101%, 0.102%, 0.103%, 0.104%, 0.105%, 0.106%, 0.107%, 0.108%, 0.109%, or 0.110%. In some embodiments, the population of cells has a frequency of CD34+ CD90+ CD45RA - cells of from about 0.046% to about 0.086%, such as a frequency of hematopoietic stem cells of about 0.046%, 0.047%, 0.048%, 0.049%, 0.050%, 0.051%, 0.052%, 0.053%, 0.054%, 0.055%, 0.056%, 0.057%, 0.058%, 0.059%, 0.060%, 0.061%, 0.062%, 0.063%, 0.064%, 0.065%, 0.066%, 0.067%, 0.068%, 0.069%, 0.070%, 0.071%, 0.072%, 0.073%, 0.074%, 0.075%, 0.076%, 0.077%, 0.078%, 0.079%, 0.080%, 0.081%, 0.082%, 0.083%, 0.084%, 0.085%, or 0.086%. In some embodiments, the population of cells has a frequency of CD34+ CD90+ CD45RA cells of about 0.066%.
[0068] In another aspect, the invention features a method of treating a stem cell disorder in a mammalian patient ( e.g ., a human patient), the method including mobilizing a population of hematopoietic stem cells in a mammalian donor (e.g., a human donor) in accordance with any of the above-described methods, and infusing a therapeutically effective amount of the hematopoietic stem cells, or progeny thereof, into the patient.
[0069] In a further aspect, the invention features a method of treating a stem cell disorder in a mammalian patient (e.g, a human patient), the method including infusing into the patient a therapeutically effective amount of the hematopoietic stem cells mobilized by any of the above-described methods, or progeny thereof.
[0070] In another aspect, the invention features a method of treating a stem cell disorder in a mammalian patient (e.g, a human patient), the method including administering to the patient any one or more of the above-described pharmaceutical compositions.
[0071] In some embodiments of any of the three preceding aspects, the stem cell disorder is a hemoglobinopathy disorder, such as sickle cell anemia, thalassemia, Fanconi anemia, aplastic anemia, and Wiskott-Aldrich syndrome. In some embodiments, the stem cell disorder is a myelodysplastic disorder. The stem cell disorder may be an immunodeficiency disorder, such as a congenital immunodeficiency or an acquired immunodeficiency, for example, human immunodeficiency virus or acquired immune deficiency syndrome. In some embodiments, the stem cell disorder is a metabolic disorder, such as a metabolic disorder selected from glycogen storage diseases, mucopolysaccharidoses, Gaucher's Disease, Hurlers Disease, sphingolipidoses, and metachromatic leukodystrophy.
[0072] In some embodiments, the stem cell disorder is cancer. The cancer may be, for example, leukemia, lymphoma, multiple myeloma, and neuroblastoma. In some
embodiments, the cancer is a hematological cancer. In some embodiments, the cancer is acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia, multiple myeloma, diffuse large B-cell lymphoma, or non-Hodgkin’s lymphoma.
[0073] In some embodiments, the stem cell disorder is a disorder selected from the group consisting of adenosine deaminase deficiency and severe combined immunodeficiency, hyper immunoglobulin M syndrome, Chediak-Higashi disease, hereditary lymphohistiocytosis, osteopetrosis, osteogenesis imperfecta, storage diseases, thalassemia major, systemic sclerosis, systemic lupus erythematosus, multiple sclerosis, and juvenile rheumatoid arthritis.
[0074] In some embodiments, the stem cell disorder is an autoimmune disorder, such as an autoimmune disorder selected from multiple sclerosis, human systemic lupus, rheumatoid arthritis, inflammatory bowel disease, treating psoriasis, Type 1 diabetes mellitus, acute disseminated encephalomyelitis, Addison's disease, alopecia universalis, ankylosing spondylitis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune
lymphoproliferative syndrome, autoimmune oophoritis, Balo disease, Behcet's disease, bullous pemphigoid, cardiomyopathy, Chagas' disease, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Crohn's disease, cicatricial pemphigoid, coeliac sprue-dermatitis herpetiformis, cold agglutinin disease, CREST syndrome, Degos disease, discoid lupus, dysautonomia, endometriosis, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, Goodpasture' s syndrome, Grave's disease, Guillain-Barre syndrome, Hashimoto' s thyroiditis, Hidradenitis suppurativa, idiopathic and/or acute thrombocytopenic purpura, idiopathic pulmonary fibrosis, IgA neuropathy, interstitial cystitis, juvenile arthritis, Kawasaki's disease, lichen planus, Lyme disease, Meniere disease, mixed connective tissue disease, myasthenia gravis, neuromyotonia, opsoclonus myoclonus syndrome, optic neuritis, Ord's thyroiditis, pemphigus vulgaris, pernicious anemia, polychondritis, polymyositis and dermatomyositis, primary biliary cirrhosis, polyarteritis nodosa, polyglandular syndromes, polymyalgia rheumatica, primary agammaglobulinemia, Raynaud phenomenon, Reiter' s syndrome, rheumatic fever, sarcoidosis, scleroderma, Sjogren's syndrome, stiff person syndrome, Takayasu's arteritis, temporal arteritis, ulcerative colitis, uveitis, vasculitis, vitiligo, vulvodynia, and Wegener's granulomatosis.
[0075] In some embodiments, the hematopoietic stem cells are autologous with respect to the patient. In some embodiments, the hematopoietic stem cells are allogeneic with respect to the patient, and may be, for example, HLA-matched with respect to the patient.
[0076] In some embodiments, the hematopoietic stem cells have been genetically modified to disrupt an endogenous gene, such as a gene encoding a major histocompatibility complex protein. The hematopoietic stem cells may be genetically modified to disrupt an endogenous by way of, for example, a CRISPR-associated protein, such as caspase 9, or another nuclease described herein, such as a transcription activator-like effector nuclease, a meganuclease, or a zinc finger nuclease.
[0077] In some embodiments, the hematopoietic stem cells, or progeny thereof, maintain hematopoietic stem cell functional potential after two or more days following infusion of the hematopoietic stem cells, or progeny thereof, into the patient. In some embodiments, the hematopoietic stem cells, or progeny thereof, localize to hematopoietic tissue and/or reestablish hematopoiesis following infusion of the hematopoietic stem cells, or progeny thereof, into the patient. In some embodiments, upon infusion into the patient, the hematopoietic stem cells, or progeny thereof, give rise to recovery of a population of cells selected from the group consisting of megakaryocytes, thrombocytes, platelets, erythrocytes, mast cells, myeoblasts, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, osteoclasts, antigen-presenting cells.
[0078] In another aspect, the disclosure relates to a method of mobilizing CD34dim cells from the bone marrow of a human donor into peripheral blood, the method comprising
administering to the donor (i) a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof at a dose of from about 50 pg/kg to about 1,000 pg/kg and (ii) a CXCR4 antagonist.
[0079] In another aspect, the disclosure relates to a method of performing an allogeneic hematopoietic stem cell transplant in a patient in need thereof, the method comprising infusing into the patient a therapeutically effective amount of allogeneic hematopoietic stem cells, wherein the hematopoietic stem cells were mobilized from bone marrow of a human donor into peripheral blood of the human donor by a method comprising administering to the donor (i) a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof at a dose of from about 50 pg/kg to about 1,000 pg/kg and (ii) a CXCR4 antagonist.
[0080] In another aspect, the disclosure relates to a method of preventing, reducing the risk of developing, or reducing the severity of a post-transplant infection in a patient in need thereof, the method comprising infusing into the patient a therapeutically effective amount of hematopoietic stem cells, wherein the hematopoietic stem cells were mobilized from bone marrow of a human donor into peripheral blood of the human donor by a method comprising administering to the human donor (i) a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof at a dose of from about 50 m /1< to about 1,000 mm/1< and (ii) a CXCR4 antagonist.
[0081] In another aspect, the disclosure relates to a method of preventing, reducing the risk of developing, or reducing the severity of graft versus host disease (GVHD) in a patient in need thereof, the method comprising infusing into the patient a therapeutically effective amount of hematopoietic stem cells, wherein the hematopoietic stem cells were mobilized from bone marrow of a human donor into peripheral blood of the human donor by a method comprising administering to the human donor (i) a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof at a dose of from about 50 pg/kg to about 1,000 pg/kg and (ii) a CXCR4 antagonist.
[0082] In certain embodiments, the CD34dim cells are present in a higher amount in the peripheral blood than if the hematopoietic stem cells were mobilized using the CXCR4 antagonist alone. In certain embodiments, the CD34dim cells are capable of suppressing alloreactive T lymphocyte proliferation when administered to a recipient.
[0083] In certain embodiments, the CXCR2 agonist is Gro-b T. In certain embodiments, the CXCR2 agonist is administered to the donor at a dose of from about 100 pg/kg to about 250 pg/kg. In certain embodiments, the CXCR2 agonist is administered to the donor at a dose of from about 125 pg/kg to about 225 pg/kg. In certain embodiments, the CXCR2 agonist is administered to the donor at a dose of about 150 pg/kg. In certain embodiments, the CXCR2 agonist is administered intravenously to the donor.
[0084] In certain embodiments, the CXCR4 antagonist is administered subcutaneously to the donor. In certain embodiments, the CXCR4 antagonist is plerixafor or a pharmaceutically acceptable salt thereof. In certain embodiments, the plerixafor or pharmaceutically acceptable salt thereof is administered to the donor at a dose of from about 50 pg/kg to about 500 pg/kg. In certain embodiments, the plerixafor or pharmaceutically acceptable salt thereof is administered to the donor at a dose of from about 200 pg/kg to about 300 pg/kg. In certain embodiments, the plerixafor or pharmaceutically acceptable salt thereof is
administered to the donor at a dose of about 240 pg/kg.
[0085] In certain embodiments, the method further includes testing a sample of peripheral blood for the presence of CD34dim cells and releasing the sample for ex vivo expansion of the CD34dim cells. [0086] In certain embodiments, the disclosure relates to the population of CD34dim cells derived from any of the above methods, or a composition comprising the same.
Brief Description of the Figures
[0087] FIG. 1A provides a graph showing that, when Gro-b T is co-administered with plerixafor (AMD3100) in mice, a synergistic increase in mobilization results, and grafts are enriched in highly engraftable, long-term hematopoietic stem cells (LT-HSC = Lin- c-kit+ Sca-l+ CDl50+ CD48+). FIG. IB provides a graph showing that grafts containing cells mobilized by Gro-b T and plerixaflor led to higher relative numbers of competitive repopulating units (CRU) at week 16 than did grafts containing cells mobilized by G-CSF alone.
[0088] FIG. 2A is a graph demonstrating the pharmacokinetic profile of various dosages of Gro-b T when administered intravenously to Rhesus monkeys. FIG. 2B is a graph demonstrating the pharmacokinetic profile of various dosages of Gro-b T when administered subcutaneously to Rhesus monkeys. In all experiments, Gro-b T was administered to subjects concurrently with plerixafor.
[0089] FIG. 3A shows a series of graphs demonstrating the mobilization response of leukocytes (white blood cells,“WBCs”) to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys. Leukocyte response is shown both in terms of the quantity of cells mobilized (top) and the fold change in leukocyte density relative to baseline leukocyte density prior to administration (bottom). FIG. 3B shows a series of graphs demonstrating the mobilization response of leukocytes (white blood cells,“WBCs”) to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys.
Leukocyte response is shown both in terms of the quantity of cells mobilized (top) and the fold change in leukocyte density relative to baseline leukocyte density prior to administration (bottom). In all experiments, Gro-b T was administered to subjects concurrently with plerixafor.
[0090] FIG. 4A shows a series of graphs demonstrating the mobilization response of neutrophils to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys. Neutrophil response is shown both in terms of the quantity of cells mobilized (top) and the fold change in neutrophil density relative to baseline neutrophil density prior to administration (bottom). FIG. 4B shows a series of graphs demonstrating the mobilization response of neutrophils to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys. Neutrophil response is shown both in terms of the quantity of cells mobilized (top) and the fold change in neutrophil density relative to baseline neutrophil density prior to administration (bottom). In all experiments, Gro-b T was administered to subjects concurrently with plerixafor.
[0091] FIG. 5A shows a series of graphs demonstrating the mobilization response of lymphocytes to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys. Lymphocyte response is shown both in terms of the quantity of cells mobilized (top) and the fold change in lymphocyte density relative to baseline lymphocyte density prior to administration (bottom). FIG. 5B shows a series of graphs demonstrating the mobilization response of lymphocytes to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys. Lymphocyte response is shown both in terms of the quantity of cells mobilized (top) and the fold change in lymphocyte density relative to baseline lymphocyte density prior to administration (bottom). In all experiments, Gro-b T was administered to subjects concurrently with plerixafor.
[0092] FIG. 6A shows a series of graphs demonstrating the mobilization response of monocytes to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys. Monocyte response is shown both in terms of the quantity of cells mobilized (top) and the fold change in monocyte density relative to baseline monocyte density prior to administration (bottom). FIG. 6B shows a series of graphs demonstrating the mobilization response of monocytes to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys. Monocyte response is shown both in terms of the quantity of cells mobilized (top) and the fold change in monocyte density relative to baseline monocyte density prior to administration (bottom). In all experiments, Gro-b T was administered to subjects concurrently with plerixafor.
[0093] FIG. 7A shows a series of graphs demonstrating the mobilization response of CD34+ cells to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys. CD34+ cell response is shown both in terms of the frequency of CD34+ cells in the sample obtained from peripheral blood of the subjects (top) and the fold change in CD34+ cell frequency relative to baseline CD34+ cell frequency prior to administration (bottom). FIG. 7B shows a series of graphs demonstrating the mobilization response of CD34+ cells to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys. CD34+ cell response is shown both in terms of the frequency of CD34+ cells in the sample obtained from peripheral blood of the subjects (top) and the fold change in CD34+ cell frequency relative to baseline CD34+ cell frequency prior to administration (bottom). In all
experiments, Gro-b T was administered to subjects concurrently with plerixafor.
[0094] FIG. 8A shows a series of graphs demonstrating the mobilization response of CD34+ cells to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys. CD34+ cell response is shown both in terms of the quantity of cells mobilized (top) and the fold change in CD34+ cell density relative to baseline CD34+ cell density prior to
administration (bottom). FIG. 8B shows a series of graphs demonstrating the mobilization response of CD34+ cells to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys. CD34+ cell response is shown both in terms of the quantity of cells mobilized (top) and the fold change in CD34+ cell density relative to baseline CD34+ cell density prior to administration (bottom). In all experiments, Gro-b T was administered to subjects concurrently with plerixafor.
[0095] FIG. 9A shows a series of graphs demonstrating the mobilization response of hematopoietic stem cells (CD34+ CD90+ CD45RA cells) to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys. CD34+ CD90+ CD45RA cell response is shown both in terms of the frequency of CD34+ CD90+ CD45RA cells in the sample obtained from peripheral blood of the subjects (top) and the fold change in CD34+ CD90+ CD45RA cell frequency relative to baseline CD34+ CD90+ CD45RA cell frequency prior to administration (bottom). FIG. 9B shows a series of graphs demonstrating the mobilization response of hematopoietic stem cells (CD34+ CD90+ CD45RA cells) to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys. CD34+ CD90+ CD45RA cell response is shown both in terms of the frequency of CD34+ CD90+ CD45RA cells in the sample obtained from peripheral blood of the subjects (top) and the fold change in CD34+ CD90+ CD45RA cell frequency relative to baseline CD34+ CD90+ CD45RA cell frequency prior to administration (bottom). In all experiments, Gro-b T was administered to subjects concurrently with plerixafor.
[0096] FIG. 10A shows a series of graphs demonstrating the mobilization response of hematopoietic stem cells (CD34+ CD90+ CD45RA cells) to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys. CD34+ CD90+ CD45RA cell response is shown both in terms of the quantity of cells mobilized (top) and the fold change in CD34+ CD90+ CD45RA cell density relative to baseline CD34+ CD90+ CD45RA cell density prior to administration (bottom). FIG. 10B shows a series of graphs demonstrating the mobilization response of hematopoietic stem cells (CD34+ CD90+ CD45RA cells) to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys. CD34+ cell response is shown both in terms of the quantity of cells mobilized (top) and the fold change in CD34+ CD90+ CD45RA cell density relative to baseline CD34+ CD90+ CD45RA cell density prior to administration (bottom). In all experiments, Gro-b T was administered to subjects concurrently with plerixafor.
[0097] FIG. 11 shows a series of graphs demonstrating the increase in the quantity of colony-forming units (CFU) of hematopoietic stem cells achieved by the intravenous administration of various dosages of Gro-b T to Rhesus monkeys. CFR response is shown both in terms of the concentration of CFUs (top) and the fold change in CFU concentration relative to baseline CFU concentration prior to administration (bottom). In all experiments, Gro-b T was administered to subjects concurrently with plerixafor.
[0098] FIG. 12A shows a series of graphs demonstrating the response of plasma matrix metalloproteinase 9 (MMP9) to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys. Plasma MMP9 response is shown both in terms of absolute
concentration (top) and the fold change in plasma MMP9 concentration relative to baseline MMP9 concentration prior to administration (bottom). FIG. 12B shows a series of graphs demonstrating the response of plasma MMP9 to various dosages of Gro-b T upon
subcutaneous administration to Rhesus monkeys. Plasma MMP9 response is shown both in terms of absolute concentration (top) and the fold change in plasma MMP9 concentration relative to baseline MMP9 concentration prior to administration (bottom). In all experiments, Gro-b T was administered to subjects concurrently with plerixafor.
[0099] FIG. 13A shows a series of graphs demonstrating the response of plasma tissue inhibitor of matrix metalloproteinase 1 (TIMP-l) to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys. Plasma TIMP-l response is shown both in terms of absolute concentration (top) and the fold change in plasma TIMP-l concentration relative to baseline TIMP-l concentration prior to administration (bottom). FIG. 13B shows a series of graphs demonstrating the response of plasma TIMP-l to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys. Plasma TIMP-l response is shown both in terms of absolute concentration (top) and the fold change in plasma TIMP-l concentration relative to baseline TIMP-l concentration prior to administration (bottom). In all experiments, Gro-b T was administered to subjects concurrently with plerixafor.
[0100] FIG. 14A is a graph showing the response of the molar ratio of plasma MMP9 to plasma TIMP-l to various dosages of Gro-b T upon intravenous administration to Rhesus monkeys. FIG. 14B is a graph showing the response of the molar ratio of plasma MMP9 to plasma TIMP-l to various dosages of Gro-b T upon subcutaneous administration to Rhesus monkeys. In all experiments, Gro-b T was administered to subjects concurrently with plerixafor.
[0101] FIG. 15 provides representative flow plots from blood samples taken four hours post mobilization from Rhesus monkeys. Intravenous administration of 450 pg/kg Gro-b T and subcutaneous administration of 1 mg/kg plerixafor (AMD3100) leads to the mobilization of a population of CD34dim cells.
[0102] FIG. 16 provides representative flow plots from blood samples taken at baseline versus four hours post-mobilization from Rhesus monkeys. Mobilization was induced by (1) intravenous administration of 450 pg/kg Gro-b T and subcutaneous administration of 1 mg/kg plerixafor (AMD3100) or (2) subcutaneous administration of 1 mg/kg plerixafor (AMD3100). The combination of Gro-b T and plerixafor (as compared to plerixafor alone) leads to enhanced mobilization of Oϋ34ώ111 cells.
[0103] FIG. 17 is a graph quantifying the concentration of CD34dim cells in peripheral blood from untreated Rhesus monkeys (“Unmobilized”), Rhesus monkeys that have been treated with intravenous administration of 450 pg/kg Gro-b T and subcutaneous administration of 1 mg/kg plerixafor (“Gro-b T + plerixafor”), Rhesus monkeys that have been treated with subcutaneous administration of 1 mg/kg plerixafor (“plerixafor”) and Rhesus monkeys that have been treated with subcutaneous administration of 50 pg/kg (q.d. x 5) G-CSF (“G-CSF”). CD34dim cells were present at a significantly higher concentration in blood mobilized using Gro-b T plus plerixafor.
[0104] FIG. 18 is a graph depicting the composition of unmobilized cells and grafts mobilized by G-CSF, Gro-b T and AMD3100 and AMD3100 alone. As shown, grafts mobilized using Gro-b T and AMD3100 show a 3 fold increase in CD34dim cells and a 3 fold increase in T-cells as compared to grafts mobilized using G-CSF.
[0105] FIG. 19 provides graphs showing that Gro-b T and AMD3100 mobilized CD34dim cells suppressed T-cell proliferation as measured by carboxyfluorescein succinimidyl ester (CFSE) staining after four days in culture.“Beads” indicates stimulation of T-cells using anti-CD2/CD3/CD28 coated microbeads.
[0106] FIG. 20 provides a survival curve showing that by day 24, all mice (13/13) transplanted with unmobilized PBMCs had died of aGVHD compared to 5/16 mice transplanted with AMD3100 mobilized peripheral blood, 3/16 mice transplanted with G-CSF mobilized PBMCs and none of the mice transplanted with Gro-b T and AMD3100 mobilized PBMCs. At day 60 post-transplant, 15/16 mice transplanted with Gro-b T and AMD3100 remained alive, whereas only 10/16 mice transplanted with AMD3100 mobilized PBMCs and 11/16 mice transplanted with G-CSF mobilized PBMCs remained alive. p<0.000l
(comparing Gro- b T and AMD3100 v. unmobilized) and p<0.05 (comparing Gro- b T and AMD3100 v. AMD3100 alone).
[0107] FIG. 21A shows rhesus CD45+CD3+ T-cell numbers in mice at day 14 post- transplant with unmobilized PBMCs, PBMCs mobilized with Gro-b T and plerixafor (i.e., AMD3100), PBMCs mobilized with plerixafor alone, and PBMCs mobilized with G-CSF alone. FIG. 21B shows T-cell numbers in mice at day 14 post-transplant with unmobilized PBMCs, Gro-b T and plerixafor (i.e., AMD3100) mobilized PBMCs, and Gro-b T and plerixafor mobilized PBMCs that have been depleted of CD34dim cells. FIG. 21C provides a survival curve of mice transplanted with unmobilzied PBMCs, Gro-b T and AMD3100 mobilized PBMCs, and Gro-b T and AMD3100 mobilized PBMCs that have been depleted of CD34dim cells.
Detailed Description
[0108] The present invention provides compositions and methods for mobilizing
hematopoietic stem and progenitor cells in a subject. For example, the subject may be a hematopoietic stem and progenitor cell donor ( i.e ., a donor), such as a mammalian donor ( e.g ., a human donor). The compositions and methods described herein can additionally be used for the treatment of one or more stem cell disorders in a patient, such as a human patient. Using the compositions and methods described herein, a C-X-C chemokine receptor type 2 (CXCR2) agonist, such as Gro-b or a variant thereof, such as a truncated form of Gro- b (e.g., Gro-b T), as described herein, optionally in combination with a C-X-C chemokine receptor type 4 (CXCR4) antagonist, such as l,r-[l,4-phenylenebis(methylene)]-bis- 1,4,8, 1 l-tetra-azacyclotetradecane or a variant thereof, may be administered to a donor, as described herein, in amounts sufficient to mobilize hematopoietic stem and progenitor cells. The compositions and methods described herein are capable of mobilizing hematopoietic stem and progenitor cells from a stem cell niche within a donor into circulating peripheral blood while reducing the mobilization of other cells of the hematopoietic lineage, such as leukocytes, neutrophils, lymphocytes, and monocytes. The compositions and methods described herein thus enable the selective mobilization of hematopoietic stem and progenitor cells in a donor, which may then be isolated from a donor for therapeutic use.
[0109] The invention is based, in part, on the discovery that administration of a CXCR2 agonist, such as Gro-b, Gro-b T, or a variant thereof, optionally in combination with a CXCR4 antagonist, such as plerixafor or a pharmaceutically acceptable salt thereof, at particular doses can provide the important clinical benefit of mobilizing populations of cells that are enriched in hematopoietic stem cells relative to other cell types, such as leukocytes, neutrophils, and monocytes. This ability is advantageous, as these other cell types may be undesirable for administration to a human patient undergoing hematopoietic stem cell transplant therapy. Thus, the populations of mobilized hematopoietic stem and progenitor cells produced using the compositions and methods described herein are particularly suitable for hematopoietic stem cell transplantation therapy.
[0110] Following mobilization, the hematopoietic stem or progenitor cells may be isolated for ex vivo expansion and/or for therapeutic use. In some embodiments, upon collection of the mobilized hematopoietic stem and/or progenitor cells, the withdrawn cells may be infused into a patient, such as the donor or another subject ( e.g ., a subject that is HLA-matched to the donor) for the treatment of one or more pathologies of the hematopoietic system.
Additionally or alternatively, the mobilized cells may be withdrawn and then expanded ex vivo , such as by contacting the cells with an aryl hydrocarbon receptor antagonist, so as to produce a population of hematopoietic stem cells having a sufficient quantity of cells for transplantation.
[0111] As described herein, hematopoietic stem cells are capable of differentiating into a multitude of cell types in the hematopoietic lineage, and can thus be administered to a patient in order to populate or repopulate a cell type that is defective or deficient in the patient. The patient may be one, for example, that is suffering from one or more blood disorders, such as an autoimmune disease, cancer, hemoglobinopathy, or other hematopoietic pathology, and is therefore in need of hematopoietic stem cell transplantation. The invention thus provides methods of treating a variety of hematopoietic conditions, such as sickle cell anemia, thalassemia, Fanconi anemia, Wiskott-Aldrich syndrome, adenosine deaminase deficiency- severe combined immunodeficiency, metachromatic leukodystrophy, Diamond-Blackfan anemia and Schwachman-Diamond syndrome, human immunodeficiency virus infection, and acquired immune deficiency syndrome, as well as cancers and autoimmune diseases, among others.
[0112] The sections that follow provide a description of CXCR4 antagonists and CXCR2 agonists that can be administered to a donor so as to induce mobilization of a population of hematopoietic stem or progenitor cells from a stem cell niche into peripheral blood, from which the cells may subsequently be isolated and infused into a patient for the treatment, for example, of one or more stem cell disorders, such as a cancer, autoimmune disease, of metabolic disorder described herein. The following sections additionally describe methods of determining whether populations of cells mobilized with a CXCR2 agonist and/or a CXCR antagonist are suitable for release for ex vivo expansion and/or for therapeutic applications.
Definitions
[0113] As used herein, the term“about” refers to a value that is within 10% above or below the value being described. For example, the term“about 5 nM” indicates a range of from 4.5 nM to 5.5 nM.
[0114] As used herein, the terms "acquire" and "acquiring" means obtaining possession of a physical entity, or a value, such as a numerical value, directly acquiring or indirectly acquiring the physical entity or value. "Directly acquiring" means performing a process ( e.g ., performing an assay or test on a sample or analyzing a sample) to obtain the physical entity or value. "Indirectly acquiring" refers to receiving the physical entity or value from another party or source (e.g., a third party laboratory that directly acquired the physical entity or value). Directly acquiring a physical entity includes performing a process, e.g, analyzing a sample, such as a sample of hematopoietic cells isolated from a donor that has undergone or is undergoing a hematopoietic stem cell mobilization regimen described herein. Directly acquiring a value includes performing a process, such as an assay, on a sample or another substance, e.g, performing an analytical process which includes determining the quantity of hematopoietic stem cells in a sample, the ratio of hematopoietic stem cells to cells of another type within the hematopoietic lineage, or the frequency of hematopoietic stem cells among the total quantity of cells in a sample.
[0115] As used herein, the term“affinity” refers to the strength of the non-covalent interaction between two or more molecules, such as two or more proteins ( e.g ., a
metalloproteinase and an endogenous inhibitor thereof as described herein). Affinity can be expressed quantitatively, for example, as an equilibrium dissociation constant (Kd) or, in cases in which one of the binding partners is an enzyme, as an inhibition constant (¾).
Binding affinity can be determined using standard techniques, such as enzyme-linked immunosorbent assays (ELISA), surface plasmon resonance assays, and isothermal titration calorimetry assays, among others.
[0116] As used herein, the term“antibody” refers to an immunoglobulin molecule that specifically binds to, or is immunologically reactive with, a particular antigen, and includes polyclonal, monoclonal, genetically engineered, and otherwise modified forms of antibodies, including but not limited to chimeric antibodies, humanized antibodies, heteroconjugate antibodies (e.g., bi- tri- and quad-specific antibodies, diabodies, triabodies, and tetrabodies), and antigen binding fragments of antibodies, including, for example, Fab', F(ab')2, Fab, Fv, rlgG, and scFv fragments. Unless otherwise indicated, the term“monoclonal antibody” (mAh) is meant to include both intact molecules, as well as antibody fragments (including, for example, Fab and F(ab')2 fragments) that are capable of specifically binding to a target protein. As used herein, the Fab and F(ab')2 fragments refer to antibody fragments that lack the Fc fragment of an intact antibody. Examples of these antibody fragments are described herein.
[0117] The term“antigen-binding fragment,” as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to a target antigen. The antigen binding function of an antibody can be performed by fragments of a full-length antibody.
The antibody fragments can be, for example, a Fab, F(ab’)2, scFv, diabody, a triabody, an affibody, a nanobody, an aptamer, or a domain antibody. Examples of binding fragments encompassed of the term“antigen-binding fragment” of an antibody include, but are not limited to: (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL, and CH! domains; (ii) a F(ab')2 fragment, a bivalent fragment containing two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CHl domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb including VH and VL domains; (vi) a dAb fragment that consists of a VH domain (see, e.g ., Ward et al. (1989 ) Nature 341 :544-546); (vii) a dAb which consists of a VH or a VL domain; (viii) an isolated complementarity determining region (CDR); and (ix) a combination of two or more (e.g, two, three, four, five, or six) isolated CDRs which may optionally be joined by a synthetic linker. Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see, for example, Bird et al. (1988) Science 242:423-426 and Huston el al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). These antibody fragments can be obtained using conventional techniques known to those of skill in the art, and the fragments can be screened for utility in the same manner as intact antibodies. Antigen-binding fragments can be produced by recombinant DNA techniques, enzymatic or chemical cleavage of intact immunoglobulins, or, in certain cases, by chemical peptide synthesis procedures known in the art.
[0118] As used herein, the term“bispecific antibody” refers to, for example, a monoclonal, often a human or humanized antibody that is capable of binding at least two different antigens.
[0119] As used herein the term“CD34dim cells” refers to a population of cells, of which at least a portion of the population expresses the markers CD34, CD1 lb, and CD45 and does not substantially express the markers CD3, CD8, or CD20, wherein CD34 and CD45 are expressed at a relatively low level. This cell population exhibits characteristics of monocytes, for example, the ability to suppress alloreactive T lymphocyte proliferation. (D’Aveni et al. (2015) Science Translational Medicine 7(281): 1-12. In some embodiments, a population of CD34dim cells may be CD14+.
[0120] The person of skill can readily recognize a CD34dim cell population when viewing a flow cytometry plot as a population of cells that is CD34+ but has a brightness between the base level of fluorescence (e.g, autofluorescence) in the cell population being examined and the brightness of a CD34+ bright cell (e.g., a hematopoietic stem cell and/or a CD34+ CD90+ cell) population. For example, in certain embodiments, a CD34dim cell population exhibits between 5% and 95% of the brightness of a CD34+ bright cell (e.g., a hematopoietic stem cell) population, but is brighter than a CD34 cell population. [0121] In certain embodiments, CD34dim cells exhibit between 10% and 90%, 10% and 80%, 10% and 70%, 10% and 60%, 10% and 50%, 10% and 40%, 10% and 30%, 10% and 20%,
20% and 90%, 20% and 80%, 20% and 70%, 20% and 60%, 20% and 50%, 20% and 40%,
20% and 30%, 30% and 90%, 30% and 80%, 30% and 70%, 30% and 60%, 30% and 50%,
30% and 40%, 40% and 90%, 40% and 80%, 40% and 70%, 40% and 60%, 40% and 50%,
50% and 90%, 50% and 80%, 50% and 70%, 50% and 60%, 60% and 90%, 60% and 80%,
60% and 70%, 70% and 90%, 70% and 80%, or 80% and 90%, of the brightness of CD34+ bright cells ( e.g ., hematopoietic stem cells), but is brighter than CD34 cells. In certain embodiments, the CD34dim cells are at least 5% brighter, at least 10% brighter, at least 20% brighter or at least 30% brighter than CD34 cells, but is less bright than CD34+ bright cells (e.g., a hematopoietic stem cells).
[0122] In certain embodiments, CD34dim cells are identified in a cell sample by using flow cytometry with magnetic beads instead of fluorescence. The magnetic beads will selectively pull down CD34+ bright cells, leaving CD34dim cells in the cell sample.
[0123] In certain embodiments, CD34dim cells are identified by measuring the number of copies of CD34 expressed by the cells. For example, CD34dim cells can exhibit between 5% and 95% of the number of copies of CD34 as compared to CD34+ bright cells (e.g., hematopoietic stem cells), or between 10% and 90%, 10% and 80%, 10% and 70%, 10% and 60%, 10% and 50%, 10% and 40%, 10% and 30%, 10% and 20%, 20% and 90%, 20% and
80%, 20% and 70%, 20% and 60%, 20% and 50%, 20% and 40%, 20% and 30%, 30% and
90%, 30% and 80%, 30% and 70%, 30% and 60%, 30% and 50%, 30% and 40%, 40% and
90%, 40% and 80%, 40% and 70%, 40% and 60%, 40% and 50%, 50% and 90%, 50% and
80%, 50% and 70%, 50% and 60%, 60% and 90%, 60% and 80%, 60% and 70%, 70% and
90%, 70% and 80%, or 80% and 90% of the number of copies of CD34 as compared to CD34+ bright cells (e.g., hematopoietic stem cells).
[0124] As used herein, the term“complementarity determining region” (CDR) refers to a hypervariable region found both in the light chain and the heavy chain variable domains of an antibody. The more highly conserved portions of variable domains are referred to as framework regions (FRs). The amino acid positions that delineate a hypervariable region of an antibody can vary, depending on the context and the various definitions known in the art. Some positions within a variable domain may be viewed as hybrid hypervariable positions in that these positions can be deemed to be within a hypervariable region under one set of criteria while being deemed to be outside a hypervariable region under a different set of criteria. One or more of these positions can also be found in extended hypervariable regions. The antibodies described herein may contain modifications in these hybrid hypervariable positions. The variable domains of native heavy and light chains each contain four framework regions that primarily adopt a b-sheet configuration, connected by three CDRs, which form loops that connect, and in some cases form part of, the b-sheet structure. The CDRs in each chain are held together in close proximity by the framework regions in the order FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 and, with the CDRs from the other antibody chains, contribute to the formation of the target binding site of antibodies (see Rabat et al ., Sequences of Proteins of Immunological Interest, National Institute of Health, Bethesda,
MD., 1987). As used herein, numbering of immunoglobulin amino acid residues is performed according to the immunoglobulin amino acid residue numbering system of Rabat et al. , unless otherwise indicated.
[0125] As used herein in the context of the administration of one or more agents to a subject, the term“completion of administration” refers to the point in time by which the one or more agents have been administered to the subject in their entirety. In some embodiments, an agent as described herein, such as a CXCR4 antagonist ( e.g ., plerixafor or a variant thereof) and/or a CXCR2 agonist (e.g., Gro-b or a variant or truncation thereof, such as Gro-b T) can be administered to a subject over a period of time, for example, by intravenous or subcutaneous injection. An agent is considered to have“completed administration” once the prescribed dosage of the agent has been administered to the subject in its entirety. In the case of the administration of multiple agents to a subject, such as both a CXCR4 antagonist (e.g, plerixafor or a variant thereof) and a CXCR2 agonist (e.g, Gro-b or a variant or truncation thereof, such as Gro-b T), the agents are considered to have“completed administration” once the prescribed dosages of all agents in a particular regimen have been administered to the subject in their entirety.
[0126] As used herein, the terms“conservative mutation,”“conservative substitution,” or “conservative amino acid substitution” refer to a substitution of one or more amino acids for one or more different amino acids that exhibit similar physicochemical properties, such as polarity, electrostatic charge, and steric volume. These properties are summarized for each of the twenty naturally-occurring amino acids in TABLE 1 below.
TABLE 1. Representative physicochemical properties of naturally-occurring amino acids
Figure imgf000090_0001
¾ased on volume in A3: 50-100 is small, 100-150 is intermediate, 150-200 is large, and >200 is bulky
[0127] From this table it is appreciated that the conservative amino acid families include, e.g., (i) G, A, V, L, I, P, and M; (ii) D and E; (iii) C, S and T; (iv) H, K and R; (v) N and Q; and (vi) F, Y and W. A conservative mutation or substitution is therefore one that substitutes one amino acid for a member of the same amino acid family ( e.g ., a substitution of Ser for Thr or Lys for Arg).
[0128] As used herein,“CRU (competitive repopulating unit)” refers to a unit of measure of long-term engrafting stem cells, which can be detected after in-vivo transplantation.
[0129] As used herein, the term“donor” refers to a subject, such as a mammalian subject (e.g., a human subject) from which one or more cells are isolated prior to administration of the cells, or progeny thereof, into a recipient. The one or more cells may be, for example, a population of hematopoietic stem or progenitor cells.
[0130] As used herein, the term“diabody” refers to a bivalent antibody containing two polypeptide chains, in which each polypeptide chain includes VH and VL domains joined by a linker that is too short (e.g, a linker composed of five amino acids) to allow for
intramolecular association of VH and VL domains on the same peptide chain. This configuration forces each domain to pair with a complementary domain on another polypeptide chain so as to form a homodimeric structure. Accordingly, the term“triabody” refers to trivalent antibodies containing three peptide chains, each of which contains one VH domain and one VL domain joined by a linker that is exceedingly short (e.g, a linker composed of 1-2 amino acids) to permit intramolecular association of VH and VL domains within the same peptide chain. In order to fold into their native structures, peptides configured in this way typically trimerize so as to position the VH and VL domains of neighboring peptide chains spatially proximal to one another (see, for example, Holliger et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-48).
[0131] As used herein, the term“disrupt” with respect to a gene refers to preventing the formation of a functional gene product. A gene product is functional only if it fulfills its normal (wild-type) functions. Disruption of the gene prevents expression of a functional factor encoded by the gene and comprises an insertion, deletion, or substitution of one or more bases in a sequence encoded by the gene and/or a promoter and/or an operator that is necessary for expression of the gene in the animal. The disrupted gene may be disrupted by, e.g, removal of at least a portion of the gene from a genome of the animal, alteration of the gene to prevent expression of a functional factor encoded by the gene, an interfering RNA, or expression of a dominant negative factor by an exogenous gene. Materials and methods of genetically modifying hematopoietic stem/progenitor cells are detailed in US 8,518,701; US 2010/0251395; and US 2012/0222143, the disclosures of each of which are incorporated herein by reference in their entirety (in case of conflict, the instant specification is controlling).
[0132] Various techniques known in the art can be used to inactivate genes to make knock out animals and/or to introduce nucleic acid constructs into animals to produce founder animals and to make animal lines, in which the knockout or nucleic acid construct is integrated into the genome. Such techniques include, without limitation, pronuclear microinjection (U.S. Pat. No. 4,873,191), retrovirus mediated gene transfer into germ lines (Van der Putten et al. (1985) Proc. Natl. Acad. Sci. USA, 82:6148-6152), gene targeting into embryonic stem cells (Thompson et al. (1989) Cell, 56:313-321), electroporation of embryos (Lo (1983 )Mol. Cell. Biol., 3: 1803-1814), sperm-mediated gene transfer (Lavitrano et al. (2002) Proc. Natl. Acad. Sci. USA, 99: 14230-14235; Lavitrano et al. (2006) Reprod. Fert. Develop., 18: 19-23), and in vitro transformation of somatic cells, such as cumulus or mammary cells, or adult, fetal, or embryonic stem cells, followed by nuclear transplantation (Wilmut et al. (1997) Nature, 385:810-813; and Wakayama et al. (1998) Nature, 394:369- 374). Pronuclear microinjection, sperm mediated gene transfer, and somatic cell nuclear transfer are particularly useful techniques. An animal that is genomically modified is an animal wherein all of its cells have the genetic modification, including its germ line cells. When methods are used that produce an animal that is mosaic in its genetic modification, the animals may be inbred and progeny that are genomically modified may be selected. Cloning, for example, may be used to make a mosaic animal if its cells are modified at the blastocyst state, or genomic modification can take place when a single-cell is modified. Animals that are modified so they do not sexually mature can be homozygous or heterozygous for the modification, depending on the specific approach that is used. If a particular gene is inactivated by a knock out modification, homozygosity would normally be required. If a particular gene is inactivated by an RNA interference or dominant negative strategy, then heterozygosity is often adequate.
[0133] As used herein, a“dual variable domain immunoglobulin” (“DVD-Ig”) refers to an antibody that combines the target-binding variable domains of two monoclonal antibodies via linkers to create a tetravalent, dual-targeting single agent (see, for example, Gu et al. (2012) Meth. Enzymol., 502:25-41).
[0134] As used herein, the term“endogenous” describes a substance, such as a molecule, cell, tissue, or organ ( e.g ., a hematopoietic stem cell or a cell of hematopoietic lineage, such as a megakaryocyte, thrombocyte, platelet, erythrocyte, mast cell, myeoblast, basophil, neutrophil, eosinophil, microglial cell, granulocyte, monocyte, osteoclast, antigen-presenting cell, macrophage, dendritic cell, natural killer cell, T-lymphocyte, or B-lymphocyte) that is found naturally in a particular organism, such as a human patient.
[0135] As used herein, the term“engraftment potential” is used to refer to the ability of hematopoietic stem and progenitor cells to repopulate a tissue, whether such cells are naturally circulating or are provided by transplantation. The term encompasses all events surrounding or leading up to engraftment, such as tissue homing of cells and colonization of cells within the tissue of interest. The engraftment efficiency or rate of engraftment can be evaluated or quantified using any clinically acceptable parameter as known to those of skill in the art and can include, for example, assessment of competitive repopulating units (CRU); incorporation or expression of a marker in tissue(s) into which stem cells have homed, colonized, or become engrafted; or by evaluation of the progress of a subject through disease progression, survival of hematopoietic stem and progenitor cells, or survival of a recipient. Engraftment can also be determined by measuring white blood cell counts in peripheral blood during a post-transplant period. Engraftment can also be assessed by measuring recovery of marrow cells by donor cells in a bone marrow aspirate sample.
[0136] As used herein, the term“exogenous” describes a substance, such as a molecule, cell, tissue, or organ ( e.g ., a hematopoietic stem cell or a cell of hematopoietic lineage, such as a megakaryocyte, thrombocyte, platelet, erythrocyte, mast cell, myeoblast, basophil, neutrophil, eosinophil, microglial cell, granulocyte, monocyte, osteoclast, antigen-presenting cell, macrophage, dendritic cell, natural killer cell, T-lymphocyte, or B-lymphocyte) that is not found naturally in a particular organism, such as a human patient. Exogenous substances include those that are provided from an external source to an organism or to cultured matter extracted therefrom.
[0137] As used herein, the term“framework region” or“FW region” includes amino acid residues that are adjacent to the CDRs of an antibody or antigen -binding fragment thereof.
FW region residues may be present in, for example, human antibodies, humanized antibodies, monoclonal antibodies, antibody fragments, Fab fragments, single chain antibody fragments, scFv fragments, antibody domains, and bispecific antibodies, among others.
[0138] As used herein, the term "hematopoietic progenitor cells" includes pluripotent cells capable of differentiating into several cell types of the hematopoietic system, including, without limitation, granulocytes, monocytes, erythrocytes, megakaryocytes, B-cells and T- cells, among others. Hematopoietic progenitor cells are committed to the hematopoietic cell lineage and generally do not self-renew. Hematopoietic progenitor cells can be identified, for example, by expression patterns of cell surface antigens, and include cells having the following immunophenotype: Lin KLS+ Flk2 CD34+. Hematopoietic progenitor cells include short-term hematopoietic stem cells, multi-potent progenitor cells, common myeloid progenitor cells, granulocyte-monocyte progenitor cells, and megakaryocyte-erythrocyte progenitor cells. The presence of hematopoietic progenitor cells can be determined functionally, for example, by detecting colony -forming unit cells, e.g ., in complete methylcellulose assays, or phenotypically through the detection of cell surface markers using flow cytometry and cell sorting assays described herein and known in the art.
[0139] As used herein, the term“hematopoietic stem cells” (“HSCs”) refers to immature blood cells having the capacity to self-renew and to differentiate into mature blood cells containing diverse lineages including but not limited to granulocytes (e.g, promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g, reticulocytes, erythrocytes), thrombocytes (e.g, megakaryoblasts, platelet producing megakaryocytes, platelets), monocytes (e.g, monocytes, macrophages), dendritic cells, microglia, osteoclasts, and lymphocytes (e.g, NK cells, B-cells and T-cells). Such cells may include CD34+ cells.
CD34+ cells are immature cells that express the CD34 cell surface marker. In humans,
CD34+ cells are believed to include a subpopulation of cells with the stem cell properties defined above, whereas in mice, HSCs are CD34-. In addition, HSCs also refer to long term repopulating HSCs (LT-HSC) and short term repopulating HSCs (ST-HSC). LT-HSCs and ST-HSCs are differentiated, based on functional potential and on cell surface marker expression. For example, human HSCs are CD34+, CD38 , CD45RA , CD90+, CD49F+, and lin (negative for mature lineage markers including CD2, CD3, CD4, CD7, CD8, CD 10, CD11B, CD 19, CD20, CD56, CD235A). In mice, bone marrow LT-HSCs are CD34-, SCA- 1+, C-kit+, CD135-, Slamfl/CDl50+, CD48-, and lin- (negative for mature lineage markers including Terl l9, CDl lb, Grl, CD3, CD4, CD8, B220, IL7ra), whereas ST-HSCs are CD34+, SCA-l+, C-kit+, CD135 , Slamfl/CDl50+, and lin (negative for mature lineage markers including Terl l9, CDl lb, Grl, CD3, CD4, CD8, B220, IL7ra). In addition, ST- HSCs are less quiescent and more proliferative than LT-HSCs under homeostatic conditions. However, LT-HSC have greater self-renewal potential (i.e., they survive throughout adulthood, and can be serially transplanted through successive recipients), whereas ST-HSCs have limited self-renewal (i.e., they survive for only a limited period of time, and do not possess serial transplantation potential). Any of these HSCs can be used in the methods described herein. ST-HSCs are particularly useful because they are highly proliferative and thus, can more quickly give rise to differentiated progeny.
[0140] As used herein, the term“hematopoietic stem cell functional potential” refers to the functional properties of hematopoietic stem cells which include 1) multi -potency (which refers to the ability to differentiate into multiple different blood lineages including, but not limited to, granulocytes ( e.g ., promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g., reticulocytes, erythrocytes), thrombocytes (e.g, megakaryoblasts, platelet producing megakaryocytes, platelets), monocytes (e.g, monocytes, macrophages), dendritic cells, microglia, osteoclasts, and lymphocytes (e.g, NK cells, B-cells and T-cells), 2) self- renewal (which refers to the ability of hematopoietic stem cells to give rise to daughter cells that have equivalent potential as the mother cell, and further that this ability can repeatedly occur throughout the lifetime of an individual without exhaustion), and 3) the ability of hematopoietic stem cells or progeny thereof to be reintroduced into a transplant recipient whereupon they home to the hematopoietic stem cell niche and re-establish productive and sustained hematopoiesis.
[0141] As used herein, the terms“Major histocompatibility complex antigens” (“MHC”, also referred to as“human leukocyte antigens” (“HLA”) in the context of humans) refer to proteins expressed on the cell surface that confer a unique antigenic identity to a cell.
MHC/HLA antigens are target molecules that are recognized by T cells and NK cells as being derived from the same source of hematopoietic stem cells as the immune effector cells ("self) or as being derived from another source of hematopoietic reconstituting cells ("non- self). Two main classes of HLA antigens are recognized: HLA class I and HLA class II. HLA class I antigens (A, B, and C in humans) render each cell recognizable as "self," whereas HLA class II antigens (DR, DP, and DQ in humans) are involved in reactions between lymphocytes and antigen presenting cells. Both have been implicated in the rejection of transplanted organs. An important aspect of the HLA gene system is its polymorphism. Each gene, MHC class I (A, B and C) and MHC class II (DP, DQ and DR) exists in different alleles. For example, two unrelated individuals may carry class I HLA-B, genes B5, and Bw4l, respectively. Allelic gene products differ in one or more amino acids in the a and/or b domain(s). Large panels of specific antibodies or nucleic acid reagents are used to type HLA haplotypes of individuals, using leukocytes that express class I and class II molecules. The genes commonly used for HLA typing are the six MHC Class I and Class II proteins, two alleles for each of HLA- A; HLA-B and HLA-DR. The HLA genes are clustered in a "super-locus" present on chromosome position 6p2l, which encodes the six classical transplantation HLA genes and at least 132 protein coding genes that have important roles in the regulation of the immune system as well as some other fundamental molecular and cellular processes. The complete locus measures roughly 3.6 Mb, with at least 224 gene loci. One effect of this clustering is that "haplotypes", i.e. the set of alleles present on a single chromosome, which is inherited from one parent, tend to be inherited as a group. The set of alleles inherited from each parent forms a haplotype, in which some alleles tend to be associated together. Identifying a patient's haplotypes can help predict the probability of finding matching donors and assist in developing a search strategy, because some alleles and haplotypes are more common than others and they are distributed at different frequencies in different racial and ethnic groups.
[0142] As used herein, the term "HLA-matched" refers to a donor-recipient pair in which none of the HLA antigens are mismatched between the donor and recipient, such as a donor providing a hematopoietic stem cell graft to a recipient in need of hematopoietic stem cell transplant therapy. HLA-matched {i.e., where all of the 6 alleles are matched) donor- recipient pairs have a decreased risk of graft rejection, as endogenous T cells and NK cells are less likely to recognize the incoming graft as foreign, and are thus less likely to mount an immune response against the transplant.
[0143] As used herein, the term "HLA-mismatched" refers to a donor-recipient pair in which at least one HLA antigen, in particular with respect to HLA-A, HLA-B and HLA-DR, is mismatched between the donor and recipient, such as a donor providing a hematopoietic stem cell graft to a recipient in need of hematopoietic stem cell transplant therapy. In some embodiments, one haplotype is matched and the other is mismatched. HLA-mismatched donor-recipient pairs may have an increased risk of graft rejection relative to HLA-matched donor-recipient pairs, as endogenous T cells and NK cells are more likely to recognize the incoming graft as foreign in the case of an HLA-mismatched donor-recipient pair, and such T cells and NK cells are thus more likely to mount an immune response against the transplant.
[0144] As used herein, the term“human antibody” refers to an antibody in which
substantially every part of the protein (for example, all CDRs, framework regions, CL, CH domains ( e.g ., CHl, CH2, CH3), hinge, and VL and VH domains) is substantially non- immunogenic in humans, with only minor sequence changes or variations. A human antibody can be produced in a human cell (for example, by recombinant expression) or by a non-human animal or a prokaryotic or eukaryotic cell that is capable of expressing functionally rearranged human immunoglobulin (such as heavy chain and/or light chain) genes. When a human antibody is a single chain antibody, it can include a linker peptide that is not found in native human antibodies. For example, an Fv can contain a linker peptide, such as two to about eight glycine or other amino acid residues, which connects the variable region of the heavy chain and the variable region of the light chain. Such linker peptides are considered to be of human origin. Human antibodies can be made by a variety of methods known in the art including phage display methods using antibody libraries derived from human immunoglobulin sequences. Human antibodies can also be produced using transgenic mice that are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes (see, for example, PCT Publication Nos. WO
1998/24893; WO 1992/01047; WO 1996/34096; WO 1996/33735; U.S. Patent Nos.
5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598).
[0145] As used herein, the term“humanized” antibody refers to a non-human antibody that contains minimal sequences derived from non-human immunoglobulin. In general, a humanized antibody contains substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non human immunoglobulin. All or substantially all of the FW regions may also be those of a human immunoglobulin sequence. The humanized antibody can also contain at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin consensus sequence. Methods of antibody humanization are known in the art and have been described, for example, in Riechmann et al. (1988) Nature 332:323-7; U.S. Patent Nos: 5,530,101; 5,585,089; 5,693,761; 5,693,762; and 6,180,370.
[0146] As used herein, patients that are“in need of’ a hematopoietic stem cell transplant include patients that exhibit a defect or deficiency in one or more blood cell types, as well as patients having a stem cell disorder, autoimmune disease, cancer, or other pathology described herein. Hematopoietic stem cells generally exhibit 1) multi-potency, and can thus differentiate into multiple different blood lineages including, but not limited to, granulocytes ( e.g ., promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g, reticulocytes, erythrocytes), thrombocytes (e.g, megakaryoblasts, platelet producing megakaryocytes, platelets), monocytes ( e.g ., monocytes, macrophages), dendritic cells, microglia, osteoclasts, and lymphocytes (e.g., NK cells, B-cells and T-cells), 2) self-renewal, and can thus give rise to daughter cells that have equivalent potential as the mother cell, and 3) the ability to be reintroduced into a transplant recipient whereupon they home to the hematopoietic stem cell niche and re-establish productive and sustained hematopoiesis. Hematopoietic stem cells can thus be administered to a patient defective or deficient in one or more cell types of the hematopoietic lineage in order to re-constitute the defective or deficient population of cells in vivo. For example, the patient may be suffering from cancer, and the deficiency may be caused by administration of a chemotherapeutic agent or other medicament that depletes, either selectively or non-specifically, the cancerous cell population. Additionally or alternatively, the patient may be suffering from a hemoglobinopathy (e.g, a non-malignant hemoglobinopathy), such as sickle cell anemia, thalassemia, Fanconi anemia, aplastic anemia, and Wiskott-Aldrich syndrome. The subject may be one that is suffering from adenosine deaminase severe combined immunodeficiency (ADA SCID), HIV/AIDS, metachromatic leukodystrophy, Diamond-Blackfan anemia, and Schwachman-Diamond syndrome. The subject may have or be affected by an inherited blood disorder (e.g, sickle cell anemia) or an autoimmune disorder. Additionally or alternatively, the subject may have or be affected by a malignancy, such as neuroblastoma or a hematologic cancer. In some embodiments, the subject may have a leukemia, lymphoma, or myeloma. In some embodiments, the subject has acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia, multiple myeloma, diffuse large B-cell lymphoma, or non-Hodgkin’s lymphoma. In some embodiments, the subject has
myelodysplastic syndrome. In some embodiments, the subject has an autoimmune disease, such as scleroderma, multiple sclerosis, ulcerative colitis, Crohn’s disease, Type 1 diabetes, or another autoimmune pathology described herein. In some embodiments, the subject is in need of chimeric antigen receptor T-cell (CART) therapy. In some embodiments, the subject has or is otherwise affected by a metabolic storage disorder. The subject may suffer or otherwise be affected by a metabolic disorder selected from the group consisting of glycogen storage diseases, mucopolysaccharidoses, Gaucher's Disease, Hurlers Disease,
sphingolipidoses, metachromatic leukodystrophy, or any other diseases or disorders which may benefit from the treatments and therapies disclosed herein and including, without limitation, severe combined immunodeficiency, Wi scott- Aldrich syndrome, hyper immunoglobulin M (IgM) syndrome, Chediak-Higashi disease, hereditary lymphohistiocytosis, osteopetrosis, osteogenesis imperfecta, storage diseases, thalassemia major, sickle cell disease, systemic sclerosis, systemic lupus erythematosus, multiple sclerosis, juvenile rheumatoid arthritis and those diseases, or disorders described in "Bone Marrow Transplantation for Non-Malignant Disease," ASH Education Book, 1 :319-338 (2000), the disclosure of which is incorporated herein by reference in its entirety as it pertains to pathologies that may be treated by administration of hematopoietic stem cell transplant therapy. Additionally or alternatively, a patient“in need of’ a hematopoietic stem cell transplant may one that is or is not suffering from one of the foregoing pathologies, but nonetheless exhibits a reduced level ( e.g ., as compared to that of an otherwise healthy subject) of one or more endogenous cell types within the hematopoietic lineage, such as megakaryocytes, thrombocytes, platelets, erythrocytes, mast cells, myeoblasts, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, osteoclasts, antigen-presenting cells, macrophages, dendritic cells, natural killer cells, T-lymphocytes, and B -lymphocytes. One of skill in the art can readily determine whether one’s level of one or more of the foregoing cell types, or other blood cell type, is reduced with respect to an otherwise healthy subject, for example, by way of flow cytometry and fluorescence activated cell sorting (FACS) methods, among other procedures, known in the art.
[0147] As used herein, the term "leukocyte" refers to a heterogeneous group of nucleated blood cell types, and excludes erythrocytes and platelets. Leukocytes can be divided into two general groups: polymorphonucleocytes, which include neutrophils, eosinophils, and basophils, and mononucleocytes, which include lymphocytes and monocytes.
Polymorphonucleocytes contain many cytoplasmic granules and a multilobed nucleus and include the following: neutrophils, which are generally amoeboid in shape, phagocytic, and stain with both basic and acidic dyes, and eosinophils and basophils, which contain cytoplasmic granules that stain with acidic dyes and with basic dyes, respectively.
[0148] As used herein, the term "lymphocyte" refers to a mononuclear leukocyte that is involved in the mounting of an immune response. In general, lymphocytes include B lymphocytes, T lymphocytes, and NK cells.
[0149] As used herein, the terms“mobilize” and“mobilization” refer to processes by which a population of hematopoietic stem or progenitor cells is released from a stem cell niche, such as the bone marrow of a subject, into circulation in the peripheral blood. Mobilization of hematopoietic stem and progenitor cells can be monitored, for example, by assessing the quantity or concentration of hematopoietic stem or progenitor cells in a peripheral blood sample isolated from a subject. For example, the peripheral blood sample may be withdrawn from the subject, and the quantity or concentration of hematopoietic stem or progenitor cells in the peripheral blood sample may subsequently be assessed, following the administration of a hematopoietic stem or progenitor cell mobilization regimen to the subject. The mobilization regimen may include, for example, a CXCR4 antagonist, such as a CXCR4 antagonist described herein ( e.g ., plerixafor or a variant thereof), and a CXCR2 agonist, such as a CXCR2 agonist described herein (e.g., Gro-b or a variant thereof, such as a truncation of Gro-b, for example, Gro-b T). The quantity or concentration of hematopoietic stem or progenitor cells in the peripheral blood sample isolated from the subject following
administration of the mobilization regimen may be compared to the quantity or concentration of hematopoietic stem or progenitor cells in a peripheral blood sample isolated from the subject prior to administration of the mobilization regimen. An observation that the quantity or concentration of hematopoietic stem or progenitor cells has increased in the peripheral blood of the subject following administration of the mobilization regimen is an indication that the subject is responding to the mobilization regimen, and that hematopoietic stem and progenitor cells have been released from one or more stem cell niches, such as the bone marrow, into peripheral blood circulation. In some embodiments, an observation that the quantity or concentration of hematopoietic stem or progenitor cells has increased in the peripheral blood of the subject by 1%, 100%, 1,000%, or more (e.g, by 1%, 2%, 3%, 4%,
5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1,000%, or more) following administration of the mobilization regimen is an indication that the subject is responding to the mobilization regimen, and that hematopoietic stem and progenitor cells have been released from one or more stem cell niches, such as the bone marrow, into peripheral blood circulation. Methods for determining the quantity or concentration of hematopoietic stem or progenitor cells are described herein and known in the art, and include, for example, flow cytometry techniques that quantify hematopoietic stem or progenitor cells on the basis of the antigen expression profile of such cells, which is described herein. For example, human HSCs are CD34+, CD38 , CD45RA , CD90+, CD49F+, and lin- (negative for mature lineage markers including CD2, CD3, CD4, CD7, CD8, CD10, CD11B, CD19, CD20, CD56, CD235A). Additional methods for determining the quantity or concentration of hematopoietic stem or progenitor cells in a peripheral blood sample isolated from a subject include assays that quantify the number of colony-forming units (CFUs) in the sample, which is a measure of the quantity of viable hematopoietic stem or progenitor cells that, upon incubation with an appropriate culture medium, give rise to an individual population of hematopoietic stem or progenitor cells.
[0150] As used herein, the term“mobilizing amount” refers to a quantity of one or more agents, such as a quantity of a CXCR4 antagonist and/or a CXCR2 agonist described herein (In some embodiments, a quantity of plerixafor, or a variant thereof, and/or Gro-b, or a variant thereof, such as a truncation of Gro-b, for example, Gro-b T) that mobilizes a population of hematopoietic stem or progenitor cells upon administration to a subject, such as a mammalian subject ( e.g ., a human subject). Exemplary mobilizing amounts of these agents include amounts sufficient to effectuate the release of a population of, for example, from about 20 to about 40 CD34+ cells/pL of peripheral blood, such as from about 21 to about 39 CD34+ cells/pL of peripheral blood, about 22 to about 38 CD34+ cells/pL of peripheral blood, about 23 to about 37 CD34+ cells/pL of peripheral blood, about 24 to about 36 CD34+ cells/pL of peripheral blood, about 25 to about 35 CD34+ cells/pL of peripheral blood, about 26 to about 34 CD34+ cells/pL of peripheral blood, about 27 to about 33 CD34+ cells/pL of peripheral blood, about 28 to about 32 CD34+ cells/pL of peripheral blood, or about 29 to about 31 CD34+ cells/pL of peripheral blood (e.g., about 20 CD34+ cells/pL of peripheral blood, 21 CD34+ cells/pL of peripheral blood, 22 CD34+ cells/pL of peripheral blood, 23 CD34+ cells/pL of peripheral blood, 24, CD34+ cells/pL of peripheral blood, 25 CD34+ cells/pL of peripheral blood, 26 CD34+ cells/pL of peripheral blood, 27 CD34+ cells/pL of peripheral blood, 28 CD34+ cells/pL of peripheral blood, 29 CD34+ cells/pL of peripheral blood, 30 CD34+ cells/pL of peripheral blood, 31 CD34+ cells/pL of peripheral blood, 32 CD34+ cells/pL of peripheral blood 33 CD34+ cells/pL of peripheral blood, 34 CD34+ cells/pL of peripheral blood, 35 CD34+ cells/pL of peripheral blood, 36 CD34+ cells/pL of peripheral blood, 37 CD34+ cells/pL of peripheral blood, 38 CD34+ cells/pL of peripheral blood, 39 CD34+ cells/pL of peripheral blood, 40 CD34+ cells/pL of peripheral blood, or more. For instance, mobilizing amounts of a CXCR2 agonist, such as Gro-b T, include from about 50 pg/kg of recipient to about 1 mg/kg of recipient, such as from about 50 pg/kg to about 300 pg/kg, 100 pg/kg to about 250 pg/kg, or about 150 pg/kg. Mobilizing amounts of a CXCR4 antagonist, such as plerixafor or a pharmaceutically acceptable salt thereof, include from about 50 pg/kg of recipient to about 500 pg/kg of recipient, such as from about 200 pg/kg to about 300 pg/kg, or about 240 pg/kg.
[0151] As used herein, the term“monoclonal antibody” refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.
[0152] As used herein, the term“monocyte” refers to a CDl4+ and CD34- peripheral blood mononuclear cell (PBMC), which is generally capable of differentiating into a macrophage and/or dendritic cell upon activation by one or more foreign substances, such as, a microbial product. In particular, a monocyte may express elevated levels of the CD 14 surface antigen marker, and may express at least one biomarker selected from CD64, CD93, CD 180, CD328 (also known as sialic acid-binding Ig-like lectin 7 or Siglec7), and CD329 (sialic acid-binding Ig-like lectin 9 or Siglec9), as well as the peanut agglutinin protein (PNA).
[0153] As used herein, a“peptide” refers to a single-chain polyamide containing a plurality of amino acid residues, such as naturally-occurring and/or non-natural amino acid residues, that are consecutively bound by amide bonds. Examples of peptides include shorter fragments of full-length proteins, such as full-length naturally-occurring proteins.
[0154] As used herein, the term“recipient” refers to a patient that receives a transplant, such as a transplant containing a population of hematopoietic stem cells. The transplanted cells administered to a recipient may be, e.g ., autologous, syngeneic, or allogeneic cells.
[0155] As used herein, the term“sample” refers to a specimen (e.g, blood, blood component (e.g, serum or plasma), urine, saliva, amniotic fluid, cerebrospinal fluid, tissue (e.g, placental or dermal), pancreatic fluid, chorionic villus sample, and cells) taken from a subject. A sample may be, for example, withdrawn peripheral blood from a donor that is undergoing or has undergone a hematopoietic stem or progenitor cell mobilization regimen described herein.
[0156] As used herein, the term“scFv” refers to a single chain Fv antibody in which the variable domains of the heavy chain and the light chain from an antibody have been joined to form one chain. scFv fragments contain a single polypeptide chain that includes the variable region of an antibody light chain (VL) (e.g, CDR-L1, CDR-L2, and/or CDR-L3) and the variable region of an antibody heavy chain (VH) (e.g, CDR-H1, CDR-H2, and/or CDR-H3) separated by a linker. The linker that joins the VL and VH regions of a scFv fragment can be a peptide linker composed of proteinogenic amino acids. Alternative linkers can be used to so as to increase the resistance of the scFv fragment to proteolytic degradation (for example, linkers containing D-amino acids), in order to enhance the solubility of the scFv fragment (for example, hydrophilic linkers such as polyethylene glycol-containing linkers or polypeptides containing repeating glycine and serine residues), to improve the biophysical stability of the molecule (for example, a linker containing cysteine residues that form intramolecular or intermolecular disulfide bonds), or to attenuate the immunogenicity of the scFv fragment (for example, linkers containing glycosylation sites). It will also be understood by one of ordinary skill in the art that the variable regions of the scFv molecules described herein can be modified such that they vary in amino acid sequence from the antibody molecule from which they were derived. For example, nucleotide or amino acid substitutions leading to conservative substitutions or changes at amino acid residues can be made ( e.g ., in CDR and/or framework residues) so as to preserve or enhance the ability of the scFv to bind to the antigen recognized by the corresponding antibody.
[0157] As used herein, the phrase "stem cell disorder" broadly refers to any disease, disorder, or condition that may be treated or cured by engrafting or transplanting a population of hematopoietic stem or progenitor cells in a target tissue within a patient. For example, Type I diabetes has been shown to be cured by hematopoietic stem cell transplant, along with various other disorders. Exemplary diseases that can be treated by infusion of hematopoietic stem or progenitor cells into a patient are sickle cell anemia, thalassemias, Fanconi anemia, aplastic anemia, Wiskott-Aldrich syndrome, ADA SCID, HIV/AIDS, metachromatic leukodystrophy, Diamond-Blackfan anemia, and Schwachman-Diamond syndrome.
Additional diseases that may be treated by transplantation of hematopoietic stem and progenitor cells as described herein include blood disorders (e.g., sickle cell anemia) and autoimmune disorders, such as scleroderma, multiple sclerosis, ulcerative colitis, and Crohn’s disease. Additional diseases that may be treated using hematopoietic stem and progenitor cell transplant therapy include cancer, such as a cancer described herein. Exemplary stem cell disorders are malignancies, such as a neuroblastoma or a hematologic cancers, such as leukemia, lymphoma, and myeloma. In some embodiments, the cancer may be acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia, multiple myeloma, diffuse large B-cell lymphoma, or non-Hodgkin’s lymphoma. Additional diseases treatable using hematopoietic stem or progenitor cell transplant therapy include myelodysplastic syndrome. In some embodiments, the patient has or is otherwise affected by a metabolic storage disorder. For example, the patient may suffer or otherwise be affected by a metabolic disorder selected from the group consisting of glycogen storage diseases, mucopolysaccharidoses, Gaucher's Disease, Hurlers Disease, sphingolipidoses,
metachromatic leukodystrophy, or any other diseases or disorders which may benefit from the treatments and therapies disclosed herein and including, without limitation, severe combined immunodeficiency, Wi scott- Aldrich syndrome, hyper immunoglobulin M (IgM) syndrome, Chediak-Higashi disease, hereditary lymphohistiocytosis, osteopetrosis, osteogenesis imperfecta, storage diseases, thalassemia major, sickle cell disease, systemic sclerosis, systemic lupus erythematosus, multiple sclerosis, juvenile rheumatoid arthritis and those diseases, or disorders described in“Bone Marrow Transplantation for Non-Malignant Disease,” ASH Education Book, 1 :319-338 (2000), the disclosure of which is incorporated herein by reference in its entirety as it pertains to pathologies that may be treated by administration of hematopoietic stem or progenitor cell transplant therapy.
[0158] As used herein in the context of hematopoietic stem cell mobilization, the term“stem cell niche” refers to a microenvironment within a donor, such as a mammalian donor ( e.g ., a human donor) in which endogenous hematopoietic stem or progenitor cells reside. An exemplary stem cell niche is bone marrow tissue.
[0159] As used herein, the terms“subject” and“patient” refer to an organism, such as a human, that receives treatment for a particular disease or condition as described herein. In some embodiments, a patient, such as a human patient, that is in need of hematopoietic stem cell transplantation may receive treatment that includes a population of hematopoietic stem cells so as to treat a stem cell disorder, such as a cancer, autoimmune disease, or metabolic disorder described herein. The hematopoietic stem cells that are transplanted into the patient may be, for example, a population of hematopoietic stem cells that has been mobilized and withdrawn from a donor in accordance with the compositions and methods described herein. In some embodiments, the hematopoietic stem cells that are transplanted into the patient may be mobilized within a donor by administration of a CXCR4 antagonist and/or a CXCR2 agonist to the donor.
[0160] As used herein, the term“transfection” refers to any of a wide variety of techniques commonly used for the introduction of exogenous DNA into a prokaryotic or eukaryotic host cell, such as electroporation, lipofection, calcium- phosphate precipitation, DEAE- dextran transfection and the like. [0161] As used herein, the terms“treat” or“treatment” refer to therapeutic treatment, in which the object is to prevent or slow down (lessen) an undesired physiological change or disorder or to promote a beneficial phenotype in the patient being treated. Beneficial or desired clinical results include, but are not limited to, promoting the engraftment of exogenous hematopoietic cells in a patient following hematopoietic stem or progenitor cell transplant therapy. In certain embodiments, the benefits include a more rapid engraftment of transplanted cells, e.g., neutrophils and platelets. For example, in certain embodiments, using the methods described herein, neutrophil recovery occurs within about 5-20 days post- transplant, about 5-15 days post-transplant, about 5-10 days post-transplant, about 7-12 days post-transplant, about 8-12 days post transplant, about 9-15 days post-transplant, about 10-15 days post-transplant, or about 10 days post-transplant. In certain embodiments, using the methods described herein, platelet recovery occurs within about 10-20 days post-transplant, about 10-15 days post-transplant, about 15-20 days post-transplant, about 12-18 days post transplant, about 12-17 days post transplant, about 13-18 days post-transplant, about 12-17 days post-transplant, or about 15 days post-transplant. Additional beneficial results include an increase in the cell count or relative concentration of hematopoietic stem cells in a patient in need of a hematopoietic stem or progenitor cell transplant following administration of an exogenous hematopoietic stem or progenitor cell graft to the patient. Beneficial results of therapy described herein may also include an increase in the cell count or relative
concentration of one or more cells of hematopoietic lineage, such as a megakaryocyte, thrombocyte, platelet, erythrocyte, mast cell, myeoblast, basophil, neutrophil, eosinophil, microglial cell, granulocyte, monocyte, osteoclast, antigen-presenting cell, macrophage, dendritic cell, natural killer cell, T-lymphocyte, or B-lymphocyte, following and subsequent hematopoietic stem cell transplant therapy. Additional beneficial results may include the reduction in quantity of a disease-causing cell population, such as a population of cancer cells or autoimmune cells.
[0162] As used herein, the terms“variant” and“derivative” are used interchangeably and refer to naturally-occurring, synthetic, and semi-synthetic analogues of a compound, peptide, protein, or other substance described herein. A variant or derivative of a compound, peptide, protein, or other substance described herein may retain or improve upon the biological activity of the original material.
[0163] A s used herein, the term“vector” includes a nucleic acid vector, such as a plasmid, a
DMA vector, a plasmid, a RNA vector, virus, or other suitable replicon. Expression vectors described herein may contain a polynucleotide sequence as well as, for example, additional sequence elements used for the expression of proteins and/or the integration of these polynucleotide sequences into the genome of a mammalian cell. Certain vectors that can be used for the expression of peptides and proteins, such as those described herein, include plasmids that contain regulatory sequences, such as promoter and enhancer regions, which direct gene transcription. Other useful vectors for expression of peptides and proteins described herein contain polynucleotide sequences that enhance the rate of translation of these genes or improve the stability or nuclear export of the mRNA that results from gene transcription. These sequence elements may include, for example, 5’ and 3’ untranslated regions and a polyadenylation signal site in order to direct efficient transcription of the gene carried on the expression vector. The expression vectors described herein may also contain a polynucleotide encoding a marker for selection of cells that contain such a vector. Examples of a suitable marker include genes that encode resistance to antibiotics, such as ampicillin, chloramphenicol, kanamycin, and nourseothricin.
[0164] As used herein, the term“alkyl” refers to a straight- or branched-chain alkyl group having, for example, from 1 to 20 carbon atoms in the chain. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and the like.
[0165] As used herein, the term“alkylene” refers to a straight- or branched-chain divalent alkyl group. The divalent positions may be on the same or different atoms within the alkyl chain. Examples of alkylene include methylene, ethylene, propylene, isopropylene, and the like.
[0166] As used herein, the term“heteroalkyl” refers to a straight or branched-chain alkyl group having, for example, from 1 to 20 carbon atoms in the chain, and further containing one or more heteroatoms ( e.g ., oxygen, nitrogen, or sulfur, among others) in the chain.
[0167] As used herein, the term“heteroalkyl ene” refers to a straight- or branched-chain divalent heteroalkyl group. The divalent positions may be on the same or different atoms within the heteroalkyl chain. The divalent positions may be one or more heteroatoms.
[0168] As used herein, the term“alkenyl” refers to a straight- or branched-chain alkenyl group having, for example, from 2 to 20 carbon atoms in the chain. Examples of alkenyl groups include vinyl, propenyl, isopropenyl, butenyl, tert-butyl enyl, hexenyl, and the like. [0169] As used herein, the term“alkenylene” refers to a straight- or branched-chain divalent alkenyl group. The divalent positions may be on the same or different atoms within the alkenyl chain. Examples of alkenylene include ethenylene, propenylene, isopropenylene, butenylene, and the like.
[0170] As used herein, the term“heteroalkenyl” refers to a straight- or branched-chain alkenyl group having, for example, from 2 to 20 carbon atoms in the chain, and further containing one or more heteroatoms ( e.g ., oxygen, nitrogen, or sulfur, among others) in the chain.
[0171] As used herein, the term“heteroalkenylene” refers to a straight- or branched-chain divalent heteroalkenyl group. The divalent positions may be on the same or different atoms within the heteroalkenyl chain. The divalent positions may be one or more heteroatoms.
[0172] As used herein, the term“alkynyl” refers to a straight- or branched-chain alkynyl group having, for example, from 2 to 20 carbon atoms in the chain. Examples of alkynyl groups include propargyl, butynyl, pentynyl, hexynyl, and the like.
[0173] As used herein, the term“alkynylene” refers to a straight- or branched-chain divalent alkynyl group. The divalent positions may be on the same or different atoms within the alkynyl chain.
[0174] As used herein, the term“heteroalkynyl” refers to a straight- or branched-chain alkynyl group having, for example, from 2 to 20 carbon atoms in the chain, and further containing one or more heteroatoms (e.g., oxygen, nitrogen, or sulfur, among others) in the chain.
[0175] As used herein, the term“heteroalkynylene” refers to a straight- or branched-chain divalent heteroalkynyl group. The divalent positions may be on the same or different atoms within the heteroalkynyl chain. The divalent positions may be one or more heteroatoms.
[0176] As used herein, the term“cycloalkyl” refers to a monocyclic, or fused, bridged, or spiro polycyclic ring structure that is saturated and has, for example, from 3 to 12 carbon ring atoms. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[3. l.0]hexane, and the like.
[0177] As used herein, the term“cycloalkylene” refers to a divalent cycloalkyl group. The divalent positions may be on the same or different atoms within the ring structure. Examples of cycloalkylene include cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, and the like.
[0178] As used herein, the term“heterocycloalkyl” refers to a monocyclic, or fused, bridged, or spiro polycyclic ring structure that is saturated and has, for example, from 3 to 12 ring atoms per ring structure selected from carbon atoms and heteroatoms selected from, e.g ., nitrogen, oxygen, and sulfur, among others. The ring structure may contain, for example, one or more oxo groups on carbon, nitrogen, or sulfur ring members.
[0179] As used herein, the term“heterocycloalkylene” refers to a divalent heterocyclolalkyl group. The divalent positions may be on the same or different atoms within the ring structure.
[0180] As used herein, the term“aryl” refers to a monocyclic or multicyclic aromatic ring system containing, for example, from 6 to 19 carbon atoms. Aryl groups include, but are not limited to, phenyl, fluorenyl, naphthyl, and the like. The divalent positions may be one or more heteroatoms.
[0181] As used herein, the term“arylene” refers to a divalent aryl group. The divalent positions may be on the same or different atoms.
[0182] As used herein, the term“heteroaryl” refers to a monocyclic heteroaromatic, or a bicyclic or a tricyclic fused-ring heteroaromatic group. Heteroaryl groups include pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, l,2,3-triazolyl, l,2,4-triazolyl, l,2,3-oxadiazolyl, l,2,4-oxadia-zolyl, l,2,5-oxadiazolyl, 1,3,4- oxadiazolyl, l,3,4-triazinyl, l,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl,
isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, imidazo[l,2-a]pyridyl, benzothiazolyl, benzoxazolyl, quinolizinyl, quinazolinyl, pthalazinyl, quinoxalinyl, cinnolinyl, napthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolyl, isoquinolyl, tetrazolyl, 5, 6,7,8- tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolyl, purinyl, pteridinyl, carbazolyl, xanthenyl, benzoquinolyl, and the like.
[0183] As used herein, the term“heteroarylene” refers to a divalent heteroaryl group. The divalent positions may be on the same or different atoms. The divalent positions may be one or more heteroatoms. [0184] Unless otherwise constrained by the definition of the individual substituent, the foregoing chemical moieties, such as“alkyl”,“alkylene”,“heteroalkyl”,“heteroalkylene”, “alkenyl”,“alkenylene”,“heteroalkenyl”,“heteroalkenylene”,“alkynyl”,“alkynylene”, “heteroalkynyl”,“heteroalkynylene”,“cycloalkyl”,“cycloalkylene”,“heterocyclolalkyl”, heterocycloalkylene”,“aryl,”“arylene”,“heteroaryl”, and“heteroarylene” groups can optionally be substituted. As used herein, the term“optionally substituted” refers to a compound or moiety containing one or more (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) substituents, as permitted by the valence of the compound or moiety or a site thereof, such as a substituent selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, alkyl aryl, alkyl heteroaryl, alkyl cycloalkyl, alkyl heterocycloalkyl, amino, ammonium, acyl, acyloxy, acylamino, aminocarbonyl, alkoxycarbonyl, ureido, carbamate, aryl, heteroaryl, sulfmyl, sulfonyl, alkoxy, sulfanyl, halogen, carboxy, trihalomethyl, cyano, hydroxy, mercapto, nitro, and the like. The substitution may include situations in which neighboring substituents have undergone ring closure, such as ring closure of vicinal functional substituents, to form, for example, lactams, lactones, cyclic anhydrides, acetals, hemiacetals, thioacetals, aminals, and hemiaminals, formed by ring closure, for example, to furnish a protecting group.
Methods of Mobilizing Hematopoietic Stem and Progenitor Cells and Releasing Cells for Expansion and Therapeutic Use
[0185] The present invention is based, in part, on the discovery that hematopoietic stem and progenitor cells can be mobilized by administering particular doses of a CXCR2 agonist, such as Gro-b, Gro-b T, or a variant thereof, optionally in combination with a CXCR4 antagonist to a mammalian donor ( e.g ., a human donor) while reducing the mobilization of other cell types, such as leukocytes, neutrophils, lymphocytes, and monocytes. This property is particularly beneficial in the context of hematopoietic stem cell transplant therapy, as hematopoietic stem cells that are mobilized and isolated from a donor using the compositions and method described herein have reduced quantities of cell types that are undesirable for administration to a human patient suffering from a stem cell disorder.
[0186] Particularly, it has been discovered that CXCR2 agonists, such as Gro-b, Gro-b T, or a variant thereof, when administered intravenously at a dose of from about 50 pg/kg to about 1 mg/kg, preferably from about 100 pg/kg to about 250 pg/kg, and even more preferably at a dose of about 150 pg/kg, exhibit the ability to rapidly mobilize hematopoietic stem and progenitor cells in a donor ( e.g ., a mammalian donor, such as a human donor) while reducing the mobilization of other cells of the hematopoietic lineage that may be undesirable for infusion into a patient (e.g., a mammalian patient, such as a human patient) that is undergoing hematopoietic stem cell transplant therapy. CXCR2 agonists, such as Gro-b, Gro-b T, or a variant thereof, when administered at the above doses to a donor exhibit the ability to selectively mobilize hematopoietic stem cells as described in detail in Example 1, below.
[0187] When determining whether hematopoietic stem cells mobilized in a donor by administration of a CXCR2 agonist, such as Gro-b, Gro-b T, or a variant thereof, and optionally, a CXCR4 antagonist, such as plerixafor or a pharmaceutically acceptable salt thereof, are suitable for release for ex vivo expansion and/or for therapeutic use, one may acquire an input value for each of one or more parameters set forth in TABLE 2 that characterize a sample of peripheral blood of the donor. The one or more parameters may be compared to the corresponding reference criterion for each parameter, and if the reference criterion is satisfied by the ample of hematopoietic stem cells, the cells isolated from the donor may be released for expansion ex vivo and/or for infusion into a patient for therapeutic use (e.g, for the treatment of one or more stem cell disorders described herein).
[0188] Exemplary hematopoietic stem cell parameters and corresponding reference criteria useful in conjunction with the compositions and methods described herein are set forth in TABLE 2, below.
TABLE 2. Hematopoietic stem cell population parameters and corresponding reference criteria
Figure imgf000111_0001
Figure imgf000112_0001
[0189] In selecting parameters for determining whether a population of hematopoietic stem cells obtained from a donor ( e.g ., a mammalian donor, such as a human donor) is suitable for release for ex vivo expansion or therapeutic use, one may select one or more input parameters listed in TABLE 2. In some embodiments, one may select an individual parameter from parameter numbers 1-21. Alternatively, one may select a combination of parameters, such as a CD34+ cell ratio parameter (e.g., one or more of parameter numbers 1-17 in TABLE 2) and a frequency parameter (e.g, one or more of parameter numbers 18-21 listed in TABLE 2).
In some embodiments, the parameters used for determining whether a population of hematopoietic stem cells obtained from a donor (e.g, a mammalian donor, such as a human donor) is suitable for release for ex vivo expansion or therapeutic use are a combination of parameters as set forth in any one of TABLES 3-6, below.
TABLE 3. Two-way combinations of hematopoietic stem cell population parameters for assessment
Figure imgf000112_0002
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
TABLE 4. Three-way combinations of hematopoietic stem cell population parameters for assessment
Figure imgf000116_0002
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
Figure imgf000127_0001
Figure imgf000128_0001
Figure imgf000129_0001
Figure imgf000130_0001
Figure imgf000131_0001
Figure imgf000132_0001
TABLE 5. Four-way combinations of hematopoietic stem cell population parameters for assessment
Figure imgf000132_0002
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Figure imgf000136_0001
Figure imgf000137_0001
Figure imgf000138_0001
Figure imgf000139_0001
Figure imgf000140_0001
Figure imgf000141_0001
Figure imgf000142_0001
Figure imgf000143_0001
Figure imgf000144_0001
Figure imgf000145_0001
Figure imgf000146_0001
Figure imgf000147_0001
Figure imgf000148_0001
Figure imgf000149_0001
Figure imgf000150_0001
Figure imgf000151_0001
Figure imgf000152_0001
Figure imgf000153_0001
Figure imgf000154_0001
Figure imgf000155_0001
Figure imgf000156_0001
Figure imgf000157_0001
Figure imgf000158_0001
Figure imgf000159_0001
Figure imgf000160_0001
Figure imgf000161_0001
Figure imgf000162_0001
Figure imgf000163_0001
Figure imgf000164_0001
Figure imgf000165_0001
Figure imgf000166_0001
TABLE 6. Five-way combinations of hematopoietic stem cell population parameters for assessment
Figure imgf000166_0002
Figure imgf000167_0001
Figure imgf000168_0001
Figure imgf000169_0001
Figure imgf000170_0001
Figure imgf000171_0001
Figure imgf000172_0001
Figure imgf000173_0001
Figure imgf000174_0001
Figure imgf000175_0001
Figure imgf000176_0001
Figure imgf000177_0001
Figure imgf000178_0001
Figure imgf000179_0001
Figure imgf000180_0001
Figure imgf000181_0001
Figure imgf000182_0001
Figure imgf000183_0001
Figure imgf000184_0001
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Figure imgf000188_0001
Figure imgf000189_0001
Figure imgf000190_0001
Figure imgf000191_0001
Figure imgf000192_0001
Figure imgf000193_0001
Figure imgf000194_0001
CXCR2 Agonists
Gro-b, Gro-b T, and variants thereof
[0190] Exemplary CXCR2 agonists that may be used in conjunction with the compositions and methods described herein are Gro-b and variants thereof. Gro-b (also referred to as growth-regulated protein b, chemokine (C-X-C motif) ligand 2 (CXCL2), and macrophage inflammatory protein 2-a (MIP2-a)) is a cytokine capable of mobilizing hematopoietic stem and progenitor cells, for example, by stimulating the release of proteases, and particularly MMP9, from peripheral neutrophils. Without being limited by mechanism, MMP9 may induce mobilization of hematopoietic stem and progenitor cells from stem cell niches, such as the bone marrow, to circulating peripheral blood by stimulating the degradation of proteins such as stem cell factor, its corresponding receptor, CD117, and CXCL12, all of which generally maintain hematopoietic stem and progenitor cells immobilized in bone marrow.
[0191] In addition to Gro-b, exemplary CXCR2 agonists that may be used in conjunction with the compositions and methods described herein are truncated forms of Gro-b, such as those that feature a deletion at the N-terminus of Gro-b of from 1 to 8 amino acids (e.g, peptides that feature an N-terminal deletion of 1 amino acids, 2 amino acids, 3 amino acids, 4 amino acids, 5 amino acids, 6 amino acids, 7 amino acids, or 8 amino acids). In some embodiments, CXCR2 agonists that may be used in conjunction with the compositions and methods described herein include Gro-b T, which is characterized by a deletion of the first four amino acids from the N-terminus of Gro-b. Gro-b T exhibits particularly advantageous biological properties, such as the ability to induce hematopoietic stem and progenitor cell mobilization with a potency superior to that of Gro-b by multiple orders of magnitude. Gro-b and Gro-b T are described, for example, in US Patent No. 6,080,398, the disclosure of which is incorporated herein by reference in its entirety. [0192] In addition, exemplary CXCR2 agonists that may be used in conjunction with the compositions and methods described herein are variants of Gro-b containing an aspartic acid residue in place of the asparagine residue at position 69 of SEQ ID NO: 1. This peptide, referred to herein as Gro-b N69D, retains the hematopoietic stem and progenitor cell- mobilizing functionality of Gro-b, yet induces this effect with a superior potency. Similarly, CXCR2 agonists that may be used with the compositions and methods described herein include variants of Gro-b T containing an aspartic acid residue in place of the asparagine residue at position 65 of SEQ ID NO: 2. This peptide, referred to herein as Gro-b T N65D, not only retains hematopoietic stem and progenitor cell-mobilizing capacity, but exhibits a potency that is substantially greater than that of Gro-b T. Gro-b N69D and Gro-b T N65D are described, for example, in US Patent No. 6,447,766, the disclosure of which is incorporated herein by reference in its entirety.
[0193] The amino acid sequences of Gro-b, Gro-b T, Gro-b N69D, and Gro-b T N65D are set forth in TABLE 7, below.
TABLE 7. Amino acid sequences of Gro-b and select variants thereof
Figure imgf000195_0001
[0194] Additional CXCR2 agonists that may be used in conjunction with the compositions and methods described herein include other variants of Gro-b, such as peptides that have one or more amino acid substitutions, insertions, and/or deletions relative to Gro-b. In some embodiments, CXCR2 agonists that may be used in conjunction with the compositions and methods described herein include peptides having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1 ( e.g ., a peptide having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 1). In some embodiments, the amino acid sequence of the CXCR2 agonist differs from that of SEQ ID NO: 1 only by way of one or more conservative amino acid substitutions. In some embodiments, in some embodiments, the amino acid sequence of the CXCR2 agonist differs from that of SEQ ID NO: 1 by no more than 20, no more than 15, no more than 10, no more than 5, or no more than 1 nonconservative amino acid substitutions.
[0195] Additional examples of CXCR2 agonists useful in conjunction with the compositions and methods described herein are variants of Gro-b T, such as peptides that have one or more amino acid substitutions, insertions, and/or deletions relative to Gro-b T. In some embodiments, the CXCR2 agonist may be a peptide having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 2 ( e.g ., a peptide having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 2). In some embodiments, the amino acid sequence of the CXCR2 agonist differs from that of SEQ ID NO: 2 only by way of one or more conservative amino acid
substitutions. In some embodiments, in some embodiments, the amino acid sequence of the CXCR2 agonist differs from that of SEQ ID NO: 2 by no more than 20, no more than 15, no more than 10, no more than 5, or no more than 1 nonconservative amino acid substitutions.
[0196] Additional examples of CXCR2 agonists useful in conjunction with the compositions and methods described herein are variants of Gro-b N69D, such as peptides that have one or more amino acid substitutions, insertions, and/or deletions relative to Gro-b N69D. In some embodiments, the CXCR2 agonist may be a peptide having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 3 (e.g., a peptide having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 3). In some embodiments, the amino acid sequence of the CXCR2 agonist differs from that of SEQ ID NO: 3 only by way of one or more conservative amino acid
substitutions. In some embodiments, in some embodiments, the amino acid sequence of the CXCR2 agonist differs from that of SEQ ID NO: 3 by no more than 20, no more than 15, no more than 10, no more than 5, or no more than 1 nonconservative amino acid substitutions.
[0197] Additional examples of CXCR2 agonists useful in conjunction with the compositions and methods described herein are variants of Gro-b T N65D, such as peptides that have one or more amino acid substitutions, insertions, and/or deletions relative to Gro-b T N65D. In some embodiments, the CXCR2 agonist may be a peptide having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 4 ( e.g ., a peptide having at least 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.%, or 100% sequence identity to the amino acid sequence of SEQ ID NO: 4). In some embodiments, the amino acid sequence of the CXCR2 agonist differs from that of SEQ ID NO: 4 only by way of one or more conservative amino acid substitutions. In some embodiments, in some embodiments, the amino acid sequence of the CXCR2 agonist differs from that of SEQ ID NO: 4 by no more than 20, no more than 15, no more than 10, no more than 5, or no more than 1 nonconservative amino acid
substitutions.
Agonistic anti-CXCR2 antibodies and antigen-binding fragments thereof
[0198] In some embodiments, the CXCR2 agonist is an antibody or antigen-binding fragment thereof that binds CXCR2 and activates CXCR2 signal transduction. In some embodiments, the CXCR2 agonist may be an antibody or antigen-binding fragment thereof that binds the same epitope on CXCR2 as Gro-b or a variant or truncation thereof, such as Gro-b T, as assessed, for example, by way of a competitive CXCR2 binding assay. In some
embodiments, the CXCR2 agonist is an antibody or an antigen-binding fragment thereof that competes with Gro-b or a variant or truncation thereof, such as Gro-b T, for binding to CXCR2.
[0199] In some embodiments of any of the above aspects, the antibody or antigen-binding fragment thereof is selected from the group consisting of a monoclonal antibody or antigen binding fragment thereof, a polyclonal antibody or antigen-binding fragment thereof, a humanized antibody or antigen-binding fragment thereof, a bispecific antibody or antigen binding fragment thereof, a dual-variable immunoglobulin domain, a single-chain Fv molecule (scFv), a diabody, a triabody, a nanobody, an antibody-like protein scaffold, a Fv fragment, a Fab fragment, a F(ab’)2 molecule, and a tandem di-scFv. In some embodiments, the antibody has an isotype selected from the group consisting of IgG, IgA, IgM, IgD, and IgE.
Synthetic CXCR2 Agonists
[0200] The peptidic CXCR2 agonists described herein, such as Gro-b, Gro-b T, and variants thereof, may be prepared synthetically, for instance, using solid phase peptide synthesis techniques. Systems and processes for performing solid phase peptide synthesis include those that are known in the art and have been described, for instance, in US Patent Nos. 9,169,287; 9,388,212; 9,206,222; 6,028,172; and 5,233,044, among others, the disclosures of each of which are incorporated herein by reference as they pertain to protocols and techniques for the synthesis of peptides on solid support. Solid phase peptide synthesis is a process in which amino acid residues are added to peptides that have been immobilized on a solid support, such as a polymeric resin ( e.g ., a hydrophilic resin, such as a polyethylene-glycol-containing resin, or hydrophobic resin, such as a polystyrene-based resin).
[0201] Peptides, such as those containing protecting groups at amino, hydroxy, thiol, and carboxy substituents, among others, may be bound to a solid support such that the peptide is effectively immobilized on the solid support. For example, the peptides may be bound to the solid support via their C termini, thereby immobilizing the peptides for subsequent reaction in at a resin-liquid interface.
[0202] The process of adding amino acid residues to immobilized peptides can include exposing a deprotection reagent to the immobilized peptides to remove at least a portion of the protection groups from at least a portion of the immobilized peptides. The deprotection reagent exposure step can be configured, for instance, such that side-chain protection groups are preserved, while N-terminal protection groups are removed. For instance, an exemplary amino protecting contains a fluorenylmethyloxycarbonyl (Fmoc) substituent. A deprotection reagent containing a strongly basic substance, such as piperidine (e.g., a piperidine solution in an appropriate organic solvent, such as dimethyl formamide (DMF)) may be exposed to the immobilized peptides such that the Fmoc protecting groups are removed from at least a portion of the immobilized peptides. Other protecting groups suitable for the protection of amino substituents include, for instance, the tert-butyloxy carbonyl (Boc) moiety. A deprotection reagent comprising a strong acid, such as trifluoroacetic acid (TFA) may be exposed to immobilized peptides containing a Boc-protected amino substituent so as to remove the Boc protecting group by an ionization process. In this way, peptides can be protected and deprotected at specific sites, such as at one or more side-chains or at the N- or C -terminus of an immobilized peptide so as to append chemical functionality regioselectively at one or more of these positions. This can be used, for instance, to derivatize a side-chain of an immobilized peptide, or to synthesize a peptide, e.g, from the C-terminus to the N- terminus.
[0203] The process of adding amino acid residues to immobilized peptides can include, for instance, exposing protected, activated amino acids to the immobilized peptides such that at least a portion of the activated amino acids are bonded to the immobilized peptides to form newly-bonded amino acid residues. For example, the peptides may be exposed to activated amino acids that react with the deprotected N-termini of the peptides so as to elongate the peptide chain by one amino acid. Amino acids can be activated for reaction with the deprotected peptides by reaction of the amino acid with an agent that enhances the electrophilicity of the backbone carbonyl carbon of the amino acid. For example, phosphonium and uronium salts can, in the presence of a tertiary base ( e.g .,
diisopropylethylamine (DIPEA) and triethylamine (TEA), among others), convert protected amino acids into activated species (for example, BOP, PyBOP, HBTEi, and TBTU all generate HOBt esters). Other reagents can be used to help prevent racemization that may be induced in the presence of a base. These reagents include carbodiimides (for example, DCC or WSCDI) with an added auxiliary nucleophile (for example, l-hy dr oxy-benzotri azole (HOBt), l-hydroxy-azabenzotriazole (HO At), or HOSu) or derivatives thereof. Another reagent that can be utilized to prevent racemization is TBTU. The mixed anhydride method, using isobutyl chloroformate, with or without an added auxiliary nucleophile, can also be used, as well as the azide method, due to the low racemization associated with this reagent. These types of compounds can also increase the rate of carbodiimide-mediated couplings, as well as prevent dehydration of Asn and Gln residues. Typical additional reagents include also bases such as N,N-diisopropylethylamine (DIPEA), triethylamine (TEA) or N- methylmorpholine (NMM). These reagents are described in detail, for instance, in US Patent No. 8,546,350, the disclosure of which is incorporated herein in its entirety.
[0204] During the recombinant expression and folding of Gro-b and Gro-b T in aqueous solution, a particular C-terminal asparagine residue (Asn69 within Gro-b and Asn65 within Gro-b T) is prone to deamidation. This process effectuates the conversion of the asparagine residue to aspartic acid. Without wishing to be bound by any theory, the chemical synthesis of Gro-b and Gro-b T may overcome this problem, for instance, by providing conditions that reduce the exposure of this asparagine residue to nucleophilic solvent. When prepared synthetically (i.e., chemically synthesized), for instance, using, e.g. , the solid phase peptide synthesis techniques described above, synthetic Gro-b, Gro-b T, and variants thereof that may be used in conjunction with the compositions and methods described herein may have a purity of, e.g., at least about 95% relative to the deamidated versions of these peptides (i.e., contain less than 5% of the corresponding deamidated peptide). For instance, synthetic Gro- b, Gro-b T, and variants thereof that may be used in conjunction with the compositions and methods described herein may have a purity of about 95%, 95.5%, 96%, 96.5%, 97%, 97.5%, 98%, 98.5%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.99%, or more, relative to the deamidated versions of these peptides ( e.g ., the Asn69 deamidated version of SEQ ID NO: 1 or the Asn65 deamidated version of SEQ ID NO: 2). For instance, synthetic Gro-b, Gro-b T, and variants thereof may have, for instance, a purity of from about 95% to about 99.99%, such as a purity of from about 95% to about 99.99%, about 96% to about 99.99%, about 97% to about 99.99%, about 98% to about 99.99%, about 99% to about 99.99%, about 99.9% to about 99.99%, about 95% to about 99.5%, about 96% to about 99.5%, about 95% to about 99%, or about 97% to about 99% relative to the deamidated versions of these peptides (e.g., the Asn69 deamidated version of SEQ ID NO: 1 or the Asn65 deamidated version of SEQ ID NO: 2).
CXCR4 Antagonists
[0205] Exemplary CXCR4 antagonists for use in conjunction with the compositions and methods described herein are compounds represented by formula (I)
Z - linker - Z’ (I)
or a pharmaceutically acceptable salt thereof, wherein Z is:
(i) a cyclic polyamine containing from 9 to 32 ring members, wherein from 2 to 8 of the ring members are nitrogen atoms separated from one another by 2 or more carbon atoms; or
(ii) an amine represented by formula (IA)
Figure imgf000200_0001
wherein A includes a monocyclic or bicyclic fused ring system including at least one nitrogen atom and B is H or a substituent of from 1 to 20 atoms; and wherein Z’ is:
(i) a cyclic polyamine containing from 9 to 32 ring members, wherein from 2 to 8 of the ring members are nitrogen atoms separated from one another by 2 or more carbon atoms;
(ii) an amine represented by formula (IB)
Figure imgf000201_0001
wherein A’ includes a monocyclic or bicyclic fused ring system including at least one nitrogen atom and B’ is H or a substituent of from 1 to 20 atoms; or (iii) a substituent represented by formula (IC)
N(R) - (CR2)n - X (IC) wherein each R is independently H or Ci-C6 alkyl, n is 1 or 2, and X is an aryl or heteroaryl group or a mercaptan;
wherein the linker is a bond, optionally substituted alkylene ( e.g ., optionally substituted Ci- C6 alkylene), optionally substituted heteroalkylene (e.g., optionally substituted Ci-C6 heteroalkyl ene), optionally substituted alkenyl ene (e.g, optionally substituted C2-C6 alkenyl ene), optionally substituted heteroalkenylene (e.g, optionally substituted C2-C6 heteroalkenyl ene), optionally substituted alkynylene (e.g, optionally substituted C2-C6 alkynylene), optionally substituted heteroalkynylene (e.g, optionally substituted C2-C6 heteroalkynylene), optionally substituted cycloalkylene, optionally substituted
heterocycloalkyl ene, optionally substituted arylene, or optionally substituted heteroaryl ene.
[0206] In some embodiments, Z and Z’ may each independently a cyclic polyamine containing from 9 to 32 ring members, of which from 2 to 8 are nitrogen atoms separated from one another by 2 or more carbon atoms. In some embodiments, Z and Z’ are identical substituents. As an example, Z may be a cyclic polyamine including from 10 to 24 ring members. In some embodiments, Z may be a cyclic polyamine that contains 14 ring members. In some embodiments, Z includes 4 nitrogen atoms. In some embodiments, Z is 1,4,8,11 -tetraazocyclotetradecane.
[0207] In some embodiments, the linker is represented by formula (ID)
Figure imgf000201_0002
wherein ring D is an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted cycloalkyl group, or an optionally substituted
heterocycloalkyl group; and
X and Y are each independently optionally substituted alkylene (e.g, optionally substituted Ci-C6 alkylene), optionally substituted heteroalkylene (e.g, optionally substituted Ci-C6 heteroalkylene), optionally substituted alkenyl ene (e.g, optionally substituted C2-C6 alkenyl ene), optionally substituted heteroalkenylene (e.g, optionally substituted C2-C6 heteroalkenylene), optionally substituted alkynylene (e.g, optionally substituted C2-C6 alkynylene), or optionally substituted heteroalkynylene (e.g, optionally substituted C2-C6 heteroalkynylene).
[0208] As an example, the linker may be represented by formula (IE)
Figure imgf000202_0001
wherein ring D is an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted cycloalkyl group, or an optionally substituted
heterocycloalkyl group; and
X and Y are each independently optionally substituted alkyl ene ( e.g ., optionally substituted Ci-C6 alkyl ene), optionally substituted heteroalkylene (e.g., optionally substituted Ci-C6 heteroalkyl ene), optionally substituted C2-C6 alkenyl ene (e.g, optionally substituted C2-C6 alkenyl ene), optionally substituted heteroalkenylene (e.g, optionally substituted C2-C6 heteroalkenyl ene), optionally substituted alkynylene (e.g, optionally substituted C2-C6 alkynylene), or optionally substituted heteroalkynylene (e.g, optionally substituted C2-C6 heteroalkynylene). In some embodiments, X and Y are each independently optionally substituted Ci-C6 alkylene. In some embodiments, X and Y are identical substituents. In some embodiments, X and Y may be each be methylene, ethylene, n-propylene, n-butylene, n-pentylene, or n-hexylene groups. In some embodiments, X and Y are each methylene groups.
[0209] The linker may be, for example, l,3-phenylene, 2,6-pyridine, 3,5-pyridine, 2,5- thiophene, 4,4'-(2,2'-bipyrimidine), 2,9-(l,l0-phenanthroline), or the like. In some embodiments, the linker is 1, 4-phenyl ene-bis-(m ethyl ene). [0210] CXCR4 antagonists useful in conjunction with the compositions and methods described herein include plerixafor (also referred to herein as“AMD3100” and“Mozibil”), or a pharmaceutically acceptable salt thereof, represented by formula (II), 1,1 '-[1,4- phenylenebis(m ethylene)] -bis- 1 ,4,8, 11 -tetra-azacyclotetradecane.
Figure imgf000203_0001
[0211] Additional CXCR4 antagonists that may be used in conjunction with the compositions and methods described herein include variants of plerixafor, such as a compound described in US Patent No. 5,583, 131, the disclosure of which is incorporated herein by reference as it pertains to CXCR4 antagonists. In some embodiments, the CXCR4 antagonist may be a compound selected from the group consisting of: l,r-[l,3-phenylenebis(methylene)]-bis- 1,4,8, 1 l-tetra-azacyclotetradecane; l,r-[l,4-phenylene-bis-(methylene)]-bis-l,4,8,l 1- tetraazacyclotetradecane; bis-zinc or bis-copper complex of l,l'-[l,4-phenylene-bis- (methylene)]-bis-l,4,8, 1 l-tetraazacyclotetradecane; 1,1 '-[3,3 '-biphenylene-bis-(methylene)]- bis-l,4,8,l l-tetraazacyclotetradecane; 11,11 '-[l,4-phenylene-bis-(methylene)]-bis-l,4,7,l 1- tetraazacyclotetradecane; 1,11 '-[l,4-phenylene-bis-(methylene)]-l,4,8, 11- tetraazacyclotetradecane- 1 , 4,7, 11 -tetraazacyclotetradecane; 1 , 1 '-[2,6-pyridine-bis- (methylene)]-bis-l,4,8, 1 l-tetraazacyclotetradecane; 1, l-[3,5-pyridine-bis-(methylene)]-bis- 1,4,8,11 -tetraazacyclotetradecane; 1 , 1 '-[2,5 -thi ophene-bis-(m ethyl ene)]-bis- 1,4,8,11- tetraazacyclotetradecane; l,r-[4,4'-(2,2'-bipyridine)-bis-(methylene)]-bis-l,4,8,l l- tetraazacyclotetradecane; 1 , 1 '-[2,9-(l , 10-phenanthroline)-bis-(m ethylene)] -bis- 1 ,4,8, 11 - tetraazacyclotetradecane; 1 , 1 '-[ 1 ,3 -phenylene-bis-(m ethyl ene)]-bis- 1,4,7,10- tetraazacyclotetradecane; 1 , 1 '-[ 1 ,4-phenylene-bis-(m ethyl ene)]-bis- 1,4,7,10- tetraazacyclotetradecane; 1 '-[5-nitro-l, 3-phenyl enebis(methylene)]bis-l, 4, 8, 11- tetraazacyclotetradecane; r,r-[2,4,5,6-tetrachloro-l,3-phenyleneis(methylene)]bis-l,4,8,l l- tetraazacyclotetradecane; l,l '-[2,3,5,6-tetra-fluoro-l,4-phenylenebis(methylene)]bis-l,4,8,l l- tetraazacyclotetradecane; l,l '-[l,4-naphthylene-bis-(methylene)]bis-l,4,8,l 1- tetraazacyclotetradecane; l,r-[l,3-phenylenebis-(methylene)]bis-l,5,9-triazacyclododecane; l,r-[l,4-phenylene-bis-(methylene)]-l,5,9-triazacyclododecane; l,l'-[2, 5-dimethyl- 1,4- phenylenebis-(methylene)]-bis-l,4,8,l l-tetraazacyclotetradecane; l,l '-[2,5-dichloro-l,4- phenylenebis-(methylene)]-bis-l,4,8,l l-tetraazacyclotetradecane; l,l '-[2-bromo-l,4- phenylenebis-(methylene)]-bis-l,4,8,l l-tetraazacyclotetradecane; and l,l'-[6-phenyl-2,4- pyridinebis-(methylene)]-bis-l,4,8,l l-tetraazacyclotetradecane.
[0212] In some embodiments, the CXCR4 antagonist is a compound described in US 2006/0035829, the disclosure of which is incorporated herein by reference as it pertains to CXCR4 antagonists. In some embodiments, the CXCR4 antagonist may be a compound selected from the group consisting of: 3,7,l l,l7-tetraazabicyclo(l3.3.l)heptadeca- l(l7),l3,l5-triene;
4,7,10,17 -tetraazabicyclo( 13.3.1 )heptadeca- 1(17), 13, 15 -triene; 1,4,7,10- tetraazacyclotetradecane; l,4,7-triazacyclotetradecane; and 4,7,10- triazabicyclo(l 3.3.1 )heptadeca- 1 ( 17), 13 , 15 -triene.
[0213] The CXCR4 antagonist may be a compound described in WO 2001/044229, the disclosure of which is incorporated herein by reference as it pertains to CXCR4 antagonists. In some embodiments, the CXCR4 antagonist may be a compound selected from the group consisting of: N-[4-(l l-fluoro-l, 4, 7-triazacyclotetradecanyl)-l, 4-phenyl enebis(methylene)]- 2-(aminomethyl)pyridine; N-[4-(l 1,1 l-difluoro-l,4,7-triazacyclotetradecanyl)-l,4- phenylenebis(methylene)]-2-(aminomethyl)pyridine; N-[4-(l,4,7-triazacyclotetradecan-2- onyl)-l,4-phenylenebis(methylene)]-2-(aminomethyl)pyridine; N-[l2-(5-oxa-l,9- diazacyclotetradecanyl)-l, 4-phenyl enebis(methylene)]-2-(aminomethyl)pyri dine; N-[4-(l l- oxa-l, 4, 7-triazacyclotetradecanyl)-l, 4-phenyl enebis(methylene)]-2-(aminomethyl)pyri dine; N-[4-(l l-thia-l, 4, 7-triazacyclotetradecanyl)-l, 4-phenyl enebis(methylene)]-2- (aminom ethyl )pyri dine; N-[4-(l 1 -sulfoxo- 1 ,4,7-triazacyclotetradecanyl)- 1 ,4- phenylenebis(methylene)]-2-(aminomethyl)pyridine; N-[4-(l l-sulfono-l,4,7- triazacyclotetradecanyl)-l,4-phenylenebis(methylene)]-2-(aminomethyl)pyridine; and N-[4- (3-carboxo- 1 ,4,7-triazacyclotetradecanyl)- 1 , 4-phenyl enebis(methylene)]-2- (aminomethyl)pyridine.
[0214] Additional CXCR4 antagonists useful in conjunction with the compositions and methods described herein include compounds described in WO 2000/002870, the disclosure of which is incorporated herein by reference as it pertains to CXCR4 antagonists. In some embodiments, the CXCR4 antagonist may be a compound selected from the group consisting of: N-[l,4,8, 1 l-tetraazacycl otetra-decanyl-l, 4-phenyl enebis-(m ethyl ene)]-2- (aminomethyl)pyridine; N-[l,4,8, 1 l-tetraazacycl otetra-decanyl-l, 4- phenylenebis(methylene)]-N-methyl-2-(aminomethyl)pyridine; N-[l,4,8,l 1- tetraazacyclotetra-decanyl-l,4-phenylenebis(methylene)]-4-(aminomethyl)pyridine; N- [l,4,8,l l-tetraazacyclotetra-decanyl-l,4-phenylenebis(methylene)]-3-(aminomethyl)pyridine; N-[l,4,8,l l-tetraazacyclotetra-decanyl-l,4-phenylenebis(methylene)]-(2-aminomethyl-5- methyl)pyrazine; N-[l,4,8, 1 l-tetraazacyclotetra-decanyl-l,4-phenylenebis(methylene)]-2- (aminoethyl) pyridine; N-[l,4,8,l l-tetraazacyclotetra-decanyl-l,4-phenylenebis(methylene)]- 2-(aminom ethyl )thiophene; N-[ 1 ,4, 8, 11 -tetraazacyclotetra-decanyl- 1 ,4- phenyl enebis(m ethylene)] -2-(aminomethyl)mercaptan; N-[l,4,8, 1 l-tetraazacyclotetra- decanyl-l,4-phenylenebis(methylene)]-2-amino benzylamine; N-[l,4,8,l l-tetraazacyclotetra- decanyl-l,4-phenylenebis(methylene)]-4-amino benzylamine; N-[l,4,8,l 1 -tetraazacyclotetra- decanyl- 1 , 4-phenyl enebis(m ethylene)] -4-(aminoethyl)imidazole; N-[ 1 ,4,8, 11 - tetraazacyclotetra-decanyl-l,4-phenylenebis(methylene)]-benzylamine; N-[4-(l,4,7- triazacyclotetra-decanyl)-l, 4-phenyl enebis(m ethylene)] -2-(aminom ethyl )pyri dine; N-[7- (4,7,l0,l7-tetraazabicyclo[l3.3. l]heptadeca-l(l7),l3,l5-trienyl)-l,4- phenyl enebi s(m ethylene)] -2-(aminomethyl)pyri dine; N-[7-(4,7,l0- triazabicyclo[l3.3.l]heptadeca-l(l7),l3,l5-trienyl)-l,4-phenylenebis(methylene)]-2- (aminomethyl)pyridine; N-[l-(l, 4, 7-triazacyclotetra-decanyl)-l, 4-phenyl enebis(methylene)]- 2-(aminomethyl)pyridine; N-[4-[4,7,l0,l7-tetraazabicyclo[l3.3.l]heptadeca-l(l7),l3,l5- trienyl]-l, 4-phenyl enebis(methylene)]-2-(aminomethyl)pyri dine; N-[4-[4,7,l0- triazabicyclo[l3.3.l]heptadeca-l(l7),l3,l5-trienyl]-l,4-phenylenebis(methylene)]-2- (aminomethyl)pyridine; N-[l,4,8, l l-tetraazacyclotetradecanyl-l,4- phenyl enebi s(m ethylene)] -purine; 1 -[ 1 ,4,8, 11 -tetraazacyclotetradecanyl- 1 ,4- phenylenebix(methylene)]-4-phenylpiperazine; N-[4-(l,7-diazacyclotetradecanyl)-l,4- phenylenebis(methylene)]-2-(aminomethyl)pyridine; and N-[7-(4, 10- diazabicyclo[l3.3. l]heptadeca-l(l7),l3,l5-trienyl)-l,4-phenylenebis(methylene)]-2- (aminomethyl)pyridine.
[0215] In some embodiments, the CXCR4 antagonist is a compound selected from the group consisting of: l-[2,6-dimethoxypyrid-4-yl(methylene)]-l,4,8,l l-tetraazacyclotetradecane; 1- [2-chloropyrid-4-yl(methylene)]-l,4,8,l l-tetraazacyclotetradecane; l-[2,6-dimethylpyrid-4- yl(methylene)]-l,4,8,l l-tetraazacyclotetradecane; l-[2-methylpyrid-4-yl(methylene)]- 1,4, 8,1 l-tetraazacyclotetradecane; l-[2,6-dichloropyrid-4-yl(methylene)]-l,4,8,l 1- tetraazacyclotetradecane; l-[2-chloropyrid-5-yl(methylene)]-l,4,8,l l- tetraazacyclotetradecane; and 7-[4-methylphenyl (methylene)] -4,7, 10,17- tetraazabicyclo[ 13.3.1 ]heptadeca- 1 (17), 13 , 15-triene. [0216] In some embodiments, the CXCR4 antagonist is a compound described in US Patent No. 5,698,546, the disclosure of which is incorporated herein by reference as it pertains to CXCR4 antagonists. In some embodiments, the CXCR4 antagonist may be a compound selected from the group consisting of: 7,7'-[l,4-phenylene-bis(methylene)]bis-3,7, 11,17- tetraazabicyclo[ 13.3.1 Jheptadeca- 1 (17), 13 , 15-triene; 7,7 '-[ 1 , 4-phenyl ene- bis(methylene)]bis[l5-chloro-3,7,l l,l7-tetraazabicyclo [l3.3. l]heptadeca-l (17), 13,15- triene] ; 7,7 '-[ 1 , 4-phenyl ene-bis(m ethyl ene)]bis[ 15-methoxy-3 ,7, 11,17- tetraazabicyclo[ 13.3.1 Jheptadeca- 1 (17), 13 , 15-triene] ; 7,7'-[ 1 , 4-phenyl ene- bis(methylene)]bis-3,7,l l,l7-tetraazabicyclo[l3.3.l]-heptadeca-l3,l6-triene-l5-one; 7,7'- [l,4-phenylene-bis(methylene)]bis-4,7,l0,l7-tetraazabicyclo[l3.3.l]-heptadeca-l(l7),l3,l5- triene; 8,8'-[l,4-phenylene-bis(methylene)]bis-4,8,l2,l9-tetraazabicyclo[l5.3. l]nonadeca- l(l9),l5,l7-triene; 6,6'-[l,4-phenylene-bis(methylene)]bis-3,6,9,l5- tetraazabicyclo[l l.3. l]pentadeca-l (l5),l l,l3-triene; 6,6'-[l,3-phenylene-bis(methylene)]bis- 3,6,9,l5-tetraazabicyclo[l l.3. l]pentadeca-l (l5),l l,l3-triene; and l7,l7'-[l,4-phenylene- bis(methylene)]bis-3,6, l4,l7,23,24-hexaazatricyclo[l7.3.l. l8 12]tetracosa- 1 (23), 8, 10, 12(24), 19,21 -hexaene.
[0217] In some embodiments, the CXCR4 antagonist is a compound described in US Patent No. 5,021,409, the disclosure of which is incorporated herein by reference as it pertains to CXCR4 antagonists. In some embodiments, the CXCR4 antagonist may be a compound selected from the group consisting of: 2,2'-bicyclam, 6,6'-bicyclam; 3,3 '-(bis-l,5,9, 13- tetraaza cyclohexadecane); 3,3'-(bis-l,5,8,l l,l4-pentaazacyclohexadecane); methylene (or polymethylene) di-l-N-l,4,8,l l-tetraaza cyclotetradecane; 3,3 '-bis-l,5,9, 13- tetraazacyclohexadecane; 3,3'-bis-l,5,8,l l,l4-pentaazacyclohexadecane; 5,5'-bis-l,4,8,l 1- tetraazacyclotetradecane; 2,5'-bis-l,4,8,l l-tetraazacyclotetradecane; 2,6'-bis-l,4,8,l 1- tetraazacyclotetradecane; 11,11 '-(l,2-ethanediyl)bis-l,4,8,l l-tetraazacyclotetradecane;
11,11 '-(l,2-propanediyl)bis-l,4,8,l l-tetraazacyclotetradecane; 11,11 '-(l,2-butanediyl)bis- 1,4, 8,1 l-tetraazacyclotetradecane; 11,11 '-(l,2-pentanediyl)bis-l,4,8,l 1- tetraazacyclotetradecane; and 11,1 l'-(l,2-hexanediyl)bis-l, 4, 8,1 l-tetraazacyclotetradecane.
[0218] In some embodiments, the CXCR4 antagonist is a compound described in WO 2000/056729, the disclosure of which is incorporated herein by reference as it pertains to CXCR4 antagonists. In some embodiments, the CXCR4 antagonist may be a compound selected from the group consisting of: N-(2-pyridinylmethyl)-N'-(6,7,8,9-tetrahydro-5H- cyclohepta[b]pyridin-9-yl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(5, 6,7,8- tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(6,7-dihydro- 5H-cyclopenta[b]pyridin-7-yl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'- (l,2,3,4-tetrahydro-l-naphthalenyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'- (l-naphthalenyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(8-quinolinyl)-l,4- benzenedimethanamine; N-(2-pyridinylmethyl)-N'-[2-[(2-pyridinylmethyl)amino]ethyl]-N'- (l-methyl-l,2,3,4-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2- pyridinylmethyl)-N'-[2-[(lH-imidazol -2 -ylmethyl)amino]ethyl]-N'-(l -methyl- 1,2, 3,4- tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(l, 2,3,4- tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-[2-[(lH- imidazol-2-ylmethyl)amino]ethyl]-N'-(l ,2,3 ,4-tetrahydro- 1 -naphthalenyl)- 1 ,4- benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(2-phenyl-5,6,7,8-tetrahydro-8- quinolinyl)-l,4-benzenedimethanamine; N,N'-bis(2-pyridinylmethyl)-N'-(2 -phenyl-5, 6,7,8- tetrahydro-8-quinolinyl)- 1 ,4-benzenedimethanamine;
[0219] N-(2-pyridinylmethyl)-N'-(5,6,7,8-tetrahydro-5-quinolinyl)-l,4- benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(lH-imidazol-2-ylmethyl)-N'-(5,6,7,8- tetrahydro-5-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(lH- imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2- pyridinylmethyl)-N'-[(2-amino-3-phenyl)propyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4- benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(lH-imidazol-4-ylmethyl)-N'-(5, 6,7,8- tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(2- quinolinylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2- pyridinylmethyl)-N'-(2-(2-naphthoyl)aminoethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4- benzenedimethanamine; N-(2-pyridinylmethyl)-N'-[(S)-(2-acetylamino-3-phenyl)propyl]-N'- (5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-[(S)- (2-acetylamino-3-phenyl)propyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4- benzenedimethanamine; N-(2-pyridinylmethyl)-N'-[3-((2- naphthalenylmethyl)amino)propyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4- benzenedimethanamine; N-(2-pyridinylmethyl)-N'-[2-(S)-pyrollidinylmethyl]-N'-(5, 6,7,8- tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-[2-(R)- pyrollidinylmethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2- pyridinylmethyl)-N'-[3-pyrazolylmethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4- benzenedimethanamine; N-(2-pyridinylmethyl)-N'-[2-pyrrolylmethyl]-N'-(5,6,7,8-tetrahydro- 8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-[2-thiopheneylmethyl]- N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'- [2-thiazolylmethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2- pyridinylmethyl)-N'-[2-furanylmethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4- benzenedimethanamine; N-(2-pyridinylmethyl)-N'-[2-[(phenylmethyl)amino]ethyl]-N'- (5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(2- aminoethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2- pyridinylmethyl)-N'-3-pyrrolidinyl-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4- benzenedimethanamine; N-(2-pyridinylmethyl)-N'-4-piperidinyl-N'-(5,6,7,8-tetrahydro-8- quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-[2-[(phenyl)amino]ethyl]- N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'- (7-methoxy-l,2,3,4-tetrahydro-2-naphthalenyl)-l,4-benzenedimethanamine; N-(2- pyridinylmethyl)-N'-(6-methoxy- 1,2,3, 4-tetrahydro-2-naphthalenyl)- 1,4- benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(l -methyl- 1,2,3, 4-tetrahydro-2- naphthalenyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(7-methoxy-3,4- dihydronaphthalenyl)-l-(aminomethyl)-4-benzamide; N-(2-pyridinylmethyl)-N'-(6-methoxy-
3.4-dihydronaphthalenyl)-l-(aminomethyl)-4-benzamide; N-(2-pyridinylmethyl)-N'-(lH- imidazol-2-ylmethyl)-N'-(7-methoxy-l,2,3,4-tetrahydro-2-naphthalenyl)-l,4- benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(8-hydroxy- 1,2,3, 4-tetrahydro-2- naphthalenyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(lH-imidazol-2- ylmethyl)-N'-(8-hydroxy- 1 ,2,3 ,4-tetrahydro-2-naphthalenyl)- 1 ,4-benzenedimethanamine; N- (2-pyridinylmethyl)-N'-(8-Fluoro- 1 ,2,3 ,4-tetrahydro-2-naphthalenyl)- 1 ,4- benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(lH-imidazol-2-ylmethyl)-N'-(8-Fluoro-
1.2.3.4-tetrahydro-2-naphthalenyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'- (5,6,7,8-tetrahydro-7-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(lH- imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-7-quinolinyl)-l,4-benzenedimethanamine; N-(2- pyridinylmethyl)-N'-[2-[(2-naphthalenylmethyl)amino]ethyl]-N'-(5,6,7,8-tetrahydro-8- quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-[2-(isobutylamino)ethyl]- N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'- [2-[(2-pyridinylmethyl)amino]ethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4- benzenedimethanamine; N-(2-pyridinylmethyl)-N'-[2-[(2-furanylmethyl)amino]ethyl]-N'- (5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(2- guanidinoethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2- pyridinylmethyl)-N'-[2-[bis-[(2-methoxy)phenylmethyl]amino]ethyl]-N'-(5,6,7,8-tetrahydro- 8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-[2-[(lH-imidazol-4- ylmethyl)amino]ethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N- (2-pyridinylmethyl)-N'-[2-[(lH-imidazol-2-ylmethyl)amino]ethyl]-N'-(5,6,7,8-tetrahydro-8- quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-[2-(phenylureido)ethyl]- N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'- [[N''-(n-butyl)carboxamido]methyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4- benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(carboxamidomethyl)-N'-(5, 6,7,8- tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-[(N"- phenyl)carboxamidomethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4- benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(carboxymethyl)-N'-(5,6,7,8-tetrahydro-8- quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(phenylmethyl)-N'- (5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(lH- benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(5, 6-dimethyl- lH-benzimidazol-2-ylmethyl)-N'-(5, 6,7,8- tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine (hydrobromide salt); N-(2- pyridinylmethyl)-N'-(5-nitro-lH-benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-8- quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-[(lH)-5-azabenzimidazol- 2-ylmethyl]-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2- pyridinylmethyl)-N-(4-phenyl-lH-imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)- l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-[2-(2-pyridinyl)ethyl]-N'-(5, 6,7,8- tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(2- benzoxazolyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2- pyridinylmethyl)-N'-(trans-2-aminocyclohexyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4- benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(2-phenylethyl)-N'-(5,6,7,8-tetrahydro-8- quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'-(3-phenylpropyl)-N'- (5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(2-pyridinylmethyl)-N'- (trans-2-aminocyclopentyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8- quinolinyl)-glycinamide; N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N- (5,6,7,8-tetrahydro-8-quinolinyl)-(L)-alaninamide; N-[[4-[[(2- pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-(L)- aspartamide; N-[[4-[[(2 -pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5, 6,7,8- tetrahydro-8 -quinolinyl)-pyrazinamide; N-[ [4- [[(2- pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-(L)- prolinamide; N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5, 6,7,8- tetrahydro-8-quinolinyl)-(L)-lysinamide; N-[[4-[[(2- pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)- benzamide; N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro- 8-quinolinyl)-picolinamide; N'-Benzyl-N-[[4-[[(2- pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)-urea; N'- phenyl-N-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydro-8- quinolinyl)-urea; N-(6,7,8,9-tetrahydro-5H-cyclohepta[bacteriapyridin-9-yl)-4-[[(2- pyridinylmethyl)amino]methyl]benzamide; N-(5,6,7,8-tetrahydro-8-quinol inyl)-4-[[(2- pyridinylmethyl)amino]methyl]benzamide; N,N'-bis(2-pyridinylmethyl)-N'-(5, 6,7,8- tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N,N'-bis(2-pyridinylmethyl)-N'- (6,7,8,9-tetrahydro-5H-cyclohepta[bacteriapyridin-9-yl)-l,4-benzenedimethanamine; N,N'- bis(2-pyridinylmethyl)-N'-(6,7-dihydro-5H-cyclopenta[bacteriapyridin-7-yl)-l,4- benzenedimethanamine; N,N'-bis(2-pyridinylmethyl)-N'-(l,2,3,4-tetrahydro-l-naphthalenyl)- l,4-benzenedimethanamine; N,N'-bis(2-pyridinylmethyl)-N'-[(5,6,7,8-tetrahydro-8- quinolinyl)m ethyl]- l,4-benzenedimethanamine; N,N'-bis(2-pyridinylmethyl)-N'[(6,7- dihydro-5H-cyclopenta[bacteriapyridin-7-yl)methyl]-l,4-benzenedimethanamine; N-(2- pyridinylmethyl)-N-(2-methoxyethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4- benzenedimethanamine; N-(2-pyridinylmethyl)-N-[2-(4-methoxyphenyl)ethyl]-N'-(5, 6,7,8- tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N,N'-bis(2-pyridinylmethyl)-l,4- (5,6,7,8-tetrahydro-8-quinolinyl)benzenedimethanamine; N-[(2,3-dimethoxyphenyl)methyl]- N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N,N'-bis(2-pyridinylmethyl)-N-[l-(N''-phenyl-N"-methylureido)-4-piperidinyl]-l,3- benzenedimethanamine; N,N'-bis(2-pyridinylmethyl)-N-[N"-p-toluenesulfonylphenylalanyl)- 4-piperidinyl]-l,3-benzenedimethanamine; N,N'-bis(2-pyridinylmethyl)-N-[l-[3-(2- chlorophenyl)-5-methyl-isoxazol-4-oyl]-4-piperidinyl]-l,3-benzenedimethanamine; N-[(2- hydroxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H- cyclohepta[bacteriapyridin-9-yl)-l,4-benzenedimethanamine; N-[(4-cyanophenyl)methyl]-N'- (2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[bacteriapyridin-9-yl)-l,4- benzenedimethanamine; N-[(4-cyanophenyl)methyl]-N'-(2-pyridinylmethyl)-N-(5, 6,7,8- tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-[(4-acetamidophenyl)methyl]-N'-(2- pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-[(4- phenoxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H- cyclohepta[bacteriapyridin-9-yl)-l,4-benzenedimethanamine; N-[(l-methyl-2- carboxamido)ethyl]-N,N'-bis(2-pyridinylmethyl)-l,3-benzenedimethanamine; N-[(4- benzyloxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H- cyclohepta[bacteriapyridin-9-yl)-l,4-benzenedimethanamine; N-[(thiophene-2-yl)methyl]-N'- (2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[bacteriapyridin-9-yl)-l,4- benzenedimethanamine; N-[ 1 -(benzyl)-3 -pyrrolidinyl] -N,N'-bis(2-pyridinylmethyl)- 1,3- benzenedimethanamine; N-[[l-methyl-3-(pyrazol-3-yl)]propyl]-N,N'-bis(2-pyridinylmethyl)- 1 ,3 -benzenedimethanamine; N-[ 1 -(phenyl)ethyl]-N,N'-bis(2-pyridinylmethyl)- 1,3- benzenedimethanamine; N-[(3, 4-methyl enedioxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N- (6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-l,4-benzenedimethanamine; N-[l-benzyl-
3-carboxymethyl-4-piperidinyl]-N,N'-bis(2-pyridinylmethyl)-l,3-benzenedimethanamine; N- [(3,4-methylenedioxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8- quinolinyl)-l,4-benzenedimethanamine; N-(3-pyridinylmethyl)-N'-(2-pyridinylmethyl)-N- (6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-l,4-benzenedimethanamine; N-[[l- methyl-2-(2-tolyl)carboxamido]ethyl]-N,N'-bis(2-pyridinylmethyl)-l,3- benzenedimethanamine; N-[(l,5-dimethyl-2-phenyl-3-pyrazolinone-4-yl)methyl]-N'-(2- pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-[(4- propoxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H- cyclohepta[b]pyridin-9-yl)-l,4-benzenedimethanamine; N-(l-phenyl-3,5-dimethylpyrazolin-
4-ylmethyl)-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4- benzenedimethanamine; N-[H-imidazol-4-ylmethyl]-N,N'-bis(2-pyridinylmethyl)-l,3- benzenedimethanamine; N-[(3-methoxy-4,5-methylenedioxyphenyl)methyl]-N'-(2- pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-l,4- benzenedimethanamine; N-[(3-cyanophenyl)methyl]-N'-(2-pyridinylmethyl)-N-(6, 7,8,9- tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-l,4-benzenedimethanamine; N-[(3- cyanophenyl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4- benzenedimethanamine; N-(5-ethylthiophene-2-ylmethyl)-N'-(2-pyridinylmethyl)-N-(6, 7,8,9- tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-l,4-benzenedimethanamine; N-(5-ethylthiophene- 2-ylmethyl)-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4- benzenedimethanamine; N-[(2,6-difluorophenyl)methyl]-N'-(2-pyridinylmethyl)-N-(6, 7,8,9- tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-l,4-benzenedimethanamine; N-[(2,6- difluorophenyl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4- benzenedimethanamine; N-[(2-difluoromethoxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N- (6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-l,4-benzenedimethanamine; N-(2- difluoromethoxyphenylmethyl)-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)- l,4-benzenedimethanamine; N-(l,4-benzodioxan-6-ylmethyl)-N'-(2-pyridinylmethyl)-N- (6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-l,4-benzenedimethanamine; N,N'-bis(2- pyridinylmethyl)-N-[l-(N''-phenyl-N''-methylureido)-4-piperidinyl]-l,4- benzenedimethanamine; N,N'-bis(2-pyridinylmethyl)-N-[N"-p-toluenesulfonylphenylalanyl)- 4-piperidinyl]-l,4-benzenedimethanamine; N-[l-(3-pyridinecarboxamido)-4-piperidinyl]- N,N'-bis(2-pyridinylmethyl)-l,4-benzenedimethanamine; N-[l-(cyclopropylcarboxamido)-4- piperidinyl]-N,N'-bis(2-pyridinylmethyl)-l,4-benzenedimethanamine; N-[l-(l- phenylcyclopropylcarboxamido)-4-piperidinyl]-N,N'-bis(2-pyridinylmethyl)-l,4- benzenedimethanamine; N-(l,4-benzodioxan-6-ylmethyl)-N'-(2-pyridinylmethyl)-N-(5,6,7,8- tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-[l-[3-(2-chlorophenyl)-5-methyl- isoxazol-4-carboxamido]-4-piperidinyl]-N,N'-bis(2-pyridinylmethyl)-l,4- benzenedimethanamine; N-[l-(2-thiomethylpyridine-3-carboxamido)-4-piperidinyl]-N,N'- bis(2-pyridinylmethyl)-l,4-benzenedimethanamine; N-[(2,4-difluorophenyl)methyl]-N'-(2- pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(l- methylpyrrol-2-ylmethyl)-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4- benzenedimethanamine; N-[(2-hydroxyphenyl)methyl]-N'-(2 -pyridinylmethyl)-N-(5, 6,7,8- tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-[(3-methoxy-4,5- methylenedioxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)- l,4-benzenedimethanamine; N-(3-pyri dinylmethyl)-N'-(2-pyridinylmethyl)-N-(5, 6,7,8- tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-[2-(N"-morpholinomethyl)-l- cyclopentyl]-N,N'-bis(2-pyridinylmethyl)-l,4-benzenedimethanamine; N-[(l-methyl-3- piperidinyl)propyl]-N,N'-bis(2-pyridinylmethyl)-l,4-benzenedimethanamine; N-(l- methylbenzimidazol-2-ylmethyl)-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8- quinolinyl)-l,4-benzenedimethanamine; N-[l-(benzyl)-3-pyrrol idinyl]-N,N'-bis(2- pyridinylmethyl)-l,4-benzenedimethanamine; N-[[(l-phenyl-3-(N"-morpholino)]propyl]- N,N'-bis(2-pyridinylmethyl)-l,4-benzenedimethanamine; N-[l-(iso-propyl)-4-piperidinyl]- N,N'-bis(2-pyridinylmethyl)- 1 ,4-benzenedimethanamine; N-[ 1 -(ethoxycarbonyl)-4- piperidinyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4- benzenedimethanamine; N-[(l-methyl-3-pyrazolyl)propyl]-N'-(2-pyridinylmethyl)-N- (5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-[l-methyl-2-(N",N"- diethylcarboxamido)ethyl]-N,N'-bis(2-pyridinylmethyl)-l,4-benzenedimethanamine; N-[(l- methyl-2-phenylsulfonyl)ethyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)- l,4-benzenedimethanamine; N-[(2-chloro-4,5-methylenedioxyphenyl)methyl]-N'-(2- pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-[l- methyl-2-[N''-(4-chlorophenyl)carboxamido]ethyl]-N'-(2-pyridinylmethyl)-N-(5, 6,7,8- tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(l-acetoxyindol-3-ylmethyl)-N'-(2- pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-l,4- benzenedimethanamine; N-[(3-benzyloxy-4-methoxyphenyl)methyl]-N'-(2-pyridinylmethyl)- N-(6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-l,4-benzenedimethanamine; N-(3- quinolylmethyl)-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4- benzenedimethanamine; N-[(8-hydroxy)-2-quinolylmethyl]-N'-(2-pyridinylmethyl)-N- (6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-l,4-benzenedimethanamine; N-(2- quinolylmethyl)-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9- yl)-l,4-benzenedimethanamine; N-[(4-acetamidophenyl)methyl]-N'-(2-pyridinylmethyl)-N- (6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-l,4-benzenedimethanamine; N-[lH- imidazol-2-ylmethyl]-N,N'-bis(2-pyridinylmethyl)-l,4-benzenedimethanamine; N-(3- quinolylmethyl)-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9- yl)-l,4-benzenedimethanamine; N-(2-thiazolylmethyl)-N'-(2-pyridinylmethyl)-N-(6, 7,8,9- tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-l,4-benzenedimethanamine; N-(4- pyridinylmethyl)-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9- yl)-l,4-benzenedimethanamine; N-[(5-benzyloxy)benzo[b]pyrrol-3-ylmethyl]-N,N'-bis(2- pyridinylmethyl)-l,4-benzenedimethanamine; N-(l-methylpyrazol-2-ylmethyl)-N'-(2- pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-l,4- benzenedimethanamine; N-[(4-methyl)-lH-imidazol-5-ylmethyl]-N,N'-bis(2- pyridinylmethyl)-l,4-benzenedimethanamine; N-[[(4-dimethylamino)-l-napthalenyl]methyl]- N,N'-bis(2-pyridinylmethyl)-l,4-benzenedimethanamine; N-[l,5-dimethyl-2-phenyl-3- pyrazolinone-4-ylmethyl]-N,N'-bis(2-pyridinylmethyl)-l,4-benzenedimethanamine; N-[l-[(l- acetyl-2-(R)-prolinyl]-4-piperidinyl]-N-[2-(2-pyridinyl)ethyl]-N'-(2-pyridinylmethyl)-l,3- benzenedimethanamine; N-[l-[2-acetamidobenzoyl-4-piperidinyl]-4-piperidinyl]-N-[2-(2- pyridinyl)ethyl]-N'-(2-pyridinylmethyl)-l,3-benzenedimethanamine; N-[(2-cyano-2- phenyl)ethyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)- l,4-benzenedimethanamine; N-[(N"-acetyltryptophanyl)-4-piperidinyl]-N-[2-(2- pyridinyl)ethyl]-N'-(2-pyridinylmethyl)-l,3-benzenedimethanamine; N-[(N"-benzoylvalinyl)- 4-piperidinyl]-N-[2-(2-pyridinyl)ethyl]-N'-(2-pyridinylmethyl)-l,3-benzenedimethanamine; N-[(4-dimethylaminophenyl)methyl]-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H- cyclohepta[b]pyridin-9-yl)-l,4-benzenedimethanamine; N-(4-pyridinylmethyl)-N'-(2- pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(l- methylbenzimadazol-2-ylmethyl)-N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H- cyclohepta[b]pyridin-9-yl)-l,4-benzenedimethanamine; N-[l-butyl-4-piperidinyl]-N-[2-(2- pyridinyl)ethyl]-N'-(2-pyridinylmethyl)-l,3-benzenedimethanamine; N-[l-benzoyl-4- piperidinyl]-N-[2-(2-pyridinyl)ethyl]-N'-(2-pyridinylmethyl)-l,3-benzenedimethanamine; N- [l-(benzyl)-3-pyrrolidinyl]-N-[2-(2-pyridinyl)ethyl]-N'-(2-pyridinylmethyl)-l,3- benzenedimethanamine; N-[(l-methyl)benzo[b]pynOl-3-ylmethyl]-N-[2-(2-pyridinyl)ethyl]- N'-(2-pyridinylmethyl)-l,3-benzenedimethanamine; N-[lH-imidazol-4-ylmethyl]-N-[2-(2- pyridinyl)ethyl]-N'-(2-pyridinylmethyl)-l,3-benzenedimethanamine; N-[l-(benzyl)-4- piperidinyl]-N-[2-(2-pyridinyl)ethyl]-N'-(2-pyridinylmethyl)-l,4-benzenedimethanamine; N- [l-methylbenzimidazol-2-ylmethyl]-N-[2-(2-pyridinyl)ethyl]-N'-(2-pyridinylmethyl)-l,4- benzenedimethanamine; N-[(2-phenyl)benzo[b]pynOl-3-ylmethyl]-N-[2-(2-pyridinyl)ethyl]- N'-(2-pyridinylmethyl)-l,4-benzenedimethanamine; N-[(6-methylpyridin-2-yl)methyl]-N'-(2- pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-l,4-benzenedimethanamine; N-(3- methyl-lH-pyrazol-5-ylmethyl)-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)- l,3-benzenedimethanamine; N-[(2-methoxyphenyl)methyl]-N'-(2-pyridinylmethyl)-N- (5,6,7,8-tetrahydro-8-quinolinyl)-l,3-benzenedimethanamine; N-[(2-ethoxyphenyl)methyl]- N'-(2-pyridinylmethyl)-N-(6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-l,3- benzenedimethanamine; N-(benzyloxyethyl)-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8- quinolinyl)-l,3-benzenedimethanamine; N-[(2-ethoxy-l-naphthalenyl)methyl]-N'-(2- pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-l,3-benzenedimethanamine; N-[(6- methylpyridin-2-yl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)-l,3- benzenedimethanamine; l-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]guanidine; N-(2-pyridinylmethyl)-N-(8-methyl-8-azabicyclo[3.2.l]octan-3-yl)-l,4- benzenedimethanamine; l-[[4-[[(2- pyridinylmethyl)amino]methyl]phenyl]methyl]homopiperazine; l-[[3-[[(2- pyridinylmethyl)amino]methyl]phenyl]methyl]homopiperazine; trans and cis-l-[[4-[[(2- pyridinylmethyl)amino]methyl]phenyl]methyl]-3,5-piperidinediamine; N,N'-[l,4- Phenylenebis(methylene)]bis-4-(2-pyrimidyl)piperazine; l-[[4-[[(2- pyridinylmethyl)amino]methyl]phenyl]methyl]-l-(2-pyridinyl)methylamine; 2-(2-pyridinyl)- 5-[[(2-pyridinylmethyl)amino]methyl]-l,2,3,4-tetrahydroisoquinoline; l-[[4-[[(2- pyridinylmethyl)amino]methyl]phenyl]methyl]-3,4-diaminopyrrolidine; l-[[4-[[(2- pyridinylmethyl)amino]methyl]phenyl]methyl]-3,4-diacetylaminopyrrolidine; 8-[[4-[[(2- pyridinylmethyl)amino]methyl]phenyl]methyl]-2,5,8-triaza-3-oxabicyclo [4.3.0]nonane; and 8-[[4-[[(2-pyridinylmethyl)amino]methyl]phenyl]methyl]-2,5,8-triazabicyclo[4.3.0]nonane.
[0220] Additional CXCR4 antagonists that may be used to in conjunction with the compositions and methods described herein include those described in WO 2001/085196, WO 1999/050461, WO 2001/094420, and WO 2003/090512, the disclosures of each of which are incorporated herein by reference as they pertain to compounds that inhibit CXCR4 activity or expression.
Expansion of Hematopoietic Stem and Progenitor Cells
[0221] Prior to infusion into a patient, hematopoietic and progenitor cells may be expanded ex vivo , for example, by contacting the cells with an aryl hydrocarbon receptor antagonist. Aryl hydrocarbon receptor antagonists useful in conjunction with the compositions and methods described herein include those described in US Patent No. 9,580,426, the disclosure of which is incorporated herein by reference in its entirety.
[0222] In some embodiments, aryl hydrocarbon receptor antagonists include those represented by formula (III)
Figure imgf000215_0001
in which:
L is selected from— NR5a(CH2)2-3,— NR5a(CH2)2NR5b— — NR5a(CH2)2S— ,—
NR5aCH2CH(OH)— and— NR5aCH(CH3)CH2— ; wherein R5a and R5b are independently selected from hydrogen and Ci-4 alkyl;
Ri is selected from thiophenyl, lH-benzoimidazolyl, isoquinolinyl, lH-imidazopyridinyl, benzothiophenyl, pyrimidinyl, pyridinyl, pyrazinyl, pyridazinyl, and thiazolyl; In some embodiments, wherein the thiophenyl, lH-benzoimidazolyl, isoquinolinyl, 1H- imidazopyridinyl, benzothiophenyl, pyrimidinyl, pyridinyl, pyrazinyl, pyridazinyl, or thiazolyl of Ri can be optionally substituted by 1 to 3 radicals independently selected from cyano, hydroxy, Cl-4 alkyl, Ci-4 alkoxy, halo, halo- sub stituted-Cl- alkyl, halo- sub stituted-Ci. 4alkoxy, amino,— C(0)R8a,— S(O)0-2R8a,— C(0)0R8a and— C(0)NR8aR8b; wherein R8a and R8b are independently selected from hydrogen and Ci-4alkyl;
R2 is selected from— S(0)2NR6aR6b,— NR aC(0)R6b— ,— NR6aC(0)NR6bRr,c, phenyl, 1H- pyrrol opyri din-3 -yl, lH-pyrrolopyridin-5-yl, lH-indolyl thiophenyl, pyridinyl, lH-l,2,4- triazolyl, 2-oxoimidazolidinyl, lH-pyrazolyl, 2-oxo-2,3-dihydro-lH-benzoimidazolyl and lH-indazolyl; wherein R6a, Rf,b and R6c are independently selected from hydrogen and Ci. 4alkyl; and the phenyl, lH-pyrrol opyri din-3 -yl, lH-pyrrolo[2,3-b]pyridin-5-yl, lH-indolyl, thiophenyl, pyridinyl, lH-l,2,4-triazolyl, 2-oxoimidazolidinyl, lH-pyrazolyl, 2-oxo-2,3- dihydro-lH-benzoimidazolyl or lH-indazolyl of R2 is optionally substituted with 1 to 3 radicals independently selected from hydroxy, halo, methyl, methoxy, amino,—
0(CH2)2NR7aR7b,— S(0)2NR7aR7b,— 0S(0)2NR7aR7b and— NR7aS(0)2R7b; wherein Rva and R7b are independently selected from hydrogen and Ci-4 alkyl;
R3 is selected from hydrogen, Ci- alkyl and biphenyl; and
Rris selected from C M O alkyl, prop-l-en-2-yl, cyclohexyl, cyclopropyl, 2-(2-oxopyrrolidin-l- yl)ethyl, oxetan-2-yl, oxetan-3-yl, benzhydryl, tetrahydro-2H-pyran-2-yl, tetrahydro-2H- pyran-3-yl, phenyl, tetrahydrofuran-3-yl, and benzyl, (4-pentylphenyl)(phenyl)methyl and 1- (l-(2-oxo-6,9, l2-trioxa-3-azatetradecan-l4-yl)-lH-l,2,3-triazol-4-yl)ethyl wherein said alkyl, cyclopropyl, cyclohexyl, 2-(2-oxopyrrolidin-l-yl)ethyl, oxetan-3-yl, oxetan-2-yl, benzhydryl, tetrahydro-2H-pyran-2-yl, tetrahydro-2H-pyran-3-yl, phenyl, tetrahydrofuran-3-yl, benzyl, (4-pentylphenyl)(phenyl)methyl or l-(l-(2-oxo-6,9, l2-trioxa-3-azatetradecan-l4-yl)-lH- l,2,3-triazol-4-yl)ethyl can be optionally substituted with 1 to 3 radicals independently selected from hydroxy, Ci- alkyl and halo-substituted-Ci- alkyl; or a salt thereof.
[0223] In some embodiments, aryl hydrocarbon receptor antagonists useful in conjunction with the compositions and methods described herein include SR-l, represented by formula (1), below.
Figure imgf000217_0001
Methods for the Recombinant Expression of Peptides and Proteins
[0224] Peptides and proteins described herein (e.g, CXCR2 agonists, such as Gro-b, Gro-b T, Gro-b N69D, Gro-b T N65D, and variants thereof) can be expressed in host cells, for example, by delivering to the host cell a nucleic acid encoding the corresponding peptide or protein. The sections that follow describe a variety of techniques that can be used for the purposes of introducing nucleic acids encoding peptides and proteins described herein to a host cell for the purposes of recombinant expression.
Transfection techniques
[0225] Techniques that can be used to introduce a polynucleotide, such as nucleic acid encoding a CXCR2 agonist, such as Gro-b, Gro-b T, Gro-b N69D, Gro-b T N65D, or a variant thereof, into a cell ( e.g ., a mammalian cell, such as a human cell) are known in the art. In some embodiments, electroporation can be used to permeabilize mammalian cells (e.g., human cells) by the application of an electrostatic potential to the cell of interest.
Mammalian cells, such as human cells, subjected to an external electric field in this manner are subsequently predisposed to the uptake of exogenous nucleic acids. Electroporation of mammalian cells is described in detail, e.g., in Chu et al. ( 1987) Nucleic Acids Research 15: 1311, the disclosure of which is incorporated herein by reference. A similar technique,
Nucleofection™, utilizes an applied electric field in order to stimulate the uptake of exogenous polynucleotides into the nucleus of a eukaryotic cell. Nucleofection™ and protocols useful for performing this technique are described in detail, e.g, in Distler el al. (2005) Experimental Dermatology 14:315, as well as in US 2010/0317114, the disclosures of each of which are incorporated herein by reference.
[0226] Additional techniques useful for the transfection of host cells for the purposes of recombinant peptide and protein expression include the squeeze-poration methodology. This technique induces the rapid mechanical deformation of cells in order to stimulate the uptake of exogenous DNA through membranous pores that form in response to the applied stress. This technology is advantageous in that a vector is not required for delivery of nucleic acids into a cell, such as a human cell. Squeeze-poration is described in detail, e.g ., in Sharei et al. (2013) Journal of Visualized Experiments 8l :e50980, the disclosure of which is incorporated herein by reference.
[0227] Lipofection represents another technique useful for transfection of cells. This method involves the loading of nucleic acids into a liposome, which often presents cationic functional groups, such as quaternary or protonated amines, towards the liposome exterior. This promotes electrostatic interactions between the liposome and a cell due to the anionic nature of the cell membrane, which ultimately leads to uptake of the exogenous nucleic acids, for example, by direct fusion of the liposome with the cell membrane or by endocytosis of the complex. Lipofection is described in detail, for example, in US Patent No. 7,442,386, the disclosure of which is incorporated herein by reference. Similar techniques that exploit ionic interactions with the cell membrane to provoke the uptake of foreign nucleic acids include contacting a cell with a cationic polymer-nucleic acid complex. Exemplary cationic molecules that associate with polynucleotides so as to impart a positive charge favorable for interaction with the cell membrane are activated dendrimers (described, e.g. , in Dennig (2003) Topics in Current Chemistry 228:227, the disclosure of which is incorporated herein by reference) and diethylaminoethyl (DEAE)-dextran, the use of which as a transfection agent is described in detail, for example, in Gulick et al. (1997) Current Protocols in
Molecular Biology 40:1:9.2:9.2.1, the disclosure of which is incorporated herein by reference. Magnetic beads are another tool that can be used to transfect cells in a mild and efficient manner, as this methodology utilizes an applied magnetic field in order to direct the uptake of nucleic acids. This technology is described in detail, for example, in US 2010/0227406, the disclosure of which is incorporated herein by reference.
[0228] Another useful tool for inducing the uptake of exogenous nucleic acids by cells is laserfection, a technique that involves exposing a cell to electromagnetic radiation of a particular wavelength in order to gently permeabilize the cells and allow polynucleotides to penetrate the cell membrane. This technique is described in detail, e.g. , in Rhodes el al. (2007) Methods in Cell Biology 82:309, the disclosure of which is incorporated herein by reference. [0229] Microvesicles represent another potential vehicle that can be used to introduce a nucleic acid encoding a peptide or protein described herein into a host cell for the purpose of recombinant expression. In some embodiments, microvesicles that have been induced by the co-overexpression of the glycoprotein VSV-G with, e.g ., a genome-modifying protein, such as a nuclease, can be used to efficiently deliver proteins into a cell that subsequently catalyze the site-specific cleavage of an endogenous polynucleotide sequence so as to prepare the genome of the cell for the covalent incorporation of a polynucleotide of interest, such as a gene or regulatory sequence. The use of such vesicles, also referred to as Gesicles, for the genetic modification of eukaryotic cells is described in detail, e.g. , in Quinn el al ., Genetic Modification of Target Cells by Direct Delivery of Active Protein [abstract]. In: Methylation changes in early embryonic genes in cancer [abstract], in: Proceedings of the 18th Annual Meeting of the American Society of Gene and Cell Therapy ; 2015 May 13, Abstract No. 122.
Viral vectors for nucleic acid delivery
[0230] Viral genomes provide a rich source of vectors that can be used for the efficient delivery of exogenous nucleic acids encoding peptides and proteins described herein, such as CXCR2 agonists, including Gro-b, Gro-b T, Gro-b N69D, Gro-b T N65D, and variants thereof, into host cells for the purpose of recombinant expression. Viral genomes are particularly useful vectors for gene delivery because the polynucleotides contained within such genomes may be incorporated into the genome of a cell, for example, by way of generalized or specialized transduction. These processes may occur as part of the natural replication cycle of a viral vector, and may not require added proteins or reagents in order to induce gene integration. Examples of viral vectors that may be used to introduce a nucleic acid molecule encoding a peptide or protein described herein into a host cell for recombinant expression include parvovirus, such as adeno-associated virus (AAV), retrovirus, adenovirus (e.g, Ad5, Ad26, Ad34, Ad35, and Ad48), coronavirus, negative strand RNA viruses such as orthomyxovirus (e.g, influenza virus), rhabdovirus (e.g, rabies and vesicular stomatitis virus), paramyxovirus (e.g. measles and Sendai), positive strand RNA viruses, such as picomavirus and alphavirus, and double stranded DNA viruses including adenovirus, herpesvirus (e.g, Herpes Simplex virus types 1 and 2, Epstein-Barr virus, cytomegalovirus), and poxvirus (e.g, vaccinia, modified vaccinia Ankara (MV A), fowlpox and canarypox). Other viruses useful for delivering polynucleotides encoding peptides and proteins described herein to host cells for recombinant expression purposes include Norwalk virus, togavirus, flavivirus, reoviruses, papovavirus, hepadnavirus, and hepatitis vims, for example. Examples of retroviruses include avian leukosis-sarcoma, mammalian C-type, B-type viruses, D-type viruses, HTLV-BLV group, lentivirus, spumavirus (Coffin, J. M., Retroviridae: The viruses and their replication, In Fundamental Virology, Third Edition, B. N. Fields, et al. , Eds., Lippincott-Raven Publishers, Philadelphia, 1996). Other examples include murine leukemia viruses, murine sarcoma viruses, mouse mammary tumor vims, bovine leukemia vims, feline leukemia vims, feline sarcoma vims, avian leukemia vims, human T-cell leukemia vims, baboon endogenous vims, Gibbon ape leukemia vims, Mason Pfizer monkey vims, simian immunodeficiency vims, simian sarcoma vims, Rous sarcoma vims and lentivimses. Other examples of vectors are described, for example, in ETS Patent No. 5,801,030, the disclosure of which is incorporated herein by reference as it pertains to viral vectors for use in gene delivery and recombinant protein and peptide expression.
Methods of Treatment
[0231] As described herein, hematopoietic stem cell transplant therapy can be administered to a subject in need of treatment so as to populate or repopulate one or more blood cell types, such as a blood cell lineage that is deficient or defective in a patient suffering from a stem cell disorder. Hematopoietic stem and progenitor cells exhibit multi-potency, and can thus differentiate into multiple different blood lineages including, but not limited to, granulocytes ( e.g ., promyelocytes, neutrophils, eosinophils, basophils), erythrocytes (e.g, reticulocytes, erythrocytes), thrombocytes (e.g, megakaryoblasts, platelet producing megakaryocytes, platelets), monocytes (e.g, monocytes, macrophages), dendritic cells, microglia, osteoclasts, and lymphocytes (e.g, NK cells, B-cells and T-cells). Hematopoietic stem cells are additionally capable of self-renewal, and can thus give rise to daughter cells that have equivalent potential as the mother cell, and also feature the capacity to be reintroduced into a transplant recipient whereupon they home to the hematopoietic stem cell niche and re- establish productive and sustained hematopoiesis. Thus, hematopoietic stem and progenitor cells represent a useful therapeutic modality for the treatment of a wide array of disorders in which a patient has a deficiency or defect in a cell type of the hematopoietic lineage. The deficiency or defect may be caused, for example, by depletion of a population of endogenous cells of the hematopoietic system due to administration of a chemotherapeutic agent (e.g, in the case of a patient suffering from a cancer, such as a hematologic cancer described herein). The deficiency or defect may be caused, for example, by depletion of a population of endogenous hematopoietic cells due to the activity of self-reactive immune cells, such as T lymphocytes or B lymphocytes that cross-react with self antigens ( e.g ., in the case of a patient suffering from an autoimmune disorder, such as an autoimmune disorder described herein). Additionally or alternatively, the deficiency or defect in cellular activity may be caused by aberrant expression of an enzyme (e.g., in the case of a patient suffering from various metabolic disorders, such as a metabolic disorder described herein).
[0232] Thus, hematopoietic stem cells can be administered to a patient defective or deficient in one or more cell types of the hematopoietic lineage in order to re-constitute the defective or deficient population of cells in vivo , thereby treating the pathology associated with the defect or depletion in the endogenous blood cell population. Hematopoietic stem and progenitor cells can be used to treat, e.g, a non-malignant hemoglobinopathy (e.g, a hemoglobinopathy selected from the group consisting of sickle cell anemia, thalassemia, Fanconi anemia, aplastic anemia, and Wiskott-Aldrich syndrome). In these cases, for example, a CXCR4 antagonist and/or a CXCR2 agonist may be administered to a donor, such as a donor identified as likely to exhibit release of a population of hematopoietic stem and progenitor cells from a stem cell niche, such as the bone marrow, into circulating peripheral blood in response to such treatment. The hematopoietic stem and progenitor cells thus mobilized may then be withdrawn from the donor and administered to a patient, where the cells may home to a hematopoietic stem cell niche and re-constitute a population of cells that are damaged or deficient in the patient.
[0233] Additionally or alternatively, hematopoietic stem and progenitor cells can be used to treat an immunodeficiency, such as a congenital immunodeficiency. Additionally or alternatively, the compositions and methods described herein can be used to treat an acquired immunodeficiency (e.g, an acquired immunodeficiency selected from the group consisting of HIV and AIDS). In these cases, for example, a CXCR4 antagonist and/or a CXCR2 agonist may be administered to a donor, such as a donor identified as likely to exhibit release of a population of hematopoietic stem and progenitor cells from a stem cell niche, such as the bone marrow, into circulating peripheral blood in response to such treatment. The hematopoietic stem and progenitor cells thus mobilized may then be withdrawn from the donor and administered to a patient, where the cells may home to a hematopoietic stem cell niche and re-constitute a population of immune cells (e.g, T lymphocytes, B lymphocytes, NK cells, or other immune cells) that are damaged or deficient in the patient. [0234] Hematopoietic stem and progenitor cells can also be used to treat a metabolic disorder (e.g, a metabolic disorder selected from the group consisting of glycogen storage diseases, mucopolysaccharidoses, Gaucher's Disease, Hurlers Disease, sphingolipidoses, and metachromatic leukodystrophy). In these cases, for example, a CXCR4 antagonist and/or a CXCR2 agonist may be administered to a donor, such as a donor identified as likely to exhibit release of a population of hematopoietic stem and progenitor cells from a stem cell niche, such as the bone marrow, into circulating peripheral blood in response to such treatment. The hematopoietic stem and progenitor cells thus mobilized may then be withdrawn from the donor and administered to a patient, where the cells may home to a hematopoietic stem cell niche and re-constitute a population of hematopoietic cells that are damaged or deficient in the patient.
[0235] Additionally or alternatively, hematopoietic stem or progenitor cells can be used to treat a malignancy or proliferative disorder, such as a hematologic cancer or
myeloproliferative disease. In the case of cancer treatment, for example, a CXCR4 antagonist and/or a CXCR2 agonist may be administered to a donor, such as a donor identified as likely to exhibit release of a population of hematopoietic stem and progenitor cells from a stem cell niche, such as the bone marrow, into circulating peripheral blood in response to such treatment. The hematopoietic stem and progenitor cells thus mobilized may then be withdrawn from the donor and administered to a patient, where the cells may home to a hematopoietic stem cell niche and re-constitute a population of cells that are damaged or deficient in the patient, such as a population of hematopoietic cells that is damaged or deficient due to the administration of one or more chemotherapeutic agents to the patient. In some embodiments, hematopoietic stem or progenitor cells may be infused into a patient in order to repopulate a population of cells depleted during cancer cell eradication, such as during systemic chemotherapy. Exemplary hematological cancers that can be treated by way of administration of hematopoietic stem and progenitor cells in accordance with the compositions and methods described herein are acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia, multiple myeloma, diffuse large B-cell lymphoma, and non-Hodgkin’s lymphoma, as well as other cancerous conditions, including neuroblastoma.
[0236] Hematopoietic stem or progenitor cells mobilized to the peripheral blood of a subject may be withdrawn (e.g, harvested or collected) from the subject by any suitable technique.
For example, the hematopoietic stem or progenitor cells may be withdrawn by a blood draw. In some embodiments, hematopoietic stem or progenitor cells mobilized to a subject’s peripheral blood as contemplated herein may be harvested (i.e., collected) using apheresis. In some embodiments, apheresis may be used to enrich a donor’s blood with mobilized hematopoietic stem or progenitor cells.
[0237] Additional diseases that can be treated by the administration of hematopoietic stem and progenitor cells to a patient include, without limitation, adenosine deaminase deficiency and severe combined immunodeficiency, hyper immunoglobulin M syndrome, Chediak- Higashi disease, hereditary lymphohistiocytosis, osteopetrosis, osteogenesis imperfecta, storage diseases, thalassemia major, systemic sclerosis, systemic lupus erythematosus, multiple sclerosis, and juvenile rheumatoid arthritis.
[0238] In addition, administration of hematopoietic stem and progenitor cells can be used to treat autoimmune disorders. In some embodiments, upon infusion into a patient, transplanted hematopoietic stem and progenitor cells may home to a stem cell niche, such as the bone marrow, and establish productive hematopoiesis. This, in turn, can re-constitute a population of cells depleted during autoimmune cell eradication, which may occur due to the activity of self-reactive lymphocytes ( e.g ., self-reactive T lymphocytes and/or self-reactive B lymphocytes). Autoimmune diseases that can be treated by way of administering
hematopoietic stem and progenitor cells to a patient include, without limitation, psoriasis, psoriatic arthritis, Type 1 diabetes mellitus (Type 1 diabetes), rheumatoid arthritis (RA), human systemic lupus (SLE), multiple sclerosis (MS), inflammatory bowel disease (IBD), lymphocytic colitis, acute disseminated encephalomyelitis (ADEM), Addison's disease, alopecia universalis, ankylosing spondylitis, antiphospholipid antibody syndrome (APS), aplastic anemia, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune lymphoproliferative syndrome (ALPS), autoimmune oophoritis, Balo disease, Behcet's disease, bullous pemphigoid, cardiomyopathy, Chagas' disease, chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, Crohn's disease, cicatricial pemphigoid, coeliac sprue- dermatitis herpetiformis, cold agglutinin disease, CREST syndrome, Degos disease, discoid lupus, dysautonomia, endometriosis, essential mixed cryoglobulinemia, fibromyalgia- fibromyositis, Goodpasture' s syndrome, Grave's disease, Guillain-Barre syndrome (GBS), Hashimoto' s thyroiditis, Hidradenitis suppurativa, idiopathic and/or acute thrombocytopenic purpura, idiopathic pulmonary fibrosis, IgA neuropathy, interstitial cystitis, juvenile arthritis,
Kawasaki's disease, lichen planus, Lyme disease, Meniere disease, mixed connective tissue disease (MCTD), myasthenia gravis, neuromyotonia, opsoclonus myoclonus syndrome (OMS), optic neuritis, Ord's thyroiditis, pemphigus vulgaris, pernicious anemia,
polychondritis, polymyositis and dermatomyositis, primary biliary cirrhosis, polyarteritis nodosa, polyglandular syndromes, polymyalgia rheumatica, primary agammaglobulinemia, Raynaud phenomenon, Reiter' s syndrome, rheumatic fever, sarcoidosis, scleroderma, Sjogren's syndrome, stiff person syndrome, Takayasu's arteritis, temporal arteritis (also known as "giant cell arteritis"), ulcerative colitis, collagenous colitis, uveitis, vasculitis, vitiligo, vulvodynia ("vulvar vestibulitis"), and Wegener' s granulomatosis.
[0239] In some embodiments, a method of harvesting hematopoietic stem cells from a human subject is provided. The method comprises administering a CXCR2 agonist and a CXCR4 antagonist to the human subject and harvesting the hematopoietic stem cells from peripheral blood of the human subject.
[0240] In some embodiments, a method of transplanting hematopoietic stem cells into a human patient in need thereof is provided. The method comprises administering a CXCR2 agonist and a CXCR4 antagonist to a hematopoietic stem cell donor, harvesting the hematopoietic stem cells from peripheral blood of the donor, and transplanting the harvested hematopoietic stem cells into the patient.
Selection of donors and patients
[0241] In some embodiments, the patient is the donor. In such cases, withdrawn hematopoietic stem or progenitor cells may be re-infused into the patient, such that the cells may subsequently home hematopoietic tissue and establish productive hematopoiesis, thereby populating or repopulating a line of cells that is defective or deficient in the patient ( e.g ., a population of megakaryocytes, thrombocytes, platelets, erythrocytes, mast cells, myeoblasts, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, osteoclasts, antigen- presenting cells, macrophages, dendritic cells, natural killer cells, T-lymphocytes, and B- lymphocytes). In this scenario, the transplanted hematopoietic stem or progenitor cells are least likely to undergo graft rejection, as the infused cells are derived from the patient and express the same HLA class I and class II antigens as expressed by the patient.
[0242] Alternatively, the patient and the donor may be distinct. In some embodiments, the patient and the donor are related, and may, for example, be HLA-matched. As described herein, HLA-matched donor-recipient pairs have a decreased risk of graft rejection, as endogenous T cells and NK cells within the transplant recipient are less likely to recognize the incoming hematopoietic stem or progenitor cell graft as foreign, and are thus less likely to mount an immune response against the transplant. Exemplary HLA-matched donor-recipient pairs are donors and recipients that are genetically related, such as familial donor-recipient pairs ( e.g ., sibling donor-recipient pairs).
[0243] In some embodiments, the patient and the donor are HLA-mismatched, which occurs when at least one HLA antigen, in particular with respect to HLA-A, HLA-B and HLA-DR, is mismatched between the donor and recipient. To reduce the likelihood of graft rejection, for example, one haplotype may be matched between the donor and recipient, and the other may be mismatched.
CD34dim cells
[0244] When the donor and patient are distinct, methods of treatment using hematopoietic stem cells comprising CD34dim cells are particularly useful, in part because CD34dim cells are capable of suppressing alloreactive T lymphocyte proliferation when administered to a recipient, thereby reducing the risk of graft vs. host disease (GVHD). (D’ Aveni el al. (2015), supra.) In certain embodiments, administration of a CXCR2 agonist and a CXCR4 antagonist according to the methods disclosed herein mobilizes hematopoietic stem cells comprising CD34dim cells from the bone marrow of a donor into peripheral blood. The CD34dim cells are present in a higher amount in the peripheral blood as compared to peripheral blood from an unmobilized mammal. In certain embodiments, the CD34dim cells are present in a higher amount in the peripheral blood than if the hematopoietic stem cells were mobilized using the CXCR4 antagonist alone.
[0245] Accordingly, the methods disclosed herein are useful in performing an allogeneic hematopoietic stem cell transplant in a patient in need thereof. For example, the method can include infusing into the patient a therapeutically effective amount of allogeneic
hematopoietic stem cells, wherein the hematopoietic stem cells were mobilized from bone marrow of a human donor into peripheral blood of the human donor using the methods herein. In certain embodiments, the method includes administering to the donor (i) a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof at a dose of from about 50 pg/kg to about 1,000 pg/kg and (ii) a CXCR4 antagonist. [0246] In addition, CD34dim cells have been shown to increase overall survival (OS), decrease non-relapse mortality (NRM, i.e., the time to death without relapse/recurrence), and lower the risk of infection ( e.g ., cytomegalovirus (CMV) infection) in a patient having a standard risk disease receiving an allogenic hematopoietic cell transplant. (Nakasone et al. “CD34+ monocytes mobilized by G-CSF in donor PB and clinical outcomes after all-HCT from related donors,” Poster presented at 44th Annual Meeting of the European Society for Blood and Marrow Transplantation, March 18-21, 2018, Lisbon, Portugal.)
[0247] Accordingly, in certain embodiments, the methods of treating a stem cell disorder in a human patient disclosed herein can include infusing into the patient a therapeutically effective amount of the hematopoietic stem cells mobilized by any one of the methods disclosed herein, wherein the mobilized hematopoietic stem cells comprise CD34dim cells, and wherein the treatment results in increased OS, decreased NRM, and/or lowered risk of infection (e.g., CMV infection).
[0248] In addition, the methods described herein can be used in preventing, reducing the risk of developing, or reducing the severity of a post-transplant infection in a patient in need thereof. The method can include infusing into the patient a therapeutically effective amount of hematopoietic stem cells, wherein the hematopoietic stem cells were mobilized from bone marrow of a human donor into peripheral blood of the human donor according to the methods described herein, for example, administering to the human donor (i) a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof at a dose of from about 50 pg/kg to about 1,000 pg/kg and (ii) a CXCR4 antagonist. In certain embodments, the infection is a CMV infection.
[0249] In addition, the disclosure relates to a method of preventing, reducing the risk of developing, or reducing the severity of graft versus host disease (GVHD) in a patient in need thereof, wherein the method includes infusing into the patient a therapeutically effective amount of hematopoietic stem cells, wherein the hematopoietic stem cells were mobilized from bone marrow of a mammalian donor into peripheral blood by the methods described herein, e.g, including administering to the mammalian donor a CXCR2 agonist and a CXCR4 antagonist.
[0250] In certain embodiments, the hematopoietic stem and progenitor cells mobilized from the bone marrow of a donor into peripheral blood comprise at least 1%, at least 2% at least 5% at least 10%, at least 15%, at least 20% or at least 20% or more CD34dim cells as compared to peripheral blood from an unmobilized mammal. In certain embodiments, the hematopoietic stem and progenitor cells mobilized from the bone marrow of a donor into peripheral blood comprise at from about 1% to about 5%, from about 1% to about 10%, from about 1% to about 15%, from about 1% to about 20%, from about 2% to about 25%, 2% to about 5%, from about 2% to about 10%, from about 2% to about 15%, from about 2% to about 20%, from about 2% to about 25%, from about 5% to about 10%, from about 5% to about 15%, from about 5% to about 20%, from about 5% to about 25%, from about 10% to about 15%, from about 10% to about 20%, from about 10% to about 25%, from about 15% to about 20%, from about 15% to about 25% CD34dim cells as compared to peripheral blood from an unmobilized mammal.
[0251] In certain embodiments, the hematopoietic stem and progenitor cells mobilized from the bone marrow of a donor into peripheral blood comprise at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least lO-fold, at least 11 -fold, at least 12-fold, at least 13 -fold, at least 14-fold, at least 15-fold, at least 20-fold, at least 30-fold, at least 50-fold more CD34dim cells as compared to peripheral blood from an unmobilized mammal. In certain embodiments, the hematopoietic stem and progenitor cells mobilized from the bone marrow of a donor into peripheral blood comprise between about 1.5-fold and 30-fold, between about 5-fold and about 25-fold, between about lO-fold and about 20-fold, or between about l2-fold and about l7-fold more CD34dim cells as compared to peripheral blood from an unmobilized mammal.
[0252] In certain embodiments, the hematopoietic stem and progenitor cells mobilized from the bone marrow of a donor into peripheral blood comprise at least 1%, at least 2% at least 5% at least 10%, at least 15%, at least 20% or at least 20% or more CD34dim cells than if the hematopoietic stem cells were mobilized using the CXCR4 antagonist alone. In certain embodiments, the hematopoietic stem and progenitor cells mobilized from the bone marrow of a donor into peripheral blood comprise at from about 1% to about 5%, from about 1% to about 10%, from about 1% to about 15%, from about 1% to about 20%, from about 2% to about 25%, 2% to about 5%, from about 2% to about 10%, from about 2% to about 15%, from about 2% to about 20%, from about 2% to about 25%, from about 5% to about 10%, from about 5% to about 15%, from about 5% to about 20%, from about 5% to about 25%, from about 10% to about 15%, from about 10% to about 20%, from about 10% to about 25%, from about 15% to about 20%, from about 15% to about 25% CD34dim cells than if the hematopoietic stem cells were mobilized using the CXCR4 antagonist alone. [0253] In certain embodiments, the hematopoietic stem and progenitor cells mobilized from the bone marrow of a donor into peripheral blood comprise at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least lO-fold, at least 11 -fold, at least 12-fold, at least 13 -fold, at least 14-fold, at least 15-fold, at least 20-fold, at least 30-fold, at least 50-fold more CD34dim cells than if the hematopoietic stem cells were mobilized using the CXCR4 antagonist alone. In certain embodiments, the hematopoietic stem and progenitor cells mobilized from the bone marrow of a donor into peripheral blood comprise between about 1.5-fold and 30-fold, between about 5-fold and about 25-fold, between about lO-fold and about 20-fold, or between about l2-fold and about 17-fold more CD34dim cells than if the hematopoietic stem cells were mobilized using the CXCR4 antagonist alone.
Methods of Genetic Modification of Hematopoietic Stem and Progenitor Cells
[0254] Prior to infusion into a patient, such as a patient having one or more stem cell disorders described herein, hematopoietic stem cells obtained from a donor (or progeny thereof) may be genetically modified, for example, by disrupting an endogenous gene. This strategy can be used, for example, to silence the expression of one or more major
histocompatibility complex genes in a hematopoietic stem cell that is allogeneic with respect to the patient, thereby reducing the likelihood of graft rejection upon transplantation.
[0255] A wide array of methods has been established for the disruption of target genes in a population of cells. In some embodiments, one such method is through the use of a clustered regularly interspaced short palindromic repeats (CRISPR)/Cas system, a system that originally evolved as an adaptive defense mechanism in bacteria and archaea against viral infection. The CRISPR/Cas system includes palindromic repeat sequences within plasmid DNA and an associated Cas9 nuclease. This ensemble of DNA and protein directs site specific DNA cleavage of a target sequence by first incorporating foreign DNA into CRISPR loci. Polynucleotides containing these foreign sequences and the repeat-spacer elements of the CRISPR locus are in turn transcribed in a host cell to create a guide RNA, which can subsequently anneal to a target sequence and localize the Cas9 nuclease to this site. In this manner, highly site-specific cas9-mediated DNA cleavage can be engendered in a foreign polynucleotide because the interaction that brings cas9 within close proximity of the target DNA molecule is governed by RNA:DNA hybridization. As a result, one can theoretically design a CRISPR/Cas system to cleave any target DNA molecule of interest. This technique has been exploited in order to edit eukaryotic genomes (Hwang et al. (2013) Nature
Biotechnology 31 :227, the disclosure of which is incorporated herein by reference) and can be used as an efficient means of site-specifically editing hematopoietic stem cell genomes in order to cleave DNA, for example, prior to the incorporation of a gene encoding a target protein. The use of CRISPR/Cas to modulate gene expression has been described in, e.g. , US 8,697,359, the disclosure of which is incorporated herein by reference. Alternative methods for site-specifically cleaving genomic DNA prior to the incorporation of a gene of interest in a hematopoietic stem cell include the use of zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs). Unlike the CRISPR/Cas system, these enzymes do not contain a guiding polynucleotide to localize to a specific target sequence. Target specificity is instead controlled by DNA binding domains within these enzymes. The use of ZFNs and TALENs in genome editing applications is described, e.g. , in Urnov et al. (2010) Nature Reviews Genetics 11 :636; and in Joung et al. (2013) Nature Reviews Molecular Cell Biology 14:49, the disclosure of both of which are incorporated herein by reference.
[0256] Additional genome editing techniques that can be used to incorporate polynucleotides encoding target genes into the genome of a hematopoietic stem cell include the use of ARCUS™ meganucleases that can be rationally designed so as to site-specifically cleave genomic DNA. The use of these enzymes for the incorporation of genes encoding target genes into the genome of a mammalian cell is advantageous in view of the defined structure- activity relationships that have been established for such enzymes. Single chain
meganucleases can be modified at certain amino acid positions in order to create nucleases that selectively cleave DNA at desired locations, enabling the site-specific incorporation of a target gene into the nuclear DNA of a hematopoietic stem cell. These single-chain nucleases have been described extensively in, e.g. , US 8,021,867 and US 8,445,251, the disclosures of each of which are incorporated herein by reference.
Kinetics of CXCR2 Agonist and CXCR4 Antagonist Dosing
[0257] For cases in which the donor is administered both a CXCR4 antagonist and a CXCR2 agonist, the two agents may be administered to the donor concurrently. In some
embodiments, the CXCR4 antagonist and the CXCR2 agonist may be co-formulated with one another and administered in the same pharmaceutical composition. Alternatively, the CXCR4 antagonist and the CXCR2 agonist may be formulated in distinct pharmaceutical compositions and administered separately but simultaneously to the donor.
[0258] In some embodiments, the CXCR4 antagonist is administered to the donor prior to administration of the CXCR2 agonist. In some embodiments, the CXCR4 antagonist may be administered to the donor from about 30 minutes to about 180 minutes prior to administration of the CXCR2 agonist, such as from about 40 minutes to about 160 minutes, about 50 minutes to about 150 minutes, about 60 minutes to about 140 minutes, about 70 minutes to about 130 minutes, about 60 minutes to about 120 minutes, about 70 minutes to about 110 minutes, or about 80 minutes to about 100 minutes ( e.g ., about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 75 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 105 minutes, about 110 minutes, about 115 minutes, about 120 minutes, about 125 minutes, about 130 minutes, about 135 minutes, about 140 minutes, about 145 minutes, about 150 minutes, about 155 minutes, about 160 minutes, about 165 minutes, about 170 minutes, about 175 minutes, or about 180 minutes prior to administration of the CXCR2 agonist). In some embodiments, the CXCR4 antagonist is administered to the donor from about 30 minutes to about 60 minutes prior to administration of the CXCR2 agonist (e.g., about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, or about 60 minutes prior to administration of the CXCR2 agonist). In some embodiments, the CXCR4 antagonist may be administered to the donor about 45 minutes prior to administration of the CXCR2 agonist.
[0259] Isolation of the population of hematopoietic stem or progenitor cells may commence from about 10 minutes to about 60 minutes following completion of the administration of the CXCR4 antagonist and the CXCR2 agonist (e.g, about 10 minutes to about 1.9 hours, about 20 minutes to about 1.8 hours, about 25 minutes to about 1.7 hours, about 30 minutes to about 1.6 hours, about 40 minutes to about 1.5 hours (e.g, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, or about 120 minutes following completion of the administration of the CXCR4 antagonist and the CXCR2 agonist). In some embodiments, isolation of the population of hematopoietic stem or progenitor cells may commence from about 10 minutes to about 20 minutes following completion of the administration of the CXCR4 antagonist and the CXCR2 agonist (e.g, about 10 minutes, about 11 minutes, about 12 minutes, about 13 minutes, about 14 minutes, about 15 minutes, about 16 minutes, about 17 minutes, about 18 minutes, about 19 minutes, or about 20 minutes following completion of the administration of the CXCR4 antagonist and the CXCR2 agonist). In some embodiments, isolation of the population of hematopoietic stem or progenitor cells commences about 15 minutes following completion of the administration of the CXCR4 antagonist and the CXCR2 agonist.
[0260] In some embodiments, the population of hematopoietic stem or progenitor cells is isolated from the donor over a period of from about 15 minutes to about 6 hours, such as from about 20 minutes to about 4.5 hours, about 30 minutes to about 4 hours, about 40 minutes to about 3.5 hours, about 50 minutes to about 3 hours, or about 1 hour to about 2 hours ( e.g ., over a period of about 15 minutes, about 20 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 75 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 105 minutes, about 110 minutes, about 115 minutes, about 120 minutes, about 180 minutes, about 240 minutes, about 300 minutes, or about 360 minutes). In some embodiments, the population of hematopoietic stem and progenitor cells may be isolated from the donor over a period of from about 30 minutes to about 1 hour (e.g., over a period of about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, or about 60 minutes).
[0261] In some embodiments, the hematopoietic stem or progenitor cells may be harvested by apheresis. In some embodiments, the hematopoietic stem or progenitor cells may be harvested by drawing peripheral blood from the donor (i.e., subject).
Routes of Administration of CXCR2 Agonists and CXCR4 Antagonists
[0262] The CXCR4 antagonists and CXCR2 agonists described herein may be administered to a patient by a variety of routes, such as intravenously, subcutaneously, intramuscularly, or parenterally. The most suitable route for administration in any given case will depend on the particular agent administered, the patient, pharmaceutical formulation methods,
administration methods (e.g, administration time and administration route), the patient's age, body weight, sex, severity of the diseases being treated, the patient’s diet, and the patient’s excretion rate. Preferably, the CXCR2 agonist (e.g, Gro-b, Gro-b T, or a variant thereof) may be administered to a donor intravenously. Under these conditions, CXCR2 agonists, such as those described herein, rapidly give rise to populations of cells that are enriched in CD34+ CD90+ CD45RA cells (hematopoietic stem cells), and reduce the mobilization of other cell types, such as leukocytes, neutrophils, lymphocytes, and monocytes. This property is described in further detail in Example 1, below.
Pharmaceutical Compositions
[0263] The CXCR2 agonists and CXCR4 antagonists contemplated herein may each be formulated into a pharmaceutical composition for administration to a subject, such as a mammalian subject ( e.g ., a human subject). For instance, contemplated herein are pharmaceutical compositions comprising a CXCR2 agonist and/or a CXCR4 antagonist, in admixture with one or more suitable diluents, carriers, and/or excipients. Pharmaceutical compositions may include sterile aqueous suspensions. Conventional procedures and ingredients for the selection and preparation of suitable formulations are described, for example, in Remington: The Science and Practice of Pharmacy (2012, 22nd ed.) and in The United States Pharmacopeia: The National Formulary (2015, USP 38 NF 33), the disclosure of which is incorporated herein by reference in its entirety.
[0264] A pharmaceutical composition may be administered to a subject, such as a human subject, alone or in combination with pharmaceutically acceptable carriers, the proportion of which may be determined by the quantity of active pharmaceutical ingredient (i.e., CXCR2 agonist and/or a CXCR4 antagonist), chosen route of administration, and standard pharmaceutical practice.
Administration and Dosing of CXCR2 Agonists and/or CXCR4 Antagonists
[0265] Contemplated CXCR2 agonists and CXCR4 antagonists, may be administered to a subject, such as a mammalian subject (e.g., a human subject), by one or more routes of administration. For instance, contemplated CXCR2 agonists and CXCR4 antagonists may be administered to a subject by intravenous, intraperitoneal, intramuscular, intraarterial, or subcutaneous infusion, among others.
[0266] Contemplated CXCR2 agonists and CXCR4 antagonists may be administered to a subject in one or more doses. For example, a CXCR2 agonist and/or CXCR4 antagonist may be administered as a single dose or in two, three, four, five, or more doses. When multiple doses are administered, subsequent doses may be provided during the same day or one or more days, weeks, months, or years following the initial dose. For instance, the contemplated CXCR2 agonists and CXCR4 antagonists described herein may be administered to a subject, such as a human subject one or more times daily, weekly, monthly, or yearly, depending on such factors as, for instance, the subject's age, body weight, sex, the subject’s diet, and the subject’s excretion rate. In certain embodiments, the contemplated CXCR2 agonists and CXCR4 antagonists are each administered in a single dose once per day.
[0267] Hematopoietic stem or progenitor cells and pharmaceutical compositions described herein may be administered to a subject in one or more doses. When multiple doses are administered, subsequent doses may be provided one or more days, weeks, months, or years following the initial dose. For instance, the hematopoietic stem cells and pharmaceutical compositions described herein may be administered to a subject, such as a human subject suffering from one or more diseases, conditions, or disorders described herein, one or more times daily, weekly, monthly, or yearly, depending on such factors as, for instance, the subject's age, body weight, sex, severity of the diseases being treated, the subject’s diet, and the subject’s excretion rate.
Examples
[0268] The following examples are put forth so as to provide those of ordinary skill in the art with a description of how the compositions and methods described herein may be used, made, and evaluated, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention.
Example 1. The effects of Gro-b T on the mobilization of hematopoietic stem cells in mice and Rhesus monkeys
[0269] Mobilized peripheral blood grafts are currently the predominant source of
hematopoietic stem and progenitor cells (HSPC) for both autologous and allogeneic transplantation. The most common clinical hematopoietic stem cell mobilization protocol is five days of Filgrastim (G-CSF). This regimen requires daily injections, has been associated with bone pain and often results in unpredictably low yields. A rapid mobilization method that ideally only required a single treatment and had robust and predictable kinetics would be a significant improvement over the current standard of care. In mice, a unique CXCR2 agonist, Gro-b T, induces rapid mobilization of stem and progenitor cells 15 minutes after a single injection. When co-administered with plerixafor (AMD3100), an inhibitor of CXCR4, a synergistic increase in mobilization results, and grafts are enriched in highly engraftable, long-term hematopoietic stem cells (see, e.g., FIG. 1A; LT-HSC = Lin- c-kit+ Sca-l+ CDl50+ CD48+). Grafts containing cells mobilized by Gro-b T and plerixaflor led to higher relative numbers of competitive repopulating units (CRU) at week 16 than did grafts containing cells mobilized by G-CSF alone (FIG. IB).
[0270] In this example, data are presented to demonstrate that combination treatment with Gro-b T and AMD3100 results in significantly enhanced mobilization of CD34+ cells and colony forming units (CFU) compared to that achieved with AMD3100 alone in nonhuman primates (NHP).
[0271] Mobilization of hematopoietic stem cells was investigated in rhesus macaques using Gro-b T and plerixafor (also referred to as AMD3100) as described below.
Methods
[0272] Male rhesus macaques were treated with AMD3100 alone or in combination with Gro-b T. Blood was collected immediately prior to and 0.5, 1, 2, 4 and 24 hours after treatment and analyzed by multicolor flow cytometry to quantitate HSPC numbers.
Additional aliquots of mobilized blood were plated in methylcellulose and CFU were enumerated seven days later.
Results
[0273] FIG. 2A shows the pharmacokinetic profile of various dosages of Gro-b T when administered intravenously to Rhesus monkeys. FIG. 2B shows the pharmacokinetic profile of various dosages of Gro-b T when administered subcutaneously to Rhesus monkeys. In all experiments, Gro-b T was administered to subjects concurrently with plerixafor.
[0274] As shown in FIGS. 3-6, Gro-b T and AMD3100 mobilizes white blood cells into the peripheral blood. Animals were mobilized with AMD3100 alone or in combination with Gro-b T. Peripheral blood was collected at the time points shown and white blood cells enumerated on a HESKA Hematology Analyzer. Total number of white blood cells, neutrophils, lymphocytes and monocytes per pL of peripheral blood were determined. Data shown in FIGS. 2-5 are expressed as mean ± SEM and represent 5 animals per group.
Statistical significance was determined based on 2-way ANOVA with post-hoc Dunnett’s multiple comparisons test (** p < 0.01). [0275] Importantly, as shown in FIGS. 7 and 8, Gro-b T and AMD3100 induces robust mobilization of CD34+ cells into the peripheral blood. The data shown in FIGS. 7 and 8include the percentage of whole blood accounted for by CD34+ hematopoietic stem and progenitor cells for each treatment group. Absolute numbers and fold change in CD34+ cells per pL of peripheral blood were quantified with a single platform quantitative method. Data shown in FIGS. 7 and 8 are expressed as mean ± SEM and represent 5 animals per group. Statistical significance was determined based on 2-way ANOVA with post-hoc Dunnett’s multiple comparisons test (* p < 0.05, ** p < 0.01, **** p < 0.0001).
[0276] Additionally, as shown in FIGS. 9 and 10, CD34+ cells mobilized in response to Gro- b T + AMD3100 are enriched for primitive CD34+ CD90+ CD45RA- stem and progenitor cells. The data shown in FIGS. 9 and 10 include the percentage of whole blood accounted for by CD34+ CD90+ CD45RA hematopoietic stem and progenitor cells for each treatment group. Absolute numbers and fold change in CD34+ CD90+ CD45RA cells per pL of peripheral blood are shown. Data shown in FIGS. 9 and 10 are expressed as mean ± SEM and represent 5 animals per group. Statistical significance was determined based on 2-way ANOVA with post-hoc Dunnett’s multiple comparisons test (* p < 0.05. **p < 0.01, *** p <
0.001, **** p < 0.0001).
[0277] Further, as shown in FIG. 11, Gro-b T and AMD3100 mobilizes hematopoietic stem and progenitor cells with colony forming potential. The number of CFET per mL of peripheral blood was enumerated after seven days of culture in methylcellulose. Data shown in FIG. 11 are expressed as mean ± SEM and represent 3-5 animals per group. Statistical significance was determined based on 2-way ANOVA with post-hoc Dunnett’s multiple comparisons test (* p < 0.05). The ratio of MMP-9 to TIMP-l is additionally elevated following treatment with Gro-b T and AMD3100 (FIGS. 12-14).
[0278] Additional data summarizing the mobilization of CD34+ cells ( e.g ., CD34+ CD90+ CD45RA cells) in Rhesus monkeys using various doses of Gro-beta T and AMD3100 are reported in TABLES 8-11, below. Quantities are reported in TABLES 8-11 using the following notation:“Median value (Minimum value observed - maximum value observed).” TABLE 8. Mobilization response observed in Rhesus monkeys upon administration of
plerixafor (1 mg/kg, subcutaneously)
Cel
C
C
C
CD
Figure imgf000236_0002
0.0009 0.0003
3.90E+07 (3.16 - 3.7 (1.0 -
WBCs (0.0006 - (0.0002 - 2.3 (1.6 - 4.6) 2.3 (1.6 - 4.6)
4.97E+07) 7.9)
0.0012) 0.0004)
0.0015 0.0006
2.10E+07 (1.61 - 3.0 (0.4 -
Neutrophils (0.0011 - (0.0004 - 5.0 (3.0 - 14.0) 2.1 (0.6 - 3.6)
3.31E+07) 6.2)
0.0021) 0.0007)
0.0025 0.0011
1.35E+07 (1.12 - 5.7 (2.4 -
Lymphocytes (0.0020 - (0.0005 - 2.5 (1.3 - 3.1) 4.0 (2.9 - 8.2)
1.62E+07) 14.0)
0.0043) 0.0013)
0.0111 0.0039
3.10E+06 (1.55 - 1.6 (0.7 -
Monocytes (0.0047 - (0.0020 - 7.9 (5.4 - 14.1) 1.2 (0.6 - 2.0)
4.93E+06) 3.5)
Figure imgf000236_0001
0.0377) 0.0115)
TABLE 9. Mobilization response observed in Rhesus monkeys upon administration of Gro- b T (450 pg/kg, intravenously) and plerixafor (1 mg/kg, subcutaneously)
Ratio of fold
Quantity of Ratio of Fold increase
increase cells observed Ratio of quantity of vs. baseline Ratio of fold
of CD34+ 4 hours quantity of CD34+ CD90 following iv increase of
CD90+
Cell type following iv CD34+ cells CD45RA administratio CD34+ cells
CD45RA administration to other cell cells to other n of Gro-beta to other cell
cells to ro-beta T populations cell T at 450 populations
other cell 50 pg/kg: populations pg/kg:
populatio ns 4 (38004 - 0.676 (0.393 - 21.7 (11.2 - 1.2 (1.1 -
CD
Figure imgf000237_0001
03119) 0.745) 27.2) 4.8)
CD34+ CD90+ 25701 (16770 - 1.479 (1.341 30.7 (18.3 - 0.8 (0.2 - CD54 76870) 2.545) 73.9) 0.9)
0.0014 0.0009
.84E+07 (2.72 5.1 (3.4 - 6.0 (5.5 -
WB (0.0008 - (0.0003 - 3.8 (2.7 - 5.4)
- 5.27E+07) 6.9) 26.9)
0.0021) 0.0016)
0.0036 0.0024
.79E+07 (1.03 6.4 (2.1 - 8.2 (3.5 -
Neutro (0.0018 - (0.0007 - 3.4 (3.1 - 5.2)
- 2.44E+07) 8.1) 22.0)
0.0058) 0.0043)
0.0031 0.0021
.76E+07 (0.8 - 5.7 (4.8 - 9.3 (5.6 -
Lymph (0.0021 - (0.0008 - 3.2 (2.0 - 5.4)
2.39E+07) 8.4) 37.0)
0.0094) 0.0069)
0.0118 0.0073
.48E+06 (3.54 11.7 (8.7 - 1.6 (1.1 - 1.9 (1.5 -
Mono (0.0071 - (0.0028 -
- 5.99E+06) 21.1) 2.3) 8.5)
Figure imgf000237_0002
0.0174) 0.0130)
TABLE 10. Mobilization response observed in Rhesus monkeys upon administration of
Gro-b T (450 pg/kg, subcutaneously and plerixafor (1 mg/kg, subcutaneously)
Ratio of
Quantity of Ratio of fold quantity of Fold increase Ratio of
cells observed Ratio of increase of
CD34+ vs. baseline fold
6 hours quantity of CD34+ CD90+
CD90+ following sc increase of
Cell type following sc CD34+ cells CD45RA
CD45RA administration CD34+ cells
administration to other cell cells to other cells to of Gro-beta T to other cell
of Gro-beta T populations cell other cell at 450 pg/kg: populations
at 450 pg/kg: populations
populations
41178 (19413 - 0.359 (0.318
CD34+
Figure imgf000238_0001
6.3 (4.8 - 13.2) 1.0 (1.0 - 1.3)
72140) - 0.441)
CD34+ CD90+ 14782 (6177 - 2.786 (2.266 1.0 (0.8 -
6.6 (6.1 - 13.6)
CD54 31841) - 3.143) 1.0)
0.0007 0.0003
.31E+07 (5.83 1.3 (0.9 -
WB (0.0003 - (0.0001 - 5.4 (4.8 - 5.8) 1.4 (1.1 - 2.3)
- 6.88E+07) 2.3)
0.0011) 0.0005)
0.0011 0.0004
.00E+07 (3.64 1.3 (0.8 -
Neutro (0.0004 - (0.0001 - 5.6 (4.8 - 6.1) 1.4 (1.0 - 2.4)
- 4.98E+07) 2.4)
0.0018) 0.0008)
0.0022 0.0008
.85E+07 (1.57 1.4 (1.2 -
Lymph (0.0012 - (0.0004 - 4.5 (3.9 - 5.7) 1.6 (1.5 - 2.4)
- 1.97E+07) 2.3)
0.0037) 0.0016)
0.0185 0.0066
.23E+06 (2.05 0.7 (0.6 -
Mono (0.0075 - (0.0024 - 9.7 (7.4 - 17.1) 0.8 (0.7 - 0.8)
- 2.60E+06) 0.8)
Figure imgf000238_0002
0.0352) 0.0155)
Figure imgf000238_0003
TABLE 11. Mobilization response observed in Rhesus monkeys upon administration of
Gro-b T (1.2 mg/kg, subcutaneously) and plerixafor (1 mg/kg, subcutaneously)
Ratio of Ratio of fold
Quantity of
quantity of Fold increase increase of cells observed Ratio of Ratio of fold
CD34+ vs. baseline CD34+ 4 hours quantity of increase of
CD90+ following sc CD90+
Cell type following sc CD34+ cells CD34+ cells
CD45RA administration CD45RA administration to other cell to other cell
cells to of Gro-beta T cells to other of Gro-beta T populations populations
other cell at 1.2 mg/kg: cell at 1.2 mg/kg:
populations populations
36219 (26331 - 0.449 (0.278 12.0 (7.2 -
CD 1.3 (0.8 - 1.9)
71704) - 0.548) 15.0)
CD
17471 (7645 - 2.232 (1.826 13.1 (10.3 -
CD 0.8 (0.5 - 1.3)
25964) - 3.594) 23.9)
CD5
0.0008 0.0003
4.94E+07 (4.07
WB (0.0005 - (0.0001 - 5.7 (4.5 - 9.7) 1.8 (1.4 - 2.7) 2.5 (1.1 - 4.2)
- 6.66E+07)
0.0011) 0.0005)
0.0013 0.0006
3.23E+07 (2.31
Neutr (0.0008 - (0.0002 - 9.7 (5.5 - 15.1) 1.2 (0.7 - 1.9) 1.6 (0.7 - 2.6)
- 3.52E+07)
0.0023) 0.0008)
Figure imgf000239_0001
0.0024 0.0010
1.36E+07 (0.66 4.9 (2.0 -
Lymphocytes (0.0019 - (0.0005 - 3.3 (1.7 - 5.2) 3.6 (2.4 - 8.9)
- 2.91E+07) 12.0)
0.0068) 0.0037)
0.0130 0.0052
.08E+06 (1.16 13.7 (7.2 -
Monocytes (0.0068 - (0.0029 - 0.8 (0.5 - 2.1) 1.1 (0.6 - 2.8)
- 5.37E+06) 23.2)
Figure imgf000239_0002
0.0237) 0.0078)
Figure imgf000239_0003
Conclusions
5 [0279] A single treatment of Gro-b T, in combination with AMD3100, induces robust mobilization of stem and progenitor cells within four hours of administration in nonhuman primates. Additionally, Gro-b T, in combination with AMD3100, results in 2-3 fold more CD34+ CD90+ CD45RA stem and progenitor cells relative to AMD3100 alone, suggesting a significant graft quality improvement.
10 [0280] Further, as evidenced by these data, Gro-b T, in combination with AMD3100, may offer a more robust and safer alternative to G-CSF in autologous and allogeneic transplant, including diseases such as sickle cell disease (SCD) and multiple sclerosis (MS) where G-CSF is contraindicated or associated with adverse events. Example 2. Determining whether a population of hematopoietic stem cells mobilized with a CXCR2 agonist and/or a CXCR4 antagonist is suitable for ex vivo expansion and/or therapeutic use
[0281] Using the compositions and methods described herein, a practitioner of skill in the art may mobilize a population of hematopoietic stem or progenitor cells in a mammalian donor, such as a human donor. In some embodiments, the practitioner may administer a CXCR4 antagonist and a CXCR2 agonist in amounts sufficient to engender the release of a population of a population of hematopoietic stem cells into circulating peripheral blood while reducing the mobilization of other cells of the hematopoietic lineage, such as leukocytes, neutrophils, lymphocytes, and monocytes.
[0282] When administering a CXCR4 antagonist in combination with a CXCR2 agonist, the physician may administer the two agents to the donor simultaneously or at different times. In some embodiments, the CXCR4 antagonist may be administered to the donor from about 30 minutes to about 180 minutes prior to administration of the CXCR2 agonist , such as from about 40 minutes to about 160 minutes, about 50 minutes to about 150 minutes, about 60 minutes to about 140 minutes, about 70 minutes to about 130 minutes, about 60 minutes to about 120 minutes, about 70 minutes to about 110 minutes, or about 80 minutes to about 100 minutes ( e.g ., about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 75 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 105 minutes, about 110 minutes, about 115 minutes, about 120 minutes, about 125 minutes, about 130 minutes, about 135 minutes, about 140 minutes, about 145 minutes, about 150 minutes, about 155 minutes, about 160 minutes, about 165 minutes, about 170 minutes, about 175 minutes, or about 180 minutes prior to administration of the CXCR2 agonist).
[0283] To assess the efficacy of the mobilization regimen, a peripheral blood sample may be isolated from the subject following administration of the CXCR2 agonist and/or CXCR4 antagonist. The sample may then be characterized, for example, by acquiring an input value for each of one or more parameters of the sample, such as a parameter listed in TABLE 2. Exemplary parameters that may be used to assess the efficacy of the hematopoietic stem cell mobilization regimen are ratios of hematopoietic stem cells to cells of other types, such as leukocytes, neutrophils, lymphocytes, and monocytes, as well as the relative frequency of hematopoietic stem cells in the sample. Input values for these parameters may be acquired, for example, using immunophenotyping methods known in the art, such as flow cytometry and fluorescence activated cell sorting (FACS) techniques.
[0284] When acquiring and analyzing input values for more than one parameter listed in TABLE 2, one may analyze a combination of parameters. In some embodiments, one may analyze a ratio of hematopoietic stem cells to leukocytes, a ratio of hematopoietic stem cells to neutrophils, a ratio of hematopoietic stem cells to lymphocytes, a ratio of hematopoietic stem cells to monocytes, and/or the relative frequency of hematopoietic stem cells in a sample obtained from the peripheral blood of a donor following administration of a CXCR2 agonist and/or a CXCR4 antagonist. One may analyze, for example, a combination of parameters set forth in any one of TABLES 3-6.
[0285] Upon acquiring an input value for each of the one or more parameters, one may then compare the input value(s) to the reference criterion for each parameter. If the reference criterion is satisfied ( e.g ., if the ratio of hematopoietic stem cells to another hematopoietic cell type is sufficiently high, or if the relative frequency of hematopoietic stem cells in the sample obtained from the peripheral blood of the donor is sufficiently high), then the cells may be released for ex vivo expansion and/or for therapeutic use.
Example 3. Treatment of a hematologic disorder by administration of a hematopoietic stem or progenitor cell graft
[0286] Using the compositions and methods described herein, a practitioner of skill in the art may treat a stem cell disorder, such as a hematologic pathology described herein, by administering to a patient a hematopoietic stem or progenitor cell graft. For example, a practitioner may identify a human donor of hematopoietic stem or progenitor cells as likely to respond to a mobilization regimen, as outlined in Example 1, and may subsequently mobilize a population of hematopoietic stem or progenitor cells accordingly, for example, as set forth in Example 2. Following mobilization, the physician may isolate a population of
hematopoietic stem or progenitor cells from the donor. Isolation of the cells may commence, for example, from about 10 minutes to about 60 minutes following completion of the administration of a CXCR4 antagonist and/or a CXCR2 agonist, such as from about 15 minutes to about 55 minutes, about 20 minutes to about 50 minutes, about 25 minutes to about 45 minutes, or about 30 minutes to about 40 minutes following completion of the administration of these agents ( e.g ., about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, or about 60 minutes following completion of the administration of the CXCR4 antagonist and the CXCR2 agonist).
[0287] The isolation procedure may be carried out over a period of from about 15 minutes to about 6 hours, such as from about 20 minutes to about 4.5 hours, about 30 minutes to about 4 hours, about 40 minutes to about 3.5 hours, about 50 minutes to about 3 hours, or about 1 hour to about 2 hours (e.g., over a period of about 15 minutes, about 20 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 65 minutes, about 70 minutes, about 75 minutes, about 80 minutes, about 85 minutes, about 90 minutes, about 95 minutes, about 100 minutes, about 105 minutes, about 110 minutes, about 115 minutes, or about 120 minutes). In some embodiments, the population of hematopoietic stem and progenitor cells may be isolated from the donor over a period of from about 30 minutes to about 1 hour (e.g, over a period of about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, or about 60 minutes).
[0288] Following the isolation process, a patient may then receive an infusion (e.g, an intravenous infusion) of the mobilized and isolated hematopoietic stem or progenitor cells. The patient may be the donor, or may be a patient that is HLA-matched with respect to the donor, thereby reducing the likelihood of graft rejection. The patient may be one that is suffering, for example, from a cancer, such as a hematologic cancer described herein.
Additionally or alternatively, the patient may be one that is suffering from an autoimmune disease or metabolic disorder described herein. The physician may administer the patient the mobilized and isolated hematopoietic stem or progenitor cells, for example, at a dosage of from 1 x 103 to 1 x 109 hematopoietic stem cells/kg (e.g, about 1 x 105 CD34+ cells/kg to about 1 x 107 CD34+ cells/kg, about 2 x 105 CD34+ cells/kg to about 9 x 106 CD34+ cells/kg, about 3 x 105 CD34+ cells/kg to about 8 x 106 CD34+ cells/kg, about 4 x 105 CD34+ cells/kg to about 7 x 106 CD34+ cells/kg, depending on various factors, such as the patient’s age, weight, and the severity of the disease being treated.
[0289] The physician may monitor the engraftment of the hematopoietic stem cell transplant, for example, by withdrawing a blood sample from the patient and determining the increase in concentration of hematopoietic stem cells or cells of the hematopoietic lineage (such as megakaryocytes, thrombocytes, platelets, erythrocytes, mast cells, myeoblasts, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, osteoclasts, antigen-presenting cells, macrophages, dendritic cells, natural killer cells, T-lymphocytes, and B -lymphocytes) following administration of the transplant. This analysis may be conducted, for example, from about 1 hour to about 6 months, from about 2 hours to about 5 months, from about 3 hours to about 4 months, from about 4 hours to about 3 months, from about 10 hours to about 7 days, from about 24 hours to about 96 hours, or more following hematopoietic stem cell transplant therapy ( e.g ., 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks,
18 weeks, 19 weeks, 20 weeks, 21 weeks, 22 weeks, 23 weeks, 24 weeks, or more). A finding that the concentration of hematopoietic stem cells or cells of the hematopoietic lineage has increased (e.g., by 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%,
40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 500%, or more) following the transplant therapy relative to the concentration of the corresponding cell type prior to transplant therapy provides one indication that the hematopoietic stem or progenitor cell transplant therapy is efficacious in treating the stem cell disorder.
Example 4: Mobilization of CD34d,m cells using a CXCR2 agonist and/or a CXCR4 antagonist
[0290] In this example, data are presented to demonstrate that combination treatment with Gro-b T and AMD3100 (plerixafor) results in significantly enhanced mobilization of CD34dim cells compared to that achieved with AMD3100 alone in nonhuman primates (NHP).
[0291] Cells were mobilized according to the method of Example 1. A sample of peripheral blood was tested using a flow cytometer for the markers CD34, CD1 lb, CD14, CD16, CD45, and SSC.
[0292] As shown in FIG. 15, intravenous administration of 450 pg/kg Gro-b T and subcutaneous administration of 1 mg/kg AMD3100 surprisingly leads to the mobilization of a population of cells that are CD34dim CD1 lb+. Subpopulations within this population are CDl4+ CDl6+, CD14 CD16 , and combinations thereof. FIG. 16 shows that mobilization of the CD34dim cells is significantly enhanced upon administration of the combination of Gro-b T and AMD3100 as compared to AMD3100 alone.
Example 5: Gro-b T in combination with AMD3100 mobilizes immunosuppressive monocytes that inhibit graft vs. host disease
[0293] This example demonstrates that combination treatment with Gro-b T and AMD3100 (plerixafor) results in significantly enhanced mobilization of CD34dim cells having
immunosuppressive properties and that transplantation of this population of cells leads to a significantly reduced incidence of acute graft versus host disease (aGVHD) in a xenograft GVHD mouse model, as compared to transplantation of peripheral blood mononuclear cells having a lower concentration of CD34dim cells.
[0294] Rhesus macaques were treated with Gro-b T, AMD3100, Gro-b T and AMD3100, or G-CSF alone. A sample of peripheral blood was tested using a flow cytometry. Animals mobilized with Gro-b T and AMD3100 showed a more than fifteen-fold increase over baseline in the number of CD34dim cells at 4 hours post-treatment (r<0.0001, n=l3, FIG. 17). By comparison, animals mobilized with G-CSF alone showed only about a nine-fold increase over baseline in the number of CD34dim cells at 4 hours after the last dose of G-CSF
(pO.OOOl, n=3, FIG. 17).
[0295] Further, the composition of unmobilized cells and grafts mobilized by G-CSF, Gro-b T and AMD3100 and AMD3100 alone is provided in FIG 18. As shown, grafts mobilized using Gro-b T and AMD3100 show a 3 fold increase in CD34dim cells and a 3 fold increase in T-cells as compared to grafts mobilized using G-CSF.
[0296] To determine if CD34dim cells had immunosuppressive properties, they were sorted from the peripheral blood of Rhesus macaques treated with Gro-b T and AMD3100. The CD34dim cells were co-cultured with carboxyfluorescein succinimidyl ester (CFSE)-labeled autologous T cells stimulated with anti-CD2/CD3/CD28-coated beads in vitro. As shown in FIG. 19, Gro-b T and AMD3100 mobilized CD34dim cells suppressed T-cell proliferation as measured by CFSE staining after four days.
[0297] To assess whether these immunosuppressive cells may prevent GVHD, we developed a xenograft GVHD model in NOD scid gamma (NSG) mice, which are immunodeficient mice. Gro-b T and AMD3100 mobilized peripheral blood (6 x 106 PBMCs) containing a high percentage of CD34dim cells were injected into sublethally irradiated NSG mice. This was compared to unmobilized primate PBMCs (6 x 106 PBMCs) containing a relatively low numbers of CD34dim cells and G-CSF mobilized primate PBMCs (6 x 106 PBMCs). As shown in the survival curve in FIG. 20, at day 24, all mice (13/13) transplanted with unmobilized PBMCs had died of aGVHD compared to 5/16 mice transplanted with
AMD3100 mobilized PBMCs, 3/16 mice transplanted with G-CSF-mobilized PBMCs and none of the mice transplanted with Gro-b T and AMD3 lOO-mobilized PBMCs. At day 60 post-transplant, 15/16 mice transplanted with Gro-b T and AMD3100 remained alive, whereas only 10/16 mice transplanted with AMD3100 mobilized peripheral blood and 11/16 mice transplanted with G-CSF mobilized peripheral blood remained alive (see FIG. 20). As shown in FIG. 21A, mice transplanted with unmobilized PBMCs (“Unmobilized”) also demonstrated higher numbers of donor T-cells (approximately l60-fold higher, see FIG.
21A) compared to mice transplanted with Gro-b T and AMD3100 mobilized PBMCs (“Gro-b T + Plerixafor”) at day 14 post-transplant (*r<0.01, n=6-8). Additionally, also as shown in FIG. 21A, mice transplanted with PBMCs mobilized with AMD3100 (i.e., plerixafor) alone (“Plerixafor”) or PBMCs mobilized with G-CSF alone (“G-CSF”) demonstrated higher numbers of T-cells (approximately 60-fold higher (p<0.05) and approximately lO-fold higher (p<0.0l), respectively) as compared to mice transplanted with Gro-b T and AMD3100- mobilized PBMCs.
[0298] To confirm that the CD34dim cells in the Gro-b T and AMD3 lOO-mobilized graft were responsible for the protection against aGvHD in the NSG mouse xenotransplantation model shown in FIG. 20, additional cohorts of mice were transplanted with 6xl06 PBMCs from Gro-b T and AMD3 lOO-mobilized rhesus monkeys, where CD34dim cells were first depleted by fluorescence activated cell sorting and T cell numbers and survival were compared to cohorts transplanted with Gro-b T and AMD3 lOO-mobilized PBMCs and cohorts
transplanted with unmobilized PBMCs. As shown in FIG. 21B, at day 14 post-transplant, mice transplanted with Gro-b T and AMD3 lOO-mobilized PBMCs (“Gro-b T + Plerixafor”) had significantly reduced numbers of rhesus CD45+ CD3+ T cells in peripheral blood as compared to mice transplanted with unmobilized PBMCs (“Unmobilized”) (p < 0.001, n=l0/group). By contrast, mice transplanted with Gro-b T and AMD3100 mobilized PBMCs that were depleted of CD34dim cells showed no significant difference in T-cell numbers by day 14 post-transplant (h=10) as compared to mice transplanted with unmobilized PBMCs (“Unmobilized”) (see FIG. 21B). As shown in FIG. 21C, by day 44 post transplant, 0/10 mice transplanted with unmobilized PBMCs (“Unmobilized”) survived versus 8/10 mice transplanted with Gro-b T and AMD3 lOO-mobilized PBMCs (“Gro-b T + plerixafor”) (p<0.05) and only 4/10 mice transplanted with Gro-b T and AMD3100 mobilized PBMCs that were depleted of CD34dim cells (“Gro-b T + plerixafor CD34dim-depleted”) (no significant difference versus Unmobilized).
[0299] Accordingly, these data demonstrate that co-administration of Gro-b T and AMD3100 results not only in rapid and efficacious mobilization of highly enriched HSCs but that these HSCs are enriched in a CD34dim cell population with potent immunosuppressive activity compared to AMD3100 alone or the current standard of care, G-CSF, and that transplant of this CD34dim cell population can result in a reduced incidence of or risk for aGVHD.
Other Embodiments
[0300] All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.
[0301] While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the invention that come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of the claims.
[0302] Other embodiments are within the claims.

Claims

CLAIMS What is claimed is:
1. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor (i) a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof at a dose of from about 50 pg/kg to about 300 mg/kg and (ii) a CXCR4 antagonist.
2. The method of claim 1, wherein the CXCR2 agonist is Gro-b T.
3. The method of claim 1 or 2, wherein the CXCR2 agonist is administered to the donor at a dose of from about 100 pg/kg to about 250 pg/kg.
4. The method of claim 3, wherein the CXCR2 agonist is administered to the donor at a dose of from about 125 pg/kg to about 225 pg/kg.
5. The method of claim 4, wherein the CXCR2 agonist is administered to the donor at a dose of about 150 pg/kg.
6. The method of any one of claims 1-5, wherein the CXCR2 agonist is administered intravenously to the donor.
7. The method of any one of claims 1-6, wherein the CXCR4 antagonist is administered subcutaneously to the donor.
8. The method of any one of claims 1-7, wherein the CXCR4 antagonist is plerixafor or a pharmaceutically acceptable salt thereof.
9. The method of claim 8, wherein the plerixafor or pharmaceutically acceptable salt thereof is administered to the donor at a dose of from about 50 pg/kg to about 500 pg/kg.
10. The method of claim 9, wherein the plerixafor or pharmaceutically acceptable salt thereof is administered to the donor at a dose of from about 200 pg/kg to about 300 pg/kg.
11. The method of claim 10, wherein the plerixafor or pharmaceutically acceptable salt thereof is administered to the donor at a dose of about 240 pg/kg.
12. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34+ cells to leukocytes of from about 0.0008 to about 0.0021 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist.
13. The method of claim 12, wherein the ratio of CD34+ stem cells to leukocytes in the sample is from about 0.0010 to about 0.0018.
14. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34+ cells relative to leukocytes by a ratio of from about 3.4: 1 to about 6.9: 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
15. The method of claim 14, wherein the peripheral blood of the donor is enriched with CD34+ cells relative to leukocytes by a ratio of from about 4.0: 1 to about 6.0: 1.
16. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34+ cells to neutrophils of from about 0.0018 to about 0.0058 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist.
17. The method of claim 16, wherein the ratio of CD34+ cells to neutrophils in the sample is from about 0.0026 to about 0.0046.
18. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34+ cells relative to neutrophils by a ratio of from about 2.1 : 1 to about 8.1 : 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
19. The method of claim 18, wherein the peripheral blood of the donor is enriched with CD34+ cells relative to neutrophils by a ratio of from about 5.4: 1 to about 7.4: 1.
20. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34+ cells to lymphocytes of from about 0.0021 to about 0.0094 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist.
21. The method of claim 20, wherein the ratio of CD34+ cells to lymphocytes in the sample is from about 0.0025 to about 0.0035.
22. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34+ cells relative to lymphocytes by a ratio of from about 4.8: 1 to about 8.4 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
23. The method of claim 22, wherein the peripheral blood of the donor is enriched with CD34+ cells relative to lymphocytes by a ratio of from about 5.0: 1 to about 6.5: 1.
24. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34+ cells to monocytes of from about 0.0071 to about 0.0174 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist.
25. The method of claim 24, wherein the ratio of CD34+ cells to monocytes in the sample is from about 0.0100 to about 0.0140.
26. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34+ cells relative to monocytes by a ratio of from about 1.1 : 1 to about 2.3: 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
27. The method of claim 26, wherein the peripheral blood of the donor is enriched with CD34+ cells relative to monocytes by a ratio of from about 1.3: 1 to about 1.9: 1.
28. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a frequency of CD34+ cells of from about 0.051% to about 0.140% in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist.
29. The method of claim 28, wherein the frequency of CD34+ cells in the sample is from about 0.080% to about 0.120%.
30. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to induce an increase in the frequency of CD34+ cells in the peripheral blood of the donor by from about 3.4-fold to about 7.1 -fold as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
31. The method of claim 30, wherein the frequency of CD34+ cells in the peripheral blood of the donor is increased by from about 4.0-fold to about 6.0-fold following administration of the CXCR2 agonist and CXCR4 antagonist.
32. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34+ CD90+ CD45RA- cells to leukocytes of from about 0.0003 to about 0.0016 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist.
33. The method of claim 32, wherein the ratio of CD34+ CD90+ CD45RA- cells to leukocytes in the sample is from about 0.0006 to about 0.0012.
34. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34+ CD90+ CD45RA- cells relative to leukocytes by a ratio of from about 5.5: 1 to about 26.9: 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
35. The method of claim 34, wherein the peripheral blood of the donor is enriched with CD34+ CD90+ CD45RA- cells relative to leukocytes by a ratio of from about 5.5: 1 to about 6.5: 1.
36. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34+ CD90+ CD45RA- cells to neutrophils of from about 0.0007 to about 0.0043 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist.
37. The method of claim 36, wherein the ratio of CD34+ CD90+ CD45RA- cells to neutrophils in the sample is from about 0.0014 to about 0.0034.
38. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34+ CD90+ CD45RA- cells relative to neutrophils by a ratio of from about 3.5: 1 to about 22.0: 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
39. The method of claim 38, wherein the peripheral blood of the donor is enriched with CD34+ CD90+ CD45RA- cells relative to neutrophils by a ratio of from about 7.0: 1 to about 9.0: 1.
40. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34+ CD90+ CD45RA- cells to lymphocytes of from about 0.0008 to about 0.0069 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist.
41. The method of claim 40, wherein the ratio of CD34+ CD90+ CD45RA- cells to lymphocytes in the sample is from about 0.0011 to about 0.0031.
42. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34+ CD90+ CD45RA- cells relative to lymphocytes by a ratio of from about 5.6: 1 to about 37.0: 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
43. The method of claim 42, wherein the peripheral blood of the donor is enriched with CD34+ CD90+ CD45RA- cells relative to lymphocytes by a ratio of from about 8.0: 1 to about 10.0: 1.
44. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34+ CD90+ CD45RA- cells to monocytes of from about 0.0028 to about 0.0130 in a sample of peripheral blood of the donor following administration of the CXCR2 agonist.
45. The method of claim 44, wherein the ratio of CD34+ CD90+ CD45RA- cells to monocytes in the sample is from about 0.0063 to about 0.0083.
46. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34+ CD90+ CD45RA- cells relative to monocytes by a ratio of from about 1.5: 1 to about 8.5: 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
47. The method of claim 46, wherein the peripheral blood of the donor is enriched with CD34+ CD90+ CD45RA- cells relative to monocytes by a ratio of from about 1.3: 1 to about 2.5: 1.
48. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a ratio of CD34+ CD90+ CD45RA- cells to CD34+ cells of from about 0.393 to about 0.745 in a sample of peripheral blood of the donor following
administration of the CXCR2 agonist and CXCR4 antagonist.
49. The method of claim 48, wherein the ratio of CD34+ CD90+ CD45RA- cells to CD34+ cells in the sample is from about 0.625 to about 0.725.
50. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to enrich the peripheral blood of the donor with CD34+ CD90+ CD45RA- cells relative to CD34+ cells by a ratio of from about 1.1 : 1 to about 4.8: 1 as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
51. The method of claim 50, wherein the peripheral blood of the donor is enriched with CD34+ CD90+ CD45RA- cells relative to CD34+ cells by a ratio of from about 1.1 : 1 to about 1.5: 1.
52. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to produce a population of cells having a frequency of CD34+ CD90+ CD45RA- cells of from about 0.020% to about 0.110% in a sample of peripheral blood of the donor following
administration of the CXCR2 agonist and CXCR4 antagonist.
53. The method of claim 52, wherein the frequency of CD34+ CD90+ CD45RA- cells in the sample is from about 0.046% to about 0.086%.
54. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising administering to the donor a CXCR2 agonist and a CXCR4 antagonist in amounts sufficient to induce an increase in the frequency of CD34+ CD90+ CD45RA- cells in the peripheral blood of the donor by from about 5. l-fold to about 25.7-fold as assessed by comparing a sample of peripheral blood of the donor following administration of the CXCR2 agonist and CXCR4 antagonist to a sample of peripheral blood of the donor prior to administration of the CXCR2 agonist and CXCR4 antagonist.
55. The method of claim 54, wherein the frequency of CD34+ CD90+ CD45RA- cells in the peripheral blood of the donor is increased by from about 5. l-fold to about 7. l-fold following administration of the CXCR2 agonist and CXCR4 antagonist.
56. A method of mobilizing a population of hematopoietic stem cells from the bone marrow of a mammalian donor into peripheral blood, the method comprising: a. administering to the donor mobilizing amounts of a CXCR2 agonist and a CXCR4 antagonist;
b. acquiring an input value for each of one or more parameters listed in TABLE 2 characterizing a sample of peripheral blood of the donor; and c. releasing the sample for ex vivo expansion of the hematopoietic stem cells or for use in the treatment of one or more stem cell disorders in a mammalian patient if the input value for each of the one or more parameters meets the corresponding reference criterion for each of the one or more parameters.
57. The method of claim 56, wherein the one or more reference parameters are a set of parameters listed in any one of TABLES 3-6.
58. The method of claim 56 or 57, further comprising expanding the hematopoietic stem cells ex vivo if the sample is released for ex vivo expansion.
59. The method of any one of claims 56-58, further comprising infusing the hematopoietic stem cells, or progeny thereof, into a mammalian patient suffering from one or more stem cell disorders if the sample is released for use in the treatment thereof.
60. The method of any one of claims 12-59, wherein the sample is isolated from the donor at from about 3 hours to about 5 hours following administration of the CXCR2 agonist and CXCR4 antagonist.
61. The method of claim 60, wherein the sample is isolated from the donor at about 4 hours following administration of the CXCR2 agonist and CXCR4 antagonist.
62. The method of any one of claims 12-61, wherein the CXCR2 agonist is Gro-b T or a variant thereof.
63. The method of claim 62, wherein the CXCR2 agonist is a peptide having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 2.
64. The method of claim 63, wherein the amino acid sequence of the CXCR2 agonist differs from that of SEQ ID NO: 2 only by way of one or more conservative amino acid substitutions.
65. The method of claim 63, wherein the CXCR2 agonist is Gro-b T.
66. The method of any one of claims 12-61, wherein the CXCR2 agonist is Gro-b or a variant thereof.
67. The method of claim 66, wherein the CXCR2 agonist is a peptide having at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1.
68. The method of claim 67, wherein the amino acid sequence of the CXCR2 agonist differs from that of SEQ ID NO: 1 only by way of one or more conservative amino acid substitutions.
69. The method of claim 67, wherein the CXCR2 agonist is Gro-b.
70. The method of any one of claims 12-69, wherein the CXCR2 agonist is administered to the donor at a dose of from about 50 pg/kg to about 1 mg/kg.
71. The method of claim 70, wherein the CXCR2 agonist is administered to the donor at a dose of from about 50 pg/kg to about 300 pg/kg.
72. The method of claim 71, wherein the CXCR2 agonist is administered to the donor at a dose of from about 100 pg/kg to about 250 pg/kg.
73. The method of claim 72, wherein the CXCR2 agonist is administered to the donor at a dose of about 150 pg/kg.
74. The method of any one of claims 1-73, wherein the CXCR2 agonist is
administered intravenously to the donor.
75. The method of any one of claims 12-74, wherein the CXCR2 agonist and the CXCR4 antagonist are administered to the donor concurrently.
76. The method of any one of claims 12-75, wherein the CXCR4 antagonist is a compound represented by formula (I)
Z - linker - Z’ (I)
or a pharmaceutically acceptable salt thereof, wherein Z is:
(i) a cyclic polyamine containing from 9 to 32 ring members, wherein from 2 to 8 of the ring members are nitrogen atoms separated from one another by 2 or more carbon atoms; or
(ii) an amine represented by formula (IA)
Figure imgf000257_0001
wherein A comprises a monocyclic or bicyclic fused ring system comprising at least one nitrogen atom and B is H or a substituent of from 1 to 20 atoms; and wherein Z’ is:
(i) a cyclic polyamine containing from 9 to 32 ring members, wherein from 2 to 8 of the ring members are nitrogen atoms separated from one another by 2 or more carbon atoms;
(ii) an amine represented by formula (IB)
Figure imgf000257_0002
wherein A’ comprises a monocyclic or bicyclic fused ring system comprising at least one nitrogen atom and B’ is H or a substituent of from 1 to 20 atoms; or
(iii) a substituent represented by formula (IC)
N(R) - (CR2)n - X (IC)
wherein each R is independently H or Ci-C6 alkyl, n is 1 or 2, and X is an aryl or heteroaryl group or a mercaptan;
wherein the linker is a bond, optionally substituted Ci-C6 alkyl ene, optionally substituted Ci-C6 heteroalkylene, optionally substituted C2-C6 alkenylene, optionally substituted C2-C6 heteroalkenylene, optionally substituted C2-C6 alkynylene, optionally substituted C2-C6 heteroalkynylene, optionally substituted cycloalkylene, optionally substituted heterocycloalkylene, optionally substituted arylene, or optionally substituted heteroaryl ene.
77. The method of claim 76, wherein Z and Z’ are each independently a cyclic polyamine containing from 9 to 32 ring members, of which from 2 to 8 are nitrogen atoms separated from one another by 2 or more carbon atoms.
78. The method of claim 76 or 77, wherein Z and Z’ are identical substituents.
79. The method of any one of claims 76-78, wherein Z is a cyclic polyamine comprising from 10 to 24 ring members.
80. The method of claim 79, wherein Z is a cyclic polyamine comprising 14 ring members.
81. The method of any one of claims 76-80, wherein Z comprises 4 nitrogen atoms.
82. The method of any one of claims 76-81, wherein Z is 1 ,4,8, 11- tetraazocyclotetradecane.
83. The method of any one of claims 76-82, wherein the linker is represented by formula (ID)
Figure imgf000258_0001
wherein ring D is an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted cycloalkyl group, or an optionally substituted heterocycloalkyl group; and
X and Y are each independently optionally substituted Ci-C6 alkylene, optionally substituted Ci-C6 heteroalkylene, optionally substituted C2-C6 alkenylene, optionally substituted C2-C6 heteroalkenylene, optionally substituted C2-C6 alkynylene, or optionally substituted C2-C6 heteroalkynylene.
84. The method of claim 83, wherein the linker is represented by formula (IE)
Figure imgf000258_0002
wherein ring D is an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted cycloalkyl group, or an optionally substituted heterocycloalkyl group; and
X and Y are each independently optionally substituted Ci-C6 alkylene, optionally substituted Ci-C6 heteroalkylene, optionally substituted C2-C6 alkenylene, optionally substituted C2-C6 heteroalkenylene, optionally substituted C2-C6 alkynylene, or optionally substituted C2-C6 heteroalkynylene.
85. The method of claim 83 or 84, wherein X and Y are each independently optionally substituted Ci-C6 alkylene.
86. The method of any one of claim 83-85, wherein X and Y are identical
substituents.
87. The method of claim 86, wherein X and Y are each methylene groups.
88. The method of any one of claims 76-87, wherein the CXCR4 antagonist is plerixafor or a pharmaceutically acceptable salt thereof.
89. The method of claim 88, wherein the plerixafor or pharmaceutically acceptable salt thereof is administered subcutaneously to the donor.
90. The method of claim 88 or 89, wherein the plerixafor or pharmaceutically acceptable salt thereof is administered to the donor at a dose of from about 50 pg/kg to about 500 pg/kg.
91. The method of claim 90, wherein the plerixafor or pharmaceutically acceptable salt thereof is administered to the donor at a dose of from about 200 pg/kg to about 300 hg/kg.
92. The method of claim 91, wherein the plerixafor or pharmaceutically acceptable salt thereof is administered to the donor at a dose of about 240 pg/kg.
93. A pharmaceutical composition comprising a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor, wherein the ratio of CD34+ cells to leukocytes in the population is from about 0.0008 to about 0.0021.
94. The pharmaceutical composition of claim 93, wherein the ratio of CD34+ cells to leukocytes in the population is from about 0.0010 to about 0.0018.
95. A pharmaceutical composition comprising a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor, wherein the ratio of CD34+ cells to neutrophils in the population is from about 0.0018 to about 0.0058.
96. The pharmaceutical composition of claim 95, wherein the ratio of CD34+ cells to neutrophils in the population is from about 0.0026 to about 0.0046.
97. A pharmaceutical composition comprising a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor, wherein the ratio of CD34+ cells to lymphocytes in the population is from about 0.0021 to about 0.0094.
98. The pharmaceutical composition of claim 97, wherein the ratio of CD34+ cells to lymphocytes in the population is from about 0.0025 to about 0.0035.
99. A pharmaceutical composition comprising a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor, wherein the ratio of CD34+ cells to monocytes in the population is from about 0.0071 to about 0.0174.
100. The pharmaceutical composition of claim 99, wherein the ratio of CD34+ cells to monocytes in the population is from about 0.0100 to about 0.0140.
101. A pharmaceutical composition comprising a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor, wherein the frequency of CD34+ cells in the population is from about 0.051% to about 0.140%.
102. The pharmaceutical composition of claim 101, wherein the frequency of CD34+ cells in the population is from about 0.080% to about 0.120%.
103. A pharmaceutical composition comprising a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor, wherein the ratio of CD34+ cells to leukocytes in the population is from about 0.0003 to about 0.0016.
104. The pharmaceutical composition of claim 103, wherein the ratio of CD34+ CD90+ CD45RA- cells to leukocytes in the population is from about 0.0006 to about 0.0012.
105. A pharmaceutical composition comprising a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor, wherein the ratio of CD34+ CD90+ CD45RA- cells to neutrophils in the population is from about 0.0007 to about 0.0043.
106. The pharmaceutical composition of claim 105, wherein the ratio of CD34+ CD90+ CD45RA- cells to neutrophils in the population is from about 0.0014 to about 0.0034.
107. A pharmaceutical composition comprising a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor, wherein the ratio of CD34+ CD90+ CD45RA- cells to lymphocytes in the population is from about 0.0008 to about 0.0069.
108. The pharmaceutical composition of claim 107, wherein the ratio of CD34+
CD90+ CD45RA- cells to lymphocytes in the population is from about 0.0011 to about 0.0031.
109. A pharmaceutical composition comprising a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor, wherein the ratio of CD34+ CD90+ CD45RA- cells to monocytes in the population is from about 0.0028 to about 0.0130.
110. The pharmaceutical composition of claim 109, wherein the ratio of CD34+ CD90+ CD45RA- cells to monocytes in the population is from about 0.0063 to about 0.0083.
111. A pharmaceutical composition comprising a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor, wherein the ratio of CD34+ CD90+ CD45RA- cells to CD34+ cells in the population is from about 0.393 to about 0.745.
112. The pharmaceutical composition of claim 111, wherein the ratio of CD34+ CD90+ CD45RA- cells to CD34+ cells in the population is from about 0.625 to about 0.725.
113. A pharmaceutical composition comprising a population of hematopoietic stem cells or progeny thereof isolated from a mammalian donor, wherein the frequency of CD34+ CD90+ CD45RA- cells in the population is from about 0.020% to about 0.110%.
114. The pharmaceutical composition of claim 113, wherein the frequency of CD34+ CD90+ CD45RA- cells in the population is from about 0.046% to about 0.086%.
115. A method of treating a stem cell disorder in a mammalian patient, the method comprising:
a. mobilizing a population of hematopoietic stem cells in a mammalian donor in accordance with the method of any one of claims 1-92; and
b. infusing a therapeutically effective amount of the hematopoietic stem cells, or progeny thereof, into the patient.
116. A method of treating a stem cell disorder in a mammalian patient, the method comprising infusing into the patient a therapeutically effective amount of the hematopoietic stem cells mobilized by the method of any one of claims 1-92, or progeny thereof.
117. A method of treating a stem cell disorder in a mammalian patient, the method comprising administering to the patient the pharmaceutical composition of any one of claims 93-114.
118. The method of any one of claims 115-117, wherein the stem cell disorder is a hemoglobinopathy disorder.
119. The method of claim 118, wherein the hemoglobinopathy disorder is selected from the group consisting of sickle cell anemia, thalassemia, Fanconi anemia, aplastic anemia, and Wiskott-Aldrich syndrome.
120. The method of any one of claims 115-117, wherein the stem cell disorder is a myelodysplastic disorder.
121. The method of any one of claims 115-117, wherein the stem cell disorder is an immunodeficiency disorder.
122. The method of claim 121, wherein the immunodeficiency disorder is a congenital immunodefi ci ency .
123. The method of claim 121, wherein the immunodeficiency disorder is an acquired immunodefi ci ency .
124. The method of claim 123, wherein the acquired immunodeficiency is human immunodeficiency virus or acquired immune deficiency syndrome.
125. The method of any one of claims 115-117, wherein the stem cell disorder is a metabolic disorder.
126. The method of claim 125, wherein the metabolic disorder is selected from the group consisting of glycogen storage diseases, mucopolysaccharidoses, Gaucher's Disease, Hurlers Disease, sphingolipidoses, and metachromatic leukodystrophy.
127. The method of any one of claims 115-117, wherein the stem cell disorder is cancer.
128. The method of claim 127, wherein the cancer is selected from the group consisting of leukemia, lymphoma, multiple myeloma, and neuroblastoma.
129. The method of claim 123, wherein the cancer is a hematological cancer.
130. The method of claim 127, wherein the cancer is acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia, multiple myeloma, diffuse large B-cell lymphoma, or non-Hodgkin’s lymphoma.
131. The method of any one of claims 115-117, wherein the stem cell disorder is a disorder selected from the group consisting of adenosine deaminase deficiency and severe combined immunodeficiency, hyper immunoglobulin M syndrome, Chediak-Higashi disease, hereditary lymphohistiocytosis, osteopetrosis, osteogenesis imperfecta, storage diseases, thalassemia major, systemic sclerosis, systemic lupus erythematosus, multiple sclerosis, and juvenile rheumatoid arthritis.
132. The method of any one of claims 115-117, wherein the stem cell disorder is an autoimmune disorder.
133. The method of claim 132, wherein the autoimmune disorder is selected from the group consisting of multiple sclerosis, human systemic lupus, rheumatoid arthritis, inflammatory bowel disease, treating psoriasis, Type 1 diabetes mellitus, acute disseminated encephalomyelitis, Addison's disease, alopecia universalis, ankylosing spondylitis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome, autoimmune oophoritis, Balo disease, Behcet's disease, bullous pemphigoid, cardiomyopathy, Chagas' disease, chronic fatigue immune dysfunction syndrome, chronic inflammatory demyelinating polyneuropathy, Crohn's disease, cicatricial pemphigoid, coeliac sprue-dermatitis herpetiformis, cold agglutinin disease, CREST syndrome, Degos disease, discoid lupus, dysautonomia, endometriosis, essential mixed cryoglobulinemia,
fibromyalgia-fibromyositis, Goodpasture' s syndrome, Grave's disease, Guillain-Barre syndrome, Hashimoto' s thyroiditis, Hidradenitis suppurativa, idiopathic and/or acute thrombocytopenic purpura, idiopathic pulmonary fibrosis, IgA neuropathy, interstitial cystitis, juvenile arthritis, Kawasaki's disease, lichen planus, Lyme disease, Meniere disease, mixed connective tissue disease, myasthenia gravis, neuromyotonia, opsoclonus myoclonus syndrome, optic neuritis, Ord's thyroiditis, pemphigus vulgaris, pernicious anemia, polychondritis, polymyositis and dermatomyositis, primary biliary cirrhosis, polyarteritis nodosa, polyglandular syndromes, polymyalgia rheumatica, primary agammaglobulinemia, Raynaud phenomenon, Reiter' s syndrome, rheumatic fever, sarcoidosis, scleroderma, Sjogren's syndrome, stiff person syndrome, Takayasu's arteritis, temporal arteritis, ulcerative colitis, uveitis, vasculitis, vitiligo, vulvodynia, and Wegener's granulomatosis.
134. The method of any one of claims 115-133, wherein the hematopoietic stem cells are autologous with respect to the patient.
135. The method of any one of claims 115-133, wherein the hematopoietic stem cells are allogeneic with respect to the patient.
136. The method of claim 135, wherein the hematopoietic stem cells are HLA-matched with respect to the patient.
137. The method of any one of claims 115-136, wherein the hematopoietic stem cells have been genetically modified to disrupt an endogenous gene.
138. The method of claim 137, wherein the endogenous gene encodes a major histocompatibility complex protein.
139. The method of any one of claims 115-138, wherein the hematopoietic stem cells, or progeny thereof, maintain hematopoietic stem cell functional potential after two or more days following infusion of the hematopoietic stem cells, or progeny thereof, into the patient.
140. The method of any one of claims 115-139, wherein the hematopoietic stem cells, or progeny thereof, localize to hematopoietic tissue and/or reestablish hematopoiesis following infusion of the hematopoietic stem cells, or progeny thereof, into the patient.
141. The method of any one of claims 115-140, wherein upon infusion into the patient, the hematopoietic stem cells, or progeny thereof, give rise to recovery of a population of cells selected from the group consisting of megakaryocytes, thrombocytes, platelets, erythrocytes, mast cells, myeoblasts, basophils, neutrophils, eosinophils, microglia, granulocytes, monocytes, osteoclasts, antigen-presenting cells.
142. The method of any one of claims 1-92, wherein the mammalian donor is a human donor.
143. The pharmaceutical composition of any one of claims 93-114, wherein the mammalian donor is a human donor.
144. The method of any one of claims 115-141, wherein the mammalian donor is a human donor and the mammalian patient is a human patient.
145. The method of any one of the above claims, further comprising isolating the hematopoietic stem cells or progeny thereof by drawing peripheral blood from the donor.
146. The method of any one of the above claims, further comprising using apheresis to collect the hematopoietic stem cells or progeny thereof from the donor.
147. The method of any one of the above claims, wherein the Gro-b, Gro-b T, and variants thereof have a purity of at least about 95% relative to the deamidated versions of these peptides.
148. An enriched preparation of human blood cells comprising a population of hematopoietic stem cells or progeny thereof, wherein the ratio of CD34+ cells to leukocytes in the preparation is from about 0.0008 to about 0.0021.
149. A enriched preparation of human blood cells comprising a population of hematopoietic stem cells or progeny thereof, wherein the ratio of CD34+ CD90+ CD45RA- cells to neutrophils in the population is from about 0.0007 to about 0.0043.
150. A human blood cell preparation comprising hematopoietic stem cells or progeny thereof prepared using the method of any one of claims 1-92.
151. A method of mobilizing Oϋ34ώpi cells from the bone marrow of a human donor into peripheral blood, the method comprising administering to the donor (i) a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof at a dose of from about 50 pg/kg to about 1,000 pg/kg and (ii) a CXCR4 antagonist.
152. A method of performing an allogeneic hematopoietic stem cell transplant in a patient in need thereof, the method comprising infusing into the patient a therapeutically effective amount of allogeneic hematopoietic stem cells, wherein the hematopoietic stem cells were mobilized from bone marrow of a human donor into peripheral blood of the human donor by a method comprising administering to the donor (i) a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof at a dose of from about 50 pg/kg to about 1,000 pg/kg and (ii) a CXCR4 antagonist.
153. A method of preventing, reducing the risk of developing, or reducing the severity of a post-transplant infection in a patient in need thereof, the method comprising infusing into the patient a therapeutically effective amount of hematopoietic stem cells, wherein the hematopoietic stem cells were mobilized from bone marrow of a human donor into peripheral blood of the human donor by a method comprising administering to the human donor (i) a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof at a dose of from about 50 pg/kg to about 1,000 pg/kg and (ii) a CXCR4 antagonist.
154. A method of preventing, reducing the risk of developing, or reducing the severity of graft versus host disease (GVHD) in a patient in need thereof, the method comprising infusing into the patient a therapeutically effective amount of hematopoietic stem cells, wherein the hematopoietic stem cells were mobilized from bone marrow of a human donor into peripheral blood of the human donor by a method comprising administering to the human donor (i) a CXCR2 agonist selected from the group consisting of Gro-b, Gro-b T, and variants thereof at a dose of from about 50 pg/kg to about 1,000 pg/kg and (ii) a CXCR4 antagonist.
155. The method of any one of claims 151-154, wherein the CD34dim cells are present in the peripheral blood in a amount that is at least two- to ten-fold higher than if the hematopoietic stem cells were mobilized using the CXCR4 antagonist alone.
156. The method of any one of claims 151-155, wherein the CD34dim cells are capable of suppressing alloreactive T lymphocyte proliferation when administered to a recipient.
157. The method of any one of claims 151-156, wherein the CXCR2 agonist is Gro-b T.
158. The method of any one of claims 151-157, wherein the CXCR2 agonist is administered to the donor at a dose of from about 100 pg/kg to about 250 pg/kg.
159. The method of claim 158, wherein the CXCR2 agonist is administered to the donor at a dose of from about 125 pg/kg to about 225 pg/kg.
160. The method of claim 159, wherein the CXCR2 agonist is administered to the donor at a dose of about 150 pg/kg.
161. The method of any one of claims 151-160, wherein the CXCR2 agonist is administered intravenously to the donor.
162. The method of any one of claims 151-161, wherein the CXCR4 antagonist is administered subcutaneously to the donor.
163. The method of any one of claims 151-162, wherein the CXCR4 antagonist is plerixafor or a pharmaceutically acceptable salt thereof.
164. The method of claim 163, wherein the plerixafor or pharmaceutically acceptable salt thereof is administered to the donor at a dose of from about 50 pg/kg to about 500 pg/kg
165. The method of claim 164, wherein the plerixafor or pharmaceutically acceptable salt thereof is administered to the donor at a dose of from about 200 pg/kg to about 300 hg/kg.
166. The method of claim 165, wherein the plerixafor or pharmaceutically acceptable salt thereof is administered to the donor at a dose of about 240 pg/kg.
167. The population of CD34dim cells derived from the method of any one of claims
151-165.
PCT/US2018/064335 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells WO2019113375A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
EP18829615.6A EP3720494A2 (en) 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
SG11202004913TA SG11202004913TA (en) 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
JP2020531468A JP2021505172A (en) 2017-12-06 2018-12-06 Dosing regimen to mobilize hematopoietic stem cells and progenitor cells
MX2020005878A MX2020005878A (en) 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells.
AU2018378804A AU2018378804A1 (en) 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CN201880088815.6A CN111712262A (en) 2017-12-06 2018-12-06 Dosing regimens for mobilizing hematopoietic stem and progenitor cells
BR112020011186-4A BR112020011186A2 (en) 2017-12-06 2018-12-06 dosing regimens for stem cell mobilization and hematopoietic progenitors
CA3083783A CA3083783A1 (en) 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
KR1020207019222A KR20200096942A (en) 2017-12-06 2018-12-06 Dosing regimen for mobilization of hematopoietic stem and progeny cells
EA202091092A EA202091092A1 (en) 2018-11-30 2018-12-06 DOSED ADMINISTRATION SCHEME FOR MOBILIZATION OF HEMOPOETIC STEM CELLS AND PRECURSOR CELLS
US16/352,578 US11260079B2 (en) 2017-12-06 2019-03-13 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
IL275077A IL275077A (en) 2017-12-06 2020-06-02 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
CONC2020/0007275A CO2020007275A2 (en) 2017-12-06 2020-06-16 Dosage guidelines for mobilization of hematopoietic stem and progenitor cells
JP2023188499A JP2024023226A (en) 2017-12-06 2023-11-02 Dosing regimen to mobilize hematopoietic stem and progenitor cells

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US15/834,017 2017-12-06
US15/834,017 US10058573B1 (en) 2017-12-06 2017-12-06 Dosing regimens for the mobilization of hematopoietic stem cells
US201762596056P 2017-12-07 2017-12-07
US62/596,056 2017-12-07
US16/101,676 2018-08-13
US16/101,676 US20190167726A1 (en) 2017-12-06 2018-08-13 Dosing Regimens for the Mobilization of Hematopoietic Stem Cells
US201862753656P 2018-10-31 2018-10-31
US62/753,656 2018-10-31
US201862773954P 2018-11-30 2018-11-30
US62/773,954 2018-11-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/101,676 Continuation-In-Part US20190167726A1 (en) 2017-12-06 2018-08-13 Dosing Regimens for the Mobilization of Hematopoietic Stem Cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/352,578 Continuation US11260079B2 (en) 2017-12-06 2019-03-13 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells

Publications (2)

Publication Number Publication Date
WO2019113375A2 true WO2019113375A2 (en) 2019-06-13
WO2019113375A3 WO2019113375A3 (en) 2019-07-18

Family

ID=66749948

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/064335 WO2019113375A2 (en) 2017-12-06 2018-12-06 Dosing regimens for the mobilization of hematopoietic stem and progenitor cells

Country Status (12)

Country Link
EP (1) EP3720494A2 (en)
JP (2) JP2021505172A (en)
KR (1) KR20200096942A (en)
CN (1) CN111712262A (en)
AU (1) AU2018378804A1 (en)
BR (1) BR112020011186A2 (en)
CA (1) CA3083783A1 (en)
CO (1) CO2020007275A2 (en)
IL (1) IL275077A (en)
MX (1) MX2020005878A (en)
SG (1) SG11202004913TA (en)
WO (1) WO2019113375A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021087406A1 (en) * 2019-11-01 2021-05-06 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
WO2021222313A1 (en) * 2020-04-27 2021-11-04 Magenta Therapeutics, Inc. Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
WO2022197776A1 (en) * 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients

Citations (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5233044A (en) 1989-06-08 1993-08-03 Millipore Corporation Active esters for solid phase peptide synthesis
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5569825A (en) 1990-08-29 1996-10-29 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5583131A (en) 1991-12-16 1996-12-10 Johnson Matthey Public Limited Company Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698546A (en) 1994-01-11 1997-12-16 Johnson Matthey Public Limted Company Cyclic polyamines
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US5939598A (en) 1990-01-12 1999-08-17 Abgenix, Inc. Method of making transgenic mice lacking endogenous heavy chains
WO1999050461A1 (en) 1998-03-30 1999-10-07 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
WO2000002870A1 (en) 1998-07-08 2000-01-20 Anormed Inc. Antiviral macrocyclic compounds
US6028172A (en) 1997-02-11 2000-02-22 Mallinckrodt Inc. Reactor and method for solid phase peptide synthesis
US6080398A (en) 1993-06-08 2000-06-27 Smithkline Beecham Corporation Truncated gro and KC chemokines having enhanced bioactivity
WO2000056729A1 (en) 1999-03-24 2000-09-28 Anormed Inc. Chemokine recpetor binding heterocyclic compounds
WO2001044229A1 (en) 1999-12-17 2001-06-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
WO2001085196A2 (en) 2000-05-09 2001-11-15 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
WO2001094420A1 (en) 2000-06-05 2001-12-13 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US6447766B1 (en) 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
WO2003090512A2 (en) 2002-04-23 2003-11-06 The Trustees Of Columbia University In The City Of New York Regeneration of endogenous myocardial tissue by induction of neovascularization
US20060035829A1 (en) 2004-08-13 2006-02-16 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
US7442386B2 (en) 2001-08-16 2008-10-28 The Trustees Of The University Of Pennsylvania Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies
US20100227406A1 (en) 2007-05-25 2010-09-09 Qiagen Gmbh Method for purifying cells, recovering cells, and transfecting cells gently
US20100251395A1 (en) 2005-06-24 2010-09-30 Harris Reuben S Using cytosine deaminases to diminish retroelement transfer from pigs to humans
US20100317114A1 (en) 2007-06-28 2010-12-16 Monika Poppe Method of generating glucose-responsive cells
US8021867B2 (en) 2005-10-18 2011-09-20 Duke University Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
US20120222143A1 (en) 2011-02-25 2012-08-30 Fahrenkrug Scott C Genetically modified animals and methods for making the same
US8445251B2 (en) 2007-10-31 2013-05-21 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
US8518701B2 (en) 2010-02-11 2013-08-27 Recombinetics, Inc. Methods and materials for producing transgenic artiodactyls
US8546350B2 (en) 2003-07-31 2013-10-01 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US9169287B2 (en) 2013-03-15 2015-10-27 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems
US9206222B2 (en) 2009-06-29 2015-12-08 Centre National De La Recherche Scientifique Solid phase peptide synthesis of peptide alcohols
US9388212B2 (en) 2013-02-21 2016-07-12 Chemical & Biopharmaceutical Laboratories Of Patras S.A. Solid phase peptide synthesis via side chain attachment
US9580426B2 (en) 2008-10-30 2017-02-28 Novartis Ag Compounds that expand hematopoietic stem cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
DK1411918T3 (en) * 2001-07-31 2012-04-23 Genzyme Global S A R L Methods for mobilizing progenitor / stem cells
WO2007047882A2 (en) * 2005-10-18 2007-04-26 Caritas St. Elizabeth Medical Center Of Boston, Inc. Combination of cxcr4 antagonist and morphogen to increase angiogenesis
CN101495115A (en) * 2006-08-02 2009-07-29 健赞股份有限公司 Combination therapy
AR062271A1 (en) * 2006-08-07 2008-10-29 Genzyme Corp USE OF AN EFFECTIVE AMOUNT OF AT LEAST A CXCR4 INHIBITOR, AT LEAST A CXCR2 AND G-CSF AGONIST TO MOBILIZE PROGENITOR CELLS AND / OR MOTHER CELLS
US11116819B2 (en) * 2013-02-28 2021-09-14 President And Fellows Of Harvard College Methods and compositions for mobilizing stem cells
US20190060366A1 (en) * 2016-02-26 2019-02-28 President And Fellows Of Harvard College Highly engraftable hematopoietic stem cells
US10058573B1 (en) * 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells

Patent Citations (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5585089A (en) 1988-12-28 1996-12-17 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5693762A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Humanized immunoglobulins
US5693761A (en) 1988-12-28 1997-12-02 Protein Design Labs, Inc. Polynucleotides encoding improved humanized immunoglobulins
US6180370B1 (en) 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same
US5233044A (en) 1989-06-08 1993-08-03 Millipore Corporation Active esters for solid phase peptide synthesis
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US5939598A (en) 1990-01-12 1999-08-17 Abgenix, Inc. Method of making transgenic mice lacking endogenous heavy chains
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5569825A (en) 1990-08-29 1996-10-29 Genpharm International Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5583131A (en) 1991-12-16 1996-12-10 Johnson Matthey Public Limited Company Aromatic-linked polyamine macrocyclic compounds with anti-HIV activity
US6447766B1 (en) 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
US6080398A (en) 1993-06-08 2000-06-27 Smithkline Beecham Corporation Truncated gro and KC chemokines having enhanced bioactivity
US5698546A (en) 1994-01-11 1997-12-16 Johnson Matthey Public Limted Company Cyclic polyamines
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1998024893A2 (en) 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
US6028172A (en) 1997-02-11 2000-02-22 Mallinckrodt Inc. Reactor and method for solid phase peptide synthesis
WO1999050461A1 (en) 1998-03-30 1999-10-07 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
WO2000002870A1 (en) 1998-07-08 2000-01-20 Anormed Inc. Antiviral macrocyclic compounds
WO2000056729A1 (en) 1999-03-24 2000-09-28 Anormed Inc. Chemokine recpetor binding heterocyclic compounds
WO2001044229A1 (en) 1999-12-17 2001-06-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
WO2001085196A2 (en) 2000-05-09 2001-11-15 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
WO2001094420A1 (en) 2000-06-05 2001-12-13 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
US7442386B2 (en) 2001-08-16 2008-10-28 The Trustees Of The University Of Pennsylvania Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies
WO2003090512A2 (en) 2002-04-23 2003-11-06 The Trustees Of Columbia University In The City Of New York Regeneration of endogenous myocardial tissue by induction of neovascularization
US8546350B2 (en) 2003-07-31 2013-10-01 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US20060035829A1 (en) 2004-08-13 2006-02-16 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
US20100251395A1 (en) 2005-06-24 2010-09-30 Harris Reuben S Using cytosine deaminases to diminish retroelement transfer from pigs to humans
US8021867B2 (en) 2005-10-18 2011-09-20 Duke University Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
US20100227406A1 (en) 2007-05-25 2010-09-09 Qiagen Gmbh Method for purifying cells, recovering cells, and transfecting cells gently
US20100317114A1 (en) 2007-06-28 2010-12-16 Monika Poppe Method of generating glucose-responsive cells
US8445251B2 (en) 2007-10-31 2013-05-21 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
US9580426B2 (en) 2008-10-30 2017-02-28 Novartis Ag Compounds that expand hematopoietic stem cells
US9206222B2 (en) 2009-06-29 2015-12-08 Centre National De La Recherche Scientifique Solid phase peptide synthesis of peptide alcohols
US8518701B2 (en) 2010-02-11 2013-08-27 Recombinetics, Inc. Methods and materials for producing transgenic artiodactyls
US20120222143A1 (en) 2011-02-25 2012-08-30 Fahrenkrug Scott C Genetically modified animals and methods for making the same
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US9388212B2 (en) 2013-02-21 2016-07-12 Chemical & Biopharmaceutical Laboratories Of Patras S.A. Solid phase peptide synthesis via side chain attachment
US9169287B2 (en) 2013-03-15 2015-10-27 Massachusetts Institute Of Technology Solid phase peptide synthesis processes and associated systems

Non-Patent Citations (33)

* Cited by examiner, † Cited by third party
Title
"Bone Marrow Transplantation for Non-Malignant Disease", ASH EDUCATION BOOK, vol. 1, 2000, pages 319 - 338
"Remington: The Science and Practice of Pharmacy", 2012
"The United States Pharmacopeia: The National Formulary", 2015
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
CHU ET AL., NUCLEIC ACIDS RESEARCH, vol. 15, 1987, pages 1311
COFFIN, J. M. ET AL.: "Retroviridae: The viruses and their replication, In Fundamental Virology", 1996, LIPPINCOTT-RAVEN PUBLISHERS
D'AVENI ET AL., SCIENCE TRANSLATIONAL MEDICINE, vol. 7, no. 281, 2015, pages 1 - 12
DENNIG, TOPICS IN CURRENT CHEMISTRY, vol. 228, 2003, pages 227
DISTLER ET AL., EXPERIMENTAL DERMATOLOGY, vol. 14, 2005, pages 315
D'SOUZA ET AL., TRANSFUSION MEDICINE REVIEWS, vol. 22, no. 4, 2008, pages 280 - 290
GU ET AL., METH. ENZYMOL., vol. 502, 2012, pages 25 - 41
GULICK ET AL., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, vol. 40, no. 9.2, 1997
HOLLIGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 48
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883
HWANG ET AL., NATURE BIOTECHNOLOGY, vol. 31, 2013, pages 227
JOUNG ET AL., NATURE REVIEWS MOLECULAR CELL BIOLOGY, vol. 14, 2013, pages 49
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1987, NATIONAL INSTITUTE OF HEALTH
LAVITRANO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 99, 2002, pages 14230 - 14235
LAVITRANO ET AL., REPROD. FERT. DEVELOP., vol. 18, 2006, pages 19 - 23
LO, MOL. CELL. BIOL., vol. 3, 1983, pages 1803 - 1814
NAIR; JACOB, J. BASIC CLIN. PHARMA., vol. 7, 2016, pages 27 - 31
NAKASONE ET AL.: "CD34+ monocytes mobilized by G-CSF in donor PB and clinical outcomes after all-HCT from related donors", POSTER PRESENTED AT 44TH ANNUAL MEETING OF THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION, 18 March 2018 (2018-03-18)
QUINN ET AL.: "Genetic Modification of Target Cells by Direct Delivery of Active Protein [abstract", METHYLATION CHANGES IN EARLY EMBRYONIC GENES IN CANCER [ABSTRACT], IN: PROCEEDINGS OF THE 18TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE AND CELL THERAPY, 13 May 2015 (2015-05-13)
RHODES ET AL., METHODS IN CELL BIOLOGY, vol. 82, 2007, pages 309
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 7
SHAREI ET AL., JOURNAL OF VISUALIZED EXPERIMENTS, vol. 81, 2013, pages e50980
THOMPSON ET AL., CELL, vol. 56, 1989, pages 313 - 321
URNOV ET AL., NATURE REVIEWS GENETICS, vol. 11, 2010, pages 636
VAN DER PUTTEN ET AL., PROC. NATL. ACA . SCI. USA, vol. 82, 1985, pages 6148 - 6152
VENDRAMIN ET AL., BBAI[T, vol. 20, no. 12, 2014, pages 2049 - 2055
WAKAYAMA ET AL., NATURE, vol. 394, 1998, pages 369 - 374
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
WILMUT ET AL., NATURE, vol. 385, 1997, pages 810 - 813

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
WO2021087406A1 (en) * 2019-11-01 2021-05-06 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
WO2021222313A1 (en) * 2020-04-27 2021-11-04 Magenta Therapeutics, Inc. Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
WO2022197776A1 (en) * 2021-03-16 2022-09-22 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients

Also Published As

Publication number Publication date
JP2021505172A (en) 2021-02-18
SG11202004913TA (en) 2020-06-29
MX2020005878A (en) 2020-10-07
CA3083783A1 (en) 2019-06-13
CO2020007275A2 (en) 2020-07-31
BR112020011186A2 (en) 2020-11-17
EP3720494A2 (en) 2020-10-14
JP2024023226A (en) 2024-02-21
AU2018378804A1 (en) 2020-06-11
CN111712262A (en) 2020-09-25
IL275077A (en) 2020-07-30
WO2019113375A3 (en) 2019-07-18
KR20200096942A (en) 2020-08-14

Similar Documents

Publication Publication Date Title
US20230130646A1 (en) Dosing regimens for the mobilization of hematopoietic stem cells
WO2019113375A2 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
JP7412341B2 (en) Compositions and methods for hematopoietic stem and progenitor cell expansion
US20220096559A1 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US11260079B2 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US20220401481A1 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US20190343885A1 (en) Compositions and methods for hematopoietic stem and progenitor cell transplant therapy
EP3735412B1 (en) Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
US20230414565A1 (en) Compositions and methods for treating hematological malignancies
EP3874027A2 (en) Methods for hematopoietic stem and progenitor cell transplant therapy
US20230330185A1 (en) Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
WO2022197776A1 (en) Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3083783

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020531468

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018378804

Country of ref document: AU

Date of ref document: 20181206

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20207019222

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018829615

Country of ref document: EP

Effective date: 20200706

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18829615

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020011186

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112020011186

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200603